{"docstore/data": {"88da5561-31d4-44fc-a4bb-31f9024da8d5": {"__data__": {"id_": "88da5561-31d4-44fc-a4bb-31f9024da8d5", "embedding": null, "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only. ", "original_text": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e2cd6a9-e422-4503-aff5-44df60ce4646", "node_type": "1", "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall. ", "original_text": "Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc. "}, "hash": "0c3f31e34d575594d1bbeb90290f2a3bfccebfd22f49655236849f6591f1546e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e2cd6a9-e422-4503-aff5-44df60ce4646": {"__data__": {"id_": "6e2cd6a9-e422-4503-aff5-44df60ce4646", "embedding": null, "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall. ", "original_text": "Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88da5561-31d4-44fc-a4bb-31f9024da8d5", "node_type": "1", "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only. ", "original_text": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a66bc9baa0084bf0089a3a24d84189c2c441955027cfb8bcf4b3c6da4247e0e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e87ae1d-c5fb-4160-8249-7a6f6144c300", "node_type": "1", "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question. ", "original_text": "Earnings \nConference Call. "}, "hash": "15cca1293dfb906f09ca86f19e58c1cc8a709b2acb380b33eae055198fd45f00", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc. ", "start_char_idx": 48, "end_char_idx": 201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e87ae1d-c5fb-4160-8249-7a6f6144c300": {"__data__": {"id_": "8e87ae1d-c5fb-4160-8249-7a6f6144c300", "embedding": null, "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question. ", "original_text": "Earnings \nConference Call. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e2cd6a9-e422-4503-aff5-44df60ce4646", "node_type": "1", "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall. ", "original_text": "Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5001a3e35c92adab185f88902ac326e007807db2920a3059f9a52a7edb69b44a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be8c35f9-ea58-466f-b3a8-935fa1801e23", "node_type": "1", "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations. ", "original_text": "Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only. "}, "hash": "91455e26678667791726882e3a777af9048e6222a0f9593a917ae68868a92a7b", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call. ", "start_char_idx": 201, "end_char_idx": 228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be8c35f9-ea58-466f-b3a8-935fa1801e23": {"__data__": {"id_": "be8c35f9-ea58-466f-b3a8-935fa1801e23", "embedding": null, "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations. ", "original_text": "Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e87ae1d-c5fb-4160-8249-7a6f6144c300", "node_type": "1", "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question. ", "original_text": "Earnings \nConference Call. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b137ae33b12be975b4020dfe9e291c4632879177e8d062a64bc8c807eaa8df9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cba687d2-bee8-440b-8f50-710c2733fb82", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n", "original_text": "However, you will have the opportunity to ask questions at the end of the \ncall. "}, "hash": "1a40f9710379ad702f86fb491bfbf16bff0e93afc047ccce6fe92d36c29d3a7b", "class_name": "RelatedNodeInfo"}}, "text": "Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only. ", "start_char_idx": 228, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cba687d2-bee8-440b-8f50-710c2733fb82": {"__data__": {"id_": "cba687d2-bee8-440b-8f50-710c2733fb82", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n", "original_text": "However, you will have the opportunity to ask questions at the end of the \ncall. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be8c35f9-ea58-466f-b3a8-935fa1801e23", "node_type": "1", "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations. ", "original_text": "Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eeac1f1baf000430092c9d004cb9574c0e3b1d7553100159cd864b9f450965d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23093277-e8ce-4309-a269-e89f1b1ccc94", "node_type": "1", "metadata": {"window": "Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome . ", "original_text": "This can be done by pressing  star one on your telephone keypad to register your question. "}, "hash": "11a9f4e495b309cfb1684c67fad450185fdcf07bc1195a71d6d724c27e4f13ff", "class_name": "RelatedNodeInfo"}}, "text": "However, you will have the opportunity to ask questions at the end of the \ncall. ", "start_char_idx": 346, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23093277-e8ce-4309-a269-e89f1b1ccc94": {"__data__": {"id_": "23093277-e8ce-4309-a269-e89f1b1ccc94", "embedding": null, "metadata": {"window": "Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome . ", "original_text": "This can be done by pressing  star one on your telephone keypad to register your question. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cba687d2-bee8-440b-8f50-710c2733fb82", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n", "original_text": "However, you will have the opportunity to ask questions at the end of the \ncall. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74651b7f657d8c8bcba33f83b9704c606af7cc411569811b2c578be571dc3c08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9915611-4e09-4b1e-8c84-240039a0ff75", "node_type": "1", "metadata": {"window": "Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 . ", "original_text": "I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations. "}, "hash": "430e5403b954d90eea2aa4fed3b7d51a2fd95391bb428d65b8ea1091f742cdf5", "class_name": "RelatedNodeInfo"}}, "text": "This can be done by pressing  star one on your telephone keypad to register your question. ", "start_char_idx": 427, "end_char_idx": 518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9915611-4e09-4b1e-8c84-240039a0ff75": {"__data__": {"id_": "c9915611-4e09-4b1e-8c84-240039a0ff75", "embedding": null, "metadata": {"window": "Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 . ", "original_text": "I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23093277-e8ce-4309-a269-e89f1b1ccc94", "node_type": "1", "metadata": {"window": "Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome . ", "original_text": "This can be done by pressing  star one on your telephone keypad to register your question. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a29ab8ae39fbedc83ff99192b60529d5474bdcf729854c3ce3841e674f1512c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "427fe606-c3bf-462e-b51b-8ae9b85dc6ab", "node_type": "1", "metadata": {"window": "However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n", "original_text": "Please, go \nahead.  \n \n"}, "hash": "334ecc6a12ce4f3269673c174adf19d93fe9c861ca2000882e85624822649096", "class_name": "RelatedNodeInfo"}}, "text": "I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations. ", "start_char_idx": 518, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "427fe606-c3bf-462e-b51b-8ae9b85dc6ab": {"__data__": {"id_": "427fe606-c3bf-462e-b51b-8ae9b85dc6ab", "embedding": null, "metadata": {"window": "However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n", "original_text": "Please, go \nahead.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9915611-4e09-4b1e-8c84-240039a0ff75", "node_type": "1", "metadata": {"window": "Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only.  However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 . ", "original_text": "I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6076b42be7d365cf325befb310c7ea1792087862e9ee3ddabfc8380be5c73eae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d32dce3-0da3-4924-b074-363556d3fb18", "node_type": "1", "metadata": {"window": "This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n", "original_text": "Kevin Moran :  Good morning , and welcome . "}, "hash": "8c97e3848a9ac074594d5bd5e36d99381fc72452d3ad65d45ab020487cf13e32", "class_name": "RelatedNodeInfo"}}, "text": "Please, go \nahead.  \n \n", "start_char_idx": 612, "end_char_idx": 635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d32dce3-0da3-4924-b074-363556d3fb18": {"__data__": {"id_": "0d32dce3-0da3-4924-b074-363556d3fb18", "embedding": null, "metadata": {"window": "This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n", "original_text": "Kevin Moran :  Good morning , and welcome . ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "427fe606-c3bf-462e-b51b-8ae9b85dc6ab", "node_type": "1", "metadata": {"window": "However, you will have the opportunity to ask questions at the end of the \ncall.  This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n", "original_text": "Please, go \nahead.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77276e63327ad3ebb96eb68dbaf68c33b950bbb28309a31d9e57ced589478269", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "917d91d7-38d8-4b37-903e-9f23c37b8477", "node_type": "1", "metadata": {"window": "I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements. ", "original_text": "Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 . "}, "hash": "aa27f82660792562be7578d0346701aa96c7fd5358251f9f24b49885fb076991", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Good morning , and welcome . ", "start_char_idx": 635, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "917d91d7-38d8-4b37-903e-9f23c37b8477": {"__data__": {"id_": "917d91d7-38d8-4b37-903e-9f23c37b8477", "embedding": null, "metadata": {"window": "I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements. ", "original_text": "Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 . ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d32dce3-0da3-4924-b074-363556d3fb18", "node_type": "1", "metadata": {"window": "This can be done by pressing  star one on your telephone keypad to register your question.  I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n", "original_text": "Kevin Moran :  Good morning , and welcome . ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5daa8665cbbd503a42d51d4b298db2dfd7cfe74a1894c4bf0bff7039c167bebf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42d28cfd-2db0-4575-9a0c-53b4d55ba7e8", "node_type": "1", "metadata": {"window": "Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n"}, "hash": "e3cfbaf96bd116e8642139d3c6028aae49ef4139b04d10d323809dd6d99bb719", "class_name": "RelatedNodeInfo"}}, "text": "Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 . ", "start_char_idx": 679, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42d28cfd-2db0-4575-9a0c-53b4d55ba7e8": {"__data__": {"id_": "42d28cfd-2db0-4575-9a0c-53b4d55ba7e8", "embedding": null, "metadata": {"window": "Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "917d91d7-38d8-4b37-903e-9f23c37b8477", "node_type": "1", "metadata": {"window": "I \nwould now like to hand the call over to Kevin Moran, Vice President of Investor Relations.  Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements. ", "original_text": "Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 . ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d110e6339c20e8b6cc0dc9c577ed8d7930619332ab990890f5aa943a5f1cb3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ad7282b-5036-435e-bcc2-dd057320ec54", "node_type": "1", "metadata": {"window": "Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n"}, "hash": "724b919c6ac98b527ff93d691987a768b599e96ec63c53d78f149c90353af231", "class_name": "RelatedNodeInfo"}}, "text": "You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n", "start_char_idx": 819, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ad7282b-5036-435e-bcc2-dd057320ec54": {"__data__": {"id_": "5ad7282b-5036-435e-bcc2-dd057320ec54", "embedding": null, "metadata": {"window": "Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42d28cfd-2db0-4575-9a0c-53b4d55ba7e8", "node_type": "1", "metadata": {"window": "Please, go \nahead.  \n \n Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5b1d2d1620afc4e6cad5d92302f3bb0c68ed6ef513e9ef8626213e98e3e11ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb472fe4-9dbf-4aa4-90db-11c11807e981", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. "}, "hash": "94cd69f9b25b0dcd4594151a65a3a628e9d8990bfb7dc792bfec85d57496b659", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n", "start_char_idx": 943, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb472fe4-9dbf-4aa4-90db-11c11807e981": {"__data__": {"id_": "eb472fe4-9dbf-4aa4-90db-11c11807e981", "embedding": null, "metadata": {"window": "Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ad7282b-5036-435e-bcc2-dd057320ec54", "node_type": "1", "metadata": {"window": "Kevin Moran :  Good morning , and welcome .  Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "original_text": "Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f8fefd06f48b70230c5887f10f4d02d2895200d1227ff6d79f2a009f4b96b19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5af57c8-dc3d-434c-9396-25267f5332db", "node_type": "1", "metadata": {"window": "You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . "}, "hash": "63808561719d2b2ad1eab2cc6df2038cdb4c8eef4890742bbad8af9831bbf91b", "class_name": "RelatedNodeInfo"}}, "text": "During the call we will be making forward -looking statements. ", "start_char_idx": 1057, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5af57c8-dc3d-434c-9396-25267f5332db": {"__data__": {"id_": "a5af57c8-dc3d-434c-9396-25267f5332db", "embedding": null, "metadata": {"window": "You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb472fe4-9dbf-4aa4-90db-11c11807e981", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s  Fourth -Quarter  \nand Fiscal Year -End 2023 results along with  our outlook for Fiscal Year 2024 .  You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c07603d9d6e03574347eb03e30c1bb721c0002e09873860b1da48ed54016e01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ae372d5-f841-4cf7-8af1-ac031b9185f8", "node_type": "1", "metadata": {"window": "Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. "}, "hash": "af945bce6d8789a510018a2e241f6f9ca5ee3300fa981d67f0147a55fd318523", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "start_char_idx": 1120, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ae372d5-f841-4cf7-8af1-ac031b9185f8": {"__data__": {"id_": "1ae372d5-f841-4cf7-8af1-ac031b9185f8", "embedding": null, "metadata": {"window": "Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5af57c8-dc3d-434c-9396-25267f5332db", "node_type": "1", "metadata": {"window": "You can find today\u2019s \npress release and earnings presentation on the IR section of our website at ir.cardinalhea lth.com . \n Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a51d706d11948ac7a39ed1fd6f47f92e6f70bf61c6a2de16c1f508e345b66826", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "205f8030-c27d-40a4-9eb2-c71787bfac5c", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. "}, "hash": "14c307a9db1a787aafd059ba5fa2fe86c969f56165bf051137e20ad29619a638", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "start_char_idx": 1292, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "205f8030-c27d-40a4-9eb2-c71787bfac5c": {"__data__": {"id_": "205f8030-c27d-40a4-9eb2-c71787bfac5c", "embedding": null, "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ae372d5-f841-4cf7-8af1-ac031b9185f8", "node_type": "1", "metadata": {"window": "Joining me today are Jason Hollar, our Chief Executive Officer, and Aaron Alt , our Chief Financial \nOfficer . \n \n During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c15b4065c8daae2fd2e59b4d6d545fc26729c5af7150a2669ef40b273c9075e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05be60c7-fe8f-4a26-a8d1-adb94e239f79", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n"}, "hash": "287e840506f15593a7a270d86b2a0011d197d62c7c7e47efc2d2e2f27cc6b008", "class_name": "RelatedNodeInfo"}}, "text": "Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "start_char_idx": 1460, "end_char_idx": 1604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05be60c7-fe8f-4a26-a8d1-adb94e239f79": {"__data__": {"id_": "05be60c7-fe8f-4a26-a8d1-adb94e239f79", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "205f8030-c27d-40a4-9eb2-c71787bfac5c", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n", "original_text": "Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33a3e0874f00d3b4f99233daece290754ae10a3b4afabcef240e528fb608243c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ef99ac2-1280-4b5c-b53b-8388160b0f8a", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n", "original_text": "For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.  "}, "hash": "9ccd40df68c386952e6422e6a8850e87854f0e92b4e3ad7e2568ac60adc4f977", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "start_char_idx": 1604, "end_char_idx": 1729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ef99ac2-1280-4b5c-b53b-8388160b0f8a": {"__data__": {"id_": "4ef99ac2-1280-4b5c-b53b-8388160b0f8a", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n", "original_text": "For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.  ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05be60c7-fe8f-4a26-a8d1-adb94e239f79", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e85720b4e8a29f73a0b1ad2f0513ecb5d8db1c84dd326eadbc650c0bd047b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de8ca352-0e50-418d-8c0b-a0d0b285fbad", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year. ", "original_text": "With that, I \u2019ll now turn the call over the Jason.  \n \n"}, "hash": "c912054d260af1e1b55235627e33c234cf6c691b508cd3430a9c4fcde518e1e4", "class_name": "RelatedNodeInfo"}}, "text": "For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.  ", "start_char_idx": 1729, "end_char_idx": 1885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de8ca352-0e50-418d-8c0b-a0d0b285fbad": {"__data__": {"id_": "de8ca352-0e50-418d-8c0b-a0d0b285fbad", "embedding": null, "metadata": {"window": "Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year. ", "original_text": "With that, I \u2019ll now turn the call over the Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ef99ac2-1280-4b5c-b53b-8388160b0f8a", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a full description of these risks and uncertainties.  Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n", "original_text": "For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.  ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efe63e525a80d424467fceb4f8d91dc3d7ceee7ae5259462e7dbed53651d844d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b59db2c-3a98-455f-85a1-a8b77910ceb7", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow. ", "original_text": "Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n"}, "hash": "5aece8ff7fc3a648f155ee8c5a632eafcd652f16c5f1a2bbd232bf2d3cc3be6b", "class_name": "RelatedNodeInfo"}}, "text": "With that, I \u2019ll now turn the call over the Jason.  \n \n", "start_char_idx": 1885, "end_char_idx": 1940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b59db2c-3a98-455f-85a1-a8b77910ceb7": {"__data__": {"id_": "1b59db2c-3a98-455f-85a1-a8b77910ceb7", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow. ", "original_text": "Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de8ca352-0e50-418d-8c0b-a0d0b285fbad", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, all our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year. ", "original_text": "With that, I \u2019ll now turn the call over the Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f544a20a233c3dd8d157d4721e4d7701cc6ec22e09bbd2e45812a19defd09430", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc511975-e2d4-4ad5-87ba-da3cab827d2f", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n", "original_text": "Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n"}, "hash": "c9cdc7afe3afbae0421f819d73e19e21b2173b85921801a1f15c709e1b8e1e3e", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n", "start_char_idx": 1940, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc511975-e2d4-4ad5-87ba-da3cab827d2f": {"__data__": {"id_": "bc511975-e2d4-4ad5-87ba-da3cab827d2f", "embedding": null, "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n", "original_text": "Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b59db2c-3a98-455f-85a1-a8b77910ceb7", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow. ", "original_text": "Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29d40833622a564fac155ec4710e24f1b95077aa2ee9b32cecb6fd05643842bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0bae8ca-c0c3-48b6-bc0c-5ce0758c09b8", "node_type": "1", "metadata": {"window": "With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation. ", "original_text": "We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year. "}, "hash": "9ece7992512c71fefd3a45c17dcf84ca098242472be18b5a716e7c3f87102cb8", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n", "start_char_idx": 2005, "end_char_idx": 2178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0bae8ca-c0c3-48b6-bc0c-5ce0758c09b8": {"__data__": {"id_": "f0bae8ca-c0c3-48b6-bc0c-5ce0758c09b8", "embedding": null, "metadata": {"window": "With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation. ", "original_text": "We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc511975-e2d4-4ad5-87ba-da3cab827d2f", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly  ask t o limit yourself to one question, so that we can try \nand give everyone in the queue an opportunity.   With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n", "original_text": "Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23fda5ebba5264c7e7a173be65db4116a04b34cf9534ccc0728c80a326359a7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c905ed45-62ca-4d5c-8944-8a57d2b23de8", "node_type": "1", "metadata": {"window": "Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow. "}, "hash": "9d9755d1f3509f0a3ce0927e600fda2a73bd88c57cc3536b0f0080ca410a07ef", "class_name": "RelatedNodeInfo"}}, "text": "We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year. ", "start_char_idx": 2178, "end_char_idx": 2309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c905ed45-62ca-4d5c-8944-8a57d2b23de8": {"__data__": {"id_": "c905ed45-62ca-4d5c-8944-8a57d2b23de8", "embedding": null, "metadata": {"window": "Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0bae8ca-c0c3-48b6-bc0c-5ce0758c09b8", "node_type": "1", "metadata": {"window": "With that, I \u2019ll now turn the call over the Jason.  \n \n Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation. ", "original_text": "We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57393072731061ccb44bf8511e5591dddd0267c3d53caca8ca9cf3913d758e39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d03b2e7-ddbf-4074-a4bf-d5d04ed5d076", "node_type": "1", "metadata": {"window": "Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n"}, "hash": "162e97e5900fb3998d6df8f16ad1b7141bd99247626c803fbd094397d6070418", "class_name": "RelatedNodeInfo"}}, "text": "We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow. ", "start_char_idx": 2309, "end_char_idx": 2423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d03b2e7-ddbf-4074-a4bf-d5d04ed5d076": {"__data__": {"id_": "3d03b2e7-ddbf-4074-a4bf-d5d04ed5d076", "embedding": null, "metadata": {"window": "Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c905ed45-62ca-4d5c-8944-8a57d2b23de8", "node_type": "1", "metadata": {"window": "Jason Hollar :  Thanks  Kevin , and g ood morning, everyone.  \n \n Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15ffba4e84faa0d31b2501dd1029788c0edab7d1af78791a9512ace1dce28f1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72684f76-71ba-44e6-a292-7dfe6e8cf14e", "node_type": "1", "metadata": {"window": "We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation. "}, "hash": "f52494a8ad059e2f885546648cd1eee29fc4afd91560fe8e42785d6aef24b515", "class_name": "RelatedNodeInfo"}}, "text": "And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n", "start_char_idx": 2423, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72684f76-71ba-44e6-a292-7dfe6e8cf14e": {"__data__": {"id_": "72684f76-71ba-44e6-a292-7dfe6e8cf14e", "embedding": null, "metadata": {"window": "We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d03b2e7-ddbf-4074-a4bf-d5d04ed5d076", "node_type": "1", "metadata": {"window": "Fiscal \u201823 was an inflection point for Cardinal Health, with improved performance, strong execution,  \nand notable progress against both our short and long -term plans.  \n \n We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9821ceac9ea17ca9b080c63aa8ccfc2c429f6a99e85af04b08b1728d14e55ecf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e59afd44-9671-4d27-b439-d3c036cae57f", "node_type": "1", "metadata": {"window": "We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  "}, "hash": "ae2f1df93083f8f70b2b8603f3af8c98841ba1e4441f0ef9e8f400a1447911cc", "class_name": "RelatedNodeInfo"}}, "text": "This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation. ", "start_char_idx": 2612, "end_char_idx": 2823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e59afd44-9671-4d27-b439-d3c036cae57f": {"__data__": {"id_": "e59afd44-9671-4d27-b439-d3c036cae57f", "embedding": null, "metadata": {"window": "We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "64802266-2d8d-491d-951b-cc5ea8f030fe", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ff9fc48dad65542c17c29abc309fece82dd8174aff279014b88ee644b3b8abb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72684f76-71ba-44e6-a292-7dfe6e8cf14e", "node_type": "1", "metadata": {"window": "We delivered record financial p erformance , including our highest non -GAAP EPS ever, reflecting 14% \ngrowth from the prior year.  We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a36c91f8a2a10e63dcbda81e8402dbd0e51f241793184ad8969c6ababf43caac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "166b63ef-9a7e-4d46-9fcc-841fa6e01a22", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n", "original_text": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.  "}, "hash": "10d722b1175df7bd45bdb1f4e1162f464031d67746d042a33e64558be6d0af33", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "start_char_idx": 2823, "end_char_idx": 3079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "166b63ef-9a7e-4d46-9fcc-841fa6e01a22": {"__data__": {"id_": "166b63ef-9a7e-4d46-9fcc-841fa6e01a22", "embedding": null, "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n", "original_text": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.  ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e59afd44-9671-4d27-b439-d3c036cae57f", "node_type": "1", "metadata": {"window": "We grew Pharma segment profit an impressive 13% and generated $2.8 \nbillion  dollars  of adjusted free cash flow.  And in Medical, we drove significant sequential improvement \nin operating performance , from a segment loss in the first quarter to over $80  million dollars  of \nsegment profit in Q4.  \n \n This year we took decisive action to advance o ur 3 strategic imperatives: building upon the resiliency \nof our Pharma segment, executing our Medical Improvement Plan and maximizing shareholder value \ncreation.  Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "original_text": "Consistent with what you heard at our June Investor Day, these results were achieved \nthrough o ur team\u2019s commitment to ruthlessly prioritize the core of our business , and to better serve \nour customers so they in turn, can focus on caring for patients.  ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa0799c0a9ea27a2883cb8836c63d4fe1e04c7a2bf03a8624f5736f1c7185697", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5078a19-a2d1-479f-b1f5-2a34316db517", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth. ", "original_text": "We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board. "}, "hash": "1c94c223411237ceff697c4091e99ffb1b11c7a54d5b5fc2bb94139dcd892afa", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.  ", "start_char_idx": 0, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5078a19-a2d1-479f-b1f5-2a34316db517": {"__data__": {"id_": "f5078a19-a2d1-479f-b1f5-2a34316db517", "embedding": null, "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth. ", "original_text": "We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "166b63ef-9a7e-4d46-9fcc-841fa6e01a22", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n", "original_text": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.  ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6339f0046b1d0766944184e6aa1f14808a1780ffa3250f8295b9ff14ca9614a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2e066dd-8c5d-4636-a3e2-9317ded7bcb2", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value. ", "original_text": "We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n"}, "hash": "50d2619eb2ffa006b77388508c528fb2e0d0d16db764dcbef597139b9ae33376", "class_name": "RelatedNodeInfo"}}, "text": "We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board. ", "start_char_idx": 193, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2e066dd-8c5d-4636-a3e2-9317ded7bcb2": {"__data__": {"id_": "d2e066dd-8c5d-4636-a3e2-9317ded7bcb2", "embedding": null, "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value. ", "original_text": "We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5078a19-a2d1-479f-b1f5-2a34316db517", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth. ", "original_text": "We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ec1f10a1592526525bc50bea9a6bdeae7f6f736644c8d23a1022e6d03fab93e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e97f9bd-edeb-4475-91d1-cdcfc0ce468b", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n", "original_text": "On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n"}, "hash": "db8b0e0d9eebb5e123e9f76cbb974834a12054fedb82963d61ca77af86063831", "class_name": "RelatedNodeInfo"}}, "text": "We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n", "start_char_idx": 327, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e97f9bd-edeb-4475-91d1-cdcfc0ce468b": {"__data__": {"id_": "6e97f9bd-edeb-4475-91d1-cdcfc0ce468b", "embedding": null, "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n", "original_text": "On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2e066dd-8c5d-4636-a3e2-9317ded7bcb2", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value. ", "original_text": "We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f333b927b7b4802f92d7ec5cfcab0a2ab0b652540a2be8ffb4b1e8816715b6eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c82c188-f51f-42e8-8bcf-a988969c87a2", "node_type": "1", "metadata": {"window": "We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824. ", "original_text": "We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth. "}, "hash": "c7fe5a28dcbfa020b41f3674b4bcb731cb3dabc0d75da70ab629e4a83ae2901a", "class_name": "RelatedNodeInfo"}}, "text": "On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n", "start_char_idx": 469, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c82c188-f51f-42e8-8bcf-a988969c87a2": {"__data__": {"id_": "3c82c188-f51f-42e8-8bcf-a988969c87a2", "embedding": null, "metadata": {"window": "We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824. ", "original_text": "We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e97f9bd-edeb-4475-91d1-cdcfc0ce468b", "node_type": "1", "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n", "original_text": "On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fd2087bf171043942c98d3f012f14a0ed66ff644dd07ae7810d1960df5f6a1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eea32ff-c933-4843-962b-566559975def", "node_type": "1", "metadata": {"window": "We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n", "original_text": "We also deployed capital responsibly, with a continued eye on maximizing value. "}, "hash": "7a5d407f849376e2ec4aae53665f3fbddacd1051c3d58d817df3dade294b0893", "class_name": "RelatedNodeInfo"}}, "text": "We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth. ", "start_char_idx": 764, "end_char_idx": 964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eea32ff-c933-4843-962b-566559975def": {"__data__": {"id_": "0eea32ff-c933-4843-962b-566559975def", "embedding": null, "metadata": {"window": "We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n", "original_text": "We also deployed capital responsibly, with a continued eye on maximizing value. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c82c188-f51f-42e8-8bcf-a988969c87a2", "node_type": "1", "metadata": {"window": "We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824. ", "original_text": "We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6945874bd90485ec32f451e289f72ea6acd9188c07080c99a51a41ad80c77339", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "515272ec-c36e-4369-a481-9cdd761a6ff8", "node_type": "1", "metadata": {"window": "On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n", "original_text": "And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n"}, "hash": "2808dfa51af7354b72e05cdb54555f6be2bf42343e375b7757d99c5bc2025373", "class_name": "RelatedNodeInfo"}}, "text": "We also deployed capital responsibly, with a continued eye on maximizing value. ", "start_char_idx": 964, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "515272ec-c36e-4369-a481-9cdd761a6ff8": {"__data__": {"id_": "515272ec-c36e-4369-a481-9cdd761a6ff8", "embedding": null, "metadata": {"window": "On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n", "original_text": "And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eea32ff-c933-4843-962b-566559975def", "node_type": "1", "metadata": {"window": "We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n", "original_text": "We also deployed capital responsibly, with a continued eye on maximizing value. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcb56c3c870a348348d52d5488cfad3fb422f0f7900eae97b70573837376f82c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4249c533-9f6f-494a-b8ce-fdba82067239", "node_type": "1", "metadata": {"window": "We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.  ", "original_text": "At Investor Day we p rovided preliminary guidance for fiscal \u201824. "}, "hash": "30cd402d9546f45148caa6c804f4e32cd000b74a569cee3f7d80108741075d34", "class_name": "RelatedNodeInfo"}}, "text": "And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n", "start_char_idx": 1044, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4249c533-9f6f-494a-b8ce-fdba82067239": {"__data__": {"id_": "4249c533-9f6f-494a-b8ce-fdba82067239", "embedding": null, "metadata": {"window": "We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.  ", "original_text": "At Investor Day we p rovided preliminary guidance for fiscal \u201824. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "515272ec-c36e-4369-a481-9cdd761a6ff8", "node_type": "1", "metadata": {"window": "On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n", "original_text": "And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf766ae40b5ed9894e95446a416761eddc3c57d246d1aa187151ce42b7149d41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d51f7a70-e11d-48d7-9d2c-19dbcd1e8305", "node_type": "1", "metadata": {"window": "We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n", "original_text": "With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n"}, "hash": "51446a2d7144898e48081cd1982ec069fcfa7dc67bdd16e80926e360eacd3a94", "class_name": "RelatedNodeInfo"}}, "text": "At Investor Day we p rovided preliminary guidance for fiscal \u201824. ", "start_char_idx": 1147, "end_char_idx": 1213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d51f7a70-e11d-48d7-9d2c-19dbcd1e8305": {"__data__": {"id_": "d51f7a70-e11d-48d7-9d2c-19dbcd1e8305", "embedding": null, "metadata": {"window": "We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n", "original_text": "With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4249c533-9f6f-494a-b8ce-fdba82067239", "node_type": "1", "metadata": {"window": "We recently closed our Outcomes \u2122 merger with Blackrock\u2019s Transaction Data Systems, which we \nsee as a big win for pharmacies and an important opportunity to accelerate the business\u2019s future \ngrowth.  We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.  ", "original_text": "At Investor Day we p rovided preliminary guidance for fiscal \u201824. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76a1761ecf8fd04f6bef3ec8ff3c5fc81e8cf0aa6a98603171e708f584a12a69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdacd99c-60a8-44b8-8217-6700cfe81252", "node_type": "1", "metadata": {"window": "And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day . ", "original_text": "Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n"}, "hash": "2b55cdaa66f64267761e33b8533d364e4f6d0980ce8ee7a12745f1d6396ce3e5", "class_name": "RelatedNodeInfo"}}, "text": "With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n", "start_char_idx": 1213, "end_char_idx": 1351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdacd99c-60a8-44b8-8217-6700cfe81252": {"__data__": {"id_": "bdacd99c-60a8-44b8-8217-6700cfe81252", "embedding": null, "metadata": {"window": "And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day . ", "original_text": "Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d51f7a70-e11d-48d7-9d2c-19dbcd1e8305", "node_type": "1", "metadata": {"window": "We also deployed capital responsibly, with a continued eye on maximizing value.  And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n", "original_text": "With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18122477ccb4d293cb9f6749a2196b7c80a1e66ecca2e7ab45dd28b274206593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "701401a6-55d0-42db-ab9e-41513da4518d", "node_type": "1", "metadata": {"window": "At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points. ", "original_text": "Aaron Alt :  Thanks Jason, and good morning.  "}, "hash": "f6ff8928374e0e03d8db6b9fa3b7782a9575d425f78621d63c3ff6d773a641fb", "class_name": "RelatedNodeInfo"}}, "text": "Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n", "start_char_idx": 1351, "end_char_idx": 1533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "701401a6-55d0-42db-ab9e-41513da4518d": {"__data__": {"id_": "701401a6-55d0-42db-ab9e-41513da4518d", "embedding": null, "metadata": {"window": "At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points. ", "original_text": "Aaron Alt :  Thanks Jason, and good morning.  ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdacd99c-60a8-44b8-8217-6700cfe81252", "node_type": "1", "metadata": {"window": "And we are \npositioned with the financial flexibility to continue driving value for shareholders .  \n \n At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day . ", "original_text": "Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f97afe3f84367c438f70d90393d9c25ae629b83f803743b1d1b38285b0c33be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "496f493c-121b-4c84-8aff-79c9bee41817", "node_type": "1", "metadata": {"window": "With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n", "original_text": "I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n"}, "hash": "3aed04f865726ab8d667e33a5bc5d01c0ce4c5f418525eb69aa4b732910a8b95", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt :  Thanks Jason, and good morning.  ", "start_char_idx": 1533, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "496f493c-121b-4c84-8aff-79c9bee41817": {"__data__": {"id_": "496f493c-121b-4c84-8aff-79c9bee41817", "embedding": null, "metadata": {"window": "With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n", "original_text": "I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "701401a6-55d0-42db-ab9e-41513da4518d", "node_type": "1", "metadata": {"window": "At Investor Day we p rovided preliminary guidance for fiscal \u201824.  With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points. ", "original_text": "Aaron Alt :  Thanks Jason, and good morning.  ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b136347dbfec70e6cc886d479bc0f84c4b4c86a9029f1219592bde3b055e5fe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7a3949c-9be4-4c8e-b58f-05d39903225b", "node_type": "1", "metadata": {"window": "Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n", "original_text": "We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day . "}, "hash": "1a436fc626a111f539ce7aa1970c0dc412a5d208e9048c6537c48485395263f2", "class_name": "RelatedNodeInfo"}}, "text": "I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n", "start_char_idx": 1579, "end_char_idx": 1753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7a3949c-9be4-4c8e-b58f-05d39903225b": {"__data__": {"id_": "a7a3949c-9be4-4c8e-b58f-05d39903225b", "embedding": null, "metadata": {"window": "Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n", "original_text": "We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day . ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "496f493c-121b-4c84-8aff-79c9bee41817", "node_type": "1", "metadata": {"window": "With the strong finish to the year and \nincreased confidence as we look ahead, I am pleased that we can raise our fiscal \u201824 outlook.  \n \n Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n", "original_text": "I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d905a88c5360e6cba0418bd2fce5f7755f5e18f447a1705beb39ed05f1030b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eed708d2-a584-4820-aefd-06aa75e1c2fb", "node_type": "1", "metadata": {"window": "Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers. ", "original_text": "For both Q4 and the year, our EPS results reached historical high points. "}, "hash": "963e89f283625f3b98e8122bc066bbfad07044f4e9f7e51daede7bf873d2ae98", "class_name": "RelatedNodeInfo"}}, "text": "We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day . ", "start_char_idx": 1753, "end_char_idx": 1878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eed708d2-a584-4820-aefd-06aa75e1c2fb": {"__data__": {"id_": "eed708d2-a584-4820-aefd-06aa75e1c2fb", "embedding": null, "metadata": {"window": "Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers. ", "original_text": "For both Q4 and the year, our EPS results reached historical high points. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7a3949c-9be4-4c8e-b58f-05d39903225b", "node_type": "1", "metadata": {"window": "Later in my remarks I will share further details on our 3 strategic prioritie s. But first, let me hand it over \nto Aaron to walk you through our financial results and guidance.  \n \n Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n", "original_text": "We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day . ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "effaae59ad4b5ef5de152c493e33a0fadf78f79612ef124b36ed72c2f482aaca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "298b7bbb-3ed7-48f9-81b6-d31044f77a64", "node_type": "1", "metadata": {"window": "I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers. ", "original_text": "We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n"}, "hash": "433d03ab9644e3c62f1497d4b0a6fb179a4efca8f5b2b1d2c96be22a5f743ceb", "class_name": "RelatedNodeInfo"}}, "text": "For both Q4 and the year, our EPS results reached historical high points. ", "start_char_idx": 1878, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "298b7bbb-3ed7-48f9-81b6-d31044f77a64": {"__data__": {"id_": "298b7bbb-3ed7-48f9-81b6-d31044f77a64", "embedding": null, "metadata": {"window": "I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers. ", "original_text": "We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eed708d2-a584-4820-aefd-06aa75e1c2fb", "node_type": "1", "metadata": {"window": "Aaron Alt :  Thanks Jason, and good morning.   I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers. ", "original_text": "For both Q4 and the year, our EPS results reached historical high points. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b478d30554bd361e53e8e16c148112f0f21d43fc8e355c230aa37fb407fb4c40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c734d1d7-1b52-4a22-a6fe-b351433e0402", "node_type": "1", "metadata": {"window": "We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n", "original_text": "Let\u2019s start with the Pharma segment on slide 6.  \n \n"}, "hash": "e54e1e7d4f7cdf1e77b796ac356b0c217751e56e8e170ec01857888dde6e796c", "class_name": "RelatedNodeInfo"}}, "text": "We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n", "start_char_idx": 1952, "end_char_idx": 2048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c734d1d7-1b52-4a22-a6fe-b351433e0402": {"__data__": {"id_": "c734d1d7-1b52-4a22-a6fe-b351433e0402", "embedding": null, "metadata": {"window": "We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n", "original_text": "Let\u2019s start with the Pharma segment on slide 6.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "298b7bbb-3ed7-48f9-81b6-d31044f77a64", "node_type": "1", "metadata": {"window": "I won\u2019t bury the lead, Q4 was a strong finish to a year in \nwhich, with Jason\u2019s guidance, the Cardinal team made significant progress against our strategic \ninitiatives.  \n \n We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers. ", "original_text": "We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db1493be7d23d17253dabd4a11897637bb13b4c3631ca9b7ed9afcc5e263a8b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4204b0f-e2ef-473b-8668-2bb2741e0c24", "node_type": "1", "metadata": {"window": "For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance. ", "original_text": "Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers. "}, "hash": "56ce207759daa57ae1749c277fe8084b86aa79e1425e6efbffda3e47b3d4ef64", "class_name": "RelatedNodeInfo"}}, "text": "Let\u2019s start with the Pharma segment on slide 6.  \n \n", "start_char_idx": 2048, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4204b0f-e2ef-473b-8668-2bb2741e0c24": {"__data__": {"id_": "e4204b0f-e2ef-473b-8668-2bb2741e0c24", "embedding": null, "metadata": {"window": "For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance. ", "original_text": "Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c734d1d7-1b52-4a22-a6fe-b351433e0402", "node_type": "1", "metadata": {"window": "We delivered fourth -quarter EPS of $1.55, and $5.79 for the full year, at the high end of our guidance \nfrom Investor Day .  For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n", "original_text": "Let\u2019s start with the Pharma segment on slide 6.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d9c32670c28cc4f6f0d7045ad9da5484a155ad1728d574886c9a31e46707754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e528811-492f-4dba-a03f-52d382c00d86", "node_type": "1", "metadata": {"window": "We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n", "original_text": "We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers. "}, "hash": "13295cf0dae3c154cfd305618370757c3d7348f989af7d360cf50406b450af4e", "class_name": "RelatedNodeInfo"}}, "text": "Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers. ", "start_char_idx": 2100, "end_char_idx": 2252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e528811-492f-4dba-a03f-52d382c00d86": {"__data__": {"id_": "4e528811-492f-4dba-a03f-52d382c00d86", "embedding": null, "metadata": {"window": "We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n", "original_text": "We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4204b0f-e2ef-473b-8668-2bb2741e0c24", "node_type": "1", "metadata": {"window": "For both Q4 and the year, our EPS results reached historical high points.  We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance. ", "original_text": "Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9ddac6f44144ec956a2ee1770106853fa91143a1573ee2c15e35358aff66721", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a922a572-68fa-4077-beb2-874a4e91445e", "node_type": "1", "metadata": {"window": "Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n", "original_text": "Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n"}, "hash": "3bc5f082f1f54f3632499bba3409d955bcb882b37e3b0bed1fe1f366fb679c57", "class_name": "RelatedNodeInfo"}}, "text": "We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers. ", "start_char_idx": 2252, "end_char_idx": 2438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a922a572-68fa-4077-beb2-874a4e91445e": {"__data__": {"id_": "a922a572-68fa-4077-beb2-874a4e91445e", "embedding": null, "metadata": {"window": "Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n", "original_text": "Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e528811-492f-4dba-a03f-52d382c00d86", "node_type": "1", "metadata": {"window": "We also \ndelivered stronger -than-expected cash flow, something I will touch on more later.  \n \n Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n", "original_text": "We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1aca043424918555f566913278ec83613d4bdbd8d2bdc7e4ccf5d20cddcd40bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8681dad-339e-45e7-8fdb-76ada0fcf283", "node_type": "1", "metadata": {"window": "Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance. "}, "hash": "c8bbb692b4660d60fae361b6cdb4edf61af0349b5da9d03b3b721367745bbb83", "class_name": "RelatedNodeInfo"}}, "text": "Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n", "start_char_idx": 2438, "end_char_idx": 2522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8681dad-339e-45e7-8fdb-76ada0fcf283": {"__data__": {"id_": "e8681dad-339e-45e7-8fdb-76ada0fcf283", "embedding": null, "metadata": {"window": "Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a922a572-68fa-4077-beb2-874a4e91445e", "node_type": "1", "metadata": {"window": "Let\u2019s start with the Pharma segment on slide 6.  \n \n Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n", "original_text": "Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c694020b28cdfd1bda142ca3cd2d485d71ecbb6acf243cb906e913f01e174254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbf2d342-f9bb-4aca-8bf4-15092edb6b10", "node_type": "1", "metadata": {"window": "We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n"}, "hash": "d81810ae34a8c484df6e2bdb793784a6ab2ca52dadb98d02fbd634346a4a92f5", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance. ", "start_char_idx": 2522, "end_char_idx": 2662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbf2d342-f9bb-4aca-8bf4-15092edb6b10": {"__data__": {"id_": "bbf2d342-f9bb-4aca-8bf4-15092edb6b10", "embedding": null, "metadata": {"window": "We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8681dad-339e-45e7-8fdb-76ada0fcf283", "node_type": "1", "metadata": {"window": "Fourth -quarter revenue increased 15% to $49.7 billion  dollars , driven by brand and specialty \npharmaceutical sales growt h, from existing customers.  We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance. ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05e9b2889e8e99a039479a89de5daff39d97f15b14c14601d96112f8309bb924", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ba345bb-0379-4987-8446-e5f2e76deab6", "node_type": "1", "metadata": {"window": "Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n"}, "hash": "abbcfcc16f0ce4763287086705dc4fcff2a114a38eb7a8193c1991883ba9d56c", "class_name": "RelatedNodeInfo"}}, "text": "Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n", "start_char_idx": 2662, "end_char_idx": 2793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ba345bb-0379-4987-8446-e5f2e76deab6": {"__data__": {"id_": "6ba345bb-0379-4987-8446-e5f2e76deab6", "embedding": null, "metadata": {"window": "Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbf2d342-f9bb-4aca-8bf4-15092edb6b10", "node_type": "1", "metadata": {"window": "We continued to see broad -based strength in \npharmaceutical demand spanning across product categories: brand, specialty, consumer health, and \ngenerics, and from our largest customers.  Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9e8bea2319293f2deab359f11c43fc1b05a1590afc55a8c6f906513f9a9bae5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5931aad-e8a4-4743-96f2-b6e86d205b12", "node_type": "1", "metadata": {"window": "Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Turning to Medical on slide 7.  "}, "hash": "addf58cc6bf205659d5e3a0c0fcd33869b8efe3cc544d90090adbc439f73a86c", "class_name": "RelatedNodeInfo"}}, "text": "Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n", "start_char_idx": 2793, "end_char_idx": 3017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5931aad-e8a4-4743-96f2-b6e86d205b12": {"__data__": {"id_": "a5931aad-e8a4-4743-96f2-b6e86d205b12", "embedding": null, "metadata": {"window": "Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Turning to Medical on slide 7.  ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "89727101-48ae-4724-ac27-149dad43c9b4", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef68f5a078d505ec0f5907552b878f97aa058cd534540109b2d5147c2a6a6aa1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ba345bb-0379-4987-8446-e5f2e76deab6", "node_type": "1", "metadata": {"window": "Similar to Q3, GLP -1 medications provided a r evenue \ntailwind in the quarter.  \n \n Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbd6bc12c4902423e5a635241a02ee50cd68cc2fae5ccf53b4929ac8adab3176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9477ede3-70e0-4693-916d-494c7167e393", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. ", "original_text": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend. "}, "hash": "87b1712c368dcbe9cfb34977822c1353034a3fa83b6a246c6d7990befc56d16c", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical on slide 7.  ", "start_char_idx": 3017, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9477ede3-70e0-4693-916d-494c7167e393": {"__data__": {"id_": "9477ede3-70e0-4693-916d-494c7167e393", "embedding": null, "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. ", "original_text": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend. ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5931aad-e8a4-4743-96f2-b6e86d205b12", "node_type": "1", "metadata": {"window": "Segment profit increased 12% to $504 million  dollars  in the fourth  quarter , primarily driven by positive \ngenerics program performance.  Within our generics program, we saw volume growth and consistent \nmarket dynamics, includ ing strong performance from Red Oak.  \n \n Increased contributions from brand and specialty products, along with nuclear, were also a positive \nfactor, partially offset by higher investment and operating expenses, including higher costs to support \nsales growth.  \n \n Turning to Medical on slide 7.  ", "original_text": "Turning to Medical on slide 7.  ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7d9951d83ba3c77c636e59a3b81c3f27ef1d7a69e3ca609c02a7f6d20682d7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba2fd48-f8ea-48ea-94b6-d1be324965c8", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n", "original_text": "We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives. "}, "hash": "c7e0451ddda941539867aeca32971dd7da89393a2f17eea07df931f03f17d317", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend. ", "start_char_idx": 0, "end_char_idx": 103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba2fd48-f8ea-48ea-94b6-d1be324965c8": {"__data__": {"id_": "aba2fd48-f8ea-48ea-94b6-d1be324965c8", "embedding": null, "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n", "original_text": "We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives. ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9477ede3-70e0-4693-916d-494c7167e393", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. ", "original_text": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend. ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "101e631929de9d95654a2e939d254495394f6516b5592c86ca2b9a56f00f34b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b44d40-1ae3-4850-8023-a81b572f2256", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.  ", "original_text": "This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n"}, "hash": "9d8f3d3f7aa2cce0d92bf4cb07930787d2c0d29246fcd234d393b291b5df46c1", "class_name": "RelatedNodeInfo"}}, "text": "We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives. ", "start_char_idx": 103, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b44d40-1ae3-4850-8023-a81b572f2256": {"__data__": {"id_": "68b44d40-1ae3-4850-8023-a81b572f2256", "embedding": null, "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.  ", "original_text": "This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba2fd48-f8ea-48ea-94b6-d1be324965c8", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n", "original_text": "We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives. ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44464f378c399936d6f3a04d0869399ba16537b741f096adc92acbdbc61180c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3b8fd27-e554-47c2-9f9c-88ddd76c956e", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n", "original_text": "In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. "}, "hash": "d9a1c0b7492c535bf386d38968976ae3cfebe1f6c6a59a981dd7d4799482a8ae", "class_name": "RelatedNodeInfo"}}, "text": "This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n", "start_char_idx": 281, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3b8fd27-e554-47c2-9f9c-88ddd76c956e": {"__data__": {"id_": "f3b8fd27-e554-47c2-9f9c-88ddd76c956e", "embedding": null, "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n", "original_text": "In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b44d40-1ae3-4850-8023-a81b572f2256", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.  ", "original_text": "This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40357faef8b86c2525f0a766db5b4ac4342538d6d2cf18481eb682b0c5c60df0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f310a3c2-5594-40a6-aa35-d5cbd5e7fe27", "node_type": "1", "metadata": {"window": "We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.  ", "original_text": "The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n"}, "hash": "8e07129c7d82bace7a0f76acc377b436e2819f25eb7c36ec3254ec71069f75e1", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. ", "start_char_idx": 377, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f310a3c2-5594-40a6-aa35-d5cbd5e7fe27": {"__data__": {"id_": "f310a3c2-5594-40a6-aa35-d5cbd5e7fe27", "embedding": null, "metadata": {"window": "We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.  ", "original_text": "The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3b8fd27-e554-47c2-9f9c-88ddd76c956e", "node_type": "1", "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n", "original_text": "In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e3c61bc4b41516397250d28991280bf8e67bfc140c6f1b181de089bc483b5d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94249de4-a430-49ba-83d3-97a53a48befd", "node_type": "1", "metadata": {"window": "This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n", "original_text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.  "}, "hash": "c7efde0c2cc109ce2364c850bddbcfc82cb76dc4cb3fefa6aba009ad0c892e42", "class_name": "RelatedNodeInfo"}}, "text": "The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n", "start_char_idx": 531, "end_char_idx": 840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94249de4-a430-49ba-83d3-97a53a48befd": {"__data__": {"id_": "94249de4-a430-49ba-83d3-97a53a48befd", "embedding": null, "metadata": {"window": "This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n", "original_text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f310a3c2-5594-40a6-aa35-d5cbd5e7fe27", "node_type": "1", "metadata": {"window": "We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.  ", "original_text": "The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3265526c4da80d02017446d2cb62c318ff6fa4df623396330ec831f92242896", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2da952b-6bca-46e4-bacb-ce2400aa64cc", "node_type": "1", "metadata": {"window": "In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n", "original_text": "Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n"}, "hash": "8c95adfb962901b32b66e3e35cadc2b316bec3529c0e7b29f9a5fdbb286bd5e9", "class_name": "RelatedNodeInfo"}}, "text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.  ", "start_char_idx": 840, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2da952b-6bca-46e4-bacb-ce2400aa64cc": {"__data__": {"id_": "c2da952b-6bca-46e4-bacb-ce2400aa64cc", "embedding": null, "metadata": {"window": "In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n", "original_text": "Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94249de4-a430-49ba-83d3-97a53a48befd", "node_type": "1", "metadata": {"window": "This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n", "original_text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c4cb4831c8b2cfa6c099e1448873280c650e867ca592ef9e5fae5ef77494146", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c8ec3f2-b4cc-4abd-8f3c-915af0a6bc07", "node_type": "1", "metadata": {"window": "The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n", "original_text": "Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.  "}, "hash": "7dc0a19778541c6a14c2f7d9ad374d1818cbc0ba6af3700c33b94e2359adb480", "class_name": "RelatedNodeInfo"}}, "text": "Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n", "start_char_idx": 1058, "end_char_idx": 1156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c8ec3f2-b4cc-4abd-8f3c-915af0a6bc07": {"__data__": {"id_": "8c8ec3f2-b4cc-4abd-8f3c-915af0a6bc07", "embedding": null, "metadata": {"window": "The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n", "original_text": "Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2da952b-6bca-46e4-bacb-ce2400aa64cc", "node_type": "1", "metadata": {"window": "In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss.  The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n", "original_text": "Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d5df1d8d8e927a4582271f0ff22490430980593fed1151b9bc57ca1f0bf903a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2eacadc9-0433-4d48-b61e-7836fb5b5fce", "node_type": "1", "metadata": {"window": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n", "original_text": "We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n"}, "hash": "9e06bf4068739195588bd2477e9a80fef1f7e167d8dd6ee3e3f62c13ef7b73ee", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.  ", "start_char_idx": 1156, "end_char_idx": 1349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2eacadc9-0433-4d48-b61e-7836fb5b5fce": {"__data__": {"id_": "2eacadc9-0433-4d48-b61e-7836fb5b5fce", "embedding": null, "metadata": {"window": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n", "original_text": "We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c8ec3f2-b4cc-4abd-8f3c-915af0a6bc07", "node_type": "1", "metadata": {"window": "The results for the quarter were consistent with our Investor \nDay commentary, composed of approximately $60 million  dollars of more core performance, driven in \nconnection with the Medical Improvement Plan, and approximately $20 million dollar s of both \nseasonality and net favorable one -time items .  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n", "original_text": "Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bb54578b1afd6a2eab24e5cd85dce91d265ba6d29e4addb6bbcf43d64a380a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bcb4f92-dc41-4672-b450-0a8d0b6e186b", "node_type": "1", "metadata": {"window": "Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.  ", "original_text": "So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n"}, "hash": "e4b64fe70c03c34e783b3591df42b2d2a0731deede1ca7f7c92dce9a46535cf2", "class_name": "RelatedNodeInfo"}}, "text": "We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n", "start_char_idx": 1349, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bcb4f92-dc41-4672-b450-0a8d0b6e186b": {"__data__": {"id_": "9bcb4f92-dc41-4672-b450-0a8d0b6e186b", "embedding": null, "metadata": {"window": "Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.  ", "original_text": "So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2eacadc9-0433-4d48-b61e-7836fb5b5fce", "node_type": "1", "metadata": {"window": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives, \nand the normalization of PPE margins , which were impacted by unfavorable price -cost timing in th e \nprior year.   Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n", "original_text": "We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44b036e583a6a1515520360e40c3c8241af45209bf7314f34cba201b9f17bc7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5feb727c-ffec-45e6-97ea-7d8e14abb7f3", "node_type": "1", "metadata": {"window": "Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n", "original_text": "Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n"}, "hash": "b7320598601a3a7628aac65b660f7ed80df043578caa5eb11b833f0662dcc83c", "class_name": "RelatedNodeInfo"}}, "text": "So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n", "start_char_idx": 1522, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5feb727c-ffec-45e6-97ea-7d8e14abb7f3": {"__data__": {"id_": "5feb727c-ffec-45e6-97ea-7d8e14abb7f3", "embedding": null, "metadata": {"window": "Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n", "original_text": "Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bcb4f92-dc41-4672-b450-0a8d0b6e186b", "node_type": "1", "metadata": {"window": "Of note, we achieved our target of exiting fiscal \u201823 with at least 50% inflation mitigation.  \n \n Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.  ", "original_text": "So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71c2e0ad4dcafc3fcde9111a1cae969610ec80cd961e7e3a58e80de47dcd36b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b8e135f-72de-4f75-ac5d-dbe9897d730a", "node_type": "1", "metadata": {"window": "We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n", "original_text": "Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n"}, "hash": "a86c8831b6ea65c1eea5d41818795693204eb78356ace4b0673db222667e6c21", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n", "start_char_idx": 1661, "end_char_idx": 1979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b8e135f-72de-4f75-ac5d-dbe9897d730a": {"__data__": {"id_": "4b8e135f-72de-4f75-ac5d-dbe9897d730a", "embedding": null, "metadata": {"window": "We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n", "original_text": "Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5feb727c-ffec-45e6-97ea-7d8e14abb7f3", "node_type": "1", "metadata": {"window": "Consistent with the expectations communicated at Investor Day, we were encouraged to see early \nindicators of an improvement in trend with respect t o our Cardinal Health Brand product sales.   We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n", "original_text": "Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1feda5cf11cb78d80afb778d34105a27ca86eeb0278c8445a764332268100f32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e2da64f-e0a9-4289-b8b6-81dfc385c65c", "node_type": "1", "metadata": {"window": "So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time . ", "original_text": "Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.  "}, "hash": "fc916e5a4643f3076b61f54c981a68c9c04be4fa1863a491ab77737920d5a620", "class_name": "RelatedNodeInfo"}}, "text": "Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n", "start_char_idx": 1979, "end_char_idx": 2134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e2da64f-e0a9-4289-b8b6-81dfc385c65c": {"__data__": {"id_": "2e2da64f-e0a9-4289-b8b6-81dfc385c65c", "embedding": null, "metadata": {"window": "So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time . ", "original_text": "Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b8e135f-72de-4f75-ac5d-dbe9897d730a", "node_type": "1", "metadata": {"window": "We \nalso saw a positive overall contribution from our growth businesses, including at -Home Solutions and \nOptiFreight, and from our ongoing cost optimization measures.  \n \n So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n", "original_text": "Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70a700932e941982678b8c1f841d175e8401967af3c1411082cfcf90a00beca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "810eeaa7-ce44-4909-8f69-08f2ece43762", "node_type": "1", "metadata": {"window": "Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n", "original_text": "The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n"}, "hash": "e5cd98b053eac2861970153169cca64776bd6e4d24c2fad827fda5777610d0e0", "class_name": "RelatedNodeInfo"}}, "text": "Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.  ", "start_char_idx": 2134, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "810eeaa7-ce44-4909-8f69-08f2ece43762": {"__data__": {"id_": "810eeaa7-ce44-4909-8f69-08f2ece43762", "embedding": null, "metadata": {"window": "Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n", "original_text": "The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e2da64f-e0a9-4289-b8b6-81dfc385c65c", "node_type": "1", "metadata": {"window": "So, with significant profit growth in both seg ments, we delivered total operating earnings of $560 \nmillion  dollars , growth of 24%.  \n \n Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time . ", "original_text": "Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a7b7bf79c7bba8968c4b6e362493c76704ca2e6753643d2815836b2e95f948b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7230ccba-4d85-4302-b5be-a39460476a13", "node_type": "1", "metadata": {"window": "Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Now, transitioning to our consolidated results for the year.  \n \n"}, "hash": "739f36a8aa65c02ad1d7c80f6c75ddf9908fbf2043bb81a1ccb85e6ffedd802e", "class_name": "RelatedNodeInfo"}}, "text": "The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n", "start_char_idx": 2387, "end_char_idx": 2471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7230ccba-4d85-4302-b5be-a39460476a13": {"__data__": {"id_": "7230ccba-4d85-4302-b5be-a39460476a13", "embedding": null, "metadata": {"window": "Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Now, transitioning to our consolidated results for the year.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "810eeaa7-ce44-4909-8f69-08f2ece43762", "node_type": "1", "metadata": {"window": "Moving below the line, Interest and Other decreased by $48 million  dollars  to $16 million  dollars , due \nto increased interest income from cash and equivalents , and increas ed income from our company\u2019s \ndeferred compensation plan investments , which as a reminder is fully offset above the line in \nCorporate.  \n \n Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n", "original_text": "The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6c0e743b833f1b135f8376485604acebd6114320132f9fff2d025026bba2d9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cf34444-fd12-4416-85a1-9fde60b51212", "node_type": "1", "metadata": {"window": "Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "We surpassed the $200 billion dollar revenue mark for the first time . "}, "hash": "a0896a2e672fe55be503b9678421da822b51f6e8677ad043cb5b924c5102434b", "class_name": "RelatedNodeInfo"}}, "text": "Now, transitioning to our consolidated results for the year.  \n \n", "start_char_idx": 2471, "end_char_idx": 2536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cf34444-fd12-4416-85a1-9fde60b51212": {"__data__": {"id_": "0cf34444-fd12-4416-85a1-9fde60b51212", "embedding": null, "metadata": {"window": "Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "We surpassed the $200 billion dollar revenue mark for the first time . ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7230ccba-4d85-4302-b5be-a39460476a13", "node_type": "1", "metadata": {"window": "Our fourth -quarter effective tax rate finished at 27 %, approximately 2 percentage points higher than \nthe prior year, due to certain discrete items.  \n \n Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Now, transitioning to our consolidated results for the year.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9726b00c4aa994a4a1379e84b3b917a147a1195c9a9568ebc49005fb343a5c73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f7ff235-6133-4602-a875-7ee53164ce90", "node_type": "1", "metadata": {"window": "The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n"}, "hash": "8468690e392ea52a1b26684cda9ad8842e01de5b81c3227d0228980d0ba0280a", "class_name": "RelatedNodeInfo"}}, "text": "We surpassed the $200 billion dollar revenue mark for the first time . ", "start_char_idx": 2536, "end_char_idx": 2607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f7ff235-6133-4602-a875-7ee53164ce90": {"__data__": {"id_": "3f7ff235-6133-4602-a875-7ee53164ce90", "embedding": null, "metadata": {"window": "The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cf34444-fd12-4416-85a1-9fde60b51212", "node_type": "1", "metadata": {"window": "Fourth -quarter average diluted shares outstanding were $256 million, 7% lower than a year ago due \nto share repurchases, including a $500 million dollar accelerated share repurchase program initiated \nin the quarter, as we ann ounced at Investor Day.   The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "We surpassed the $200 billion dollar revenue mark for the first time . ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d53bed82f2f471191f6cce17852bf49e2bdb51edbdd3a3603aaca8b536660cec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b57cd05-297e-443e-b587-6f190f09810a", "node_type": "1", "metadata": {"window": "Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  "}, "hash": "d151287aa3789dce497880693357ec9d90a3b4851f1ad25456b40027fc364b72", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n", "start_char_idx": 2607, "end_char_idx": 2767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b57cd05-297e-443e-b587-6f190f09810a": {"__data__": {"id_": "1b57cd05-297e-443e-b587-6f190f09810a", "embedding": null, "metadata": {"window": "Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75c5db2422c7c822e1f58117f7ee2a9bcf361deb7c5c78ba53c701b88c4c1bae", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f7ff235-6133-4602-a875-7ee53164ce90", "node_type": "1", "metadata": {"window": "The net result of all of this was fourth -quarter EPS \nof $1.55, growth of 48%.  \n \n Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a760b38cf9bc91bfdf7f3f43e9596d8fe9a503ffc5970105e33c4eb8b39d98c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5ccb620-9390-44ba-b5be-c33e37aa1e25", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n", "original_text": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n"}, "hash": "30cecf0e791f7fe98becce1658d311279039cc821f3ea7b285b5c26aff487066", "class_name": "RelatedNodeInfo"}}, "text": "Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "start_char_idx": 2767, "end_char_idx": 3065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5ccb620-9390-44ba-b5be-c33e37aa1e25": {"__data__": {"id_": "d5ccb620-9390-44ba-b5be-c33e37aa1e25", "embedding": null, "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n", "original_text": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b57cd05-297e-443e-b587-6f190f09810a", "node_type": "1", "metadata": {"window": "Now, transitioning to our consolidated results for the year.  \n \n We surpassed the $200 billion dollar revenue mark for the first time .  Fiscal \u201823 revenue in creased \n13% to $205 billion  dollars , and gross margin increased 5% to $6.9 billion  dollars , both driven by the \nPharma segment .  \n \n Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "original_text": "Total company SG&A increased 6% to $4.8 billion  dollars , primarily reflecting inflationary supply chain \ncosts and higher invest ment and operating expenses, such as higher costs to support sales growth, \nwhich were partially offset by our comprehensive enterprise -wide cost -savings measures.  ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef612a4c147ab004403a8e09d6ac5d6fc2254e80408f8dc402b0faac0a75d17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0d4a4e8-7835-41cb-9585-c30ed44b6cb9", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n", "original_text": "Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents. "}, "hash": "d033915d6a70327a33a666631509ab48cfe00da9b39bc423f6a70d67bacf8a2a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n", "start_char_idx": 0, "end_char_idx": 80, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0d4a4e8-7835-41cb-9585-c30ed44b6cb9": {"__data__": {"id_": "d0d4a4e8-7835-41cb-9585-c30ed44b6cb9", "embedding": null, "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n", "original_text": "Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5ccb620-9390-44ba-b5be-c33e37aa1e25", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n", "original_text": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c898ca8e7aa4153746e5c5f9d289a361186418efffce0248095f4c5ded07e927", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a68372-53cf-4801-b78f-e652f16a4c5b", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n", "original_text": "As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n"}, "hash": "42127fcb1eddfa9e69ae9499cb4af1db455d979a9564310c9dbfacedf66e2be4", "class_name": "RelatedNodeInfo"}}, "text": "Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents. ", "start_char_idx": 80, "end_char_idx": 214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a68372-53cf-4801-b78f-e652f16a4c5b": {"__data__": {"id_": "17a68372-53cf-4801-b78f-e652f16a4c5b", "embedding": null, "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n", "original_text": "As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0d4a4e8-7835-41cb-9585-c30ed44b6cb9", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n", "original_text": "Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee500ee9e3ccff66248813e27b095f3b445851bd8407a28368f3960d4cdd0224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6eaeb18-9326-4db6-8f46-1743ba2e94ae", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs. ", "original_text": "Our annual effective tax rate finished at  23%.  \n \n"}, "hash": "17986eee5149fb04873b5210ea0bb56cd7e84ab13b66cb0ca98b793e8430a09a", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n", "start_char_idx": 214, "end_char_idx": 338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6eaeb18-9326-4db6-8f46-1743ba2e94ae": {"__data__": {"id_": "c6eaeb18-9326-4db6-8f46-1743ba2e94ae", "embedding": null, "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs. ", "original_text": "Our annual effective tax rate finished at  23%.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a68372-53cf-4801-b78f-e652f16a4c5b", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n", "original_text": "As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e07d1d2b8ce41f9ba1adcc8ea6beaee8060e1ee5aae58526b6716c8f90afc104", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a71b7f4d-6ec7-4f26-9199-81688b358d2b", "node_type": "1", "metadata": {"window": "Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n", "original_text": "The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n"}, "hash": "ce8786d2513ebfd7dc4bbe008ff6206da9233063f6cabaff670f8243f3696f4f", "class_name": "RelatedNodeInfo"}}, "text": "Our annual effective tax rate finished at  23%.  \n \n", "start_char_idx": 338, "end_char_idx": 390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a71b7f4d-6ec7-4f26-9199-81688b358d2b": {"__data__": {"id_": "a71b7f4d-6ec7-4f26-9199-81688b358d2b", "embedding": null, "metadata": {"window": "Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n", "original_text": "The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6eaeb18-9326-4db6-8f46-1743ba2e94ae", "node_type": "1", "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs. ", "original_text": "Our annual effective tax rate finished at  23%.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c97a28fe2d8dcdcff6016eb1b435b53e871fc11a85aa3f2d3f4509426e4c7e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93ec2ed2-7a20-47df-97a8-e5bc9ed2b813", "node_type": "1", "metadata": {"window": "As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n", "original_text": "As for the segment's full year results, beginning with Pharma on slide 10.  \n \n"}, "hash": "23d713571bfb2305157eff4de066f3a60c078558f8311891f31d569acc3401d3", "class_name": "RelatedNodeInfo"}}, "text": "The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n", "start_char_idx": 390, "end_char_idx": 456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93ec2ed2-7a20-47df-97a8-e5bc9ed2b813": {"__data__": {"id_": "93ec2ed2-7a20-47df-97a8-e5bc9ed2b813", "embedding": null, "metadata": {"window": "As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n", "original_text": "As for the segment's full year results, beginning with Pharma on slide 10.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a71b7f4d-6ec7-4f26-9199-81688b358d2b", "node_type": "1", "metadata": {"window": "Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n", "original_text": "The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f85315036f0b17a9ba7d2dfd4b86042efab0c14b69104313679d370a411ab6eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4957ebc6-7375-47aa-92e7-568d224a0105", "node_type": "1", "metadata": {"window": "Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives. ", "original_text": "Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs. "}, "hash": "a6c554bb5eb2b13157ced81badbbe2e552a7ace17f7595fbb5c496cdaae6f499", "class_name": "RelatedNodeInfo"}}, "text": "As for the segment's full year results, beginning with Pharma on slide 10.  \n \n", "start_char_idx": 456, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4957ebc6-7375-47aa-92e7-568d224a0105": {"__data__": {"id_": "4957ebc6-7375-47aa-92e7-568d224a0105", "embedding": null, "metadata": {"window": "Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives. ", "original_text": "Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93ec2ed2-7a20-47df-97a8-e5bc9ed2b813", "node_type": "1", "metadata": {"window": "As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n", "original_text": "As for the segment's full year results, beginning with Pharma on slide 10.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d021abf317888a3076657bbeb8de4aa685af07284a1e56dfbac15af4641d9f82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66296142-3ea9-4693-b2b8-3de48fc7ead8", "node_type": "1", "metadata": {"window": "The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n", "original_text": "Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n"}, "hash": "3c7cb4823f63f3ca3e3ec554546fcfcb96f19dc6d284f99c6ed6c303d624751f", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs. ", "start_char_idx": 535, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66296142-3ea9-4693-b2b8-3de48fc7ead8": {"__data__": {"id_": "66296142-3ea9-4693-b2b8-3de48fc7ead8", "embedding": null, "metadata": {"window": "The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n", "original_text": "Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4957ebc6-7375-47aa-92e7-568d224a0105", "node_type": "1", "metadata": {"window": "Our annual effective tax rate finished at  23%.  \n \n The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives. ", "original_text": "Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1791816d537f78fe97abd7f1964ccf36f04e8565cdde73c2ebd24638fb98e54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d21ed4f5-d7c7-43ca-938b-a88fe9e83a2e", "node_type": "1", "metadata": {"window": "As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n", "original_text": "Moving to Medical on slide 11.  \n \n"}, "hash": "5b4a0c23ce06d09c0351862519a48dba259b11cccda931c6044d20e7bbcd13d2", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n", "start_char_idx": 762, "end_char_idx": 1075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d21ed4f5-d7c7-43ca-938b-a88fe9e83a2e": {"__data__": {"id_": "d21ed4f5-d7c7-43ca-938b-a88fe9e83a2e", "embedding": null, "metadata": {"window": "As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n", "original_text": "Moving to Medical on slide 11.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66296142-3ea9-4693-b2b8-3de48fc7ead8", "node_type": "1", "metadata": {"window": "The net result was, for fiscal \u201823 EPS, $5.79, growth of 14%.  \n \n As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n", "original_text": "Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eb581bcc24e43d7348522e8ca8f5c319d6e483141327ae58afa83cc39a78c0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54b4afec-538a-47e0-aeb7-b10387dec56c", "node_type": "1", "metadata": {"window": "Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year. ", "original_text": "Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives. "}, "hash": "0747c06f9e11ceb3d77826bbb0a072e212e260155af9e1a5f475ffd0881d4cb7", "class_name": "RelatedNodeInfo"}}, "text": "Moving to Medical on slide 11.  \n \n", "start_char_idx": 1075, "end_char_idx": 1110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54b4afec-538a-47e0-aeb7-b10387dec56c": {"__data__": {"id_": "54b4afec-538a-47e0-aeb7-b10387dec56c", "embedding": null, "metadata": {"window": "Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year. ", "original_text": "Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d21ed4f5-d7c7-43ca-938b-a88fe9e83a2e", "node_type": "1", "metadata": {"window": "As for the segment's full year results, beginning with Pharma on slide 10.  \n \n Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n", "original_text": "Moving to Medical on slide 11.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "994db891ea756882c723f83561aaa80d987babed7765db98f7dc8ab24e7b53b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "303a45e0-c2d4-45a6-81e7-1e62bf0c02d1", "node_type": "1", "metadata": {"window": "Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n", "original_text": "This decline was partially offset by normalization of PPE margins.  \n \n"}, "hash": "bec4089b1087712fda45844563ece8b7d6e6e11dd386c383e7938ffc6333bc5e", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives. ", "start_char_idx": 1110, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "303a45e0-c2d4-45a6-81e7-1e62bf0c02d1": {"__data__": {"id_": "303a45e0-c2d4-45a6-81e7-1e62bf0c02d1", "embedding": null, "metadata": {"window": "Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n", "original_text": "This decline was partially offset by normalization of PPE margins.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54b4afec-538a-47e0-aeb7-b10387dec56c", "node_type": "1", "metadata": {"window": "Pharma segment profit increased 13% to $2.0 billion  dollars , driven by positive generics program \nperformance and a higher contribution from brand and specialty products, partially offset by \ninflationary supply chain costs.  Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year. ", "original_text": "Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea942e1c3f8ec74d0db45e3750845ef206279515aab117c2c1403cbdf93316d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbec174d-a558-424f-9dac-183ed63da9db", "node_type": "1", "metadata": {"window": "Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses. ", "original_text": "But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n"}, "hash": "1f0d5d00d7d516c03f92ed3782c7f4d2f633c99e92ee1b48824caf143fe4796b", "class_name": "RelatedNodeInfo"}}, "text": "This decline was partially offset by normalization of PPE margins.  \n \n", "start_char_idx": 1315, "end_char_idx": 1386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbec174d-a558-424f-9dac-183ed63da9db": {"__data__": {"id_": "cbec174d-a558-424f-9dac-183ed63da9db", "embedding": null, "metadata": {"window": "Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses. ", "original_text": "But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "303a45e0-c2d4-45a6-81e7-1e62bf0c02d1", "node_type": "1", "metadata": {"window": "Fiscal \u201823 year -over-year growth also included a modest benefit from \nbranded manufacturer price increases, which we are assuming w ill not repeat in fiscal \u201824, as well as \na favorable prior year comparison related to higher opioid -related legal costs and costs for technology \nenhancements in fiscal \u201822.  \n \n Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n", "original_text": "This decline was partially offset by normalization of PPE margins.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e4e958fe56c4b64036e8dd74c35bb7a36318673ecdca4fd91eafb0d58e0e9fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb917c0-0111-4b7d-b5f6-f81ce3ff94bb", "node_type": "1", "metadata": {"window": "Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n", "original_text": "In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year. "}, "hash": "9953b6eeb59a6f28dca9e74395eb1ef89be47179007bfa18fc4c3eb6c7b03b70", "class_name": "RelatedNodeInfo"}}, "text": "But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n", "start_char_idx": 1386, "end_char_idx": 1455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb917c0-0111-4b7d-b5f6-f81ce3ff94bb": {"__data__": {"id_": "1bb917c0-0111-4b7d-b5f6-f81ce3ff94bb", "embedding": null, "metadata": {"window": "Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n", "original_text": "In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbec174d-a558-424f-9dac-183ed63da9db", "node_type": "1", "metadata": {"window": "Moving to Medical on slide 11.  \n \n Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses. ", "original_text": "But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbfa741408f6f8254cd6c1b062886cd9a141f9dd625708a8b4357d23405c9781", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dac417ef-2c88-48f8-bf8b-e74c9e17450b", "node_type": "1", "metadata": {"window": "This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n", "original_text": "We ended the year with $4 billion  dollars  of cash on hand.  \n \n"}, "hash": "2605c3837dc121090d8ca9eb73dee82a2b6007fc1e68799d9aa54bd1c499f30f", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year. ", "start_char_idx": 1455, "end_char_idx": 1602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dac417ef-2c88-48f8-bf8b-e74c9e17450b": {"__data__": {"id_": "dac417ef-2c88-48f8-bf8b-e74c9e17450b", "embedding": null, "metadata": {"window": "This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n", "original_text": "We ended the year with $4 billion  dollars  of cash on hand.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb917c0-0111-4b7d-b5f6-f81ce3ff94bb", "node_type": "1", "metadata": {"window": "Segment profit decreased 49% to $111 million  dolla rs, primarily due to lower Products and \nDistribution volumes and unfavorable sales mix and net inflationary impacts, including mitigation \ninitiatives.  This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n", "original_text": "In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1ba4c337eb452fc8e375dd34b4cc7e883e0fc842cd54495cd123f86c1e2c701", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9668c0a-50c8-4e12-935b-e3da688d0571", "node_type": "1", "metadata": {"window": "But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.  ", "original_text": "At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses. "}, "hash": "d796d13cf1e263a5b56b481e5e46f7b3052f768c3646512f59274a0da30a6bc1", "class_name": "RelatedNodeInfo"}}, "text": "We ended the year with $4 billion  dollars  of cash on hand.  \n \n", "start_char_idx": 1602, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9668c0a-50c8-4e12-935b-e3da688d0571": {"__data__": {"id_": "e9668c0a-50c8-4e12-935b-e3da688d0571", "embedding": null, "metadata": {"window": "But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.  ", "original_text": "At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dac417ef-2c88-48f8-bf8b-e74c9e17450b", "node_type": "1", "metadata": {"window": "This decline was partially offset by normalization of PPE margins.  \n \n But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n", "original_text": "We ended the year with $4 billion  dollars  of cash on hand.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8168051e69d86e9a7d120af52db53622e28198f8915ca12096f07b7ad22d0e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a968db3-c1a8-473c-8552-aeb2cc0be92c", "node_type": "1", "metadata": {"window": "In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.  ", "original_text": "This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n"}, "hash": "ddacbb330e22e7a991e4999f3275c4909c683da2246cc5acd44a5735a7424da4", "class_name": "RelatedNodeInfo"}}, "text": "At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses. ", "start_char_idx": 1667, "end_char_idx": 1836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a968db3-c1a8-473c-8552-aeb2cc0be92c": {"__data__": {"id_": "2a968db3-c1a8-473c-8552-aeb2cc0be92c", "embedding": null, "metadata": {"window": "In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.  ", "original_text": "This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9668c0a-50c8-4e12-935b-e3da688d0571", "node_type": "1", "metadata": {"window": "But before I turn to fiscal \u201824, let\u2019 s cover the balance sheet.  \n \n In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.  ", "original_text": "At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses. ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "317c9e0a49c3b6ba09f7fbeaa714d845875b136c2c8026ab96d0b1235149a412", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "039a43d0-3a80-4dfd-b5a6-865c5805d052", "node_type": "1", "metadata": {"window": "We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n", "original_text": "We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n"}, "hash": "ed04751b8cee52852ef4599e769b98b25fc3c568614dcfcbb3c946bd2f07e3a1", "class_name": "RelatedNodeInfo"}}, "text": "This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n", "start_char_idx": 1836, "end_char_idx": 1979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "039a43d0-3a80-4dfd-b5a6-865c5805d052": {"__data__": {"id_": "039a43d0-3a80-4dfd-b5a6-865c5805d052", "embedding": null, "metadata": {"window": "We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n", "original_text": "We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a968db3-c1a8-473c-8552-aeb2cc0be92c", "node_type": "1", "metadata": {"window": "In fiscal \u201823, we generated robust adjusted free cash flow of $2.8 billion  dollars , with particularly \nstrong cash flow toward the end the year.  We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.  ", "original_text": "This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d767165e0c9a8da9e5517a3e429c0d987f53119a53d28deb05b403234d2941a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a608b3b-7906-4156-acfc-34febd97ab85", "node_type": "1", "metadata": {"window": "At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.  "}, "hash": "895644235b5dac14df4bc0991eee969d33019a69c6eef89b195b685a8c62adb0", "class_name": "RelatedNodeInfo"}}, "text": "We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n", "start_char_idx": 1979, "end_char_idx": 2087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a608b3b-7906-4156-acfc-34febd97ab85": {"__data__": {"id_": "9a608b3b-7906-4156-acfc-34febd97ab85", "embedding": null, "metadata": {"window": "At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.  ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "039a43d0-3a80-4dfd-b5a6-865c5805d052", "node_type": "1", "metadata": {"window": "We ended the year with $4 billion  dollars  of cash on hand.  \n \n At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n", "original_text": "We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0292961fa646ecc480a1a6645b21d2a14fbdfd7c9242b15c845b44f8e28b560", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e95e9fff-78be-4b45-b2c5-74b2fc03c77d", "node_type": "1", "metadata": {"window": "This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.  "}, "hash": "45115706df643141de53995055f507fdba4c5c4f37b95780f40505cdb0035dee", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.  ", "start_char_idx": 2087, "end_char_idx": 2208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e95e9fff-78be-4b45-b2c5-74b2fc03c77d": {"__data__": {"id_": "e95e9fff-78be-4b45-b2c5-74b2fc03c77d", "embedding": null, "metadata": {"window": "This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.  ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a608b3b-7906-4156-acfc-34febd97ab85", "node_type": "1", "metadata": {"window": "At our Investor Day we h ighlighted that cash flow optimization was an area of go -forward focus for our \nteams, and the Cardinal Team delivered, across our businesses.  This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.  ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6741f57d2ad094732db3629b199bd63cefda4106ee1917a69abd6f98d0611e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ae75bd2-2843-4625-8bca-608f5cba6a80", "node_type": "1", "metadata": {"window": "We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n"}, "hash": "681d9355b3d8099e5aa614466a15a62d94f26444b36da104dcc124d4ef47b487", "class_name": "RelatedNodeInfo"}}, "text": "Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.  ", "start_char_idx": 2208, "end_char_idx": 2321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ae75bd2-2843-4625-8bca-608f5cba6a80": {"__data__": {"id_": "2ae75bd2-2843-4625-8bca-608f5cba6a80", "embedding": null, "metadata": {"window": "We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e95e9fff-78be-4b45-b2c5-74b2fc03c77d", "node_type": "1", "metadata": {"window": "This effort will continue in fiscal \u2018 24, \nnotwithstanding that it is a tougher calendar from an inflow/outflow days  of week perspective.  \n \n We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.  ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "249d2c521304126ce1f7c37b10a768a4050a49153b9ea2872b384fad31c0dfca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "413e2623-6363-44dc-a16f-f5e09d1d5c6a", "node_type": "1", "metadata": {"window": "In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 13.  \n "}, "hash": "14eb3902057c2ba4e54500dcc46e73336e21c23dcb8a3e39d8c53e7001c097cf", "class_name": "RelatedNodeInfo"}}, "text": "Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n", "start_char_idx": 2321, "end_char_idx": 2518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "413e2623-6363-44dc-a16f-f5e09d1d5c6a": {"__data__": {"id_": "413e2623-6363-44dc-a16f-f5e09d1d5c6a", "embedding": null, "metadata": {"window": "In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1379ec5a675b2a49c5fc147f51f1b2a5f8042334a9c40b6d8e0dd176d1487cef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ae75bd2-2843-4625-8bca-608f5cba6a80", "node_type": "1", "metadata": {"window": "We remained focused on deploying capital in a balanced, disciplined, and shareholder -friendly \nmanner.  \n \n In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "077f3311ee7d2dc787784bb60bfaabe96f4336aa4fa4d59d3c083a38ae5544a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfa107dc-1a42-4e88-a3cd-033b20cd0adc", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. ", "original_text": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75. "}, "hash": "22b1419703eef03b55f541aadefc7e691a8a1a4d6bb24b7b831275156dacfbc7", "class_name": "RelatedNodeInfo"}}, "text": "Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "start_char_idx": 2518, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfa107dc-1a42-4e88-a3cd-033b20cd0adc": {"__data__": {"id_": "dfa107dc-1a42-4e88-a3cd-033b20cd0adc", "embedding": null, "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. ", "original_text": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "413e2623-6363-44dc-a16f-f5e09d1d5c6a", "node_type": "1", "metadata": {"window": "In fiscal \u201823, we  invested approximately $480 million dollars of capex back into the business to drive \nfuture growth.   Paid down $5 50 million  dollars  in debt to reduce leverage and maintain our strong \ninvestment grade ratings.   Returned over $2.5 billion dollars to shareholders, including through the \ndividend that our board increased in May, for the 34th year in a row, and $2 billion  dollars  of share \nrepurchases.  \n \n Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 13.  \n ", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b37d2aec9ccb7a5f6a00b6a6339c038be031006194453a0f681799b2cdf05e56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc4e15b-64bb-43df-9f07-e421bb90e1a2", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n", "original_text": "This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point. "}, "hash": "59009742d1b9c418846d5a803ff75953e52a5d8a84ccd2ae813ab2e5accd5fbf", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75. ", "start_char_idx": 0, "end_char_idx": 99, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bc4e15b-64bb-43df-9f07-e421bb90e1a2": {"__data__": {"id_": "2bc4e15b-64bb-43df-9f07-e421bb90e1a2", "embedding": null, "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n", "original_text": "This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfa107dc-1a42-4e88-a3cd-033b20cd0adc", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. ", "original_text": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da54deeaf20f709a0586b571f7350872c92fb73708f7054a0e8b2ed77053dab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43757f29-9c46-4c9e-8d1e-99cef10bf522", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n", "original_text": "We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n"}, "hash": "950b4a05e84133cb815e998e984cfee33a017bfcfaf7772c08a3b37cedec300f", "class_name": "RelatedNodeInfo"}}, "text": "This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point. ", "start_char_idx": 99, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43757f29-9c46-4c9e-8d1e-99cef10bf522": {"__data__": {"id_": "43757f29-9c46-4c9e-8d1e-99cef10bf522", "embedding": null, "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n", "original_text": "We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc4e15b-64bb-43df-9f07-e421bb90e1a2", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n", "original_text": "This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64fea267a456aca318ec16f2e1cfb34a30bb050ca4fa79187874c562795737e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac71937-96e4-4830-9780-741dc0e61a27", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business . ", "original_text": "As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. "}, "hash": "d28998aafdb8ec9d070ae957082b6b51067edd7cd61c500e26b28fd5b0bfd7a8", "class_name": "RelatedNodeInfo"}}, "text": "We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n", "start_char_idx": 250, "end_char_idx": 495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac71937-96e4-4830-9780-741dc0e61a27": {"__data__": {"id_": "6ac71937-96e4-4830-9780-741dc0e61a27", "embedding": null, "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business . ", "original_text": "As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43757f29-9c46-4c9e-8d1e-99cef10bf522", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n", "original_text": "We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c960ead9b8213c27c7941574c9216b86ca74ef0128bb86095c98b40b00fc6941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea31b501-eba6-412c-941a-0ae6a7db57c9", "node_type": "1", "metadata": {"window": "This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n", "original_text": "There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n"}, "hash": "b07675aa27458080dbd8df62c8aee20e208908b35616484026ec43a68d8885c9", "class_name": "RelatedNodeInfo"}}, "text": "As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. ", "start_char_idx": 495, "end_char_idx": 620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea31b501-eba6-412c-941a-0ae6a7db57c9": {"__data__": {"id_": "ea31b501-eba6-412c-941a-0ae6a7db57c9", "embedding": null, "metadata": {"window": "This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n", "original_text": "There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac71937-96e4-4830-9780-741dc0e61a27", "node_type": "1", "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business . ", "original_text": "As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1430bb2a4fccd1049a77d5c4059931c5d073f9f38654b10396e1e05bacf17546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5503f90-2bd1-499d-8d0c-0cb490ad3993", "node_type": "1", "metadata": {"window": "We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day. ", "original_text": "Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n"}, "hash": "a864eed6cf4cd6bd126596b9632b598a01fffa55fda9bab4047386cda4bc0176", "class_name": "RelatedNodeInfo"}}, "text": "There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n", "start_char_idx": 620, "end_char_idx": 908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5503f90-2bd1-499d-8d0c-0cb490ad3993": {"__data__": {"id_": "d5503f90-2bd1-499d-8d0c-0cb490ad3993", "embedding": null, "metadata": {"window": "We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day. ", "original_text": "Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea31b501-eba6-412c-941a-0ae6a7db57c9", "node_type": "1", "metadata": {"window": "This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n", "original_text": "There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "059b304f63ea5abf96577799d49692703e5789980276a59317efae27e05edd17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36cabcb7-e0a7-4711-baba-3be6fceaffee", "node_type": "1", "metadata": {"window": "As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts. ", "original_text": "Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business . "}, "hash": "99c8baf394f6e1a9efed883aff0e65f3ba6a06ecdc5a5ac9bb2323f4eeeb13ca", "class_name": "RelatedNodeInfo"}}, "text": "Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n", "start_char_idx": 908, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36cabcb7-e0a7-4711-baba-3be6fceaffee": {"__data__": {"id_": "36cabcb7-e0a7-4711-baba-3be6fceaffee", "embedding": null, "metadata": {"window": "As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts. ", "original_text": "Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5503f90-2bd1-499d-8d0c-0cb490ad3993", "node_type": "1", "metadata": {"window": "We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day. ", "original_text": "Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5067331db05172bac6726fbcf11ba5403a0d9ce1290fa5e9ab11447d061273ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30fab555-74f4-42f5-bd78-28d5595fd877", "node_type": "1", "metadata": {"window": "There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n", "original_text": "We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n"}, "hash": "b61fda00ac15f6a8e1b0c13f19e1a62e91fef6a1681a9babcfa4a2f090509349", "class_name": "RelatedNodeInfo"}}, "text": "Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business . ", "start_char_idx": 1162, "end_char_idx": 1244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30fab555-74f4-42f5-bd78-28d5595fd877": {"__data__": {"id_": "30fab555-74f4-42f5-bd78-28d5595fd877", "embedding": null, "metadata": {"window": "There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n", "original_text": "We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36cabcb7-e0a7-4711-baba-3be6fceaffee", "node_type": "1", "metadata": {"window": "As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results.  There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts. ", "original_text": "Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c87259d79c4ad964eea9e012d4bd8e221769545a63dd72c14d13a50d783233f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa648c58-6d82-48a2-8129-61b57d4bcdd7", "node_type": "1", "metadata": {"window": "Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns. ", "original_text": "We are reiterating our key assumptions provide d at Investor Day. "}, "hash": "e7c27fb23d38133b732d1611554854942179b913be31026c91c853574aedd8fd", "class_name": "RelatedNodeInfo"}}, "text": "We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n", "start_char_idx": 1244, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa648c58-6d82-48a2-8129-61b57d4bcdd7": {"__data__": {"id_": "fa648c58-6d82-48a2-8129-61b57d4bcdd7", "embedding": null, "metadata": {"window": "Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns. ", "original_text": "We are reiterating our key assumptions provide d at Investor Day. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30fab555-74f4-42f5-bd78-28d5595fd877", "node_type": "1", "metadata": {"window": "There are no changes to the other corporate guidance assumptions provided \nat Investor Day: Intere st and Other between $110 to $130 million  dollars , an effective tax rate in the \nrange of 2 3 to 25% and adjusted free cash flow of approximately $2 billion  dollars  in fiscal \u201824 .  \n \n Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n", "original_text": "We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0b86254374a34b1b758042903e754c2ee7fb031f2c7cfc3e177293bb538f757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24bdd1c5-fa2d-477f-acb3-7865b9fe1403", "node_type": "1", "metadata": {"window": "Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n", "original_text": "We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts. "}, "hash": "6def5a2515db7e24ff3d6b368e735da15a9e1619508d1b63d6d038649e7623e1", "class_name": "RelatedNodeInfo"}}, "text": "We are reiterating our key assumptions provide d at Investor Day. ", "start_char_idx": 1450, "end_char_idx": 1516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24bdd1c5-fa2d-477f-acb3-7865b9fe1403": {"__data__": {"id_": "24bdd1c5-fa2d-477f-acb3-7865b9fe1403", "embedding": null, "metadata": {"window": "Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n", "original_text": "We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa648c58-6d82-48a2-8129-61b57d4bcdd7", "node_type": "1", "metadata": {"window": "Our segment outlooks for fiscal \u201824 are also unchanged, with one exception: a higher revenue range \nfor Pharma, driven by the continued accelerations of GLP -1\u2019s, which as a branded product category \ndo not meaningfully contribute to segment profit.  \n \n Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns. ", "original_text": "We are reiterating our key assumptions provide d at Investor Day. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "827982604af185599368d49eba3400435919d63728f02a9d1d6bfa1bc939e336", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85e23d64-bfa4-46fe-823d-80d3dbe4985b", "node_type": "1", "metadata": {"window": "We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost. ", "original_text": "We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n"}, "hash": "a1339b40ce1d77b5b8d3ce85b3dc76551202997ff0c6e6f1cc1e8b90eebe4e1f", "class_name": "RelatedNodeInfo"}}, "text": "We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts. ", "start_char_idx": 1516, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85e23d64-bfa4-46fe-823d-80d3dbe4985b": {"__data__": {"id_": "85e23d64-bfa4-46fe-823d-80d3dbe4985b", "embedding": null, "metadata": {"window": "We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost. ", "original_text": "We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24bdd1c5-fa2d-477f-acb3-7865b9fe1403", "node_type": "1", "metadata": {"window": "Slide 14 shows our fiscal \u201824 outlook for Pharma, our build -and-grow  business .  We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n", "original_text": "We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90fec14292c64b6179d2668bc2d10a5b3025db0e180b9ff0f36fe304f1810f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5084410c-c200-4d36-833f-3012139888c7", "node_type": "1", "metadata": {"window": "We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n", "original_text": "On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns. "}, "hash": "5b97fb90a97693a04adcb4c0d81c54e43c9404399f4c43fdd9c4aa9e9de5309a", "class_name": "RelatedNodeInfo"}}, "text": "We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n", "start_char_idx": 1687, "end_char_idx": 1822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5084410c-c200-4d36-833f-3012139888c7": {"__data__": {"id_": "5084410c-c200-4d36-833f-3012139888c7", "embedding": null, "metadata": {"window": "We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n", "original_text": "On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85e23d64-bfa4-46fe-823d-80d3dbe4985b", "node_type": "1", "metadata": {"window": "We expect revenue \ngrowth in the range of 10 to 12% and segment profit growth in the range of 4  to 6%, which is now on \na larger fiscal year \u201823 reference point due to our strong finish to the year .   \n \n We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost. ", "original_text": "We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64de0c40141e6dc44fd7cd7abb744526b94838632ab0f965c2c1ef88e9a7d785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63e5ded4-9739-4ff4-8f07-d897a17dc707", "node_type": "1", "metadata": {"window": "We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted. ", "original_text": "As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n"}, "hash": "c77e562dbf930e4e28278500cf11c03d1bf584af63731e0b89d744c1ffb36aff", "class_name": "RelatedNodeInfo"}}, "text": "On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns. ", "start_char_idx": 1822, "end_char_idx": 1916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63e5ded4-9739-4ff4-8f07-d897a17dc707": {"__data__": {"id_": "63e5ded4-9739-4ff4-8f07-d897a17dc707", "embedding": null, "metadata": {"window": "We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted. ", "original_text": "As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5084410c-c200-4d36-833f-3012139888c7", "node_type": "1", "metadata": {"window": "We are reiterating our key assumptions provide d at Investor Day.  We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n", "original_text": "On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de858490e47bed357e678ed8ef04fcafde054507433673b97209d3bf7679054d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76920d0f-a3e4-48b5-9c5b-b9e44c6792ad", "node_type": "1", "metadata": {"window": "We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n", "original_text": "Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost. "}, "hash": "c8325268592af3e2c3a3fd274af617dd6345485a031e4780d2a514ab226ec662", "class_name": "RelatedNodeInfo"}}, "text": "As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n", "start_char_idx": 1916, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76920d0f-a3e4-48b5-9c5b-b9e44c6792ad": {"__data__": {"id_": "76920d0f-a3e4-48b5-9c5b-b9e44c6792ad", "embedding": null, "metadata": {"window": "We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n", "original_text": "Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63e5ded4-9739-4ff4-8f07-d897a17dc707", "node_type": "1", "metadata": {"window": "We expect growth from our \ngenerics program, with volume growth and consistent market dynamics, and positive operational \nexecution against our organic Specialty efforts.  We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted. ", "original_text": "As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e542a4cdebc14aac6fb983229e18799a1289464e461d648ce8025c47c65a992", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "582b388b-9156-4ef5-bc1c-854d0192abfa", "node_type": "1", "metadata": {"window": "On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year . ", "original_text": "For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n"}, "hash": "d069ab54798f5f43ddd2c0ed14f3a8cda783e4e11ecab5fa59063599bf65ac25", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost. ", "start_char_idx": 2067, "end_char_idx": 2322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "582b388b-9156-4ef5-bc1c-854d0192abfa": {"__data__": {"id_": "582b388b-9156-4ef5-bc1c-854d0192abfa", "embedding": null, "metadata": {"window": "On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year . ", "original_text": "For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76920d0f-a3e4-48b5-9c5b-b9e44c6792ad", "node_type": "1", "metadata": {"window": "We are not assuming outsized benefits from branded \ninflation, in con trast to some of the benefits that we did see in fiscal \u201823.  \n \n On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n", "original_text": "Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45b9f35dcfbc61d6c5758002147bd5579b2ec65cedc8d413d5879f95945fe034", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "009dd424-b337-44fd-a353-cf0460f16909", "node_type": "1", "metadata": {"window": "As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition . ", "original_text": "Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted. "}, "hash": "5be8be516c373b1206b1084727863a8be570849f503d65acd88887f876099925", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n", "start_char_idx": 2322, "end_char_idx": 2532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "009dd424-b337-44fd-a353-cf0460f16909": {"__data__": {"id_": "009dd424-b337-44fd-a353-cf0460f16909", "embedding": null, "metadata": {"window": "As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition . ", "original_text": "Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "582b388b-9156-4ef5-bc1c-854d0192abfa", "node_type": "1", "metadata": {"window": "On the Pharma fiscal \u201824 cadence , we expect the year to follow typical seasonality patterns.  As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year . ", "original_text": "For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b033aa409b48605cd67734d10da5168e694f008ac7cbad89189a0de45f840d65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ecdcae3-1d99-47eb-89d1-925cf0ba6ced", "node_type": "1", "metadata": {"window": "Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year . ", "original_text": "We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n"}, "hash": "876cc500033aa456c6c0808be1b2b3efd918c000940b6625afde5790583e4ad6", "class_name": "RelatedNodeInfo"}}, "text": "Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted. ", "start_char_idx": 2532, "end_char_idx": 2620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ecdcae3-1d99-47eb-89d1-925cf0ba6ced": {"__data__": {"id_": "8ecdcae3-1d99-47eb-89d1-925cf0ba6ced", "embedding": null, "metadata": {"window": "Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year . ", "original_text": "We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "009dd424-b337-44fd-a353-cf0460f16909", "node_type": "1", "metadata": {"window": "As usual, \nwe see our fiscal Q3 being the largest segment profit dollar quarter due to the usual timin g of branded \nmanufacturer price increases.  \n \n Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition . ", "original_text": "Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e66037db2097a11429bbb11ac47ebe823b0d1dadb2c1367071eaf519564e1411", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab5a66fe-efa7-46d2-8972-869105e580d2", "node_type": "1", "metadata": {"window": "For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "There are a couple of factors for why Q1 is the low point in the year . "}, "hash": "13a6d0bd8e682e61393bebaeb0aff610e3aae494cbe01b893715617d04d5fe37", "class_name": "RelatedNodeInfo"}}, "text": "We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n", "start_char_idx": 2620, "end_char_idx": 2802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab5a66fe-efa7-46d2-8972-869105e580d2": {"__data__": {"id_": "ab5a66fe-efa7-46d2-8972-869105e580d2", "embedding": null, "metadata": {"window": "For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "There are a couple of factors for why Q1 is the low point in the year . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ecdcae3-1d99-47eb-89d1-925cf0ba6ced", "node_type": "1", "metadata": {"window": "Turning to Medical, I want to recognize the progress that the Medical team made during fiscal \u2018 23, \nparticularly in Q4 and also acknowledge that we still have blocking and tackling to do against the \nturnaround to both drive demand and improve our cost.  For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year . ", "original_text": "We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c44dd08af5aae0667fdd340cffd32a14a37b4f41ed8eee63f75c659a621c73b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae901550-525d-434b-bb1c-eeae49d28bfc", "node_type": "1", "metadata": {"window": "Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition . "}, "hash": "af43c5475c2d542464c8359070723842280771657c7ca82478add4968d3e585b", "class_name": "RelatedNodeInfo"}}, "text": "There are a couple of factors for why Q1 is the low point in the year . ", "start_char_idx": 2802, "end_char_idx": 2874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae901550-525d-434b-bb1c-eeae49d28bfc": {"__data__": {"id_": "ae901550-525d-434b-bb1c-eeae49d28bfc", "embedding": null, "metadata": {"window": "Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab5a66fe-efa7-46d2-8972-869105e580d2", "node_type": "1", "metadata": {"window": "For the full year, we are reiterating our \nassumptions of revenue growth of approximately 3% and segment profit of approximately $400  \nmillion dollars  for the year, while providing some additional color.  \n \n Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "There are a couple of factors for why Q1 is the low point in the year . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3906f264de2c08e11381a808ea38df907b5b3b863807d2ba6961d2e12dae4f52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d8ed1b2-e5cc-43af-8085-e5b97dd00590", "node_type": "1", "metadata": {"window": "We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year . "}, "hash": "7d67d063119943fae60c9346e8fb4f26c34ab05237b3ccdc085948b0fe04fd95", "class_name": "RelatedNodeInfo"}}, "text": "First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition . ", "start_char_idx": 2874, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d8ed1b2-e5cc-43af-8085-e5b97dd00590": {"__data__": {"id_": "7d8ed1b2-e5cc-43af-8085-e5b97dd00590", "embedding": null, "metadata": {"window": "We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae901550-525d-434b-bb1c-eeae49d28bfc", "node_type": "1", "metadata": {"window": "Like fiscal \u2018 23, we anticipate segment profit to be significantly back -half weighted.  We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89f14eb760d6416e6763282aafa34383b4b36d76ac385fec39117f79ce7a854a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "903b2121-9f48-45ed-91d0-44cdb113b1f3", "node_type": "1", "metadata": {"window": "There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n "}, "hash": "f2f7c26d305f1f2c846b1de75a2d5b5fba414bcb3c6096df7459d729a131410b", "class_name": "RelatedNodeInfo"}}, "text": "Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year . ", "start_char_idx": 3036, "end_char_idx": 3242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "903b2121-9f48-45ed-91d0-44cdb113b1f3": {"__data__": {"id_": "903b2121-9f48-45ed-91d0-44cdb113b1f3", "embedding": null, "metadata": {"window": "There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3101b821-a68d-4b32-9de5-866a93fd0c59", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353dcd2f367fa95d3fe177fcc17e7d049942adbacdb4f77af2aa0e63b63532dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d8ed1b2-e5cc-43af-8085-e5b97dd00590", "node_type": "1", "metadata": {"window": "We expect Q1 to be \ngenerally consistent with the core performance from Q4, with quarterly sequential improvement \nthereafter driven by our Medical Improvement Plan initiatives.  \n \n There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year . ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5099f61cd489755ab4813a70dd1391f7be6a921e99d496e6b578dfcb86e0d15b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d169ac13-3016-43b5-bb8c-30e27fd50300", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. ", "original_text": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n"}, "hash": "960648a702d28fa2f0d71024f5f33af84f835765b2ddf1fc4beceb5f94b6f212", "class_name": "RelatedNodeInfo"}}, "text": "And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "start_char_idx": 3242, "end_char_idx": 3389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d169ac13-3016-43b5-bb8c-30e27fd50300": {"__data__": {"id_": "d169ac13-3016-43b5-bb8c-30e27fd50300", "embedding": null, "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. ", "original_text": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "903b2121-9f48-45ed-91d0-44cdb113b1f3", "node_type": "1", "metadata": {"window": "There are a couple of factors for why Q1 is the low point in the year .  First, keep in mind that Q1 is the \nseasonal low point for our global Medical products and distribution business, due to timing of volume \nand cost recognition .  Second, while we continue to exp ect to exit fiscal \u201824 offsetting the impact of \ngross inflation, those improvements are expected to grow over time making the impact greater over \nthe course of the year .  And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "original_text": "And finally, we continue to plan for slight Cardinal Health Brand volume \ngrowth, that will largely hit in the second half of the fiscal year .  \n ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9406a3bb67ffc31a0bef070d939a74818bc64f758bd0f8c262e1253beb47d28a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eae0238-20e6-4b39-b7f5-acb4be36b288", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n", "original_text": "Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n"}, "hash": "6f34d5dab1d85b03d085fcc0fe3eb32b1f0272cd7242f59264eb5a3be8030d82", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n", "start_char_idx": 0, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eae0238-20e6-4b39-b7f5-acb4be36b288": {"__data__": {"id_": "0eae0238-20e6-4b39-b7f5-acb4be36b288", "embedding": null, "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n", "original_text": "Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d169ac13-3016-43b5-bb8c-30e27fd50300", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. ", "original_text": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc51e5a40914e24c6c81ea026879bd8936f667bceb1ce70e806eb156d90b8f24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e3788b9-cc70-4e3a-b06b-edccf696b23a", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year. ", "original_text": "Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n"}, "hash": "56788900ecbe8b60925b133f0a93b830399fd4ba000d64751d5209527ba21d68", "class_name": "RelatedNodeInfo"}}, "text": "Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n", "start_char_idx": 236, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e3788b9-cc70-4e3a-b06b-edccf696b23a": {"__data__": {"id_": "8e3788b9-cc70-4e3a-b06b-edccf696b23a", "embedding": null, "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year. ", "original_text": "Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eae0238-20e6-4b39-b7f5-acb4be36b288", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n", "original_text": "Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac1f8254fe5ab239acb7a96a332919fdb04bd3b9a2c05f15916bf23ef46d5403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca1d4ad1-b8c0-4904-88c3-4d3c3164a536", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n", "original_text": "Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. "}, "hash": "d4da71fbdf27376fe04609f0f951a0cad87f6985db87c8f1fb89737d37b2f963", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n", "start_char_idx": 330, "end_char_idx": 504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca1d4ad1-b8c0-4904-88c3-4d3c3164a536": {"__data__": {"id_": "ca1d4ad1-b8c0-4904-88c3-4d3c3164a536", "embedding": null, "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n", "original_text": "Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e3788b9-cc70-4e3a-b06b-edccf696b23a", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year. ", "original_text": "Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6f7b52798737899e9a004e34d6759c5033c8b4bb7348015d0866c6ced624a76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c61208e-040c-4cb7-968c-7c895e50debd", "node_type": "1", "metadata": {"window": "Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823. ", "original_text": "After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n"}, "hash": "c87927abe6be78edbcd24b78f1589a6919d8c6be0ff645098c3d15eac8dd7186", "class_name": "RelatedNodeInfo"}}, "text": "Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. ", "start_char_idx": 504, "end_char_idx": 645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c61208e-040c-4cb7-968c-7c895e50debd": {"__data__": {"id_": "3c61208e-040c-4cb7-968c-7c895e50debd", "embedding": null, "metadata": {"window": "Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823. ", "original_text": "After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca1d4ad1-b8c0-4904-88c3-4d3c3164a536", "node_type": "1", "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n", "original_text": "Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aeaa92f05019ee04571b7474076e5755eec4731a8fc979e1c23d4b4f82c90e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9507469-333e-4c6e-b45b-edf3ab438e36", "node_type": "1", "metadata": {"window": "Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health. ", "original_text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year. "}, "hash": "ce9adfd8aa7854ecbcbd26234cbefaaec7960e8727cb990062bbdcadd6cd1dc9", "class_name": "RelatedNodeInfo"}}, "text": "After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n", "start_char_idx": 645, "end_char_idx": 1114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9507469-333e-4c6e-b45b-edf3ab438e36": {"__data__": {"id_": "e9507469-333e-4c6e-b45b-edf3ab438e36", "embedding": null, "metadata": {"window": "Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health. ", "original_text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c61208e-040c-4cb7-968c-7c895e50debd", "node_type": "1", "metadata": {"window": "Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823. ", "original_text": "After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62db4e9f429af71fdf4c6e95cc674f52de0a87e233566ab99e7fff3a0ff8617a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43f2e71c-8d4d-45a8-8d50-656c7389a198", "node_type": "1", "metadata": {"window": "Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n", "original_text": "We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n"}, "hash": "163ad99585d14ed17f2f551ad6a24282bc5d5a1723feba768784f0ef9de27366", "class_name": "RelatedNodeInfo"}}, "text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year. ", "start_char_idx": 1114, "end_char_idx": 1456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43f2e71c-8d4d-45a8-8d50-656c7389a198": {"__data__": {"id_": "43f2e71c-8d4d-45a8-8d50-656c7389a198", "embedding": null, "metadata": {"window": "Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n", "original_text": "We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9507469-333e-4c6e-b45b-edf3ab438e36", "node_type": "1", "metadata": {"window": "Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health. ", "original_text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aac951d6f0cade7410a1d4133ffaf4f97a51974a77239da56800f46e5affc2fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e47404-edb1-45d2-912a-f71c80b29416", "node_type": "1", "metadata": {"window": "After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  ", "original_text": "To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823. "}, "hash": "8e465eb3689ac5815ffeebbfbf7ff9c60f969cd862700c30d2c9448fd331568e", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n", "start_char_idx": 1456, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e47404-edb1-45d2-912a-f71c80b29416": {"__data__": {"id_": "24e47404-edb1-45d2-912a-f71c80b29416", "embedding": null, "metadata": {"window": "After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  ", "original_text": "To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43f2e71c-8d4d-45a8-8d50-656c7389a198", "node_type": "1", "metadata": {"window": "Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18.  After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n", "original_text": "We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1261be5f39e98128cec29018469edd5d7991030e4896eec7e9a3c8c839883e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c68c68b5-e242-4a46-b245-701abd2daa21", "node_type": "1", "metadata": {"window": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n", "original_text": "Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health. "}, "hash": "4d222cf5eed1a9a2e3103f0e45617f51f7b486042f514a528cc654a982bca1e4", "class_name": "RelatedNodeInfo"}}, "text": "To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823. ", "start_char_idx": 1556, "end_char_idx": 1663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c68c68b5-e242-4a46-b245-701abd2daa21": {"__data__": {"id_": "c68c68b5-e242-4a46-b245-701abd2daa21", "embedding": null, "metadata": {"window": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n", "original_text": "Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e47404-edb1-45d2-912a-f71c80b29416", "node_type": "1", "metadata": {"window": "After investing approximately $500 million  dollars  back into \nthe business to drive organic growth, m aking approximately $500 million dollars of litigation \npayments, including our 3rd payment under the national opioid settlement back in July, and our $1  \nbillion dollar  baseline return of capital, we expect to have strong flexibility as we assess further \ninvestments in the business, M&A and the possibility of incremental return of capital to shareholders .  \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  ", "original_text": "To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64a36bbfce4030d7904dc3eab9b5e6432b9fffcac8c03fef34ef52667d4b4c0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20f8ceb3-671b-489a-807e-195fe926871f", "node_type": "1", "metadata": {"window": "We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients. ", "original_text": "With that, I will turn it back over to Jason.  \n \n"}, "hash": "2b960c005e80b297f527322a760fe17cbacb742306c21ec19e7b895e57e177b7", "class_name": "RelatedNodeInfo"}}, "text": "Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health. ", "start_char_idx": 1663, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20f8ceb3-671b-489a-807e-195fe926871f": {"__data__": {"id_": "20f8ceb3-671b-489a-807e-195fe926871f", "embedding": null, "metadata": {"window": "We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients. ", "original_text": "With that, I will turn it back over to Jason.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c68c68b5-e242-4a46-b245-701abd2daa21", "node_type": "1", "metadata": {"window": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance or our long -term \ntargets reflect potential opportunistic deployment  of capital, including M&A, which is difficult to predict \nin timing or magnitude, or additional share repurchases beyond our $500  million dollars  of baseline \nrepurchases each year.  We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n", "original_text": "Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "460a47411658f0c1b48800a8911f0b65284ea21ccf9345848ae95d99c2457cf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6161f968-d565-40b4-b694-64989d6e554f", "node_type": "1", "metadata": {"window": "To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.  ", "original_text": "Jason Hollar:  Thanks, Aaron.  "}, "hash": "789f2eaf26166e4fa513d29968caa063e42d23382983c4b83408503d2e091395", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will turn it back over to Jason.  \n \n", "start_char_idx": 1901, "end_char_idx": 1951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6161f968-d565-40b4-b694-64989d6e554f": {"__data__": {"id_": "6161f968-d565-40b4-b694-64989d6e554f", "embedding": null, "metadata": {"window": "To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.  ", "original_text": "Jason Hollar:  Thanks, Aaron.  ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20f8ceb3-671b-489a-807e-195fe926871f", "node_type": "1", "metadata": {"window": "We will continue to evaluate both of these levers opportunistically to driv e \nlong-term value.  \n \n To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients. ", "original_text": "With that, I will turn it back over to Jason.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d25cc8603e0389323f5c5508efbe8942d60878b27f494321f88e2befac8a805", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa802423-d3f7-4bcb-8046-cccbe5958639", "node_type": "1", "metadata": {"window": "Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824. ", "original_text": "Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n"}, "hash": "91bca0278e72cce197fe9609c335e03a37c9f7927183b6495549a8a0a8c76003", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Aaron.  ", "start_char_idx": 1951, "end_char_idx": 1982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa802423-d3f7-4bcb-8046-cccbe5958639": {"__data__": {"id_": "aa802423-d3f7-4bcb-8046-cccbe5958639", "embedding": null, "metadata": {"window": "Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824. ", "original_text": "Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6161f968-d565-40b4-b694-64989d6e554f", "node_type": "1", "metadata": {"window": "To close, the Cardinal Team has a lot of be proud of with respect to their accomplishments in fiscal \n\u201823.  Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.  ", "original_text": "Jason Hollar:  Thanks, Aaron.  ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "238591906f741b0ceec4ab6b187faf46c25d11d3d9c19e31399d0bd977c5036c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ef56dbf-8817-48f2-84c9-dda7278bf258", "node_type": "1", "metadata": {"window": "With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n", "original_text": "In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients. "}, "hash": "ba4b12bb34e18e936240c2a10e8986e859657b91a348822f6c28c8c9ba8dcb14", "class_name": "RelatedNodeInfo"}}, "text": "Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n", "start_char_idx": 1982, "end_char_idx": 2173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ef56dbf-8817-48f2-84c9-dda7278bf258": {"__data__": {"id_": "9ef56dbf-8817-48f2-84c9-dda7278bf258", "embedding": null, "metadata": {"window": "With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n", "original_text": "In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa802423-d3f7-4bcb-8046-cccbe5958639", "node_type": "1", "metadata": {"window": "Jason and I are pleased with the progress our teams have made, we are confident in the plans \nwe have in place,  and we are excited f or our team to realize the significant value creation \nopportunities still in front of Cardinal Health.  With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824. ", "original_text": "Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c92639d501cb2e1e750af17a9105bece475566e5182ce6915af6b76bb2303a60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f983785-1bba-493d-8759-15e9aa145c31", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing. ", "original_text": "The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.  "}, "hash": "8314cc66222383c663e50a0f75fa5673709fb1f1af2b8dd91b2f2a8d56ba4c18", "class_name": "RelatedNodeInfo"}}, "text": "In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients. ", "start_char_idx": 2173, "end_char_idx": 2370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f983785-1bba-493d-8759-15e9aa145c31": {"__data__": {"id_": "6f983785-1bba-493d-8759-15e9aa145c31", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing. ", "original_text": "The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.  ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ef56dbf-8817-48f2-84c9-dda7278bf258", "node_type": "1", "metadata": {"window": "With that, I will turn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n", "original_text": "In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "964d15c49950cf5f00450156a54c9be3dc81d061d36ddbfcc4c59c4f8e33b6ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e98f7dce-8c50-4095-8341-04585798811d", "node_type": "1", "metadata": {"window": "Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n", "original_text": "We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824. "}, "hash": "d1a231f24245a6104a15b1e4acc2229d8150a13415db7939d14a301c57e9c3b9", "class_name": "RelatedNodeInfo"}}, "text": "The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.  ", "start_char_idx": 2370, "end_char_idx": 2520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e98f7dce-8c50-4095-8341-04585798811d": {"__data__": {"id_": "e98f7dce-8c50-4095-8341-04585798811d", "embedding": null, "metadata": {"window": "Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n", "original_text": "We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f983785-1bba-493d-8759-15e9aa145c31", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks, Aaron.   Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing. ", "original_text": "The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.  ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1810cc5dbefed720187509abe80b6b521400a2166cbee2ef02394a8b646f210c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "644ba488-4644-4c1d-b7d2-d27586cab05c", "node_type": "1", "metadata": {"window": "In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day. ", "original_text": "Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n"}, "hash": "d7560bb10229ec9d6450dbaf1a13c02b5956ee63e6c16c41da7048d11566aab0", "class_name": "RelatedNodeInfo"}}, "text": "We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824. ", "start_char_idx": 2520, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "644ba488-4644-4c1d-b7d2-d27586cab05c": {"__data__": {"id_": "644ba488-4644-4c1d-b7d2-d27586cab05c", "embedding": null, "metadata": {"window": "In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day. ", "original_text": "Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e98f7dce-8c50-4095-8341-04585798811d", "node_type": "1", "metadata": {"window": "Let\u2019s now dive deeper into the actions we are taking to execute our 3 \nstrate gic priorities, beginning with priority number one, and building upon the resiliency of the Pharma \nsegment . \n \n In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n", "original_text": "We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "432e76103aed5bb0c996152240d4f5ebf41d43f34f00a040a4edc912700a29b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3942536-000f-4d64-9dd2-80ccd74a300f", "node_type": "1", "metadata": {"window": "The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing. "}, "hash": "705bdbb5629bccec31b7d15dc99f947e2b6da1fa2b3c0768772416024b7c2b8d", "class_name": "RelatedNodeInfo"}}, "text": "Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n", "start_char_idx": 2718, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3942536-000f-4d64-9dd2-80ccd74a300f": {"__data__": {"id_": "b3942536-000f-4d64-9dd2-80ccd74a300f", "embedding": null, "metadata": {"window": "The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "644ba488-4644-4c1d-b7d2-d27586cab05c", "node_type": "1", "metadata": {"window": "In our largest, most significant business, the Pharma segment has been performing well by prioritizing \nwhat matters most: focusing on the core and delivering for our customers and their patients.  The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day. ", "original_text": "Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "438bb4e49ffc6652efcca05fede7a4861808aa337c3646a21bbd0113666f569e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c38f6a0-4fa6-418c-a1e7-4feb8012cf1c", "node_type": "1", "metadata": {"window": "We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n"}, "hash": "0709e2f7e58bdf88f1cc9c13fc43d5c073144142e17372bc3433612f4dd543d4", "class_name": "RelatedNodeInfo"}}, "text": "Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing. ", "start_char_idx": 2942, "end_char_idx": 3080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c38f6a0-4fa6-418c-a1e7-4feb8012cf1c": {"__data__": {"id_": "0c38f6a0-4fa6-418c-a1e7-4feb8012cf1c", "embedding": null, "metadata": {"window": "We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3942536-000f-4d64-9dd2-80ccd74a300f", "node_type": "1", "metadata": {"window": "The \nbusiness is positioned at the forefront of favorable secular industry trends and has also benefited \nfrom our specific actions and performance.   We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe40cf9a607e19d59f77028bde2b0c6fb5144ced98a6d9a9785d846168a7c73a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9d15344-245a-4899-b32b-87f7abf9bdf6", "node_type": "1", "metadata": {"window": "Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day. "}, "hash": "8bc82d3a864cf6b4608b9596042232866348a11b8304ff2f93b4297d9e21f6ae", "class_name": "RelatedNodeInfo"}}, "text": "In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n", "start_char_idx": 3080, "end_char_idx": 3293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9d15344-245a-4899-b32b-87f7abf9bdf6": {"__data__": {"id_": "d9d15344-245a-4899-b32b-87f7abf9bdf6", "embedding": null, "metadata": {"window": "Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c38f6a0-4fa6-418c-a1e7-4feb8012cf1c", "node_type": "1", "metadata": {"window": "We were pleased to recently raise our long -term segment \nprofit target to 4 to 6% growth , solidly in the mid -single digits and consistent with the segment profit \ngrowth we expect in fiscal \u201824.  Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c51033e7b29f760f92bac0a079b95b49c5608d41d9ca4fde4e188cf5833b5014", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2f1c861-06a0-4079-8b26-8a922199654b", "node_type": "1", "metadata": {"window": "Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "More recently, we hosted our 31st annual Retail Business Conference, where "}, "hash": "d9e453425cafbe19813ec17034f0b488b92541843be12ca7517586a5f59fbc6b", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day. ", "start_char_idx": 3293, "end_char_idx": 3413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2f1c861-06a0-4079-8b26-8a922199654b": {"__data__": {"id_": "e2f1c861-06a0-4079-8b26-8a922199654b", "embedding": null, "metadata": {"window": "Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "More recently, we hosted our 31st annual Retail Business Conference, where ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d755be45-a796-4158-87c6-ee9e872de8b5", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e1ba3eecf4e7176cdeb0c46a8626392f5a3d3ae952e7ae29a67eb8ecc279d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9d15344-245a-4899-b32b-87f7abf9bdf6", "node_type": "1", "metadata": {"window": "Our growth is enabled by a scaled, stable,  and resilient core \npharmaceutical distribution business, growing in the low -single digits, and double -digit growth from \nour higher margin Specialty and Nuclear businesses.  \n \n Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day. ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06b4a667160bfb4157694062dbf0f78db0fd8385190b9fcd8bfb65dc75a789e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bd256b5-b63f-4732-a9ae-c101380448b5", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n", "original_text": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations. "}, "hash": "c432338070f56436cacc28a4d3f7ab2775930c1b53fae7d34aa585ada3e12ad5", "class_name": "RelatedNodeInfo"}}, "text": "More recently, we hosted our 31st annual Retail Business Conference, where ", "start_char_idx": 3413, "end_char_idx": 3488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bd256b5-b63f-4732-a9ae-c101380448b5": {"__data__": {"id_": "9bd256b5-b63f-4732-a9ae-c101380448b5", "embedding": null, "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n", "original_text": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2f1c861-06a0-4079-8b26-8a922199654b", "node_type": "1", "metadata": {"window": "Within the core, our generics program remains a critical component of our overall offering and \nperformance, enabled by Red Oak Sourcing.  In addition to its lead ing scale, Red Oak\u2019s proprietary \nanalytical tools and deep industry expertise puts us in the best position possible whenever product \nshortages occur to continue servicing customers .  \n \n We\u2019re committed to providing customer -focused solutions across our many classes of trade as we \nnoted at Investor Day.  More recently, we hosted our 31st annual Retail Business Conference, where ", "original_text": "More recently, we hosted our 31st annual Retail Business Conference, where ", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a5d1f56452a8d8c3dcf747e8223906bb6003c624e10d21272265e16037ea8a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a12ffec3-05a8-4189-b17b-765f85a8a9e9", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent. ", "original_text": "For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n"}, "hash": "79e22286bcc21f534422600cf59e555bec73c45d98b1aa7ea13775f217c4f675", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations. ", "start_char_idx": 0, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a12ffec3-05a8-4189-b17b-765f85a8a9e9": {"__data__": {"id_": "a12ffec3-05a8-4189-b17b-765f85a8a9e9", "embedding": null, "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent. ", "original_text": "For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bd256b5-b63f-4732-a9ae-c101380448b5", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n", "original_text": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a00e98ba0aa500475b62511e6a237f091a5e152befee7be0ed1423866c3eb1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60441b74-8d09-4a3d-956f-5817d4d90bad", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent. ", "original_text": "We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth. "}, "hash": "9b4d84ca13c0e665a938cd953c51484082d0ccf37459ae7876893d2665c2032e", "class_name": "RelatedNodeInfo"}}, "text": "For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n", "start_char_idx": 256, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60441b74-8d09-4a3d-956f-5817d4d90bad": {"__data__": {"id_": "60441b74-8d09-4a3d-956f-5817d4d90bad", "embedding": null, "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent. ", "original_text": "We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a12ffec3-05a8-4189-b17b-765f85a8a9e9", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent. ", "original_text": "For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5672e2ce18b8a7bad51cfddfc730715477334f514cbc3f8d3bb179df5e8c6ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b29fc33-4272-4eb2-bd15-7a6715d9ee50", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board. ", "original_text": "We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n"}, "hash": "aa3326cc27a39bb3080569d4e4e5033dd9a48eaf9399ee518d47cddbb18d0ab2", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth. ", "start_char_idx": 499, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b29fc33-4272-4eb2-bd15-7a6715d9ee50": {"__data__": {"id_": "4b29fc33-4272-4eb2-bd15-7a6715d9ee50", "embedding": null, "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board. ", "original_text": "We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60441b74-8d09-4a3d-956f-5817d4d90bad", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent. ", "original_text": "We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e49e1ac146d9f59853bdb330913d8f7951805f181ae682d367ad55ffd783038", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56827d84-4870-4a32-b6af-92a760db2f83", "node_type": "1", "metadata": {"window": "For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n", "original_text": "We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent. "}, "hash": "234a9dae868aacbde8deb38e5dda70df6bb117e9e600e4c1fb7a742762179e9e", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n", "start_char_idx": 606, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56827d84-4870-4a32-b6af-92a760db2f83": {"__data__": {"id_": "56827d84-4870-4a32-b6af-92a760db2f83", "embedding": null, "metadata": {"window": "For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n", "original_text": "We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b29fc33-4272-4eb2-bd15-7a6715d9ee50", "node_type": "1", "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board. ", "original_text": "We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b75de621a7a8e531691bc4495a700e3999376a6834d8025a93154f482574175e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5d61093-2145-40a3-8d60-3ce4fd3ca80c", "node_type": "1", "metadata": {"window": "We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services. ", "original_text": "To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent. "}, "hash": "b3da65e96e5ce553042323bbbfb1875db36aec5cc9e1cdde5f9435bf7138ae38", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent. ", "start_char_idx": 747, "end_char_idx": 969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5d61093-2145-40a3-8d60-3ce4fd3ca80c": {"__data__": {"id_": "e5d61093-2145-40a3-8d60-3ce4fd3ca80c", "embedding": null, "metadata": {"window": "We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services. ", "original_text": "To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56827d84-4870-4a32-b6af-92a760db2f83", "node_type": "1", "metadata": {"window": "For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n", "original_text": "We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcdd414c86c9914305cd5169af2acf926654233f0ce4fc822f878eace6ef63a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ed78569-4e0f-4f54-ba35-6e79b80921de", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth. ", "original_text": "We continue to seek input from customers and have created an \nAdvisory Board. "}, "hash": "8160cd15d8baef2b139153a632f5a21fe347271ea2fe27f50749e1c08d4d8727", "class_name": "RelatedNodeInfo"}}, "text": "To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent. ", "start_char_idx": 969, "end_char_idx": 1192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ed78569-4e0f-4f54-ba35-6e79b80921de": {"__data__": {"id_": "9ed78569-4e0f-4f54-ba35-6e79b80921de", "embedding": null, "metadata": {"window": "We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth. ", "original_text": "We continue to seek input from customers and have created an \nAdvisory Board. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5d61093-2145-40a3-8d60-3ce4fd3ca80c", "node_type": "1", "metadata": {"window": "We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services. ", "original_text": "To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d759276a2088f8cbe2ce051cce2266a395fb2e5c63168db8a79780462831891f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed3e882d-f1f1-41bb-92c2-28a169fcc427", "node_type": "1", "metadata": {"window": "We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n", "original_text": "While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n"}, "hash": "ec8d8732ec134dbce6b3ce2e1aa2c9433dd72d5ca630b4c2531551bf607abed0", "class_name": "RelatedNodeInfo"}}, "text": "We continue to seek input from customers and have created an \nAdvisory Board. ", "start_char_idx": 1192, "end_char_idx": 1270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed3e882d-f1f1-41bb-92c2-28a169fcc427": {"__data__": {"id_": "ed3e882d-f1f1-41bb-92c2-28a169fcc427", "embedding": null, "metadata": {"window": "We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n", "original_text": "While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ed78569-4e0f-4f54-ba35-6e79b80921de", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth. ", "original_text": "We continue to seek input from customers and have created an \nAdvisory Board. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d9bfe6c337845a337684684cfc39604d47aa7ddac70e25694c61e3979508301", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95885a67-5975-47cd-98a0-ccb5e430324d", "node_type": "1", "metadata": {"window": "To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings. ", "original_text": "Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services. "}, "hash": "4ccd667cb92dc0a1f9e2e63da0f0f4eed43cdb11134489d63d76ddd000505fdf", "class_name": "RelatedNodeInfo"}}, "text": "While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n", "start_char_idx": 1270, "end_char_idx": 1375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95885a67-5975-47cd-98a0-ccb5e430324d": {"__data__": {"id_": "95885a67-5975-47cd-98a0-ccb5e430324d", "embedding": null, "metadata": {"window": "To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings. ", "original_text": "Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed3e882d-f1f1-41bb-92c2-28a169fcc427", "node_type": "1", "metadata": {"window": "We\u2019re excited to build upon our existing capabilities with the recent launc h of our Navista \u2122 Network , \na specific suite of offerings for community Oncologists, supporting their growth and desire to remain \nindependent.  To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n", "original_text": "While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dd7d0bc19955df40ee284558cfff14c7bf1ed84d434533cee8940e94dade5e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccdfbcee-4cd0-439b-8845-51730a89fa1a", "node_type": "1", "metadata": {"window": "We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n", "original_text": "In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth. "}, "hash": "4edde14ec38cebd0cb9635b6bbaa4dde3860d895d30087bccda1efabc57a25be", "class_name": "RelatedNodeInfo"}}, "text": "Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services. ", "start_char_idx": 1375, "end_char_idx": 1473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccdfbcee-4cd0-439b-8845-51730a89fa1a": {"__data__": {"id_": "ccdfbcee-4cd0-439b-8845-51730a89fa1a", "embedding": null, "metadata": {"window": "We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n", "original_text": "In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95885a67-5975-47cd-98a0-ccb5e430324d", "node_type": "1", "metadata": {"window": "To ensure the Navista \u2122 Network\u2019s success and development, we\u2019ve recently appointed \nnew leadership with deep indust ry and clinical experience and continue to build out the organization \nwith internal and external talent.  We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings. ", "original_text": "Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2f2ea3b3a341b06fdb182ef96ac89762226bcd8099af4280fe7703650ee1985", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74d331ba-baca-4416-a4cb-abf62ed789c6", "node_type": "1", "metadata": {"window": "While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n", "original_text": "At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n"}, "hash": "d79b368df140a94d8b692467f39580b0b2cded763c24d0c9cd776ddd9043bd10", "class_name": "RelatedNodeInfo"}}, "text": "In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth. ", "start_char_idx": 1473, "end_char_idx": 1590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74d331ba-baca-4416-a4cb-abf62ed789c6": {"__data__": {"id_": "74d331ba-baca-4416-a4cb-abf62ed789c6", "embedding": null, "metadata": {"window": "While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n", "original_text": "At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccdfbcee-4cd0-439b-8845-51730a89fa1a", "node_type": "1", "metadata": {"window": "We continue to seek input from customers and have created an \nAdvisory Board.  While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n", "original_text": "In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03f4ffce1dfd8a8dafaec6cb18f278c7ae3e812c5b7cb2a730180e9d393c426f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb47b4f-07d9-4b6c-bc98-213a83e379a6", "node_type": "1", "metadata": {"window": "Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine. ", "original_text": "We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings. "}, "hash": "e97fb36d2b7bd85d84905c7e346d37d3295358401e6a9d8d9380c5c5f760fce6", "class_name": "RelatedNodeInfo"}}, "text": "At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n", "start_char_idx": 1590, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb47b4f-07d9-4b6c-bc98-213a83e379a6": {"__data__": {"id_": "9fb47b4f-07d9-4b6c-bc98-213a83e379a6", "embedding": null, "metadata": {"window": "Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine. ", "original_text": "We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74d331ba-baca-4416-a4cb-abf62ed789c6", "node_type": "1", "metadata": {"window": "While still early innings, I\u2019m pleased with the engagement from current an d potential \ncustomers .   \n \n Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n", "original_text": "At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "231450db6dec8e4ce1421c0d7aefe899685f25c47b4956cbb8a5f6652334d4de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b265f6cd-963b-47b4-a2dc-2c22251086f9", "node_type": "1", "metadata": {"window": "In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n", "original_text": "For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n"}, "hash": "dc9685220d022435a45233a559d9840bb66e299959f0e2f6321029c210976ad1", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings. ", "start_char_idx": 1782, "end_char_idx": 1934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b265f6cd-963b-47b4-a2dc-2c22251086f9": {"__data__": {"id_": "b265f6cd-963b-47b4-a2dc-2c22251086f9", "embedding": null, "metadata": {"window": "In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n", "original_text": "For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb47b4f-07d9-4b6c-bc98-213a83e379a6", "node_type": "1", "metadata": {"window": "Upstream in Specialty, we\u2019re expecting continued double -digit growth from Manufacturer Services.  In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine. ", "original_text": "We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89ac2d9cb353ced4c4c57c70e333d28795097ece28e67ae5d3e126fd023824c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9db3d0a9-1819-4468-9b36-28f603133d86", "node_type": "1", "metadata": {"window": "At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine. ", "original_text": "Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n"}, "hash": "142a54273fd2e1fc858643b83e425cdf714c43b64c74064216b1230915bed067", "class_name": "RelatedNodeInfo"}}, "text": "For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n", "start_char_idx": 1934, "end_char_idx": 2154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9db3d0a9-1819-4468-9b36-28f603133d86": {"__data__": {"id_": "9db3d0a9-1819-4468-9b36-28f603133d86", "embedding": null, "metadata": {"window": "At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine. ", "original_text": "Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b265f6cd-963b-47b4-a2dc-2c22251086f9", "node_type": "1", "metadata": {"window": "In \nour leading 3PL, we\u2019re expanding our ambient and cold chain space to keep up with our business\u2019s \nstrong growth.  At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n", "original_text": "For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c08dd030d2891661c90e4979a7b7a99fb59ca12ec3e3e650d7aeca30460ca54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a9b5ca7-5999-47b1-bbd7-aa86b5c9f846", "node_type": "1", "metadata": {"window": "We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine. "}, "hash": "dc4f82d7a5b6f5df42302eb8fc6bfade3775fb70ea57fedf3716bf3492b20aae", "class_name": "RelatedNodeInfo"}}, "text": "Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n", "start_char_idx": 2154, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a9b5ca7-5999-47b1-bbd7-aa86b5c9f846": {"__data__": {"id_": "6a9b5ca7-5999-47b1-bbd7-aa86b5c9f846", "embedding": null, "metadata": {"window": "We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9db3d0a9-1819-4468-9b36-28f603133d86", "node_type": "1", "metadata": {"window": "At Sonexus \u2122 Access  and Patient Support, we delivered on a record number of new \nclient implementations and continue to launch new innovative products to streamline the patient \njourney.  \n \n We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine. ", "original_text": "Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87d14cbc3fa59f33da61cc5154afec054569e43cb54d987a005d865d0da5e54f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed1cf52f-9cb6-4115-b33c-48c01dff6fc0", "node_type": "1", "metadata": {"window": "For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n"}, "hash": "1904fb3f570474524918996884539446f91f3bfcc0ccd8a358c934452a84b79c", "class_name": "RelatedNodeInfo"}}, "text": "Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine. ", "start_char_idx": 2361, "end_char_idx": 2542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed1cf52f-9cb6-4115-b33c-48c01dff6fc0": {"__data__": {"id_": "ed1cf52f-9cb6-4115-b33c-48c01dff6fc0", "embedding": null, "metadata": {"window": "For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a9b5ca7-5999-47b1-bbd7-aa86b5c9f846", "node_type": "1", "metadata": {"window": "We\u2019re also supporting the growth of pharmaceutical manufacturers in the cell and gene the rapy space \nthrough our Advanced Therapy Solutions offerings.  For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2af6b718bf40d8e2895c029f9a8f1b0deff078512b8538a51129ccf5f5bccd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73f6d7f3-b9cb-46fd-9b4e-72785e761d93", "node_type": "1", "metadata": {"window": "Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine. "}, "hash": "dfdfcdbe38d0572ff897765aed51f4cdae74b0a5e8c55dfb9a49332e7323c2ee", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n", "start_char_idx": 2542, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73f6d7f3-b9cb-46fd-9b4e-72785e761d93": {"__data__": {"id_": "73f6d7f3-b9cb-46fd-9b4e-72785e761d93", "embedding": null, "metadata": {"window": "Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed1cf52f-9cb6-4115-b33c-48c01dff6fc0", "node_type": "1", "metadata": {"window": "For example, we\u2019re partnering with TrakCel to \nbring visibility and tracking capabilities to biopharma companies by helping them navigate cell \ntherapies through multiple stages of development and commercialization.  \n \n Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec205b2e69e6fd98ccd60a1e4b62358392b733b7989046b5f1dca2d2e0e3c3a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bce6ae60-570b-4207-a697-42a23520b943", "node_type": "1", "metadata": {"window": "Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n "}, "hash": "6a424c03219e594b5fbb282e4906e420628629e1822f4d679d570c63b242d78c", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine. ", "start_char_idx": 2826, "end_char_idx": 3011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bce6ae60-570b-4207-a697-42a23520b943": {"__data__": {"id_": "bce6ae60-570b-4207-a697-42a23520b943", "embedding": null, "metadata": {"window": "Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0891f7c992d2ad8c2f965c1dfa1a61c5fedb981528741174740c9dd569c5e5d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73f6d7f3-b9cb-46fd-9b4e-72785e761d93", "node_type": "1", "metadata": {"window": "Overall  in Specialty, we\u2019re confident that the connection between our downstream and upstream \nstrategies, what we call our Specialty growth cycle, will drive double -digit growth well into the future.  \n \n Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dabc408d53f30a576c38e2faa9c3791c987ad6f36df2a9f8e6709f80fb63964a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63268705-9624-4a76-8639-38d2793ebe1c", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n", "original_text": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n"}, "hash": "f6eb70bb9b9608be9ec62f2f5bd3e0c46b7dced4587c2c25f21f890a057a06a4", "class_name": "RelatedNodeInfo"}}, "text": "As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "start_char_idx": 3011, "end_char_idx": 3371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63268705-9624-4a76-8639-38d2793ebe1c": {"__data__": {"id_": "63268705-9624-4a76-8639-38d2793ebe1c", "embedding": null, "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n", "original_text": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bce6ae60-570b-4207-a697-42a23520b943", "node_type": "1", "metadata": {"window": "Our Nuclear business, which is on t rack to double profits by fiscal \u201826 as of our fiscal \u201821 baseline, is \nstrategically positioned for growth at the center of precision medicine.  We\u2019re further investing in this \nspace with a Phase 2 investment of $30 million  dollars  over the next several yea rs to expand our \nCenter for Theranostics Advancement and support our manufacturer partners\u2019 projects as they \nadvance through the commercial development pipeline.  \n \n We\u2019re encouraged to see pharmaceutical innovation expanding the breadth of conditions that ar e \nbeing addressed with emerging therapies, such as cell and gene, and precision medicine.  As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "original_text": "As the \nfuture of healthcare continues to evolve, our breadth of capabilities, from pharmaceutical and \nspecialty distribution, radiopharmaceuticals and theranostics, t o biopharma and manufacturer \nservices, enables us to offer multiple touch points for manufacturers, providers,  and patients to realize \nvalue from these promising new treatment options.  \n ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67d6d40596626bc7f3643f22a6e359da9e753a19977ee23a30864cc54daae7bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49476bc3-4d31-4b27-a9df-587a9cf6bb68", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.  ", "original_text": "When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n"}, "hash": "de134a5e5ee41b4d5874b1722ee8d4ff04ca36a9370e258869dfa8c5cdf6dea1", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n", "start_char_idx": 0, "end_char_idx": 70, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49476bc3-4d31-4b27-a9df-587a9cf6bb68": {"__data__": {"id_": "49476bc3-4d31-4b27-a9df-587a9cf6bb68", "embedding": null, "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.  ", "original_text": "When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63268705-9624-4a76-8639-38d2793ebe1c", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n", "original_text": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85ea23ad95b24f116a3b6200f69db99617d4d2ec6dceb3d01188cd0878aab3e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c71a0fe-7e6f-4a3e-9b2f-3964fe6fac1e", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n", "original_text": "We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824. "}, "hash": "29f7f01ef8edcfebcc35947271021be5ab478805682eaa95aa67a90241587e41", "class_name": "RelatedNodeInfo"}}, "text": "When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n", "start_char_idx": 70, "end_char_idx": 301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c71a0fe-7e6f-4a3e-9b2f-3964fe6fac1e": {"__data__": {"id_": "6c71a0fe-7e6f-4a3e-9b2f-3964fe6fac1e", "embedding": null, "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n", "original_text": "We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49476bc3-4d31-4b27-a9df-587a9cf6bb68", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.  ", "original_text": "When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6190b104bd1f7646c0b7e3b9475c5f2cf953fed41d0910b5abe3eb8d444501cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5030e6c0-fbf2-4509-8fc9-8b9aff5cced6", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs. ", "original_text": "This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n"}, "hash": "64cb686a332cab8092f9cfa6d5215209ed1f27a9899137e8aa09668e5de35e9d", "class_name": "RelatedNodeInfo"}}, "text": "We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824. ", "start_char_idx": 301, "end_char_idx": 421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5030e6c0-fbf2-4509-8fc9-8b9aff5cced6": {"__data__": {"id_": "5030e6c0-fbf2-4509-8fc9-8b9aff5cced6", "embedding": null, "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs. ", "original_text": "This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c71a0fe-7e6f-4a3e-9b2f-3964fe6fac1e", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n", "original_text": "We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48156f5d5e3c642bc11bdc32507a8806d1d16a3b989e9e02d800e9518eec3360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b19c0ca7-41cc-4f2e-a1ce-bdd2ee12c994", "node_type": "1", "metadata": {"window": "When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution. ", "original_text": "We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.  "}, "hash": "3bd1461db72c808dbb2be602bd886f60a72ffe574e7b90862ecee91cea6998b5", "class_name": "RelatedNodeInfo"}}, "text": "This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n", "start_char_idx": 421, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b19c0ca7-41cc-4f2e-a1ce-bdd2ee12c994": {"__data__": {"id_": "b19c0ca7-41cc-4f2e-a1ce-bdd2ee12c994", "embedding": null, "metadata": {"window": "When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution. ", "original_text": "We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.  ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5030e6c0-fbf2-4509-8fc9-8b9aff5cced6", "node_type": "1", "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs. ", "original_text": "This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e89d027a6222436dbe171e2c79d1ea674b793564951cb9386cd7fd4ab300b87a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ca61a85-1032-4ede-8117-bf76dfdf53d3", "node_type": "1", "metadata": {"window": "We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n", "original_text": "While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n"}, "hash": "c68809638c84e83265212a8f6ab53754ab43daf27637cbaf605bc6b1f1c501d2", "class_name": "RelatedNodeInfo"}}, "text": "We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.  ", "start_char_idx": 555, "end_char_idx": 810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ca61a85-1032-4ede-8117-bf76dfdf53d3": {"__data__": {"id_": "9ca61a85-1032-4ede-8117-bf76dfdf53d3", "embedding": null, "metadata": {"window": "We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n", "original_text": "While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b19c0ca7-41cc-4f2e-a1ce-bdd2ee12c994", "node_type": "1", "metadata": {"window": "When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution. ", "original_text": "We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.  ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89d5560fed8f13404c0ef4c579658319b8ad3b4ed58b1fc3cf0b73ac09e7c3bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8680e73-fd21-4b4d-b37e-4bbca6f28825", "node_type": "1", "metadata": {"window": "This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n", "original_text": "We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs. "}, "hash": "d1e891d95f4bfcd17777f1bd4d50fbf53373d4addaeb00f81e2e4f987e77bb22", "class_name": "RelatedNodeInfo"}}, "text": "While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n", "start_char_idx": 810, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8680e73-fd21-4b4d-b37e-4bbca6f28825": {"__data__": {"id_": "a8680e73-fd21-4b4d-b37e-4bbca6f28825", "embedding": null, "metadata": {"window": "This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n", "original_text": "We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ca61a85-1032-4ede-8117-bf76dfdf53d3", "node_type": "1", "metadata": {"window": "We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n", "original_text": "While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e63bbb43feed83fafa460b4c66d967b9c042243c40019def1eed329378251bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25954ea2-7485-4b5b-94a7-ce3ad65d10ea", "node_type": "1", "metadata": {"window": "We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n", "original_text": "This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution. "}, "hash": "a5a9ac8c309f332531bac03ac601e69acb83fc956e097baccc4ebf205bbd4138", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs. ", "start_char_idx": 998, "end_char_idx": 1149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25954ea2-7485-4b5b-94a7-ce3ad65d10ea": {"__data__": {"id_": "25954ea2-7485-4b5b-94a7-ce3ad65d10ea", "embedding": null, "metadata": {"window": "We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n", "original_text": "This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8680e73-fd21-4b4d-b37e-4bbca6f28825", "node_type": "1", "metadata": {"window": "This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n", "original_text": "We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e79c4db41978b03674c6c052d3d69654894738b7ccc8aa96277c93f8ac33d79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9943039-9864-413b-bd41-01de4a434964", "node_type": "1", "metadata": {"window": "While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n", "original_text": "We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n"}, "hash": "db57af6ac58fc7a194a9b3fcbcc6b1e1bed615f5edbe67329780c85841a3a282", "class_name": "RelatedNodeInfo"}}, "text": "This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution. ", "start_char_idx": 1149, "end_char_idx": 1311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9943039-9864-413b-bd41-01de4a434964": {"__data__": {"id_": "f9943039-9864-413b-bd41-01de4a434964", "embedding": null, "metadata": {"window": "While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n", "original_text": "We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25954ea2-7485-4b5b-94a7-ce3ad65d10ea", "node_type": "1", "metadata": {"window": "We continue to execute our mitigation initiatives to offset ele vated inflation and make progress with \nour commercial contracting efforts , and we are exploring other offsets with urgency, such as our \nmanufacturing excellence and sourcing initiatives.   While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n", "original_text": "This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea4e9e1166c19222be862896e779b28ac9526b3ad93da48be70cd6e0269fd5a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e48fd71-bc99-4345-8557-6935e60ee1ac", "node_type": "1", "metadata": {"window": "We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth. ", "original_text": "At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n"}, "hash": "f321e67354e242fa1ce632c5d9999f065742f890cddd7625347e14114baee830", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n", "start_char_idx": 1311, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e48fd71-bc99-4345-8557-6935e60ee1ac": {"__data__": {"id_": "4e48fd71-bc99-4345-8557-6935e60ee1ac", "embedding": null, "metadata": {"window": "We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth. ", "original_text": "At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9943039-9864-413b-bd41-01de4a434964", "node_type": "1", "metadata": {"window": "While overall costs remain elevated, international \nfreight has genera lly returned to pre -pandemic levels, and we expect this improvement to be reflected \nin our fiscal \u201824 results.  \n \n We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n", "original_text": "We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d7415e7c3c5c148c89dca4aafecbf9473b1fdfae442432f5d81d3e0898c0654", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03618b23-cad9-448c-8b19-092fd7a44e30", "node_type": "1", "metadata": {"window": "This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n", "original_text": "We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n"}, "hash": "1d4a684e617e83183160eaa0734c07e2545fd48afa55ba26776a7ceb7f2eb4fd", "class_name": "RelatedNodeInfo"}}, "text": "At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n", "start_char_idx": 1444, "end_char_idx": 1746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03618b23-cad9-448c-8b19-092fd7a44e30": {"__data__": {"id_": "03618b23-cad9-448c-8b19-092fd7a44e30", "embedding": null, "metadata": {"window": "This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n", "original_text": "We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e48fd71-bc99-4345-8557-6935e60ee1ac", "node_type": "1", "metadata": {"window": "We\u2019re driving significant progress through our 5 -point plan to grow Cardinal Health Brand volume and \nseeing improvements in our leading indicato rs.  This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth. ", "original_text": "At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "546fe4d966257a628cea7e828eaf4b9c8e531b55cf2ee5e621954a6e8b18ccbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b16a1e49-c49e-4f63-ba8a-db1af107a74b", "node_type": "1", "metadata": {"window": "We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating. ", "original_text": "Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n"}, "hash": "c088abe2458d27010c5c726e2a5b058ffe6620d926fcadb8f2854f7dfc785499", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n", "start_char_idx": 1746, "end_char_idx": 1910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b16a1e49-c49e-4f63-ba8a-db1af107a74b": {"__data__": {"id_": "b16a1e49-c49e-4f63-ba8a-db1af107a74b", "embedding": null, "metadata": {"window": "We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating. ", "original_text": "Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03618b23-cad9-448c-8b19-092fd7a44e30", "node_type": "1", "metadata": {"window": "This includes better portfolio health for key product \ncategories and higher service levels, Customer Loyalty Index scores and retention rates for \ndistribution.  We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n", "original_text": "We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39ad3b46243839ef86aaac7c875049743956fa8c9f7cfc3db55fe87f858d7f8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ebfb7a0-4340-458b-85ef-ac782b54f3c5", "node_type": "1", "metadata": {"window": "At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter. ", "original_text": "In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth. "}, "hash": "6f97a5be459eb545ba3c9f26a17b51069b079c1099ca9a81261571629201bb15", "class_name": "RelatedNodeInfo"}}, "text": "Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n", "start_char_idx": 1910, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ebfb7a0-4340-458b-85ef-ac782b54f3c5": {"__data__": {"id_": "8ebfb7a0-4340-458b-85ef-ac782b54f3c5", "embedding": null, "metadata": {"window": "At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter. ", "original_text": "In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b16a1e49-c49e-4f63-ba8a-db1af107a74b", "node_type": "1", "metadata": {"window": "We\u2019re driving enhanced customer experience through investments in product availability \nand a utomation, while optimizing costs.  \n \n At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating. ", "original_text": "Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02d1856277b6bc20dacc486b9518e1b516f7d80a022b330768ef6c20032c14f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0aef6e2-59f7-4db5-8f92-4caa835adb49", "node_type": "1", "metadata": {"window": "We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n", "original_text": "For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n"}, "hash": "e525131b086b8993f4b4e4570af2c2c4bccc3495a40fe44b97f1aa4275e2c48e", "class_name": "RelatedNodeInfo"}}, "text": "In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth. ", "start_char_idx": 2150, "end_char_idx": 2378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0aef6e2-59f7-4db5-8f92-4caa835adb49": {"__data__": {"id_": "d0aef6e2-59f7-4db5-8f92-4caa835adb49", "embedding": null, "metadata": {"window": "We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n", "original_text": "For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ebfb7a0-4340-458b-85ef-ac782b54f3c5", "node_type": "1", "metadata": {"window": "At Investor Day we highlighted our two -pronged approach to portfolio lifecycle management , which \nhas enabled us to completely exit our non -healthcare portfolio, and we are in the process of reducing \nover 2,000 SKUs acros s our Cardinal Health Branded product categories to simplify the business. \n We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter. ", "original_text": "In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31d8eddcca6df432038850ef6e32b100a71b5f219e1ad2f7b1d9384d42d6bd93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcde74a7-b781-4a5d-bda5-7acbf38d5c3b", "node_type": "1", "metadata": {"window": "Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses. ", "original_text": "As a result of our combined efforts, commercial momentum is accelerating. "}, "hash": "4274e7bd9143db6433b9d5d1e2e2e387d7519f41d66e8d62363ea355f85e2876", "class_name": "RelatedNodeInfo"}}, "text": "For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n", "start_char_idx": 2378, "end_char_idx": 2469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcde74a7-b781-4a5d-bda5-7acbf38d5c3b": {"__data__": {"id_": "bcde74a7-b781-4a5d-bda5-7acbf38d5c3b", "embedding": null, "metadata": {"window": "Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses. ", "original_text": "As a result of our combined efforts, commercial momentum is accelerating. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0aef6e2-59f7-4db5-8f92-4caa835adb49", "node_type": "1", "metadata": {"window": "We\u2019re focusing our investments in new product development and capacity expansion in key growth \nareas, such as compression, enteral feeding,  and incontinence.  \n \n Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n", "original_text": "For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "090216642add9f7cc99b429d9f4a96b614759f9ff1e1270bf07a82b18555f700", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dd9527f-609c-4e61-b008-8fdcb09428ec", "node_type": "1", "metadata": {"window": "In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home. ", "original_text": "During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter. "}, "hash": "c76d0da8619746f0391160491964759b6723f6776d9758b027062b51368faba7", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our combined efforts, commercial momentum is accelerating. ", "start_char_idx": 2469, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dd9527f-609c-4e61-b008-8fdcb09428ec": {"__data__": {"id_": "2dd9527f-609c-4e61-b008-8fdcb09428ec", "embedding": null, "metadata": {"window": "In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home. ", "original_text": "During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcde74a7-b781-4a5d-bda5-7acbf38d5c3b", "node_type": "1", "metadata": {"window": "Within our products tha t are Core to Distribution, we\u2019ve seen continued stabilization with PPE , a \nsmaller part of our portfolio but a source of volatility during the pandemic , and growth in our \nPresource surgical kitting category.  \n \n In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses. ", "original_text": "As a result of our combined efforts, commercial momentum is accelerating. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5fc171b5766f6f692f2aaf0ee955e2e1701128cc44a84ed4a9f0c6c3f38dbdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f420e328-08a1-45ea-a922-2092dc4336fe", "node_type": "1", "metadata": {"window": "For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n"}, "hash": "1e05718c86c78404c4114acf59ad8baa38e5caf59fe07af571951aaad3b3fb6e", "class_name": "RelatedNodeInfo"}}, "text": "During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter. ", "start_char_idx": 2543, "end_char_idx": 2650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f420e328-08a1-45ea-a922-2092dc4336fe": {"__data__": {"id_": "f420e328-08a1-45ea-a922-2092dc4336fe", "embedding": null, "metadata": {"window": "For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dd9527f-609c-4e61-b008-8fdcb09428ec", "node_type": "1", "metadata": {"window": "In our Specialty products portfolio, comprised of clinically differentiated products and leading brands \nlike Kangaroo, Kendall and Protexis, we\u2019re investing in innovation to meet customers\u2019 needs and \ndrive sustainable growth.  For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home. ", "original_text": "During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2cafe7ef6678b4dc48ff94d938d026ef0cd401118812b27139d44f33771d8dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16f966a3-667c-4557-9833-b4fe43c251d3", "node_type": "1", "metadata": {"window": "As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "Outside of the core, we\u2019re on track to accelerate our growth businesses. "}, "hash": "6617438582c229e9d880f76d505fb94baa1f56e030e960f39e637cb05c433b63", "class_name": "RelatedNodeInfo"}}, "text": "These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n", "start_char_idx": 2650, "end_char_idx": 2813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16f966a3-667c-4557-9833-b4fe43c251d3": {"__data__": {"id_": "16f966a3-667c-4557-9833-b4fe43c251d3", "embedding": null, "metadata": {"window": "As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "Outside of the core, we\u2019re on track to accelerate our growth businesses. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f420e328-08a1-45ea-a922-2092dc4336fe", "node_type": "1", "metadata": {"window": "For example, the launch of our new Kangaroo OMNI \u2122 enteral feeding \nsystem this month.  \n \n As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4eb45a3aef5fe59ff78bf23b7a23261017d130047552298ef6d2858dcb7e268c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c88371d-e90a-49e0-8128-8ce91603198a", "node_type": "1", "metadata": {"window": "During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home. "}, "hash": "55840020b696c1cf58613ea6a5784a316efc90d3364d8124fad05bc42d8315a1", "class_name": "RelatedNodeInfo"}}, "text": "Outside of the core, we\u2019re on track to accelerate our growth businesses. ", "start_char_idx": 2813, "end_char_idx": 2886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c88371d-e90a-49e0-8128-8ce91603198a": {"__data__": {"id_": "0c88371d-e90a-49e0-8128-8ce91603198a", "embedding": null, "metadata": {"window": "During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16f966a3-667c-4557-9833-b4fe43c251d3", "node_type": "1", "metadata": {"window": "As a result of our combined efforts, commercial momentum is accelerating.  During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "Outside of the core, we\u2019re on track to accelerate our growth businesses. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5736168e9273dad76f963bf241b780db49bca40b02bfae4307ae24e01861c3ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f64570f-3207-4ffd-9956-6b7127e380bb", "node_type": "1", "metadata": {"window": "These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "For example, we recently began construction for a new 350 thousand square foot "}, "hash": "91404da61ab3f7ffa28c6a92ccf6c36aed46f3e9d39f78da57ccfa616dd4057d", "class_name": "RelatedNodeInfo"}}, "text": "In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home. ", "start_char_idx": 2886, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f64570f-3207-4ffd-9956-6b7127e380bb": {"__data__": {"id_": "6f64570f-3207-4ffd-9956-6b7127e380bb", "embedding": null, "metadata": {"window": "These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "For example, we recently began construction for a new 350 thousand square foot ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4011977a-fb56-4b0a-9225-35b630559899", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e07c75bb77c887e15b4a25aaf65f536b3b31570599630a069bebd9f5871d1bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c88371d-e90a-49e0-8128-8ce91603198a", "node_type": "1", "metadata": {"window": "During Q4 we renewed \nseveral key distribution customers and saw positive net new wins during the quarter.  These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home. ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e10a843df2077c5ee48b63f39baa8d6b668f892bef3fe9632dce49ff6504a1d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f79a725-8ddb-4748-83ab-cf44b417fcc3", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n", "original_text": " \nPage 9 of 17 \n \nGreenville, South Carolina DC. "}, "hash": "d92524cc614e0123be5a6e409112cb54e49203c367232d667a95170a38cff8c9", "class_name": "RelatedNodeInfo"}}, "text": "For example, we recently began construction for a new 350 thousand square foot ", "start_char_idx": 3029, "end_char_idx": 3108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f79a725-8ddb-4748-83ab-cf44b417fcc3": {"__data__": {"id_": "7f79a725-8ddb-4748-83ab-cf44b417fcc3", "embedding": null, "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n", "original_text": " \nPage 9 of 17 \n \nGreenville, South Carolina DC. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f64570f-3207-4ffd-9956-6b7127e380bb", "node_type": "1", "metadata": {"window": "These leading \nindicators give us confidence that moving f orward, we\u2019ll participate in the growth from an overall \nimproving Medical utilization environment.  \n \n Outside of the core, we\u2019re on track to accelerate our growth businesses.  In at -Home Solutions, we\u2019re \ninvesting in DC network expansion to keep pace with inc reased demand as care continues to shift \ninto the home.  For example, we recently began construction for a new 350 thousand square foot ", "original_text": "For example, we recently began construction for a new 350 thousand square foot ", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1a868288e4950366b3a57ad1d08b2f8f004cc8ad8d6ca04d57942fa8034d9ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0bd912c-f0c2-409a-9ef6-6987eb4fafbf", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint. ", "original_text": "This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies. "}, "hash": "43dfb8f5e5588e2232e2c9c6c8d9e7beb1587327a5a599408fd3b9cab3557a0a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 17 \n \nGreenville, South Carolina DC. ", "start_char_idx": 0, "end_char_idx": 49, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0bd912c-f0c2-409a-9ef6-6987eb4fafbf": {"__data__": {"id_": "a0bd912c-f0c2-409a-9ef6-6987eb4fafbf", "embedding": null, "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint. ", "original_text": "This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f79a725-8ddb-4748-83ab-cf44b417fcc3", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n", "original_text": " \nPage 9 of 17 \n \nGreenville, South Carolina DC. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6c88a0f91e4286f1e237c0cbb56bcbd41f0513571c07c6b0a8aa32836c04a36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da4e7b2c-e0f6-4356-b1eb-b033bee04b3f", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n", "original_text": "In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise. "}, "hash": "96490c11c5a47c43585bb1aa55b5e39b9b0d1ab5f22f057044a29cb0744fd0d5", "class_name": "RelatedNodeInfo"}}, "text": "This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies. ", "start_char_idx": 49, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da4e7b2c-e0f6-4356-b1eb-b033bee04b3f": {"__data__": {"id_": "da4e7b2c-e0f6-4356-b1eb-b033bee04b3f", "embedding": null, "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n", "original_text": "In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0bd912c-f0c2-409a-9ef6-6987eb4fafbf", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint. ", "original_text": "This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d809a699f22c6cf66388df4ce557ddf5cbf7f990c785c5d3f1369a6eb035fe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb132b82-a764-4d82-b913-680cce267497", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan. ", "original_text": "We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n"}, "hash": "8dcdae9ab8264db554afa07c71bca71b7023845898a7ac120b47d329c1f75034", "class_name": "RelatedNodeInfo"}}, "text": "In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise. ", "start_char_idx": 241, "end_char_idx": 352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb132b82-a764-4d82-b913-680cce267497": {"__data__": {"id_": "cb132b82-a764-4d82-b913-680cce267497", "embedding": null, "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan. ", "original_text": "We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da4e7b2c-e0f6-4356-b1eb-b033bee04b3f", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n", "original_text": "In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aff1ac44448d8d55c2e1daa9dd12b0564980184b5dd0fda63a71d3e91bf22dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea292c90-a592-48e0-9774-25123687cb42", "node_type": "1", "metadata": {"window": "This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n", "original_text": "Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint. "}, "hash": "7e8b61ea41efb00695c7f442341872aa2c2a9dd9f64cececef0b56d641f9a27f", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n", "start_char_idx": 352, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea292c90-a592-48e0-9774-25123687cb42": {"__data__": {"id_": "ea292c90-a592-48e0-9774-25123687cb42", "embedding": null, "metadata": {"window": "This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n", "original_text": "Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb132b82-a764-4d82-b913-680cce267497", "node_type": "1", "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan. ", "original_text": "We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "899be76aa8bf4ea81355b6bec093a33daad4db64f5d583c9b0a5bbf21ada82ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdc82a0a-a47f-43e6-a5ee-914fac439699", "node_type": "1", "metadata": {"window": "In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.  ", "original_text": "For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n"}, "hash": "f15c9beffaa4535af6ae1b37314fbaac532b81ed1865a54511c32b82c1863013", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint. ", "start_char_idx": 468, "end_char_idx": 649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdc82a0a-a47f-43e6-a5ee-914fac439699": {"__data__": {"id_": "bdc82a0a-a47f-43e6-a5ee-914fac439699", "embedding": null, "metadata": {"window": "In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.  ", "original_text": "For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea292c90-a592-48e0-9774-25123687cb42", "node_type": "1", "metadata": {"window": "This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n", "original_text": "Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b69fc8edb4f9e6c4988ee2ada7651db2102f43c61f7cd6ae7f06e5c692d1391", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ad1eb2a-7f5c-4b61-8921-f6fb62033a11", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n", "original_text": "In short, we are making progress with our Medical Improvement Plan. "}, "hash": "aab6c51be8fa72a9b64bbe81c7fbda3932817f8ce3228836fbccc67cc052734d", "class_name": "RelatedNodeInfo"}}, "text": "For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n", "start_char_idx": 649, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ad1eb2a-7f5c-4b61-8921-f6fb62033a11": {"__data__": {"id_": "0ad1eb2a-7f5c-4b61-8921-f6fb62033a11", "embedding": null, "metadata": {"window": "We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n", "original_text": "In short, we are making progress with our Medical Improvement Plan. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdc82a0a-a47f-43e6-a5ee-914fac439699", "node_type": "1", "metadata": {"window": "In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.  ", "original_text": "For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e0142440dfe10949d976543913822eaab590a7b8b1e240065f6a3dac64b3824", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "800a78dc-7051-44bf-9802-571f8e1cc924", "node_type": "1", "metadata": {"window": "Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements. ", "original_text": "While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n"}, "hash": "5572419d25c9250709af3d1b4a06b99767e3f73d94089d5cbd3ca35477110c87", "class_name": "RelatedNodeInfo"}}, "text": "In short, we are making progress with our Medical Improvement Plan. ", "start_char_idx": 753, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "800a78dc-7051-44bf-9802-571f8e1cc924": {"__data__": {"id_": "800a78dc-7051-44bf-9802-571f8e1cc924", "embedding": null, "metadata": {"window": "Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements. ", "original_text": "While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ad1eb2a-7f5c-4b61-8921-f6fb62033a11", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n", "original_text": "In short, we are making progress with our Medical Improvement Plan. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68287c10485b2bde45478adf75d428bc6417a095c021dd6f0e11f8a06b1e63c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f3ea902-562e-42af-bb22-86d1b7773529", "node_type": "1", "metadata": {"window": "For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year. ", "original_text": "Finally, priority number three , maximizing shareholder value creation.  "}, "hash": "e169122b4bc50ab3609cf338e88ff1feb66d8107fc5ae477e3b9444a0f1d4793", "class_name": "RelatedNodeInfo"}}, "text": "While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n", "start_char_idx": 821, "end_char_idx": 962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f3ea902-562e-42af-bb22-86d1b7773529": {"__data__": {"id_": "4f3ea902-562e-42af-bb22-86d1b7773529", "embedding": null, "metadata": {"window": "For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year. ", "original_text": "Finally, priority number three , maximizing shareholder value creation.  ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "800a78dc-7051-44bf-9802-571f8e1cc924", "node_type": "1", "metadata": {"window": "Finally, we\u2019re continuing to execute our simplification and cost savings initiatives, such as optimizing \nour global manufacturing and supply chain and our international footprint.  For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements. ", "original_text": "While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54ea0afb8a0f044dd253d1b66f89620f9c4d60127d009c42fe8293d3432ffacf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3366999-d480-4ffa-9f62-33d8c97b4ca9", "node_type": "1", "metadata": {"window": "In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n", "original_text": "We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n"}, "hash": "9a5f3171f765305659a241c31a265e20934e1a2c683633ae23b76210aaef214d", "class_name": "RelatedNodeInfo"}}, "text": "Finally, priority number three , maximizing shareholder value creation.  ", "start_char_idx": 962, "end_char_idx": 1035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3366999-d480-4ffa-9f62-33d8c97b4ca9": {"__data__": {"id_": "d3366999-d480-4ffa-9f62-33d8c97b4ca9", "embedding": null, "metadata": {"window": "In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n", "original_text": "We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f3ea902-562e-42af-bb22-86d1b7773529", "node_type": "1", "metadata": {"window": "For example, we exited four \nadditional countries and two additional manufacturing sites this year.  \n \n In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year. ", "original_text": "Finally, priority number three , maximizing shareholder value creation.  ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ed9bc698a5aa7a378e9002da22f22574749420fef53d8b84d228d4703c64270", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e8306f4-4e14-4a2d-86ee-136a14589b61", "node_type": "1", "metadata": {"window": "While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us. ", "original_text": "At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements. "}, "hash": "b56a42f2f6ce23986eb7887f14eee4d3202f76cf58e411f34b59fdff977877a7", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n", "start_char_idx": 1035, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e8306f4-4e14-4a2d-86ee-136a14589b61": {"__data__": {"id_": "5e8306f4-4e14-4a2d-86ee-136a14589b61", "embedding": null, "metadata": {"window": "While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us. ", "original_text": "At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3366999-d480-4ffa-9f62-33d8c97b4ca9", "node_type": "1", "metadata": {"window": "In short, we are making progress with our Medical Improvement Plan.  While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n", "original_text": "We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a6930d56ef3751149b1b56bc48859b5dbae91063492ae179236669ae3a4bfa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f67619bf-d96e-472b-8fd3-95382688d1eb", "node_type": "1", "metadata": {"window": "Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n", "original_text": "We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year. "}, "hash": "dcf02e8d20c0fc90b9041ea67d8132edb945994041919c96d882e1dedc4aaf4b", "class_name": "RelatedNodeInfo"}}, "text": "At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements. ", "start_char_idx": 1190, "end_char_idx": 1352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f67619bf-d96e-472b-8fd3-95382688d1eb": {"__data__": {"id_": "f67619bf-d96e-472b-8fd3-95382688d1eb", "embedding": null, "metadata": {"window": "Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n", "original_text": "We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e8306f4-4e14-4a2d-86ee-136a14589b61", "node_type": "1", "metadata": {"window": "While there is still execution in \nfront of us, I\u2019m excited for the business to return to more signifi cant profitability in fiscal \u201824.  \n \n Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us. ", "original_text": "At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3f8f79aac9238f93fec1dc1f580c0556b4c95987e4e162854bead9b0e121ea9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55f8472b-6686-495c-a08d-188e05384f3e", "node_type": "1", "metadata": {"window": "We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients. ", "original_text": "And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n"}, "hash": "0e32039722741c95cb34e8e9292805916a8384e80c2ab09e9270a9f7884652b1", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year. ", "start_char_idx": 1352, "end_char_idx": 1537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55f8472b-6686-495c-a08d-188e05384f3e": {"__data__": {"id_": "55f8472b-6686-495c-a08d-188e05384f3e", "embedding": null, "metadata": {"window": "We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients. ", "original_text": "And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f67619bf-d96e-472b-8fd3-95382688d1eb", "node_type": "1", "metadata": {"window": "Finally, priority number three , maximizing shareholder value creation.   We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n", "original_text": "We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2776a2feec1301b784a81efeac977506f7191ea1d4191d3e4c35e3278d75148a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b88111c-17fe-408d-9c97-3f1c9720ee60", "node_type": "1", "metadata": {"window": "At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward. ", "original_text": "While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us. "}, "hash": "33c38148849e8bc815414d370b6f531530def87d371d2dc2659cd33ffbaf7b2b", "class_name": "RelatedNodeInfo"}}, "text": "And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n", "start_char_idx": 1537, "end_char_idx": 1714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b88111c-17fe-408d-9c97-3f1c9720ee60": {"__data__": {"id_": "2b88111c-17fe-408d-9c97-3f1c9720ee60", "embedding": null, "metadata": {"window": "At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward. ", "original_text": "While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55f8472b-6686-495c-a08d-188e05384f3e", "node_type": "1", "metadata": {"window": "We\u2019re maximizing shareholder \nvalue creation through operational performance, robust cash flow generation and the responsible \nallocation of capital .  \n \n At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients. ", "original_text": "And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1e2b1a022c9c481a1f6128a4f20e3afbc255ecd528e47a6b4a2bed5ffb8e3ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f63e2b-5df2-4908-8b25-2f41ca8a34af", "node_type": "1", "metadata": {"window": "We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n", "original_text": "We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n"}, "hash": "35a716a8851b95dea6a3fbd55d800b7bf13a71becacc4ebce33d96d8d5481ccb", "class_name": "RelatedNodeInfo"}}, "text": "While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us. ", "start_char_idx": 1714, "end_char_idx": 1900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f63e2b-5df2-4908-8b25-2f41ca8a34af": {"__data__": {"id_": "f4f63e2b-5df2-4908-8b25-2f41ca8a34af", "embedding": null, "metadata": {"window": "We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n", "original_text": "We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b88111c-17fe-408d-9c97-3f1c9720ee60", "node_type": "1", "metadata": {"window": "At Investor Day, Aaron detailed our new long -term capital allocation framework, which builds upon \nour long -standing priorities with some notable enhancements.  We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward. ", "original_text": "While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "683605afe7dd8ac02f3ec40a5d375e13ec84092d72a0b067e7e3a03cdc17357f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9048aac-e95c-4976-b8ea-555e8a71a832", "node_type": "1", "metadata": {"window": "And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n", "original_text": "To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients. "}, "hash": "d21444fcd2f32e5aee24196eba4abb855a38d7d84a3c0b239d80bff82e396531", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n", "start_char_idx": 1900, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9048aac-e95c-4976-b8ea-555e8a71a832": {"__data__": {"id_": "c9048aac-e95c-4976-b8ea-555e8a71a832", "embedding": null, "metadata": {"window": "And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n", "original_text": "To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f63e2b-5df2-4908-8b25-2f41ca8a34af", "node_type": "1", "metadata": {"window": "We\u2019re pleased that with our strong \ncash flow profile and the significant progress we\u2019ve made on o ur balance sheet, we have the flexibility \nfor share repurchases each and every year.  And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n", "original_text": "We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2eb46e88b65d0ca178eba52e488b00df5795411b6846a461ef6abcc210772b43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4e5a609-4d37-450c-b488-b4906c4c9264", "node_type": "1", "metadata": {"window": "While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad. ", "original_text": "Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward. "}, "hash": "553037fea9f34c3c3271971652d12f434164d65a8d1b573b91c70e4f7419f6d8", "class_name": "RelatedNodeInfo"}}, "text": "To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients. ", "start_char_idx": 2055, "end_char_idx": 2221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4e5a609-4d37-450c-b488-b4906c4c9264": {"__data__": {"id_": "e4e5a609-4d37-450c-b488-b4906c4c9264", "embedding": null, "metadata": {"window": "While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad. ", "original_text": "Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9048aac-e95c-4976-b8ea-555e8a71a832", "node_type": "1", "metadata": {"window": "And, with the residual cash flow that we anticipate, we\u2019ll \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  \n \n While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n", "original_text": "To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "216a204150d31d76b5163d7630e36c829b4fa1239f7e8dd4a31d43cde3d031a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2443380e-8a22-4cb2-8558-49d5c37d92b5", "node_type": "1", "metadata": {"window": "We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P. ", "original_text": "I am excited for the opportunities still to \ncome.  \n \n"}, "hash": "31116c977b89032b176979d47ece17f693f52438ec23316b852d34b475a17d28", "class_name": "RelatedNodeInfo"}}, "text": "Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward. ", "start_char_idx": 2221, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2443380e-8a22-4cb2-8558-49d5c37d92b5": {"__data__": {"id_": "2443380e-8a22-4cb2-8558-49d5c37d92b5", "embedding": null, "metadata": {"window": "We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P. ", "original_text": "I am excited for the opportunities still to \ncome.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4e5a609-4d37-450c-b488-b4906c4c9264", "node_type": "1", "metadata": {"window": "While our team has made significant progress over the past year, particularly in realigning our \noperations for focus and simplicity, there is still work and opportunity in front of us.  We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad. ", "original_text": "Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe80413c23a4b8bb18967db56f8f4d133dc2ac660c735f3500477fa84db8d646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03686922-a56d-4235-8a0f-0749474c7300", "node_type": "1", "metadata": {"window": "To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n", "original_text": "With that, we will take your questions.  \n \n"}, "hash": "292799ad850aaa62462b56b86ede9d2fce1e66a58197ffca25a5aa985f4f8488", "class_name": "RelatedNodeInfo"}}, "text": "I am excited for the opportunities still to \ncome.  \n \n", "start_char_idx": 2319, "end_char_idx": 2374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03686922-a56d-4235-8a0f-0749474c7300": {"__data__": {"id_": "03686922-a56d-4235-8a0f-0749474c7300", "embedding": null, "metadata": {"window": "To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n", "original_text": "With that, we will take your questions.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2443380e-8a22-4cb2-8558-49d5c37d92b5", "node_type": "1", "metadata": {"window": "We continue to \nevaluate additional value creation initiatives, includi ng the progress we are making with our ongoing \nbusiness and portfolio review.  \n \n To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P. ", "original_text": "I am excited for the opportunities still to \ncome.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11c5c48bf60ec97d0fb085326dcd29cc1717ee04618e098f3db7e529204b42fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b77b4473-6615-4004-87e9-74f8b78a68da", "node_type": "1", "metadata": {"window": "Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad. "}, "hash": "10fb596a841db5749699336760a10b204b8771f4f465d0436b719b5546ca91fe", "class_name": "RelatedNodeInfo"}}, "text": "With that, we will take your questions.  \n \n", "start_char_idx": 2374, "end_char_idx": 2418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b77b4473-6615-4004-87e9-74f8b78a68da": {"__data__": {"id_": "b77b4473-6615-4004-87e9-74f8b78a68da", "embedding": null, "metadata": {"window": "Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03686922-a56d-4235-8a0f-0749474c7300", "node_type": "1", "metadata": {"window": "To wrap up, I want to acknowledge our dedicated Cardinal Health employees, who are fulfilling our \nessential role in healthcare serving customers and their patients.  Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n", "original_text": "With that, we will take your questions.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1001e1a03429873123489913e2be4c67f722c03d37ce5e8e4fa97d7dd7312205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae2a8932-de6a-48fd-961c-5157ec1c23e8", "node_type": "1", "metadata": {"window": "I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter. ", "original_text": "Our first question today comes from Lisa Gill of J.P. "}, "hash": "e63f731366606c309c769cac6e87c2499bfb00c54b12fcc4a73508125999df11", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad. ", "start_char_idx": 2418, "end_char_idx": 2539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae2a8932-de6a-48fd-961c-5157ec1c23e8": {"__data__": {"id_": "ae2a8932-de6a-48fd-961c-5157ec1c23e8", "embedding": null, "metadata": {"window": "I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter. ", "original_text": "Our first question today comes from Lisa Gill of J.P. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b77b4473-6615-4004-87e9-74f8b78a68da", "node_type": "1", "metadata": {"window": "Thank you fo r your determination in \nadvancing our key priorities and moving healthcare forward.  I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7b8fc752db035c3daacd78d3efd7247bdd335525d91890df6b9b09a47d750c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae0fee92-7240-41db-b108-b0feb6cb2082", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment. ", "original_text": "Morgan.  \n \n"}, "hash": "3a66cb3651d06c3cd954616dd2cfeea6f859eb8dc3c9ed443d54ce9ab8a3c9f2", "class_name": "RelatedNodeInfo"}}, "text": "Our first question today comes from Lisa Gill of J.P. ", "start_char_idx": 2539, "end_char_idx": 2593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae0fee92-7240-41db-b108-b0feb6cb2082": {"__data__": {"id_": "ae0fee92-7240-41db-b108-b0feb6cb2082", "embedding": null, "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment. ", "original_text": "Morgan.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae2a8932-de6a-48fd-961c-5157ec1c23e8", "node_type": "1", "metadata": {"window": "I am excited for the opportunities still to \ncome.  \n \n With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter. ", "original_text": "Our first question today comes from Lisa Gill of J.P. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f46d8712da056f80b6700ed371c5664527eb4298271bcb0ba92c1a4cea149d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "191e01eb-05f9-4ee9-a66b-69ba49d8ba0a", "node_type": "1", "metadata": {"window": "Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points. ", "original_text": "Lisa Gill:  Thanks very much. "}, "hash": "88c92939f74208312dbbf5568562d1598d0ead2765ff81c0f3a824713763c5d4", "class_name": "RelatedNodeInfo"}}, "text": "Morgan.  \n \n", "start_char_idx": 2593, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "191e01eb-05f9-4ee9-a66b-69ba49d8ba0a": {"__data__": {"id_": "191e01eb-05f9-4ee9-a66b-69ba49d8ba0a", "embedding": null, "metadata": {"window": "Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points. ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae0fee92-7240-41db-b108-b0feb6cb2082", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment. ", "original_text": "Morgan.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e66afcc34d6df8a6d0a338c069f572ec3ac6e1e9ae43724a5454b7fd2a6efa5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26d356bd-8427-4027-a4a7-3ae524604852", "node_type": "1", "metadata": {"window": "Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1? ", "original_text": "Good morning , and congratulations on the quarter. "}, "hash": "d486d5317da510adabb0a662aa35367b779dd7c9f8c899f1384e2946aedffb64", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Thanks very much. ", "start_char_idx": 2605, "end_char_idx": 2635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26d356bd-8427-4027-a4a7-3ae524604852": {"__data__": {"id_": "26d356bd-8427-4027-a4a7-3ae524604852", "embedding": null, "metadata": {"window": "Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1? ", "original_text": "Good morning , and congratulations on the quarter. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "191e01eb-05f9-4ee9-a66b-69ba49d8ba0a", "node_type": "1", "metadata": {"window": "Operator :  And as a reminder, if you do have a question, please signal by pressi ng star one on your \ntelephone keypad.  Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points. ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64ed265c80ef6f6ece143f1d929d117eff1660ebae6a1d0496cdb3dbd75bfa7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3d0c591-1f9b-4bb5-b11a-7f118013f2cd", "node_type": "1", "metadata": {"window": "Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars. ", "original_text": "I just really want to \nstart with the GLP -1 comment. "}, "hash": "a1f1659a66450c612380e4c5e1176a344af0925b171f25dc4377bd2462bad27a", "class_name": "RelatedNodeInfo"}}, "text": "Good morning , and congratulations on the quarter. ", "start_char_idx": 2635, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3d0c591-1f9b-4bb5-b11a-7f118013f2cd": {"__data__": {"id_": "b3d0c591-1f9b-4bb5-b11a-7f118013f2cd", "embedding": null, "metadata": {"window": "Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars. ", "original_text": "I just really want to \nstart with the GLP -1 comment. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26d356bd-8427-4027-a4a7-3ae524604852", "node_type": "1", "metadata": {"window": "Our first question today comes from Lisa Gill of J.P.  Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1? ", "original_text": "Good morning , and congratulations on the quarter. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cb5584230841b32daf8c3daeeab1ba119b264b9bf68623e6ddb4104628e4d31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f63a07ed-a853-4268-b87c-fd7e2162e3e9", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "So , I understand you're raising revenue by 200 basis points. "}, "hash": "04f1b62bc56ecd56b7150e601dc30d223452bd716afcc5a5bebbccc2d6178c65", "class_name": "RelatedNodeInfo"}}, "text": "I just really want to \nstart with the GLP -1 comment. ", "start_char_idx": 2686, "end_char_idx": 2740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f63a07ed-a853-4268-b87c-fd7e2162e3e9": {"__data__": {"id_": "f63a07ed-a853-4268-b87c-fd7e2162e3e9", "embedding": null, "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "So , I understand you're raising revenue by 200 basis points. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3d0c591-1f9b-4bb5-b11a-7f118013f2cd", "node_type": "1", "metadata": {"window": "Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars. ", "original_text": "I just really want to \nstart with the GLP -1 comment. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d490fe0d3ac211a28dce4040f074e895d6484e9a16ddc518ff2cc4e478a86618", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6317ab7a-0b39-427b-93ba-5d08b7cf8bd7", "node_type": "1", "metadata": {"window": "Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "One, is \nthat all GLP -1? "}, "hash": "a671e40c483f68b954597de0bcb6f6f7b07654cec085212a89e126695d76a4a8", "class_name": "RelatedNodeInfo"}}, "text": "So , I understand you're raising revenue by 200 basis points. ", "start_char_idx": 2740, "end_char_idx": 2802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6317ab7a-0b39-427b-93ba-5d08b7cf8bd7": {"__data__": {"id_": "6317ab7a-0b39-427b-93ba-5d08b7cf8bd7", "embedding": null, "metadata": {"window": "Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "One, is \nthat all GLP -1? ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f63a07ed-a853-4268-b87c-fd7e2162e3e9", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "So , I understand you're raising revenue by 200 basis points. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54bcd9fa4f7cdeadd7e39ade2a0399557371a1678cb5a61446b1b586908e23a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acb59e7b-56ba-4cf5-a983-4e3e864d6a48", "node_type": "1", "metadata": {"window": "I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars. "}, "hash": "d340938e03edf711f11b496fe8397ccb7283207c1f6ba7a503658e5e6096563a", "class_name": "RelatedNodeInfo"}}, "text": "One, is \nthat all GLP -1? ", "start_char_idx": 2802, "end_char_idx": 2828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acb59e7b-56ba-4cf5-a983-4e3e864d6a48": {"__data__": {"id_": "acb59e7b-56ba-4cf5-a983-4e3e864d6a48", "embedding": null, "metadata": {"window": "I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6317ab7a-0b39-427b-93ba-5d08b7cf8bd7", "node_type": "1", "metadata": {"window": "Good morning , and congratulations on the quarter.  I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "One, is \nthat all GLP -1? ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bfa506829ba0f04f29ef48efcdd2242ba9da2d7a7b779eef10db51491173b70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc7f1541-c476-4604-beb1-19798eff413b", "node_type": "1", "metadata": {"window": "So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n "}, "hash": "d9a354fed07e5ce9e8a354c27996dd9691f64926560a719c1100b43d56a851f9", "class_name": "RelatedNodeInfo"}}, "text": "And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars. ", "start_char_idx": 2828, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc7f1541-c476-4604-beb1-19798eff413b": {"__data__": {"id_": "bc7f1541-c476-4604-beb1-19798eff413b", "embedding": null, "metadata": {"window": "So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8efea8cff7572820d5edeaba412dab3b8e286ad1b4351c38421611c33edbcdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acb59e7b-56ba-4cf5-a983-4e3e864d6a48", "node_type": "1", "metadata": {"window": "I just really want to \nstart with the GLP -1 comment.  So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "975b5fefa3977991c319df8135875ac3ec1f2432fb78a4bcb2ace6194c1c7bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a390a3a-cf35-4939-a7ee-aa78f3ec08b5", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. ", "original_text": " \nPage 10 of 17 \n \nJason Hollar:  Yeah. "}, "hash": "766e99f9acbdb640cb52d839c1e927ac10f4d0e1da193bc76cf47d0b328bb0fa", "class_name": "RelatedNodeInfo"}}, "text": "Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "start_char_idx": 2942, "end_char_idx": 3069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a390a3a-cf35-4939-a7ee-aa78f3ec08b5": {"__data__": {"id_": "8a390a3a-cf35-4939-a7ee-aa78f3ec08b5", "embedding": null, "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. ", "original_text": " \nPage 10 of 17 \n \nJason Hollar:  Yeah. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc7f1541-c476-4604-beb1-19798eff413b", "node_type": "1", "metadata": {"window": "So , I understand you're raising revenue by 200 basis points.  One, is \nthat all GLP -1?  And two, my understanding is that they are a low er margin, but they are contributory \nto overall margin dollars.  Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "original_text": "Is that not the case when you're keeping the profit the same , and when I \nthink about the Pharmaceutical segment for 2024?  \n ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc7e486ece0b4ca845ed4da3de1cf854bb365d159173a6b96abf97ae3732aaca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baf9fa0d-35a0-459a-bb12-384a702a05df", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n", "original_text": "Good morning, Lisa. "}, "hash": "913568a7fc4afe990908a6a5cc5e2a12cac0a8cd87cb75a3a2be94add6d48ef6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 17 \n \nJason Hollar:  Yeah. ", "start_char_idx": 0, "end_char_idx": 40, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baf9fa0d-35a0-459a-bb12-384a702a05df": {"__data__": {"id_": "baf9fa0d-35a0-459a-bb12-384a702a05df", "embedding": null, "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n", "original_text": "Good morning, Lisa. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a390a3a-cf35-4939-a7ee-aa78f3ec08b5", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. ", "original_text": " \nPage 10 of 17 \n \nJason Hollar:  Yeah. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd8f26f8f3ac312210a425728653b4b2bd88fdfc1fca91547a1258e76a64c360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64f389c1-dc97-4993-9f65-a7a1ae70da62", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that. ", "original_text": "Thanks for the question. "}, "hash": "365ee46371e158b37637fc7497d8b215e36f679c648da9c8fc05c10cbd349d37", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Lisa. ", "start_char_idx": 40, "end_char_idx": 60, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64f389c1-dc97-4993-9f65-a7a1ae70da62": {"__data__": {"id_": "64f389c1-dc97-4993-9f65-a7a1ae70da62", "embedding": null, "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that. ", "original_text": "Thanks for the question. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baf9fa0d-35a0-459a-bb12-384a702a05df", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n", "original_text": "Good morning, Lisa. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b120492ad60ec3f4f2ab5ed1b9f70ab84ea0203423cf51478a37301f0bc4f1ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f920913-5773-4b2e-b747-b7f8cb653cad", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends. ", "original_text": "Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. "}, "hash": "d3da2cbffcff4c460ca0fae8b3ded5c23fe045d8f18cd63bc269a24ca28d50cb", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 60, "end_char_idx": 85, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f920913-5773-4b2e-b747-b7f8cb653cad": {"__data__": {"id_": "4f920913-5773-4b2e-b747-b7f8cb653cad", "embedding": null, "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends. ", "original_text": "Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64f389c1-dc97-4993-9f65-a7a1ae70da62", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that. ", "original_text": "Thanks for the question. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d55c5f333cf37b1923e7874b2da31cf6d3b1c322fa6da986cd14de527fb86a36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "605be9d0-65f7-47ba-bc46-9a1f9d7f30da", "node_type": "1", "metadata": {"window": "Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter. ", "original_text": "So, we did not call out anything else. \n"}, "hash": "19212261cd786957121d2d959bddc791638ed1451a6d88bfaecc21d92f361908", "class_name": "RelatedNodeInfo"}}, "text": "Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. ", "start_char_idx": 85, "end_char_idx": 181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "605be9d0-65f7-47ba-bc46-9a1f9d7f30da": {"__data__": {"id_": "605be9d0-65f7-47ba-bc46-9a1f9d7f30da", "embedding": null, "metadata": {"window": "Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter. ", "original_text": "So, we did not call out anything else. \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f920913-5773-4b2e-b747-b7f8cb653cad", "node_type": "1", "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends. ", "original_text": "Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06bc54ae02320cd94baeec3be94e1f6e58a441b855ef490637b08ba5fec6383f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d639fc70-5340-4de3-9ec8-cccdabca7f2c", "node_type": "1", "metadata": {"window": "Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant. ", "original_text": "We saw a strong finish to the year as it relates to that. "}, "hash": "944b5f63e55e8468a3b05428cc6d2c3e4f1e8787e9dd508bd9bd6da922cadacd", "class_name": "RelatedNodeInfo"}}, "text": "So, we did not call out anything else. \n", "start_char_idx": 181, "end_char_idx": 221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d639fc70-5340-4de3-9ec8-cccdabca7f2c": {"__data__": {"id_": "d639fc70-5340-4de3-9ec8-cccdabca7f2c", "embedding": null, "metadata": {"window": "Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant. ", "original_text": "We saw a strong finish to the year as it relates to that. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "605be9d0-65f7-47ba-bc46-9a1f9d7f30da", "node_type": "1", "metadata": {"window": "Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter. ", "original_text": "So, we did not call out anything else. \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72a456fbcee55d7c36157ec17fe23f02d875b26b1a7916e32fa0b7f9f7a6a7c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fd36ed9-bf10-426d-a8d9-cf6587ffe8ba", "node_type": "1", "metadata": {"window": "Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.  ", "original_text": "And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends. "}, "hash": "a209aed2ef265290baafa8cfb9f2ec4073ebc1cf901d1dc47c6ac3dea1ef7107", "class_name": "RelatedNodeInfo"}}, "text": "We saw a strong finish to the year as it relates to that. ", "start_char_idx": 221, "end_char_idx": 279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fd36ed9-bf10-426d-a8d9-cf6587ffe8ba": {"__data__": {"id_": "6fd36ed9-bf10-426d-a8d9-cf6587ffe8ba", "embedding": null, "metadata": {"window": "Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.  ", "original_text": "And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d639fc70-5340-4de3-9ec8-cccdabca7f2c", "node_type": "1", "metadata": {"window": "Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant. ", "original_text": "We saw a strong finish to the year as it relates to that. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357a6a46e302a6adcb67c3426b5e3bbb4376bb073721db416bd824eb8dc52845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "befbbe65-c5c6-4cd4-abfa-547deb152c09", "node_type": "1", "metadata": {"window": "So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor. ", "original_text": "As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter. "}, "hash": "32b232bd318d261c9d2609f3c27aa05475d6830d89da93d8013fcd073d490d9e", "class_name": "RelatedNodeInfo"}}, "text": "And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends. ", "start_char_idx": 279, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "befbbe65-c5c6-4cd4-abfa-547deb152c09": {"__data__": {"id_": "befbbe65-c5c6-4cd4-abfa-547deb152c09", "embedding": null, "metadata": {"window": "So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor. ", "original_text": "As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fd36ed9-bf10-426d-a8d9-cf6587ffe8ba", "node_type": "1", "metadata": {"window": "Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1.  So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.  ", "original_text": "And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba1bbc7c010ead271b85b76bee8891e1f08e7bd413de8ece509fdd16a2db64da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4bfad88-458c-4406-8fd5-2cda264161dc", "node_type": "1", "metadata": {"window": "We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n", "original_text": "So, we have kind of a -- there was growth before that, but not as significant. "}, "hash": "795f3298b722f2a27385090ac4b740f445ac5d91776dcf1ea9783fe88d00e385", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter. ", "start_char_idx": 398, "end_char_idx": 550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4bfad88-458c-4406-8fd5-2cda264161dc": {"__data__": {"id_": "d4bfad88-458c-4406-8fd5-2cda264161dc", "embedding": null, "metadata": {"window": "We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n", "original_text": "So, we have kind of a -- there was growth before that, but not as significant. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "befbbe65-c5c6-4cd4-abfa-547deb152c09", "node_type": "1", "metadata": {"window": "So, we did not call out anything else. \n We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor. ", "original_text": "As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc0d3e4e7773066c1997a3f72b9c8b43b64e49afbcb1e3eae726f9063b02bcaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc407028-0830-46f2-92c7-35ba1feb53ca", "node_type": "1", "metadata": {"window": "And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products. ", "original_text": "And so, \nit was more meaningful in Q3 and Q4.  "}, "hash": "c45432151324eaa30a33f3f33bff22f2d64309ed8d81fa21fb68b206512a8a03", "class_name": "RelatedNodeInfo"}}, "text": "So, we have kind of a -- there was growth before that, but not as significant. ", "start_char_idx": 550, "end_char_idx": 629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc407028-0830-46f2-92c7-35ba1feb53ca": {"__data__": {"id_": "dc407028-0830-46f2-92c7-35ba1feb53ca", "embedding": null, "metadata": {"window": "And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products. ", "original_text": "And so, \nit was more meaningful in Q3 and Q4.  ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4bfad88-458c-4406-8fd5-2cda264161dc", "node_type": "1", "metadata": {"window": "We saw a strong finish to the year as it relates to that.  And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n", "original_text": "So, we have kind of a -- there was growth before that, but not as significant. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42ce9815a4f12ce885276a979e87b6e2b41c9854b3aac6584a035b11c9955d72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "002c969e-2743-4f35-a0b5-8623944eea17", "node_type": "1", "metadata": {"window": "As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n", "original_text": "So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor. "}, "hash": "82c5c050b4cc3bbce6864d76421ba42b7daf4ed1c29657169781fe7b7c848284", "class_name": "RelatedNodeInfo"}}, "text": "And so, \nit was more meaningful in Q3 and Q4.  ", "start_char_idx": 629, "end_char_idx": 676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "002c969e-2743-4f35-a0b5-8623944eea17": {"__data__": {"id_": "002c969e-2743-4f35-a0b5-8623944eea17", "embedding": null, "metadata": {"window": "As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n", "original_text": "So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc407028-0830-46f2-92c7-35ba1feb53ca", "node_type": "1", "metadata": {"window": "And looking forward, we see that there's \nnothing that we can foresee in the near -term that will change those trends.  As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products. ", "original_text": "And so, \nit was more meaningful in Q3 and Q4.  ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b842286dfb285b13a68aac2185fb0dabb210b754cad6c97218719b9c0267c6d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92ad6e4d-0d29-4630-8652-1cec521e4630", "node_type": "1", "metadata": {"window": "So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n", "original_text": "Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n"}, "hash": "17acb36d0aaf134f918880f04c46a8fd26c94c5b1bc052f4254e59521c8fa012", "class_name": "RelatedNodeInfo"}}, "text": "So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor. ", "start_char_idx": 676, "end_char_idx": 832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92ad6e4d-0d29-4630-8652-1cec521e4630": {"__data__": {"id_": "92ad6e4d-0d29-4630-8652-1cec521e4630", "embedding": null, "metadata": {"window": "So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n", "original_text": "Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "002c969e-2743-4f35-a0b5-8623944eea17", "node_type": "1", "metadata": {"window": "As a reminder, we did call \nout for the first time GLP -1 as a benef it to our revenue from a year -over-year growth perspective in \nthe third quarter.  So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n", "original_text": "So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d3eed6cc8ea8026b8f64b84fb8f0e71b5f3ede61aaef088013f1720f3726eb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68dc9ab7-a5ac-4c75-bd4b-85c17d4eb99d", "node_type": "1", "metadata": {"window": "And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n", "original_text": "And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products. "}, "hash": "68cc490515ebb2cfd4d1cd412824efb98834a990d80c9c39f75f89967b46e951", "class_name": "RelatedNodeInfo"}}, "text": "Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n", "start_char_idx": 832, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68dc9ab7-a5ac-4c75-bd4b-85c17d4eb99d": {"__data__": {"id_": "68dc9ab7-a5ac-4c75-bd4b-85c17d4eb99d", "embedding": null, "metadata": {"window": "And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n", "original_text": "And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92ad6e4d-0d29-4630-8652-1cec521e4630", "node_type": "1", "metadata": {"window": "So, we have kind of a -- there was growth before that, but not as significant.  And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n", "original_text": "Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "663cf8134ddad5fa1b0daae37294dafdadcc4abaceeb33407df3b14d53194786", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50730c4f-18ae-4282-a42d-48db5afa7ed8", "node_type": "1", "metadata": {"window": "So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance. ", "original_text": "And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n"}, "hash": "7d03a4979a303e71c135e6a76d28f35748834eadb5d7485d5ee6ea62ea7e65ea", "class_name": "RelatedNodeInfo"}}, "text": "And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products. ", "start_char_idx": 1054, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50730c4f-18ae-4282-a42d-48db5afa7ed8": {"__data__": {"id_": "50730c4f-18ae-4282-a42d-48db5afa7ed8", "embedding": null, "metadata": {"window": "So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance. ", "original_text": "And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68dc9ab7-a5ac-4c75-bd4b-85c17d4eb99d", "node_type": "1", "metadata": {"window": "And so, \nit was more meaningful in Q3 and Q4.   So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n", "original_text": "And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c36c6ecc27ef5bc3606e7cc2debef75a4183a2ebe784f43dfe6cae31e7a93bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70636836-aac2-4955-8aca-5aaf9d58aaba", "node_type": "1", "metadata": {"window": "Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million. ", "original_text": "Kevin Moran:   Next question please.  \n \n"}, "hash": "0a756166db6318ce9df9ff992ea17af0f2d812f9ef46817121db6f690d8cdc02", "class_name": "RelatedNodeInfo"}}, "text": "And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n", "start_char_idx": 1175, "end_char_idx": 1280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70636836-aac2-4955-8aca-5aaf9d58aaba": {"__data__": {"id_": "70636836-aac2-4955-8aca-5aaf9d58aaba", "embedding": null, "metadata": {"window": "Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million. ", "original_text": "Kevin Moran:   Next question please.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50730c4f-18ae-4282-a42d-48db5afa7ed8", "node_type": "1", "metadata": {"window": "So, as you look forward to fiscal \u201824, you would expec t that \nrevenue growth to be stronger in the first half of the year as that's more of a contributor.  Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance. ", "original_text": "And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "101f8aac56354246b64783b83920e8ccb567980f254ea5d6385a37c19f8b9dbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6ca834b-3f89-43c1-bcf4-50dff9aff771", "node_type": "1", "metadata": {"window": "And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n", "original_text": "Operator:  The next question comes from Eric Percher of Nephron Research . \n \n"}, "hash": "2ed3349b0014406550c3dafb260ec7828b0e8c26f40ca6ff56fc0b8b95b815e3", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:   Next question please.  \n \n", "start_char_idx": 1280, "end_char_idx": 1321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6ca834b-3f89-43c1-bcf4-50dff9aff771": {"__data__": {"id_": "e6ca834b-3f89-43c1-bcf4-50dff9aff771", "embedding": null, "metadata": {"window": "And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n", "original_text": "Operator:  The next question comes from Eric Percher of Nephron Research . \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70636836-aac2-4955-8aca-5aaf9d58aaba", "node_type": "1", "metadata": {"window": "Now of \ncourse, we don't know what that slope is going to look like into \u201824, but we would anticipate as you \nstart to lap the second half of \u201823 that, that w ill be more muted in terms of the year -over-year benefit.  \n \n And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million. ", "original_text": "Kevin Moran:   Next question please.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "522530e78de0bd6cb648d029e1b530b4c77c4492359714fcec86b9e2b615d68c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d2bb25c-2cd2-48bb-9b13-58f4ba30f85e", "node_type": "1", "metadata": {"window": "And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning. ", "original_text": "Eric Percher:  Thanks for all the commentary on Medical performance. "}, "hash": "503c2437a27ce5be43f31f785d9a8fc48e92fc0f49d27b500d9db379c2ddda59", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from Eric Percher of Nephron Research . \n \n", "start_char_idx": 1321, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d2bb25c-2cd2-48bb-9b13-58f4ba30f85e": {"__data__": {"id_": "5d2bb25c-2cd2-48bb-9b13-58f4ba30f85e", "embedding": null, "metadata": {"window": "And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning. ", "original_text": "Eric Percher:  Thanks for all the commentary on Medical performance. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6ca834b-3f89-43c1-bcf4-50dff9aff771", "node_type": "1", "metadata": {"window": "And I guess as it relates to your second part of your question, I would just reiterate that these are \nbranded products.  And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n", "original_text": "Operator:  The next question comes from Eric Percher of Nephron Research . \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c242192dbd280aaa7e546940aed45ac44116c009b6fc15717356bc5fa2b337a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7173154b-5743-4e9d-8f35-11e9a9cb720c", "node_type": "1", "metadata": {"window": "Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that. ", "original_text": "I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million. "}, "hash": "73a35996c6ff4e5f9e3799a6356e458b15bf34304a8570f090833f184f7d7d3e", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:  Thanks for all the commentary on Medical performance. ", "start_char_idx": 1399, "end_char_idx": 1468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7173154b-5743-4e9d-8f35-11e9a9cb720c": {"__data__": {"id_": "7173154b-5743-4e9d-8f35-11e9a9cb720c", "embedding": null, "metadata": {"window": "Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that. ", "original_text": "I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d2bb25c-2cd2-48bb-9b13-58f4ba30f85e", "node_type": "1", "metadata": {"window": "And as such, they're just not a meaningful contributor to segment profit and just \nleave it at that.  \n \n Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning. ", "original_text": "Eric Percher:  Thanks for all the commentary on Medical performance. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cb8d1dfd6f2c891b555ccdd5c7f7703541bcf9fc17e43b3f85e711b91619eff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2a85ba8-fa02-422a-bf8b-4fa2b0682cfe", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results. ", "original_text": "And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n"}, "hash": "49832431579916725d748a60e82426c9b3f873de5092b38df68809ace3022a37", "class_name": "RelatedNodeInfo"}}, "text": "I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million. ", "start_char_idx": 1468, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2a85ba8-fa02-422a-bf8b-4fa2b0682cfe": {"__data__": {"id_": "d2a85ba8-fa02-422a-bf8b-4fa2b0682cfe", "embedding": null, "metadata": {"window": "Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results. ", "original_text": "And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7173154b-5743-4e9d-8f35-11e9a9cb720c", "node_type": "1", "metadata": {"window": "Kevin Moran:   Next question please.  \n \n Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that. ", "original_text": "I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f0c9aba4021cd74163da9277b38af1ff044075008a51f7a984be36e019f8556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cddc03d-83e0-47d4-b30e-6b09528272b5", "node_type": "1", "metadata": {"window": "Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter . ", "original_text": "Aaron Alt:   Eric, good morning. "}, "hash": "5c248e4872f62daf7a3071de2b935c43b4bbb480b9ca117e4b2bc1c16b62d3f4", "class_name": "RelatedNodeInfo"}}, "text": "And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n", "start_char_idx": 1615, "end_char_idx": 1784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cddc03d-83e0-47d4-b30e-6b09528272b5": {"__data__": {"id_": "2cddc03d-83e0-47d4-b30e-6b09528272b5", "embedding": null, "metadata": {"window": "Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter . ", "original_text": "Aaron Alt:   Eric, good morning. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2a85ba8-fa02-422a-bf8b-4fa2b0682cfe", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Eric Percher of Nephron Research . \n \n Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results. ", "original_text": "And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "397bc79fe8392736c5fc0974feb5c9d282021e885bd1f90aa73a2cf2e506e926", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e61369bd-8c50-4609-a430-63917b232bb1", "node_type": "1", "metadata": {"window": "I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n", "original_text": "Good to hear your voice , and happy to give you a little more context \non that. "}, "hash": "f877b631ef4bcdbc41cb7606f9a8533cc81c0e9ee443517affb2ed6e260cb265", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:   Eric, good morning. ", "start_char_idx": 1784, "end_char_idx": 1817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e61369bd-8c50-4609-a430-63917b232bb1": {"__data__": {"id_": "e61369bd-8c50-4609-a430-63917b232bb1", "embedding": null, "metadata": {"window": "I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n", "original_text": "Good to hear your voice , and happy to give you a little more context \non that. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cddc03d-83e0-47d4-b30e-6b09528272b5", "node_type": "1", "metadata": {"window": "Eric Percher:  Thanks for all the commentary on Medical performance.  I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter . ", "original_text": "Aaron Alt:   Eric, good morning. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab6c5e66c896da414b4466eaa6572bb9cc332e86f2f07cf23b4bc1b7434285b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7ddf1bd-edc4-435c-aedc-ab0910d482c2", "node_type": "1", "metadata": {"window": "And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear. ", "original_text": "Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results. "}, "hash": "19d73cb0c944010fe500e3f50e5977fea48bd9de73f030a7b0ff76a9b3a0d888", "class_name": "RelatedNodeInfo"}}, "text": "Good to hear your voice , and happy to give you a little more context \non that. ", "start_char_idx": 1817, "end_char_idx": 1897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7ddf1bd-edc4-435c-aedc-ab0910d482c2": {"__data__": {"id_": "f7ddf1bd-edc4-435c-aedc-ab0910d482c2", "embedding": null, "metadata": {"window": "And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear. ", "original_text": "Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e61369bd-8c50-4609-a430-63917b232bb1", "node_type": "1", "metadata": {"window": "I want to make sure we're kind \nof precise on the core performance and the stepping off point there would be around $60 million, not \n$82 million.  And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n", "original_text": "Good to hear your voice , and happy to give you a little more context \non that. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb9ba7ac0fe87ecd6421fe153f984745c105cce1cde6d026000f832090d52113", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a03e2ac-c3a6-4881-8955-f383ecde5cff", "node_type": "1", "metadata": {"window": "Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well. ", "original_text": "That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter . "}, "hash": "a5d2cfb7882f3e125ef3ef5aace91e7cbb694bded8819651756b95f93f5f578e", "class_name": "RelatedNodeInfo"}}, "text": "Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results. ", "start_char_idx": 1897, "end_char_idx": 2025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a03e2ac-c3a6-4881-8955-f383ecde5cff": {"__data__": {"id_": "5a03e2ac-c3a6-4881-8955-f383ecde5cff", "embedding": null, "metadata": {"window": "Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well. ", "original_text": "That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter . ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7ddf1bd-edc4-435c-aedc-ab0910d482c2", "node_type": "1", "metadata": {"window": "And then, can you define seasonality and one -time benefit s this quarter, and any \nexpectation that those will recur as we look at that cadence for fiscal year \u201824? \n \n Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear. ", "original_text": "Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "758c40f17f6da819837afce4c3629ae1443b21748577ef720d997d4bf6800d54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f55b4d3-5b7f-4cbb-a5b8-828c23fff459", "node_type": "1", "metadata": {"window": "Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces . ", "original_text": "And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n"}, "hash": "57d5b1f11cb43ab41814a8fdc96fa70cb6d9e45def28d9bd00f2001955708dd5", "class_name": "RelatedNodeInfo"}}, "text": "That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter . ", "start_char_idx": 2025, "end_char_idx": 2220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f55b4d3-5b7f-4cbb-a5b8-828c23fff459": {"__data__": {"id_": "0f55b4d3-5b7f-4cbb-a5b8-828c23fff459", "embedding": null, "metadata": {"window": "Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces . ", "original_text": "And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a03e2ac-c3a6-4881-8955-f383ecde5cff", "node_type": "1", "metadata": {"window": "Aaron Alt:   Eric, good morning.  Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well. ", "original_text": "That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter . ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c34c33c936f3cc6fac6d90f1c3a4eb646ebf3db1bbe3e37225a46377c7fdb791", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "877438de-935c-4c62-a1eb-5b1f60d6a7da", "node_type": "1", "metadata": {"window": "Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.  ", "original_text": "Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear. "}, "hash": "c8c15417bb09e321ffa618290c3260fa96f21722b9464352bedb663400da7e12", "class_name": "RelatedNodeInfo"}}, "text": "And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n", "start_char_idx": 2220, "end_char_idx": 2360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "877438de-935c-4c62-a1eb-5b1f60d6a7da": {"__data__": {"id_": "877438de-935c-4c62-a1eb-5b1f60d6a7da", "embedding": null, "metadata": {"window": "Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.  ", "original_text": "Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f55b4d3-5b7f-4cbb-a5b8-828c23fff459", "node_type": "1", "metadata": {"window": "Good to hear your voice , and happy to give you a little more context \non that.  Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces . ", "original_text": "And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f0ee7e28d6b823681e7aee560a8ebde69817422d83851f4c5fe356b68942f8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe8ce034-8adf-4f73-a340-089f9764eb67", "node_type": "1", "metadata": {"window": "That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this. ", "original_text": "The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well. "}, "hash": "f44b8b4ff619eee4fac9c3ee83c32059c55d0ca126bcddec8570f8e7ac4a9b74", "class_name": "RelatedNodeInfo"}}, "text": "Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear. ", "start_char_idx": 2360, "end_char_idx": 2574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe8ce034-8adf-4f73-a340-089f9764eb67": {"__data__": {"id_": "fe8ce034-8adf-4f73-a340-089f9764eb67", "embedding": null, "metadata": {"window": "That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this. ", "original_text": "The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "877438de-935c-4c62-a1eb-5b1f60d6a7da", "node_type": "1", "metadata": {"window": "Look, we were quite pleased with the re sults for Medical, as you can imagine, delivering that \n$82 million dollars of results.  That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.  ", "original_text": "Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ff9c84fb67779b68d24d86f1f3cadcf3fe5ca831d0127f0afd72ea8a74f73b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6d7e618-5423-4c20-8435-63511e745d0b", "node_type": "1", "metadata": {"window": "And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right? ", "original_text": "But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces . "}, "hash": "7050f6ddc4ab07d09275fe427c200f32be592a0f465781f926a2605b30edf706", "class_name": "RelatedNodeInfo"}}, "text": "The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well. ", "start_char_idx": 2574, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6d7e618-5423-4c20-8435-63511e745d0b": {"__data__": {"id_": "a6d7e618-5423-4c20-8435-63511e745d0b", "embedding": null, "metadata": {"window": "And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right? ", "original_text": "But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces . ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe8ce034-8adf-4f73-a340-089f9764eb67", "node_type": "1", "metadata": {"window": "That was $60 million  dollars  of what we're referring to as core \nperformance , and $20 million dollars in aggregate combined positive seasonality and one -time items \nin the  fourth  quarter .  And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this. ", "original_text": "The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4f0b18fe3dc6c95fe9b4904349b2198c63f46c3dc94ae8fe2a85974c9683e99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a51c71e-c819-4e16-8fb8-2b93809f9f95", "node_type": "1", "metadata": {"window": "Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total. ", "original_text": "The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.  "}, "hash": "fbccbc3af7e8637239451c702491e3edce6f6b99fc8b2b8b140ce9d9f88e2101", "class_name": "RelatedNodeInfo"}}, "text": "But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces . ", "start_char_idx": 2697, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a51c71e-c819-4e16-8fb8-2b93809f9f95": {"__data__": {"id_": "6a51c71e-c819-4e16-8fb8-2b93809f9f95", "embedding": null, "metadata": {"window": "Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total. ", "original_text": "The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.  ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6d7e618-5423-4c20-8435-63511e745d0b", "node_type": "1", "metadata": {"window": "And I called , I call it out purposely that way because it does impact how we think \nthrough the cadence of quarters during fiscal \u201824.  \n \n Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right? ", "original_text": "But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces . ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "543f5516dc116f85fbe8f6832737f4178d1670832d69d01715ed0866af98a7f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ccf31a6-3812-4e44-adae-f7882741a3ec", "node_type": "1", "metadata": {"window": "The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera. ", "original_text": "So, look from a full year perspective, the way I would have \nyou think about  it is this. "}, "hash": "7a76fe183d6f076deb2e04115d7f1c7e824906603ca3573da609d4eb1207920e", "class_name": "RelatedNodeInfo"}}, "text": "The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.  ", "start_char_idx": 2821, "end_char_idx": 2910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ccf31a6-3812-4e44-adae-f7882741a3ec": {"__data__": {"id_": "6ccf31a6-3812-4e44-adae-f7882741a3ec", "embedding": null, "metadata": {"window": "The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera. ", "original_text": "So, look from a full year perspective, the way I would have \nyou think about  it is this. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a51c71e-c819-4e16-8fb8-2b93809f9f95", "node_type": "1", "metadata": {"window": "Now before giving you a little more context on the quarterly guidance, I do want to go back and just \nobserve that we are reiterating the $400 million  dollar  profit target for the Medical segment from the \nyear.  The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total. ", "original_text": "The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.  ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d4b68dd5d0d8d341cac0f31216328be8c14086f612da92bfb8227adb1156f32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fb8a479-db7d-426f-844d-9e38327b5129", "node_type": "1", "metadata": {"window": "But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right? "}, "hash": "4468a19d16ca652f04c47c507492befb45cb482de19b147b75f6a734b707c708", "class_name": "RelatedNodeInfo"}}, "text": "So, look from a full year perspective, the way I would have \nyou think about  it is this. ", "start_char_idx": 2910, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fb8a479-db7d-426f-844d-9e38327b5129": {"__data__": {"id_": "0fb8a479-db7d-426f-844d-9e38327b5129", "embedding": null, "metadata": {"window": "But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right? ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ccf31a6-3812-4e44-adae-f7882741a3ec", "node_type": "1", "metadata": {"window": "The Medical Improvement Plan, the key components, that remain unchanged from our \ndescription at the Investor Day as well.  But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera. ", "original_text": "So, look from a full year perspective, the way I would have \nyou think about  it is this. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "959f9bb40773fab792f94f5a90023e11e4c8cdf64183813f01fc3aa7d87cc6d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c21a018f-e7e0-492a-8412-d0cbfad66933", "node_type": "1", "metadata": {"window": "The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total. "}, "hash": "0c3a9f1b3303946c91ce76b5de95a0ba618f7512c87c55aaf86061a8ff410e40", "class_name": "RelatedNodeInfo"}}, "text": "As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right? ", "start_char_idx": 3000, "end_char_idx": 3160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c21a018f-e7e0-492a-8412-d0cbfad66933": {"__data__": {"id_": "c21a018f-e7e0-492a-8412-d0cbfad66933", "embedding": null, "metadata": {"window": "The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fb8a479-db7d-426f-844d-9e38327b5129", "node_type": "1", "metadata": {"window": "But we are providing a litt le more color relative to how we see \nthe year playing out, given the number of moving pieces .  The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right? ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7581cfd5b236c7860e3a9ad08795d215e63cef4bd535964e4059412d62c0565", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17401196-61f6-4928-9d46-a057791dae04", "node_type": "1", "metadata": {"window": "So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera. "}, "hash": "b687d3d34cb2d019a3c5a408473e82067b9b8f1e087b26805fd355ef7ba51875", "class_name": "RelatedNodeInfo"}}, "text": "If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total. ", "start_char_idx": 3160, "end_char_idx": 3280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17401196-61f6-4928-9d46-a057791dae04": {"__data__": {"id_": "17401196-61f6-4928-9d46-a057791dae04", "embedding": null, "metadata": {"window": "So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c21a018f-e7e0-492a-8412-d0cbfad66933", "node_type": "1", "metadata": {"window": "The blocking and tackling as I referred to in \nmy prepared remarks as we carry forward.   So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b28598579edc5994e9bc1916e163280c322eba731b9e01121bd16f5c5b58a16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efd66b2f-a89d-4c23-8dbd-890b38674cf9", "node_type": "1", "metadata": {"window": "As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "That's a full year view of \nhow to think about it.  \n "}, "hash": "d786947b8134ae38a9b8ba1af4cc573385222c4d8796fa6d8343105c0843acce", "class_name": "RelatedNodeInfo"}}, "text": "And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera. ", "start_char_idx": 3280, "end_char_idx": 3476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efd66b2f-a89d-4c23-8dbd-890b38674cf9": {"__data__": {"id_": "efd66b2f-a89d-4c23-8dbd-890b38674cf9", "embedding": null, "metadata": {"window": "As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "That's a full year view of \nhow to think about it.  \n ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465fef64d24dce7298afdd09c1a1ca51f8264de92ceeb28ec7084e8ed23dcdc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17401196-61f6-4928-9d46-a057791dae04", "node_type": "1", "metadata": {"window": "So, look from a full year perspective, the way I would have \nyou think about  it is this.  As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f59668c76c56f129b3a8523acadf72afa686f4c44abbac2d9693368bb24fd47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13e9b329-f899-4eef-b7e3-70be7695dd47", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.  ", "original_text": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823. "}, "hash": "f4f356d34c618f96c9e29f022b6ac4e8d6965b6143d7ae20ca97af296a9de892", "class_name": "RelatedNodeInfo"}}, "text": "That's a full year view of \nhow to think about it.  \n ", "start_char_idx": 3476, "end_char_idx": 3530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13e9b329-f899-4eef-b7e3-70be7695dd47": {"__data__": {"id_": "13e9b329-f899-4eef-b7e3-70be7695dd47", "embedding": null, "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.  ", "original_text": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efd66b2f-a89d-4c23-8dbd-890b38674cf9", "node_type": "1", "metadata": {"window": "As I said at Investor Day, if you take $60 million dollars of core performance \nand multiply that by 4, that gets you to $240 million dollars of profit, right?  If you add $100 million  \ndollars  of incremental inflation net on top of that, that gets you to $340 million in total.  And as we \ntalked about at Investor Day, that leaves about $60 million  dollars  of contribution from other elements \nacross the year, the simplification of the Cardinal Heal th brand, et cetera.  That's a full year view of \nhow to think about it.  \n ", "original_text": "That's a full year view of \nhow to think about it.  \n ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9aecbb609f406fe85d7f5c5719d37d0e4e8944e0421d26013a22db3511019ce1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2a88f7c-7ad2-4635-847a-7b061eb457d2", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well. ", "original_text": "Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter. "}, "hash": "c046af08014db8c8c1ffece7eee78ad377fa32a91f7ea6175c5e16220e4f135c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823. ", "start_char_idx": 0, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2a88f7c-7ad2-4635-847a-7b061eb457d2": {"__data__": {"id_": "d2a88f7c-7ad2-4635-847a-7b061eb457d2", "embedding": null, "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well. ", "original_text": "Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13e9b329-f899-4eef-b7e3-70be7695dd47", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.  ", "original_text": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c200ee788795aea611cd7aa3a9b1e235161d51ff72a9f754992402b0adf02cb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02d25b04-8d8b-4c50-ba9a-ac7ea264906d", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half. ", "original_text": "Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition. "}, "hash": "ce11fd08dcd38a8ca712fc5c7e10b403269496a16a1039df1ac56093bd88a845", "class_name": "RelatedNodeInfo"}}, "text": "Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter. ", "start_char_idx": 179, "end_char_idx": 286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02d25b04-8d8b-4c50-ba9a-ac7ea264906d": {"__data__": {"id_": "02d25b04-8d8b-4c50-ba9a-ac7ea264906d", "embedding": null, "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half. ", "original_text": "Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2a88f7c-7ad2-4635-847a-7b061eb457d2", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well. ", "original_text": "Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6087b7620fe9a621f21ca6cb6f4ac472975e27c4cfe8e2c713e31c3570d4705", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64195392-e73e-40d7-8520-36a75f5f608d", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted. ", "original_text": "That's an important point.  "}, "hash": "db80b19f2d99565cfeabba489e37625eea3b8349ebddd0e42aa6f6809dc93fe7", "class_name": "RelatedNodeInfo"}}, "text": "Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition. ", "start_char_idx": 286, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64195392-e73e-40d7-8520-36a75f5f608d": {"__data__": {"id_": "64195392-e73e-40d7-8520-36a75f5f608d", "embedding": null, "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted. ", "original_text": "That's an important point.  ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02d25b04-8d8b-4c50-ba9a-ac7ea264906d", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half. ", "original_text": "Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "302585917cb5f807dd0a87e7b3d26a61925671c00717f417dde469380d7910a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b198f3a-87d5-4cb2-acc1-132fb5868a77", "node_type": "1", "metadata": {"window": "Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n", "original_text": "And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well. "}, "hash": "113ef551f3042c524fb8e345e7ea76a2a1de972a1a96cedcedadd7fe549654e1", "class_name": "RelatedNodeInfo"}}, "text": "That's an important point.  ", "start_char_idx": 432, "end_char_idx": 460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b198f3a-87d5-4cb2-acc1-132fb5868a77": {"__data__": {"id_": "8b198f3a-87d5-4cb2-acc1-132fb5868a77", "embedding": null, "metadata": {"window": "Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n", "original_text": "And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64195392-e73e-40d7-8520-36a75f5f608d", "node_type": "1", "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted. ", "original_text": "That's an important point.  ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afbf2e610e08436c2bd2a755dec4ca5d0bf7fde396d20da612ff30374b382c0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a72f48f-3ee6-4964-84ac-78d47c3aa632", "node_type": "1", "metadata": {"window": "Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "So that will push the profit from a weighting \nperspective in the back -half. "}, "hash": "9f3f8473e11c8c1ae97ad408d72c81059ba4dff9c695363c865344486eb0bd2e", "class_name": "RelatedNodeInfo"}}, "text": "And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well. ", "start_char_idx": 460, "end_char_idx": 579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a72f48f-3ee6-4964-84ac-78d47c3aa632": {"__data__": {"id_": "2a72f48f-3ee6-4964-84ac-78d47c3aa632", "embedding": null, "metadata": {"window": "Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "So that will push the profit from a weighting \nperspective in the back -half. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b198f3a-87d5-4cb2-acc1-132fb5868a77", "node_type": "1", "metadata": {"window": "Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n", "original_text": "And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9cb43a0d6c6805f15cb803a9372da1928f285112a04bd017199c3fdcc3abdaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b4f069f-1d1e-4747-b109-50438ac43f52", "node_type": "1", "metadata": {"window": "That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n", "original_text": "And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted. "}, "hash": "0277a7a59439a85d70826df2545fbdf4a95c819f1383e5c27fbf82ee3f8537e6", "class_name": "RelatedNodeInfo"}}, "text": "So that will push the profit from a weighting \nperspective in the back -half. ", "start_char_idx": 579, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b4f069f-1d1e-4747-b109-50438ac43f52": {"__data__": {"id_": "4b4f069f-1d1e-4747-b109-50438ac43f52", "embedding": null, "metadata": {"window": "That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n", "original_text": "And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a72f48f-3ee6-4964-84ac-78d47c3aa632", "node_type": "1", "metadata": {"window": "Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "So that will push the profit from a weighting \nperspective in the back -half. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c2b3474a6d93f4a2c3cb5a143a2b875e2ca3e8eaae0b359870622b4ea5b2f95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "870dccb7-9ac5-4270-8bd3-911a37178daf", "node_type": "1", "metadata": {"window": "And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "Hope that helps.  \n \n"}, "hash": "3f1625f437fa582082a513fc3ef03fae5b8420149bcb4c02b694fb6a44e4a514", "class_name": "RelatedNodeInfo"}}, "text": "And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted. ", "start_char_idx": 657, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "870dccb7-9ac5-4270-8bd3-911a37178daf": {"__data__": {"id_": "870dccb7-9ac5-4270-8bd3-911a37178daf", "embedding": null, "metadata": {"window": "And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "Hope that helps.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b4f069f-1d1e-4747-b109-50438ac43f52", "node_type": "1", "metadata": {"window": "That's an important point.   And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n", "original_text": "And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "361b679acebf092c10db972aa29241f6156a7bed1f47b97e80ee460d0166f365", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ecb31e9-ef17-4d5e-8322-072f3bdb3d58", "node_type": "1", "metadata": {"window": "So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit. ", "original_text": "Kevin Moran:  Next question, please.  \n \n"}, "hash": "0c97ba470d1e6d5cbbf7b50b3bdea9a8a208c080892868039d2eca00be4429c2", "class_name": "RelatedNodeInfo"}}, "text": "Hope that helps.  \n \n", "start_char_idx": 888, "end_char_idx": 909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ecb31e9-ef17-4d5e-8322-072f3bdb3d58": {"__data__": {"id_": "6ecb31e9-ef17-4d5e-8322-072f3bdb3d58", "embedding": null, "metadata": {"window": "So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "870dccb7-9ac5-4270-8bd3-911a37178daf", "node_type": "1", "metadata": {"window": "And simi larly, we do expect that continued acceleration of \ninflation mitigation over the course of the year as well.  So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "Hope that helps.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "934545cc84cd618d906e6bc7053530ec408322c442e67b84df6eb5dd96a783f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4384bbcf-99ac-4a4e-8c3d-72976522aea0", "node_type": "1", "metadata": {"window": "And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n", "original_text": "Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n"}, "hash": "dcdf03ef9811fccffe8e893a157acb00905a318eb55e757910cb341f589d1065", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n \n", "start_char_idx": 909, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4384bbcf-99ac-4a4e-8c3d-72976522aea0": {"__data__": {"id_": "4384bbcf-99ac-4a4e-8c3d-72976522aea0", "embedding": null, "metadata": {"window": "And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n", "original_text": "Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ecb31e9-ef17-4d5e-8322-072f3bdb3d58", "node_type": "1", "metadata": {"window": "So that will push the profit from a weighting \nperspective in the back -half.  And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d817c72ca6a6f1cebcf36167d65e481c8ba01e42c3797f16e57b6f0b0625c744", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c6f492-b753-4292-bef3-67156e8e8cc6", "node_type": "1", "metadata": {"window": "Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400. ", "original_text": "Kevin Caliendo:   Thanks. "}, "hash": "4d1c45860cf39927e2df01392419348061f2931351a221211eabbd474bd7a1a4", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n", "start_char_idx": 950, "end_char_idx": 1018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c6f492-b753-4292-bef3-67156e8e8cc6": {"__data__": {"id_": "a8c6f492-b753-4292-bef3-67156e8e8cc6", "embedding": null, "metadata": {"window": "Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400. ", "original_text": "Kevin Caliendo:   Thanks. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4384bbcf-99ac-4a4e-8c3d-72976522aea0", "node_type": "1", "metadata": {"window": "And then don't forget that while we were very pleased to call out a sig n \nof change in trend in Cardinal Health Brand, we're also clear at Investor Day that the Cardinal Health \nBrand volume growth is largely back -half weighted.  Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n", "original_text": "Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35976599e65c9d3b940a7c2ffed0028cc6b545594ca28d414d8491f111149d7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3de03b4-25d3-4e1a-aea7-e890410cbd57", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n", "original_text": "Maybe to follow -up on that a little bit. "}, "hash": "f0a0f55cbfc8d1925a4ad2efbd8aeeafe3b960a4ef36ae715f261faad159521a", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:   Thanks. ", "start_char_idx": 1018, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3de03b4-25d3-4e1a-aea7-e890410cbd57": {"__data__": {"id_": "c3de03b4-25d3-4e1a-aea7-e890410cbd57", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n", "original_text": "Maybe to follow -up on that a little bit. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c6f492-b753-4292-bef3-67156e8e8cc6", "node_type": "1", "metadata": {"window": "Hope that helps.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400. ", "original_text": "Kevin Caliendo:   Thanks. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8acd2d237e6336dae7058f34ce2a40bd768c79777fecdc26620c2e63c196a2c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e8f62b7-546f-4812-86de-42f050f48705", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year? ", "original_text": "So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n"}, "hash": "dd82b6b5b69392cfa8d6123c95244578a9cea4167aebe66af569c209c634c0dc", "class_name": "RelatedNodeInfo"}}, "text": "Maybe to follow -up on that a little bit. ", "start_char_idx": 1044, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e8f62b7-546f-4812-86de-42f050f48705": {"__data__": {"id_": "4e8f62b7-546f-4812-86de-42f050f48705", "embedding": null, "metadata": {"window": "Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year? ", "original_text": "So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3de03b4-25d3-4e1a-aea7-e890410cbd57", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n", "original_text": "Maybe to follow -up on that a little bit. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "170f9d598dcc8377d9f58dd73e5dcb8bc9895315548ba29f882030ec86b14bf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74b4f385-e3f6-4f61-8e0b-66d135aeff63", "node_type": "1", "metadata": {"window": "Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities? ", "original_text": "The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400. "}, "hash": "abbad534d890f67e3b1f37d221bbae177797af7f52b21538dbaac59e68a627bd", "class_name": "RelatedNodeInfo"}}, "text": "So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n", "start_char_idx": 1086, "end_char_idx": 1233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74b4f385-e3f6-4f61-8e0b-66d135aeff63": {"__data__": {"id_": "74b4f385-e3f6-4f61-8e0b-66d135aeff63", "embedding": null, "metadata": {"window": "Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities? ", "original_text": "The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e8f62b7-546f-4812-86de-42f050f48705", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Kevi n Caliendo of UBS.  \n \n Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year? ", "original_text": "So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f426c5a1c5bc0f88691fc9d9736446600ac5e9c5c9aaf6f75ded548e5966f93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60426720-1e22-4b84-a88c-3be230105588", "node_type": "1", "metadata": {"window": "Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted? ", "original_text": "I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n"}, "hash": "955d97cf9901fe169369019a4b28fedcb60f4e44d1cd38b812c63a5dd1a065eb", "class_name": "RelatedNodeInfo"}}, "text": "The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400. ", "start_char_idx": 1233, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60426720-1e22-4b84-a88c-3be230105588": {"__data__": {"id_": "60426720-1e22-4b84-a88c-3be230105588", "embedding": null, "metadata": {"window": "Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted? ", "original_text": "I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74b4f385-e3f6-4f61-8e0b-66d135aeff63", "node_type": "1", "metadata": {"window": "Kevin Caliendo:   Thanks.  Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities? ", "original_text": "The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d081f1e9101cce4393d6d3fc7bd7bc703ba3f714bb4d36ec3268fd8b7e47e5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2507812e-8faf-491e-be5a-24145b1f670e", "node_type": "1", "metadata": {"window": "So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n", "original_text": "And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year? "}, "hash": "a88746a291f9a27d0ae0141d4ef429e7466016b90b6ea6e37fd18ec619a0d8fb", "class_name": "RelatedNodeInfo"}}, "text": "I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n", "start_char_idx": 1335, "end_char_idx": 1424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2507812e-8faf-491e-be5a-24145b1f670e": {"__data__": {"id_": "2507812e-8faf-491e-be5a-24145b1f670e", "embedding": null, "metadata": {"window": "So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n", "original_text": "And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year? ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60426720-1e22-4b84-a88c-3be230105588", "node_type": "1", "metadata": {"window": "Maybe to follow -up on that a little bit.  So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted? ", "original_text": "I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "337418c8419018a88c7e06c20c4f2dc047daa7f18a4b5d13e87b3aa7cc1d1fa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7848d64-0b0d-4e24-8e27-f27f903f0848", "node_type": "1", "metadata": {"window": "The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason. ", "original_text": "Is that because of new product launches or manufacturing \ncapabilities? "}, "hash": "7251ac33325d385f9128614f65f2c0b2f6dbd16a7a57b44ed2abe72a65f2be71", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year? ", "start_char_idx": 1424, "end_char_idx": 1562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7848d64-0b0d-4e24-8e27-f27f903f0848": {"__data__": {"id_": "b7848d64-0b0d-4e24-8e27-f27f903f0848", "embedding": null, "metadata": {"window": "The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason. ", "original_text": "Is that because of new product launches or manufacturing \ncapabilities? ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2507812e-8faf-491e-be5a-24145b1f670e", "node_type": "1", "metadata": {"window": "So, if we're thinking about 82, the \nbaseline is really 60, the first quarter is likely because of the $20 million in seasonals' and one -timers. \n The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n", "original_text": "And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year? ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7ae1e78542d44bed9d94fca87826e65db02202d874a9b0c98377267462d2b29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3364032f-cd81-4ce3-97ac-03d1e3d3e183", "node_type": "1", "metadata": {"window": "I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line. ", "original_text": "Is it contractually like new contracts coming on that are higher -weighted? "}, "hash": "fcd46abf7a1aefd683d2443ecbe2460dbbff0d59421bd2104d3f73c23f2cf25f", "class_name": "RelatedNodeInfo"}}, "text": "Is that because of new product launches or manufacturing \ncapabilities? ", "start_char_idx": 1562, "end_char_idx": 1634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3364032f-cd81-4ce3-97ac-03d1e3d3e183": {"__data__": {"id_": "3364032f-cd81-4ce3-97ac-03d1e3d3e183", "embedding": null, "metadata": {"window": "I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line. ", "original_text": "Is it contractually like new contracts coming on that are higher -weighted? ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7848d64-0b0d-4e24-8e27-f27f903f0848", "node_type": "1", "metadata": {"window": "The first quarter is likely  to be down sequentially , and then grow off that base to get to the 400.  I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason. ", "original_text": "Is that because of new product launches or manufacturing \ncapabilities? ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "623444f60c1c9e6ee4a1cea2a86074e41164f04b704cf6fdd9d05ace61df70ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3d77d07-5751-4c85-a6cd-a1b4e0dfdf59", "node_type": "1", "metadata": {"window": "And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4. ", "original_text": "Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n"}, "hash": "8e1fc988fa5f8179933f1f498cdb5e7e47162697dfed45ed696f37bd4ea31812", "class_name": "RelatedNodeInfo"}}, "text": "Is it contractually like new contracts coming on that are higher -weighted? ", "start_char_idx": 1634, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3d77d07-5751-4c85-a6cd-a1b4e0dfdf59": {"__data__": {"id_": "e3d77d07-5751-4c85-a6cd-a1b4e0dfdf59", "embedding": null, "metadata": {"window": "And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4. ", "original_text": "Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3364032f-cd81-4ce3-97ac-03d1e3d3e183", "node_type": "1", "metadata": {"window": "I just \nwant to make sure that, that's what you're committing to , or commenting on.  \n \n And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line. ", "original_text": "Is it contractually like new contracts coming on that are higher -weighted? ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ceaa4c12edcdbe0e91561e014bb0243c8df922250ef1a90c107ee87172f134d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40e68b07-92ee-4470-a0b8-0c19a624f7d9", "node_type": "1", "metadata": {"window": "Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results. ", "original_text": "Aaron Alt:  Well, I'll start, and then toss it over to Jason. "}, "hash": "c80eb49c47c5f8485d40ebaf81c2095374881a779b2125e94bd58200ef9d347b", "class_name": "RelatedNodeInfo"}}, "text": "Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n", "start_char_idx": 1710, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40e68b07-92ee-4470-a0b8-0c19a624f7d9": {"__data__": {"id_": "40e68b07-92ee-4470-a0b8-0c19a624f7d9", "embedding": null, "metadata": {"window": "Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results. ", "original_text": "Aaron Alt:  Well, I'll start, and then toss it over to Jason. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3d77d07-5751-4c85-a6cd-a1b4e0dfdf59", "node_type": "1", "metadata": {"window": "And then secondly, or incrementally, the new products or the Cardinal brand products, is that the \nincrease in the back half of the year?  Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4. ", "original_text": "Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72325185895af63df3560d76bc2688de9eaa623f1342e9cb67cb30a6354f64f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e145d2cb-0394-4d8b-9abf-2222f4db3f4c", "node_type": "1", "metadata": {"window": "Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n", "original_text": "You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line. "}, "hash": "49494c0fd2f3d8a41c60fc16171a59420be7860280520bf08d39f864ace9819a", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Well, I'll start, and then toss it over to Jason. ", "start_char_idx": 1798, "end_char_idx": 1860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e145d2cb-0394-4d8b-9abf-2222f4db3f4c": {"__data__": {"id_": "e145d2cb-0394-4d8b-9abf-2222f4db3f4c", "embedding": null, "metadata": {"window": "Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n", "original_text": "You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40e68b07-92ee-4470-a0b8-0c19a624f7d9", "node_type": "1", "metadata": {"window": "Is that because of new product launches or manufacturing \ncapabilities?  Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results. ", "original_text": "Aaron Alt:  Well, I'll start, and then toss it over to Jason. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6d21310587e4f31ca2521b6dd2f31d13e975a49ea2b9fb7bbba37ec0644cc7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "980eaa4e-eccc-437c-adab-dc5d1f3522d5", "node_type": "1", "metadata": {"window": "Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah. ", "original_text": "And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4. "}, "hash": "1cf8a4991b6767d66698f30eddec27a2d40bca8eedccaf837e520418a87b58d6", "class_name": "RelatedNodeInfo"}}, "text": "You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line. ", "start_char_idx": 1860, "end_char_idx": 1978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "980eaa4e-eccc-437c-adab-dc5d1f3522d5": {"__data__": {"id_": "980eaa4e-eccc-437c-adab-dc5d1f3522d5", "embedding": null, "metadata": {"window": "Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah. ", "original_text": "And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e145d2cb-0394-4d8b-9abf-2222f4db3f4c", "node_type": "1", "metadata": {"window": "Is it contractually like new contracts coming on that are higher -weighted?  Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n", "original_text": "You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ad1c0cc67d7477a9cfb122af0f044bff669888af836a54e19c07397db254aa3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c67930b-6e0e-4501-9439-6afdc9219642", "node_type": "1", "metadata": {"window": "Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n", "original_text": "So that's why the jumping off point is core performance versus the Q4 results. "}, "hash": "54a03070c68016333b137bf661b6752cc149f0e753a5c20ff61257c5ec4d613d", "class_name": "RelatedNodeInfo"}}, "text": "And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4. ", "start_char_idx": 1978, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c67930b-6e0e-4501-9439-6afdc9219642": {"__data__": {"id_": "3c67930b-6e0e-4501-9439-6afdc9219642", "embedding": null, "metadata": {"window": "Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n", "original_text": "So that's why the jumping off point is core performance versus the Q4 results. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "980eaa4e-eccc-437c-adab-dc5d1f3522d5", "node_type": "1", "metadata": {"window": "Can you just \nsort of explain the dynamics of the Cardinal brand pr oducts as well?  \n \n Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah. ", "original_text": "And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14890cefbac83a9f12ef8d7e3717ceacfbe6e58f18d8910f6e3cf9973da314d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2261992-db97-41db-9c81-7670742ae1ee", "node_type": "1", "metadata": {"window": "You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent. ", "original_text": "Jason?  \n \n"}, "hash": "055ef4fbcd080bcbe9c9969f7b6cf11476b2de220648efc6747c22fac371300b", "class_name": "RelatedNodeInfo"}}, "text": "So that's why the jumping off point is core performance versus the Q4 results. ", "start_char_idx": 2114, "end_char_idx": 2193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2261992-db97-41db-9c81-7670742ae1ee": {"__data__": {"id_": "f2261992-db97-41db-9c81-7670742ae1ee", "embedding": null, "metadata": {"window": "You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent. ", "original_text": "Jason?  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c67930b-6e0e-4501-9439-6afdc9219642", "node_type": "1", "metadata": {"window": "Aaron Alt:  Well, I'll start, and then toss it over to Jason.  You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n", "original_text": "So that's why the jumping off point is core performance versus the Q4 results. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b3f193e77d5f0efa3cdd0f6db8b4fcedbbcfdcf4011cb8edfdb7dde4d37684c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "956e5be3-57e1-467c-b40e-72ed31a6ad9f", "node_type": "1", "metadata": {"window": "And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.  ", "original_text": "Jason Hollar:  Yeah. "}, "hash": "5c3ea34bd2b66b8d6799884e945ddb5deddb912338bb1f2b7fbfacdf019bee57", "class_name": "RelatedNodeInfo"}}, "text": "Jason?  \n \n", "start_char_idx": 2193, "end_char_idx": 2204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "956e5be3-57e1-467c-b40e-72ed31a6ad9f": {"__data__": {"id_": "956e5be3-57e1-467c-b40e-72ed31a6ad9f", "embedding": null, "metadata": {"window": "And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.  ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2261992-db97-41db-9c81-7670742ae1ee", "node_type": "1", "metadata": {"window": "You are correct in that the way we're thinking \nabout this is that core performance Q4 to Q1 will be roughly in line.  And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent. ", "original_text": "Jason?  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7d9c9d077db8ec3423079cad28647139d467e703943437e4d6c5cec119dc5e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41eb43c8-34cb-4b70-8f5b-a13aeb69f2e5", "node_type": "1", "metadata": {"window": "So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working. ", "original_text": "I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n"}, "hash": "12f45f918a443a3db20b993929c277b5eaf9ba193c06c366e722ab0b9e49dc82", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah. ", "start_char_idx": 2204, "end_char_idx": 2225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41eb43c8-34cb-4b70-8f5b-a13aeb69f2e5": {"__data__": {"id_": "41eb43c8-34cb-4b70-8f5b-a13aeb69f2e5", "embedding": null, "metadata": {"window": "So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working. ", "original_text": "I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "956e5be3-57e1-467c-b40e-72ed31a6ad9f", "node_type": "1", "metadata": {"window": "And if you interpret what I was \njust saying in response to an earlier question, we do have some negative seasonality in Q1 versus \nQ4.  So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.  ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff84c069caae125fa1fe1ba4639f20a462a4226778245a750cefc13a3deec763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57723e69-045e-4572-a45a-ba8a5e34cae7", "node_type": "1", "metadata": {"window": "Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n", "original_text": "First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent. "}, "hash": "ac961e782214ef60acd575fe046e3b54dd6ce31397bd148cea6963a27214ccc0", "class_name": "RelatedNodeInfo"}}, "text": "I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n", "start_char_idx": 2225, "end_char_idx": 2341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57723e69-045e-4572-a45a-ba8a5e34cae7": {"__data__": {"id_": "57723e69-045e-4572-a45a-ba8a5e34cae7", "embedding": null, "metadata": {"window": "Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n", "original_text": "First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41eb43c8-34cb-4b70-8f5b-a13aeb69f2e5", "node_type": "1", "metadata": {"window": "So that's why the jumping off point is core performance versus the Q4 results.  Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working. ", "original_text": "I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4755fe560f5c740ef09e53f3c290937650eec37eaaeff3827b168c6d910a44d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7302a17e-301d-4532-9c64-f743b776ebaa", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter. ", "original_text": "So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.  "}, "hash": "50ea08e060b064315c52a76bd3391c001303b60e6a5c382fe2a45f7716790797", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent. ", "start_char_idx": 2341, "end_char_idx": 2468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7302a17e-301d-4532-9c64-f743b776ebaa": {"__data__": {"id_": "7302a17e-301d-4532-9c64-f743b776ebaa", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter. ", "original_text": "So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.  ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57723e69-045e-4572-a45a-ba8a5e34cae7", "node_type": "1", "metadata": {"window": "Jason?  \n \n Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n", "original_text": "First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95f466f8159ba064642f4d34727c3e2708637c2e256f459d8ce1bba7ec047a57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "063572b8-3cf1-4ac0-bb0b-3d37c632a121", "node_type": "1", "metadata": {"window": "I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working. "}, "hash": "6617eb5d2e236f3fb956d4ce120771393c18c7bc669b36dc7ced20dee61a148c", "class_name": "RelatedNodeInfo"}}, "text": "So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.  ", "start_char_idx": 2468, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "063572b8-3cf1-4ac0-bb0b-3d37c632a121": {"__data__": {"id_": "063572b8-3cf1-4ac0-bb0b-3d37c632a121", "embedding": null, "metadata": {"window": "I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7302a17e-301d-4532-9c64-f743b776ebaa", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter. ", "original_text": "So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.  ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea75196400e0b3a6fe07c6e0c11fc80028aadcc63d7186d82cd635bfbb3d81ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85de2d77-6d1b-4793-be03-37167c508054", "node_type": "1", "metadata": {"window": "First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n"}, "hash": "e342a41be9f1a98b5cbb56224b4abc6f204b474654304c313ed6a83791a7b7dd", "class_name": "RelatedNodeInfo"}}, "text": "And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working. ", "start_char_idx": 2564, "end_char_idx": 2802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85de2d77-6d1b-4793-be03-37167c508054": {"__data__": {"id_": "85de2d77-6d1b-4793-be03-37167c508054", "embedding": null, "metadata": {"window": "First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "063572b8-3cf1-4ac0-bb0b-3d37c632a121", "node_type": "1", "metadata": {"window": "I'd think about the Cardinal brand volume growth being back -half loaded through \na couple of different lenses.  \n \n First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fea2c6fc09bd8bea181f97e1ea78af70a9a40bf020a8fd43752143b6da2acaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc1f09cd-eb42-461b-88e9-22ae7aa24427", "node_type": "1", "metadata": {"window": "So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter. "}, "hash": "d7bda3893a212b67e801d8ef047a837b77bcc996f5277e9d593f9a565b6c3162", "class_name": "RelatedNodeInfo"}}, "text": "Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n", "start_char_idx": 2802, "end_char_idx": 2929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc1f09cd-eb42-461b-88e9-22ae7aa24427": {"__data__": {"id_": "bc1f09cd-eb42-461b-88e9-22ae7aa24427", "embedding": null, "metadata": {"window": "So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85de2d77-6d1b-4793-be03-37167c508054", "node_type": "1", "metadata": {"window": "First of all, we do think that the underlying utilization will be , for the market will continue to be \nrelatively consistent.  So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "253a7689d29b20180e14a4f71680e00415b7c01b2cf434e9ad672e2a98dc76f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c910911-4b9b-4dbc-8c65-542065802d5d", "node_type": "1", "metadata": {"window": "And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n "}, "hash": "437075ec44f3d8331e5c03e78f9e69ab485ffd9e29442fc1a7bc3e3fd13d7c09", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter. ", "start_char_idx": 2929, "end_char_idx": 3110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c910911-4b9b-4dbc-8c65-542065802d5d": {"__data__": {"id_": "0c910911-4b9b-4dbc-8c65-542065802d5d", "embedding": null, "metadata": {"window": "And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24d28397-258c-43d0-b16c-9fb41cefe513", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e62a5f69c50c8a18d22f501aee069ffb77f469f60c27a926968db3df0288b62", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc1f09cd-eb42-461b-88e9-22ae7aa24427", "node_type": "1", "metadata": {"window": "So, we do see same -store sales growth out there, and we anticipate that, that \nwill continue.   And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94154bf1282e07e5c7508d6c5b040446de9208cf4399855b3ab5aefbfe9ef278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19c8a1d7-0982-4149-80fb-fa06ca5d1cf2", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah. ", "original_text": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n"}, "hash": "31c58194ce9b36ef206141fa2d4ae29650b0d9efabf1d36037cd37cba61f31fa", "class_name": "RelatedNodeInfo"}}, "text": "That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "start_char_idx": 3110, "end_char_idx": 3340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19c8a1d7-0982-4149-80fb-fa06ca5d1cf2": {"__data__": {"id_": "19c8a1d7-0982-4149-80fb-fa06ca5d1cf2", "embedding": null, "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah. ", "original_text": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c910911-4b9b-4dbc-8c65-542065802d5d", "node_type": "1", "metadata": {"window": "And within our performance within that, we highlighted that our comparison point to the \nprior year is becoming easier as we did lose some business over the last 18 months or so that we \nnow are lapping,  and our 5-point plan is working.  Our 5-point  plan to improve , that includes improving \nthe customer experience and importantly, that supply chain health.  \n \n We're seeing strong progress as it relates to service levels, CLI scores that gave us very good \ncustomer retention in the quarter, net new wins th at were positive in the quarter.  That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "original_text": "That gives us the \nfoundation that gives us confidence that we'll grow with the underlying market, especially as we \ncontinue to lap that prior year impact, which we think will be more impactful in the second half of the \nyear. \n ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1b30a9ddb320115ee80f65aa7ee7f66bb66158d93146bcb323d89b0f2bdc2ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d61f5004-2a3c-4109-a040-cd6014e0e351", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions. ", "original_text": "Kevin Moran:  Next question, please.  \n \n"}, "hash": "4586ec380425bc324050771639fcf64820caa76f3cc310b22702b7522da2fbf0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n", "start_char_idx": 0, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d61f5004-2a3c-4109-a040-cd6014e0e351": {"__data__": {"id_": "d61f5004-2a3c-4109-a040-cd6014e0e351", "embedding": null, "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19c8a1d7-0982-4149-80fb-fa06ca5d1cf2", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah. ", "original_text": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97adba7d917877cc1c4895b86caaea77e0a1e8b8c564a5d0180bb3e990072efb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e1dd03-da54-4761-9b3f-04c4e505132e", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction. ", "original_text": "Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n"}, "hash": "fcdbc0f58c34d84fde8bed78f8fd2bd8a6ce394c1ba7b8a87ba7e96fa5f2e9c2", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n \n", "start_char_idx": 317, "end_char_idx": 358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e1dd03-da54-4761-9b3f-04c4e505132e": {"__data__": {"id_": "19e1dd03-da54-4761-9b3f-04c4e505132e", "embedding": null, "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction. ", "original_text": "Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d61f5004-2a3c-4109-a040-cd6014e0e351", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65196ad532f6b5b128d1044cade30ce3eb405973c2e6e708fe819028f3455881", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e98a8c6-a7ed-43ed-8236-54d9225e39ea", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.  ", "original_text": "George Hill:  Yeah. "}, "hash": "64e03c3733f90c15bc2155be619f052b8a28edc898697f5529d233db407819ac", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n", "start_char_idx": 358, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e98a8c6-a7ed-43ed-8236-54d9225e39ea": {"__data__": {"id_": "9e98a8c6-a7ed-43ed-8236-54d9225e39ea", "embedding": null, "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.  ", "original_text": "George Hill:  Yeah. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e1dd03-da54-4761-9b3f-04c4e505132e", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction. ", "original_text": "Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5919305b640d08d1a304c56c46eff0086b723387e6a0e1fc77b4e975643c98c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f60e3ea-15cd-465e-9cac-26ccc2ef0acf", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond . ", "original_text": "Good morning,  guys , and thanks for taking my questions. "}, "hash": "61e1c13eb7827e4a8b76ad8544aaaf54600538d3220c9cae3196b1de0c3d5108", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Yeah. ", "start_char_idx": 432, "end_char_idx": 452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f60e3ea-15cd-465e-9cac-26ccc2ef0acf": {"__data__": {"id_": "3f60e3ea-15cd-465e-9cac-26ccc2ef0acf", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond . ", "original_text": "Good morning,  guys , and thanks for taking my questions. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e98a8c6-a7ed-43ed-8236-54d9225e39ea", "node_type": "1", "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.  ", "original_text": "George Hill:  Yeah. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bad437e7d7b453fefd6aef841f31814b84cf3887c3124b91d93f85e50f1b56b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c535ef5-8533-4d2f-aaaf-aa5e044e6085", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution? ", "original_text": "I'll take it in a little bit \ndifferent direction. "}, "hash": "38e2243d3445c921eab54517e594f04a36b256d25b088a7add290c4fcb4155f9", "class_name": "RelatedNodeInfo"}}, "text": "Good morning,  guys , and thanks for taking my questions. ", "start_char_idx": 452, "end_char_idx": 510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c535ef5-8533-4d2f-aaaf-aa5e044e6085": {"__data__": {"id_": "8c535ef5-8533-4d2f-aaaf-aa5e044e6085", "embedding": null, "metadata": {"window": "Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution? ", "original_text": "I'll take it in a little bit \ndifferent direction. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f60e3ea-15cd-465e-9cac-26ccc2ef0acf", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond . ", "original_text": "Good morning,  guys , and thanks for taking my questions. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f76f33dec67b0fb1172e4f215e4956c2f66e7952dad12cb9af02e86d034b805", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b8e502c-5284-458d-86a7-8bad55ff2609", "node_type": "1", "metadata": {"window": "George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n", "original_text": "Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.  "}, "hash": "c4a39aef76d04bdc3e0fd4dceff69b6416bcd8ae2a31a536bf2d3a859ad27078", "class_name": "RelatedNodeInfo"}}, "text": "I'll take it in a little bit \ndifferent direction. ", "start_char_idx": 510, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b8e502c-5284-458d-86a7-8bad55ff2609": {"__data__": {"id_": "8b8e502c-5284-458d-86a7-8bad55ff2609", "embedding": null, "metadata": {"window": "George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n", "original_text": "Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c535ef5-8533-4d2f-aaaf-aa5e044e6085", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution? ", "original_text": "I'll take it in a little bit \ndifferent direction. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd923beffdbf4542024c3c95bd46a5702c573dd5cac59b096df08c3d107fa283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "279c9a10-60dd-496d-8a5a-a2221e01df39", "node_type": "1", "metadata": {"window": "Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure. ", "original_text": "And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond . "}, "hash": "3403042e756b363c97ff0f14c550e15ff22ac0bc5b8f12847acecb9dc36e1bcc", "class_name": "RelatedNodeInfo"}}, "text": "Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.  ", "start_char_idx": 561, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "279c9a10-60dd-496d-8a5a-a2221e01df39": {"__data__": {"id_": "279c9a10-60dd-496d-8a5a-a2221e01df39", "embedding": null, "metadata": {"window": "Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure. ", "original_text": "And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond . ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b8e502c-5284-458d-86a7-8bad55ff2609", "node_type": "1", "metadata": {"window": "George Hill:  Yeah.  Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n", "original_text": "Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfd18533ab5b57736a3e99a1ec0725f0fa1bcfb231e6bd6d09dc556602fb26f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c379a6fc-2b83-42f9-9e5c-50fcd09f5713", "node_type": "1", "metadata": {"window": "I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great. ", "original_text": "So, just kind of progress in ramping \ncontribution? "}, "hash": "23afabaebf1ff0f47d9b224a485613be0187f0e3606ff576c5743ca0c3a1086c", "class_name": "RelatedNodeInfo"}}, "text": "And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond . ", "start_char_idx": 711, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c379a6fc-2b83-42f9-9e5c-50fcd09f5713": {"__data__": {"id_": "c379a6fc-2b83-42f9-9e5c-50fcd09f5713", "embedding": null, "metadata": {"window": "I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great. ", "original_text": "So, just kind of progress in ramping \ncontribution? ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "279c9a10-60dd-496d-8a5a-a2221e01df39", "node_type": "1", "metadata": {"window": "Good morning,  guys , and thanks for taking my questions.  I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure. ", "original_text": "And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond . ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d546d35762298326448bee0b7482632eb6cd45b4a16b7e948dab779f1379857e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78500d99-3926-45bb-bf18-540a3db139ba", "node_type": "1", "metadata": {"window": "Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George. ", "original_text": "Thank you.  \n \n"}, "hash": "eb3c75c350cd6176862c2aeb0fd213cefa14649172a01cd217a0e6cee0da0957", "class_name": "RelatedNodeInfo"}}, "text": "So, just kind of progress in ramping \ncontribution? ", "start_char_idx": 907, "end_char_idx": 959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78500d99-3926-45bb-bf18-540a3db139ba": {"__data__": {"id_": "78500d99-3926-45bb-bf18-540a3db139ba", "embedding": null, "metadata": {"window": "Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George. ", "original_text": "Thank you.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c379a6fc-2b83-42f9-9e5c-50fcd09f5713", "node_type": "1", "metadata": {"window": "I'll take it in a little bit \ndifferent direction.  Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great. ", "original_text": "So, just kind of progress in ramping \ncontribution? ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "135c0248e3dbf8e403000eca1133b2279353ffa49cb4e59a56ec6708249ca5ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "708e8218-7914-4388-be12-cd345da97183", "node_type": "1", "metadata": {"window": "And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place. ", "original_text": "Jason Hollar:  Sure. "}, "hash": "368c6f87cfb9b37d7f8688615d1b3770b030598232afd62bd4ae59a86d7a76c6", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 959, "end_char_idx": 974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "708e8218-7914-4388-be12-cd345da97183": {"__data__": {"id_": "708e8218-7914-4388-be12-cd345da97183", "embedding": null, "metadata": {"window": "And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place. ", "original_text": "Jason Hollar:  Sure. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78500d99-3926-45bb-bf18-540a3db139ba", "node_type": "1", "metadata": {"window": "Jason, I'd love to hear the kind of the progress that you guys have made on the \nNavista offering, si nce it was first announced at the Analyst Day.   And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George. ", "original_text": "Thank you.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "109d61169ba951c0c31f1a4e28f965a999514f06ee8ba4cdcc81713e31aa1c61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0806f6a1-6143-4fbd-bb02-3db53301301d", "node_type": "1", "metadata": {"window": "So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.  ", "original_text": "Yeah , great. "}, "hash": "3d33cab2a8fab833d3c5733bddf11648a1793a6ef4193e8ea8204cf6d7c32360", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure. ", "start_char_idx": 974, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0806f6a1-6143-4fbd-bb02-3db53301301d": {"__data__": {"id_": "0806f6a1-6143-4fbd-bb02-3db53301301d", "embedding": null, "metadata": {"window": "So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.  ", "original_text": "Yeah , great. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "708e8218-7914-4388-be12-cd345da97183", "node_type": "1", "metadata": {"window": "And I guess, given the growth and \nthe size of the specialty market, particularly in oncology, I guess how should we think about the ramp \nof that business , maybe through fiscal \u201824 and beyond .  So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place. ", "original_text": "Jason Hollar:  Sure. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3eda524c9ce6da906d477b7a2028149e49d4291aecc82b7ebdb009757354dfd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "794ba273-bcb7-4a18-9c92-f3d30f46bb71", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives. ", "original_text": "Thanks for the question, George. "}, "hash": "5feabc09396fd9984718695f1c48e746c4b0cd3abb53a040c3e6b3a45fd362b7", "class_name": "RelatedNodeInfo"}}, "text": "Yeah , great. ", "start_char_idx": 995, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "794ba273-bcb7-4a18-9c92-f3d30f46bb71": {"__data__": {"id_": "794ba273-bcb7-4a18-9c92-f3d30f46bb71", "embedding": null, "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives. ", "original_text": "Thanks for the question, George. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0806f6a1-6143-4fbd-bb02-3db53301301d", "node_type": "1", "metadata": {"window": "So, just kind of progress in ramping \ncontribution?  Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.  ", "original_text": "Yeah , great. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19048756aadaf5cc3234480ad31789651ec3dab5f0693ccb33a8cc92f7115f3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f99c5ca1-2698-43d7-8d00-8924bc7a0f06", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support. ", "original_text": "Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place. "}, "hash": "573c805c28c733f99a9daed1b04c9182a7dcfe07512af75ec919c6024fb50dac", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, George. ", "start_char_idx": 1009, "end_char_idx": 1042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f99c5ca1-2698-43d7-8d00-8924bc7a0f06": {"__data__": {"id_": "f99c5ca1-2698-43d7-8d00-8924bc7a0f06", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support. ", "original_text": "Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "794ba273-bcb7-4a18-9c92-f3d30f46bb71", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives. ", "original_text": "Thanks for the question, George. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5bbd4210e46f9f7fcde53f7d602b054769c021cba94b286330904d3a2d3ef1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6cba428-eb4e-4d6b-b17a-b2edd419ac7f", "node_type": "1", "metadata": {"window": "Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.  ", "original_text": "We have a foundation in \nplace, built off of our existing specialty business.  "}, "hash": "c130691c25a8a79c2957ea9ee692d7e94007ac142b0ac512fd4bd4bacc9ee5b1", "class_name": "RelatedNodeInfo"}}, "text": "Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place. ", "start_char_idx": 1042, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6cba428-eb4e-4d6b-b17a-b2edd419ac7f": {"__data__": {"id_": "b6cba428-eb4e-4d6b-b17a-b2edd419ac7f", "embedding": null, "metadata": {"window": "Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.  ", "original_text": "We have a foundation in \nplace, built off of our existing specialty business.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f99c5ca1-2698-43d7-8d00-8924bc7a0f06", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.  Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support. ", "original_text": "Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1517112bedd7b4116d0789ba9f63a11a7910c648852ee99052deb887929d12e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f352954c-d5e4-4640-8955-9fddfa65a81f", "node_type": "1", "metadata": {"window": "Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place. ", "original_text": "We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives. "}, "hash": "b49bc87e80fd7440e482fd5a931df4e92077eacd4c2d7ac8a8fd9849f4232dc6", "class_name": "RelatedNodeInfo"}}, "text": "We have a foundation in \nplace, built off of our existing specialty business.  ", "start_char_idx": 1152, "end_char_idx": 1231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f352954c-d5e4-4640-8955-9fddfa65a81f": {"__data__": {"id_": "f352954c-d5e4-4640-8955-9fddfa65a81f", "embedding": null, "metadata": {"window": "Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place. ", "original_text": "We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6cba428-eb4e-4d6b-b17a-b2edd419ac7f", "node_type": "1", "metadata": {"window": "Yeah , great.  Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.  ", "original_text": "We have a foundation in \nplace, built off of our existing specialty business.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f114904c38b97dceafb1ccc63836d7ee3d9ef6351d50603d5e1d5001635e24eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17ef221b-0ccb-4a96-8bce-e5c363ff20ba", "node_type": "1", "metadata": {"window": "Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients. ", "original_text": "Of course, other data and insights, \nclinical research support. "}, "hash": "ee2f1fcb83ff3a32e275502aec1e73f2a5ccfc2753a618174badd7f0f1a9ec6a", "class_name": "RelatedNodeInfo"}}, "text": "We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives. ", "start_char_idx": 1231, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17ef221b-0ccb-4a96-8bce-e5c363ff20ba": {"__data__": {"id_": "17ef221b-0ccb-4a96-8bce-e5c363ff20ba", "embedding": null, "metadata": {"window": "Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients. ", "original_text": "Of course, other data and insights, \nclinical research support. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f352954c-d5e4-4640-8955-9fddfa65a81f", "node_type": "1", "metadata": {"window": "Thanks for the question, George.  Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place. ", "original_text": "We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34fc6c78b6fbc6f98a8b2f176c05013577c710713f5d0c7a15f6ab6f2a9a6bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a4dd7f9-75f8-481e-9771-007c4c527eb1", "node_type": "1", "metadata": {"window": "We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent. ", "original_text": "So , we have a lot of the tools.  "}, "hash": "d366abb0e718694b65b1e18bdc7a498dc089e5193de702e21aa1b71983fd502c", "class_name": "RelatedNodeInfo"}}, "text": "Of course, other data and insights, \nclinical research support. ", "start_char_idx": 1444, "end_char_idx": 1508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a4dd7f9-75f8-481e-9771-007c4c527eb1": {"__data__": {"id_": "6a4dd7f9-75f8-481e-9771-007c4c527eb1", "embedding": null, "metadata": {"window": "We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent. ", "original_text": "So , we have a lot of the tools.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17ef221b-0ccb-4a96-8bce-e5c363ff20ba", "node_type": "1", "metadata": {"window": "Yeah, so when we think about \nNavista, I think it's important to recognize that we had a foundation in place.  We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients. ", "original_text": "Of course, other data and insights, \nclinical research support. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df3e2b2608c3be68ee0f1b05407e86f10a8f31f6a2568652b067f46198f80e06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dabc60ea-5ad6-4d35-807c-4d0f6686ed25", "node_type": "1", "metadata": {"window": "We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.  ", "original_text": "What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place. "}, "hash": "5545a47209ec87ebf8a2bcff5a2b15d823520186c2ebe7b4a065857ecd2d2100", "class_name": "RelatedNodeInfo"}}, "text": "So , we have a lot of the tools.  ", "start_char_idx": 1508, "end_char_idx": 1542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dabc60ea-5ad6-4d35-807c-4d0f6686ed25": {"__data__": {"id_": "dabc60ea-5ad6-4d35-807c-4d0f6686ed25", "embedding": null, "metadata": {"window": "We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.  ", "original_text": "What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a4dd7f9-75f8-481e-9771-007c4c527eb1", "node_type": "1", "metadata": {"window": "We have a foundation in \nplace, built off of our existing specialty business.   We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent. ", "original_text": "So , we have a lot of the tools.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb44d414f05d8aae6f4a003a726cc889c4922dda493efa8e8e2035d4840e12d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eee40301-ff20-4f59-9024-67fa71f1b440", "node_type": "1", "metadata": {"window": "Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding. ", "original_text": "So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients. "}, "hash": "c848025d5bfd5ca44e66312aea78eb7b6fc64ce067de8bae7dca1355e876651a", "class_name": "RelatedNodeInfo"}}, "text": "What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place. ", "start_char_idx": 1542, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eee40301-ff20-4f59-9024-67fa71f1b440": {"__data__": {"id_": "eee40301-ff20-4f59-9024-67fa71f1b440", "embedding": null, "metadata": {"window": "Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding. ", "original_text": "So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dabc60ea-5ad6-4d35-807c-4d0f6686ed25", "node_type": "1", "metadata": {"window": "We had plenty of programs and initiatives in place, \nplatforms like our, Navista TS, where we are already providing capabilities to the community \noncologists to help support their value -based care initiat ives.  Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.  ", "original_text": "What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eabe39dcc44917c0ad59032e8a122157f4862b863697dadc6e349b964424a807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bb175f5-480b-4bad-b5f9-320d75a6e120", "node_type": "1", "metadata": {"window": "So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence. ", "original_text": "So, we are building that out \nfurther with both internal , as well as external talent. "}, "hash": "8a2a0c9af174e58b67570d5354b5b8d258fd3a09979feb429aa64bc4208ecc34", "class_name": "RelatedNodeInfo"}}, "text": "So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients. ", "start_char_idx": 1688, "end_char_idx": 1968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bb175f5-480b-4bad-b5f9-320d75a6e120": {"__data__": {"id_": "7bb175f5-480b-4bad-b5f9-320d75a6e120", "embedding": null, "metadata": {"window": "So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence. ", "original_text": "So, we are building that out \nfurther with both internal , as well as external talent. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eee40301-ff20-4f59-9024-67fa71f1b440", "node_type": "1", "metadata": {"window": "Of course, other data and insights, \nclinical research support.  So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding. ", "original_text": "So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73962d49053a9800d5dc11e25c8fbc9b71d4866ec9d3591a219248c58696ed1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "980f54ab-372c-4c9d-9379-7e844abc3216", "node_type": "1", "metadata": {"window": "What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for. ", "original_text": "We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.  "}, "hash": "26f117c959826f3e75d333a4743576b743960efaf3fe0c622506ba47a57d444d", "class_name": "RelatedNodeInfo"}}, "text": "So, we are building that out \nfurther with both internal , as well as external talent. ", "start_char_idx": 1968, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "980f54ab-372c-4c9d-9379-7e844abc3216": {"__data__": {"id_": "980f54ab-372c-4c9d-9379-7e844abc3216", "embedding": null, "metadata": {"window": "What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for. ", "original_text": "We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bb175f5-480b-4bad-b5f9-320d75a6e120", "node_type": "1", "metadata": {"window": "So , we have a lot of the tools.   What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence. ", "original_text": "So, we are building that out \nfurther with both internal , as well as external talent. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de0478620e2a92ea952d370f48c775352226e73347693e97a7ad5a3930916e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f8b2dde-bb88-426c-99e3-6e951cfa0523", "node_type": "1", "metadata": {"window": "So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n", "original_text": "We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding. "}, "hash": "a7397425641b704183134de0c5a76d7f8643a63c7a744e584ec80eb8a9ab4dbe", "class_name": "RelatedNodeInfo"}}, "text": "We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.  ", "start_char_idx": 2055, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f8b2dde-bb88-426c-99e3-6e951cfa0523": {"__data__": {"id_": "1f8b2dde-bb88-426c-99e3-6e951cfa0523", "embedding": null, "metadata": {"window": "So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n", "original_text": "We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "980f54ab-372c-4c9d-9379-7e844abc3216", "node_type": "1", "metadata": {"window": "What Navista \u2122 Network is doing is, bringing \nthat all together in the form of a business with new additional senior leadership brought in place.  So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for. ", "original_text": "We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80b0fdcc6bd5a36c0532af2308182f620b122994caa70dacf41e367bf23eea71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59c9327f-2d90-4619-b4ec-079ccb8bf479", "node_type": "1", "metadata": {"window": "So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence. "}, "hash": "330a6939cd0879a0023eb3e0f3ebddd8c64d05e22114c8504cf98283e6d5ba94", "class_name": "RelatedNodeInfo"}}, "text": "We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding. ", "start_char_idx": 2319, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59c9327f-2d90-4619-b4ec-079ccb8bf479": {"__data__": {"id_": "59c9327f-2d90-4619-b4ec-079ccb8bf479", "embedding": null, "metadata": {"window": "So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f8b2dde-bb88-426c-99e3-6e951cfa0523", "node_type": "1", "metadata": {"window": "So \nthat's o ne of the key things that's happened since the announcement a couple of months ago, is we \nhave brought in additional leadership to bring on top of the strong team that we already had in place \nthat were already serving these important customers and their pa tients.  So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n", "original_text": "We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8bc5403328923799b6acb9cecfc6a6f006c92cf45eafe66853a0b951abc01d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e581b466-6efb-4b1b-a0f8-64c983f7f705", "node_type": "1", "metadata": {"window": "We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n", "original_text": "We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for. "}, "hash": "fbde93de284a618741e3efc80a05435dff7f43773923dabfeeff083d1a2faa39", "class_name": "RelatedNodeInfo"}}, "text": "What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence. ", "start_char_idx": 2534, "end_char_idx": 2700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e581b466-6efb-4b1b-a0f8-64c983f7f705": {"__data__": {"id_": "e581b466-6efb-4b1b-a0f8-64c983f7f705", "embedding": null, "metadata": {"window": "We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n", "original_text": "We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59c9327f-2d90-4619-b4ec-079ccb8bf479", "node_type": "1", "metadata": {"window": "So, we are building that out \nfurther with both internal , as well as external talent.  We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e2289626cc094d75f5414b54a4e634da59422572a3f7005fae74f22329bdbb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81209834-c320-4adb-8c68-f5739cca4651", "node_type": "1", "metadata": {"window": "We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys. ", "original_text": "So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n"}, "hash": "248238ae85fdeb28d4f85f9c90b1fd36a4cf0eff3e4d5afbac032078816120ad", "class_name": "RelatedNodeInfo"}}, "text": "We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for. ", "start_char_idx": 2700, "end_char_idx": 2854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81209834-c320-4adb-8c68-f5739cca4651": {"__data__": {"id_": "81209834-c320-4adb-8c68-f5739cca4651", "embedding": null, "metadata": {"window": "We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys. ", "original_text": "So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e581b466-6efb-4b1b-a0f8-64c983f7f705", "node_type": "1", "metadata": {"window": "We also created an advisory board to ensure that \nwe are working directly with both current and prospective customers, more than anything to make \nsure that they have  a strong voice as to where we go next with the development of this platform in \nthis business.   We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n", "original_text": "We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "398ff05e4c4c9a21f4866bd974e9fe96ca9ea365360711de123165ed3df5d645", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c03621df-75af-48f8-8955-e0f539d6a5d8", "node_type": "1", "metadata": {"window": "What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question. ", "original_text": "Kevin Moran:  Next question, please.  \n \n"}, "hash": "4fa6e58ff01897948a691ed199823be84bf9d0af6f2a5d2d36d36cd3c1b00eed", "class_name": "RelatedNodeInfo"}}, "text": "So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n", "start_char_idx": 2854, "end_char_idx": 3139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c03621df-75af-48f8-8955-e0f539d6a5d8": {"__data__": {"id_": "c03621df-75af-48f8-8955-e0f539d6a5d8", "embedding": null, "metadata": {"window": "What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81209834-c320-4adb-8c68-f5739cca4651", "node_type": "1", "metadata": {"window": "We continue to listen and be out in the field doing a lot of research, but we're also \nbuilding what were already notably to be some of the key attributes of this  platform and this network \nthat they're demanding.  What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys. ", "original_text": "So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2613646553d459efe5a84c790d24af6d48c6e99ca138c92e0b1ceff5dc02157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4c113b7-8bb6-4bb9-8902-b4fbc5e89419", "node_type": "1", "metadata": {"window": "We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.  ", "original_text": "Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n"}, "hash": "fb78c237ed9c02d4e6711a27aaebd9c7eaee8ce4c94b12977fe45f608a909372", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n \n", "start_char_idx": 317, "end_char_idx": 358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4c113b7-8bb6-4bb9-8902-b4fbc5e89419": {"__data__": {"id_": "e4c113b7-8bb6-4bb9-8902-b4fbc5e89419", "embedding": null, "metadata": {"window": "We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.  ", "original_text": "Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c03621df-75af-48f8-8955-e0f539d6a5d8", "node_type": "1", "metadata": {"window": "What's key and what we highlighted before is that these are , the 1,500 that \nwe're focused on here , are very strongly interested in maintaining their independence.  We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cb3876013a4b60b1dd93708921c4d941f4b9728c161794ded2a3ca7bf72e6cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b296e85-5ecc-4954-9187-8c1ec6100996", "node_type": "1", "metadata": {"window": "So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year? ", "original_text": "Elizabeth Anderson:  Hey, guys. "}, "hash": "03529e878c7e03d7f428ab86c390d34849a494129a4b067874956e8a84bb66c2", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n", "start_char_idx": 3180, "end_char_idx": 3251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b296e85-5ecc-4954-9187-8c1ec6100996": {"__data__": {"id_": "8b296e85-5ecc-4954-9187-8c1ec6100996", "embedding": null, "metadata": {"window": "So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year? ", "original_text": "Elizabeth Anderson:  Hey, guys. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4c113b7-8bb6-4bb9-8902-b4fbc5e89419", "node_type": "1", "metadata": {"window": "We're also \nhearing a strong desire for ong oing transparency, which as healthcare's most trusted partner we feel \nlike we're really well positioned for.  So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.  ", "original_text": "Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41142bcc2845e30b26b831121db4593e57a4b5e32e8c98eb9933aa6a3bcdee6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17c1dcd8-804a-482c-8726-dbddad326536", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Thanks so much for the question. "}, "hash": "3c1b2fe74353ac6a3450485eeb81392d492daa59a1e052a3c3f0dc5052c6bf78", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:  Hey, guys. ", "start_char_idx": 3251, "end_char_idx": 3283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17c1dcd8-804a-482c-8726-dbddad326536": {"__data__": {"id_": "17c1dcd8-804a-482c-8726-dbddad326536", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Thanks so much for the question. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b296e85-5ecc-4954-9187-8c1ec6100996", "node_type": "1", "metadata": {"window": "So , it's only been a couple of months since we rolled this out , but \nin that timeframe,  we've got the team in place, better definition of what the pl atform needs to be built \nout with and continue to work with those prospective customers to make sure that their needs are \nmet. \n \n Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year? ", "original_text": "Elizabeth Anderson:  Hey, guys. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2daf1a9392a0cdecfb2270a5367df4fc003a07b9cec17c11cb37c8690333429", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5bab8ac-680a-4513-b489-afc8fd99bdb0", "node_type": "1", "metadata": {"window": "Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.  "}, "hash": "1e51a5354cb6e5aeefdafc4484bdbe6f8854aeb02fb8ecdd75512e7fefabaefb", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 3283, "end_char_idx": 3316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5bab8ac-680a-4513-b489-afc8fd99bdb0": {"__data__": {"id_": "b5bab8ac-680a-4513-b489-afc8fd99bdb0", "embedding": null, "metadata": {"window": "Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17c1dcd8-804a-482c-8726-dbddad326536", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Thanks so much for the question. ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7bf9434d290a020f046b8177d608e48b74b99d1f113489ad281c0dd37a64864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c4e400d-9e93-4aca-9714-2d699d52322b", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Is that something \nthat you also expect to like ramp ratably over the course of the year? "}, "hash": "d9866434bf66454a6c29b3b0c103f6c114dcd337d3644c8ae6031d864058563c", "class_name": "RelatedNodeInfo"}}, "text": "I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.  ", "start_char_idx": 3316, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c4e400d-9e93-4aca-9714-2d699d52322b": {"__data__": {"id_": "5c4e400d-9e93-4aca-9714-2d699d52322b", "embedding": null, "metadata": {"window": "Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Is that something \nthat you also expect to like ramp ratably over the course of the year? ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5bab8ac-680a-4513-b489-afc8fd99bdb0", "node_type": "1", "metadata": {"window": "Operator:   Next question comes from Elizabeth Anderson of Evercore.  \n Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.  ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec46b42b343164365d3e4670fe1dbc7d9b509b222b6d7964554faaf8f12cb87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d65a6f4-d9fd-4cc1-bfba-63edb820966c", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Is th at something that has gone "}, "hash": "f5e77d71e7375c1ab56d84ca623f1c615fd47e65e96af56a61cbbaed4b58873c", "class_name": "RelatedNodeInfo"}}, "text": "Is that something \nthat you also expect to like ramp ratably over the course of the year? ", "start_char_idx": 3437, "end_char_idx": 3527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d65a6f4-d9fd-4cc1-bfba-63edb820966c": {"__data__": {"id_": "0d65a6f4-d9fd-4cc1-bfba-63edb820966c", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Is th at something that has gone ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a39adb85-e94b-4022-a926-62e962c0fefc", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eab7989f96fe43cec8582acc73c7ce21d013a3b50038f43a0bd4b607a798d6fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c4e400d-9e93-4aca-9714-2d699d52322b", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hey, guys.  Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Is that something \nthat you also expect to like ramp ratably over the course of the year? ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da4063986145c3f35d98c9d3b00c13db2fb480f2bc4b9bc6d5da35ac33264bd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28a93f70-ec3d-4174-aee8-45bd1021c682", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. ", "original_text": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing? "}, "hash": "7f8e83b952f859aaf076300e960789aaad09c8efab27f78131972c0c76173d53", "class_name": "RelatedNodeInfo"}}, "text": "Is th at something that has gone ", "start_char_idx": 3527, "end_char_idx": 3560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28a93f70-ec3d-4174-aee8-45bd1021c682": {"__data__": {"id_": "28a93f70-ec3d-4174-aee8-45bd1021c682", "embedding": null, "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. ", "original_text": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing? ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d65a6f4-d9fd-4cc1-bfba-63edb820966c", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I don't know if you could comment \non the corporate costs that you just discussed in Medical, the $60 million  dollars.   Is that something \nthat you also expect to like ramp ratably over the course of the year?  Is th at something that has gone ", "original_text": "Is th at something that has gone ", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1c9a5ef14e33dca4f7dad4f9674fb804bd096bd1bf3bf064fdba16d4eecedb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbe8a030-9b9e-400a-b960-1f093f4c0879", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n", "original_text": "A little \nbit more help there would be very helpful.  \n"}, "hash": "f33e4c61a4e99d1d6f5643e7130113e725ae78016b700cf5a7f0ed350fad0a71", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing? ", "start_char_idx": 0, "end_char_idx": 113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbe8a030-9b9e-400a-b960-1f093f4c0879": {"__data__": {"id_": "dbe8a030-9b9e-400a-b960-1f093f4c0879", "embedding": null, "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n", "original_text": "A little \nbit more help there would be very helpful.  \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28a93f70-ec3d-4174-aee8-45bd1021c682", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. ", "original_text": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing? ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36807df2eb18877d54556975256731a2e2bcc86bd9932328dbc3727fb016c039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9672a73-6dee-495a-9a60-c458db0d5f36", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay. ", "original_text": "And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year? "}, "hash": "ab189dac08d66577a9c9cfaed939e32743407130cedc82a2b5cf6b598d1d1450", "class_name": "RelatedNodeInfo"}}, "text": "A little \nbit more help there would be very helpful.  \n", "start_char_idx": 113, "end_char_idx": 168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9672a73-6dee-495a-9a60-c458db0d5f36": {"__data__": {"id_": "f9672a73-6dee-495a-9a60-c458db0d5f36", "embedding": null, "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay. ", "original_text": "And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year? ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbe8a030-9b9e-400a-b960-1f093f4c0879", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n", "original_text": "A little \nbit more help there would be very helpful.  \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01677af0789cccc676bca11880d8e14c18a28a6b682a5dbe3430d18cf620f59c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee3e92ec-643f-4ef8-8456-7d595fdde3b1", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start. ", "original_text": "We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. "}, "hash": "5dac019c6272f5bc58efb90e9ceb98002fa4e0e8362ad61f8d010cb16638f4ac", "class_name": "RelatedNodeInfo"}}, "text": "And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year? ", "start_char_idx": 168, "end_char_idx": 323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee3e92ec-643f-4ef8-8456-7d595fdde3b1": {"__data__": {"id_": "ee3e92ec-643f-4ef8-8456-7d595fdde3b1", "embedding": null, "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start. ", "original_text": "We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9672a73-6dee-495a-9a60-c458db0d5f36", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay. ", "original_text": "And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year? ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eea694891ca7f9a228f4030df173fd44aad52ff87baee0965a5f3fb2595182d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c143f4a-683d-4c9c-934a-e8cc37751e66", "node_type": "1", "metadata": {"window": "A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half. ", "original_text": "Thanks.  \n \n"}, "hash": "2e36e8f38d5a993cbe46ecb22a88fba0e5b1d17553396f086f81ab7d0b2f886a", "class_name": "RelatedNodeInfo"}}, "text": "We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. ", "start_char_idx": 323, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c143f4a-683d-4c9c-934a-e8cc37751e66": {"__data__": {"id_": "3c143f4a-683d-4c9c-934a-e8cc37751e66", "embedding": null, "metadata": {"window": "A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half. ", "original_text": "Thanks.  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee3e92ec-643f-4ef8-8456-7d595fdde3b1", "node_type": "1", "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start. ", "original_text": "We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc3768ae4ad37ccbcaa3b8d3d450a89e975011d950d93afbdb098c5e2b456da2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6070d7fb-823d-4b6b-bab1-241665eeb980", "node_type": "1", "metadata": {"window": "And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp. ", "original_text": "Jason Hollar:  Okay. "}, "hash": "db51bbeb88bd1f07a7c9a16a746ce14413755a04a6435a94a0841e4e323b92ac", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 545, "end_char_idx": 557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6070d7fb-823d-4b6b-bab1-241665eeb980": {"__data__": {"id_": "6070d7fb-823d-4b6b-bab1-241665eeb980", "embedding": null, "metadata": {"window": "And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp. ", "original_text": "Jason Hollar:  Okay. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c143f4a-683d-4c9c-934a-e8cc37751e66", "node_type": "1", "metadata": {"window": "A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half. ", "original_text": "Thanks.  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd696cff5697068becc733275b4d3d2312226508f723e5841e9b4ee40c9b275b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72c7ed76-2f3f-41db-a3b8-a663e74cc34c", "node_type": "1", "metadata": {"window": "We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n", "original_text": "I think I caught the essence of at least part of that , so let me start. "}, "hash": "2b5da43d8899d944ccd4621a499f954a732af7209a98dcbe6867ae12b30c3757", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Okay. ", "start_char_idx": 557, "end_char_idx": 578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72c7ed76-2f3f-41db-a3b8-a663e74cc34c": {"__data__": {"id_": "72c7ed76-2f3f-41db-a3b8-a663e74cc34c", "embedding": null, "metadata": {"window": "We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n", "original_text": "I think I caught the essence of at least part of that , so let me start. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6070d7fb-823d-4b6b-bab1-241665eeb980", "node_type": "1", "metadata": {"window": "And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp. ", "original_text": "Jason Hollar:  Okay. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96dc2960d55010e6cd400fc090faaf6f7bd4a243c6eb8ef288393e56877794f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ea2f5cc-1fb2-41df-b2a5-566fc0ee54df", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%. ", "original_text": "I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half. "}, "hash": "43a1539016170c352e1eeb846c95b76bc0272363e56e362b3975767d1b2c7504", "class_name": "RelatedNodeInfo"}}, "text": "I think I caught the essence of at least part of that , so let me start. ", "start_char_idx": 578, "end_char_idx": 651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ea2f5cc-1fb2-41df-b2a5-566fc0ee54df": {"__data__": {"id_": "7ea2f5cc-1fb2-41df-b2a5-566fc0ee54df", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%. ", "original_text": "I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72c7ed76-2f3f-41db-a3b8-a663e74cc34c", "node_type": "1", "metadata": {"window": "We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%.  Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n", "original_text": "I think I caught the essence of at least part of that , so let me start. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62cdb1e407a29007b70db64cd8aabac294ec2f8985cc5ea466026d3332d649ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c681f77c-4a5a-4724-9dea-a87bd1bfef6e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight. ", "original_text": "I think the \nother question related to the corporate cost ramp. "}, "hash": "e85adfeb69315c9b5868d1e0151b3ce95bc800fec07a550fd3684d92ef3626db", "class_name": "RelatedNodeInfo"}}, "text": "I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half. ", "start_char_idx": 651, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c681f77c-4a5a-4724-9dea-a87bd1bfef6e": {"__data__": {"id_": "c681f77c-4a5a-4724-9dea-a87bd1bfef6e", "embedding": null, "metadata": {"window": "Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight. ", "original_text": "I think the \nother question related to the corporate cost ramp. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ea2f5cc-1fb2-41df-b2a5-566fc0ee54df", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%. ", "original_text": "I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f00345491196344e94b4e7c36a788ece7d149366dc01781c1707a9e6f29646a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efc97c6a-4dde-4fde-8a93-8996aeb9f450", "node_type": "1", "metadata": {"window": "I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago. ", "original_text": "So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n"}, "hash": "21277215e9ca4fdf5d16a82f056602ff91892fd83bbaa6e3756d4a8537a90560", "class_name": "RelatedNodeInfo"}}, "text": "I think the \nother question related to the corporate cost ramp. ", "start_char_idx": 761, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efc97c6a-4dde-4fde-8a93-8996aeb9f450": {"__data__": {"id_": "efc97c6a-4dde-4fde-8a93-8996aeb9f450", "embedding": null, "metadata": {"window": "I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago. ", "original_text": "So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c681f77c-4a5a-4724-9dea-a87bd1bfef6e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Okay.  I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight. ", "original_text": "I think the \nother question related to the corporate cost ramp. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40c4b99a4c5ca0c643e9586b6c1b6cbb31cdcc19202cffaeff219a66cb6de651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d36a4926-bfaf-479a-bc9c-9193c426e079", "node_type": "1", "metadata": {"window": "I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823. ", "original_text": "So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%. "}, "hash": "f3a3bf9ce0d75c40cbc142a738245d2e85dd536b2a53a4b5bf9df145a7cda18c", "class_name": "RelatedNodeInfo"}}, "text": "So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n", "start_char_idx": 825, "end_char_idx": 921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d36a4926-bfaf-479a-bc9c-9193c426e079": {"__data__": {"id_": "d36a4926-bfaf-479a-bc9c-9193c426e079", "embedding": null, "metadata": {"window": "I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823. ", "original_text": "So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efc97c6a-4dde-4fde-8a93-8996aeb9f450", "node_type": "1", "metadata": {"window": "I think I caught the essence of at least part of that , so let me start.  I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago. ", "original_text": "So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89475264e12da2e3e720adab279c9a4b4f2237788085562c0f5628f6b831f9be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "725c4fb5-9752-4c52-9f02-b5938d873a70", "node_type": "1", "metadata": {"window": "I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that. ", "original_text": "So, in both cases, what we've seen is a moderation of the \ninternational freight. "}, "hash": "fa05b394c17d8046df1859a7b99b4b7b0ea4062bee69b7623f2a1e5386930171", "class_name": "RelatedNodeInfo"}}, "text": "So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%. ", "start_char_idx": 921, "end_char_idx": 1065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "725c4fb5-9752-4c52-9f02-b5938d873a70": {"__data__": {"id_": "725c4fb5-9752-4c52-9f02-b5938d873a70", "embedding": null, "metadata": {"window": "I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that. ", "original_text": "So, in both cases, what we've seen is a moderation of the \ninternational freight. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d36a4926-bfaf-479a-bc9c-9193c426e079", "node_type": "1", "metadata": {"window": "I believe part \nof the question was re lated to the next part of the inflation mitigation in the second half.  I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823. ", "original_text": "So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0137adea31fa8b09e4633d3e348fc0b55e6964d9949fb2088821ffc2f6dd3402", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca507966-194c-481a-bb73-afc6a154b0e8", "node_type": "1", "metadata": {"window": "So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories. ", "original_text": "That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago. "}, "hash": "a048da36ffe9184b6f9d6695b99cfdcb0bd75a92bd7a2687864556850cd5e507", "class_name": "RelatedNodeInfo"}}, "text": "So, in both cases, what we've seen is a moderation of the \ninternational freight. ", "start_char_idx": 1065, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca507966-194c-481a-bb73-afc6a154b0e8": {"__data__": {"id_": "ca507966-194c-481a-bb73-afc6a154b0e8", "embedding": null, "metadata": {"window": "So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories. ", "original_text": "That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "725c4fb5-9752-4c52-9f02-b5938d873a70", "node_type": "1", "metadata": {"window": "I think the \nother question related to the corporate cost ramp.  So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that. ", "original_text": "So, in both cases, what we've seen is a moderation of the \ninternational freight. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da48b41068c0a5466e89f0742b677ba44740ab382fbda1acbeac856ecfed4344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47d710a6-8088-4ba8-a576-d7ce181ce336", "node_type": "1", "metadata": {"window": "So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.  ", "original_text": "So , that has \nstarted to benefit us as we especially exited fiscal \u201823. "}, "hash": "ea6217c038337102da4b680e22389c926c5a199a55b1591e92da9615a8e1bebf", "class_name": "RelatedNodeInfo"}}, "text": "That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago. ", "start_char_idx": 1147, "end_char_idx": 1309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47d710a6-8088-4ba8-a576-d7ce181ce336": {"__data__": {"id_": "47d710a6-8088-4ba8-a576-d7ce181ce336", "embedding": null, "metadata": {"window": "So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.  ", "original_text": "So , that has \nstarted to benefit us as we especially exited fiscal \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca507966-194c-481a-bb73-afc6a154b0e8", "node_type": "1", "metadata": {"window": "So , let me start with the second part and then \nthrow it over to Aaron for the first part.  \n \n So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories. ", "original_text": "That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6689ff3126f8e3dfc9350634b316cdf5ad07f2bf64faf5637f5cbce6d111fb49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0d1ddfa-3abf-4f65-af41-887446e5f344", "node_type": "1", "metadata": {"window": "So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts. ", "original_text": "So, we did start to see that. "}, "hash": "4189df1193a603f007b34c24c786257b71b28bae0c9836bf1f96508dee125154", "class_name": "RelatedNodeInfo"}}, "text": "So , that has \nstarted to benefit us as we especially exited fiscal \u201823. ", "start_char_idx": 1309, "end_char_idx": 1382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0d1ddfa-3abf-4f65-af41-887446e5f344": {"__data__": {"id_": "d0d1ddfa-3abf-4f65-af41-887446e5f344", "embedding": null, "metadata": {"window": "So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts. ", "original_text": "So, we did start to see that. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47d710a6-8088-4ba8-a576-d7ce181ce336", "node_type": "1", "metadata": {"window": "So, as you think about the inflation mitigation and the next piece, there's \u2013 it's really the same for the \nsecond 50% as it was the first 50%.  So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.  ", "original_text": "So , that has \nstarted to benefit us as we especially exited fiscal \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6452951192e58b6e2a53ad626a528ffa4adbbcaaa0fdc0755735a6599254336c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e35f47ed-cdb3-48ba-bda6-8ad46e3ac2ed", "node_type": "1", "metadata": {"window": "That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued. ", "original_text": "It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories. "}, "hash": "3f092ec4fca5c989c6b33af34ff91e3e6de02bf3266146f52ef713fc2bde23c3", "class_name": "RelatedNodeInfo"}}, "text": "So, we did start to see that. ", "start_char_idx": 1382, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e35f47ed-cdb3-48ba-bda6-8ad46e3ac2ed": {"__data__": {"id_": "e35f47ed-cdb3-48ba-bda6-8ad46e3ac2ed", "embedding": null, "metadata": {"window": "That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued. ", "original_text": "It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0d1ddfa-3abf-4f65-af41-887446e5f344", "node_type": "1", "metadata": {"window": "So, in both cases, what we've seen is a moderation of the \ninternational freight.  That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts. ", "original_text": "So, we did start to see that. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d332ab2a275c0c803ba8157d0c4f7133e9c8c1089104f616a748fcb13fd06c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a5374b4-3d14-49e2-98a4-c0098afd6521", "node_type": "1", "metadata": {"window": "So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down. ", "original_text": "So, it took a little while for \nthat to benefit our P&L as a cost reduce.  "}, "hash": "d8393a2464a4080a57cf0802906b6af839835f2838e94043de1a6bd37acc1f5a", "class_name": "RelatedNodeInfo"}}, "text": "It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories. ", "start_char_idx": 1412, "end_char_idx": 1511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a5374b4-3d14-49e2-98a4-c0098afd6521": {"__data__": {"id_": "1a5374b4-3d14-49e2-98a4-c0098afd6521", "embedding": null, "metadata": {"window": "So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down. ", "original_text": "So, it took a little while for \nthat to benefit our P&L as a cost reduce.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e35f47ed-cdb3-48ba-bda6-8ad46e3ac2ed", "node_type": "1", "metadata": {"window": "That spiked significantly about two years ago and started c oming down about a \nyear ago and  got back down to pre -pandemic levels maybe six to nine months ago.  So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued. ", "original_text": "It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "303f22a4666f8d6f62128f84a7e02d710390eabe16a57b338f0ac8e3515a6783", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49cae840-e330-430e-9761-a064fb688ab3", "node_type": "1", "metadata": {"window": "So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down. ", "original_text": "And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts. "}, "hash": "c0c5a1a31c0df599d04aaa5cf97a77c77589a4bc289424c7305fad2bc82f81a4", "class_name": "RelatedNodeInfo"}}, "text": "So, it took a little while for \nthat to benefit our P&L as a cost reduce.  ", "start_char_idx": 1511, "end_char_idx": 1586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49cae840-e330-430e-9761-a064fb688ab3": {"__data__": {"id_": "49cae840-e330-430e-9761-a064fb688ab3", "embedding": null, "metadata": {"window": "So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down. ", "original_text": "And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a5374b4-3d14-49e2-98a4-c0098afd6521", "node_type": "1", "metadata": {"window": "So , that has \nstarted to benefit us as we especially exited fiscal \u201823.  So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down. ", "original_text": "So, it took a little while for \nthat to benefit our P&L as a cost reduce.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58f8caa32d259c92b761d1658647904b62db1e04f96927ea2c4af82977dc63db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b41b0a2-8bb7-42ab-8606-26c6b4ab5a35", "node_type": "1", "metadata": {"window": "It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.  ", "original_text": "All those other costs have plateaued. "}, "hash": "e749a0454bec09501ae22bc162f41496e7e7c3f9e4b9b41002e06d99407306d1", "class_name": "RelatedNodeInfo"}}, "text": "And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts. ", "start_char_idx": 1586, "end_char_idx": 1856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b41b0a2-8bb7-42ab-8606-26c6b4ab5a35": {"__data__": {"id_": "0b41b0a2-8bb7-42ab-8606-26c6b4ab5a35", "embedding": null, "metadata": {"window": "It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.  ", "original_text": "All those other costs have plateaued. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49cae840-e330-430e-9761-a064fb688ab3", "node_type": "1", "metadata": {"window": "So, we did start to see that.  It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down. ", "original_text": "And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1f9fe0aa85468672ef6e99d4ac5c482766f5b941124b18e3acc2e4728475006", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa6ce2c4-668c-4b42-acb9-ef9022b40c5d", "node_type": "1", "metadata": {"window": "So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight. ", "original_text": "They are not coming down. "}, "hash": "190c32b3f8956ae33e338f177e7a281ae219512ec993c5a9a0b7b1737b7baa2a", "class_name": "RelatedNodeInfo"}}, "text": "All those other costs have plateaued. ", "start_char_idx": 1856, "end_char_idx": 1894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa6ce2c4-668c-4b42-acb9-ef9022b40c5d": {"__data__": {"id_": "fa6ce2c4-668c-4b42-acb9-ef9022b40c5d", "embedding": null, "metadata": {"window": "So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight. ", "original_text": "They are not coming down. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b41b0a2-8bb7-42ab-8606-26c6b4ab5a35", "node_type": "1", "metadata": {"window": "It, of course, was \ninventoried into our inventory, capit alized those costs into our inventories.  So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.  ", "original_text": "All those other costs have plateaued. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf2a1f2266a90f7a468c22c6fea99c7af3aacc6e46541cfed1c164d3423a24aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9d6ca22-4517-4070-905c-6228d5449031", "node_type": "1", "metadata": {"window": "And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices. ", "original_text": "We don't see any signs of \nthem coming down. "}, "hash": "017c17b2c6be3c5ec9eaab9dce06ce6571b35d5a0451305c5f8d67418d424b6d", "class_name": "RelatedNodeInfo"}}, "text": "They are not coming down. ", "start_char_idx": 1894, "end_char_idx": 1920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9d6ca22-4517-4070-905c-6228d5449031": {"__data__": {"id_": "a9d6ca22-4517-4070-905c-6228d5449031", "embedding": null, "metadata": {"window": "And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices. ", "original_text": "We don't see any signs of \nthem coming down. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa6ce2c4-668c-4b42-acb9-ef9022b40c5d", "node_type": "1", "metadata": {"window": "So, it took a little while for \nthat to benefit our P&L as a cost reduce.   And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight. ", "original_text": "They are not coming down. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6de49b346339c79aa58a3744bb6bb25cefaa5762c832a5c8206dba8d4cb576f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d1d74e2-e230-4d32-b6f3-0b2a9555114b", "node_type": "1", "metadata": {"window": "All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices. ", "original_text": "And so , we have to price p ermanently for those items.  "}, "hash": "6245fdea1aff4420d1b9487de57f9fdf7ad7a8d67df090c1795aaff592a1d948", "class_name": "RelatedNodeInfo"}}, "text": "We don't see any signs of \nthem coming down. ", "start_char_idx": 1920, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d1d74e2-e230-4d32-b6f3-0b2a9555114b": {"__data__": {"id_": "2d1d74e2-e230-4d32-b6f3-0b2a9555114b", "embedding": null, "metadata": {"window": "All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices. ", "original_text": "And so , we have to price p ermanently for those items.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9d6ca22-4517-4070-905c-6228d5449031", "node_type": "1", "metadata": {"window": "And along the way, in parallel with that  of course, we were \npricing mainly on a temporary basis the first year for those increases as well as i ncreases in other \ncommodity costs and transportation, domestic transportation, increased labor and all those other \ncosts.  All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices. ", "original_text": "We don't see any signs of \nthem coming down. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e1cc3142a7cdeba59aebf0661bce49358215d2d892652108bae428d2cec3ebf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ec0e57d-0fd1-4870-b9ba-7edc704089cb", "node_type": "1", "metadata": {"window": "They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized. ", "original_text": "We priced temporarily for \nthe international freight. "}, "hash": "6dbe537ad4d2a58c5f0afd25ca630e7597b55f2cebf048cf3343da9e4e0f4a12", "class_name": "RelatedNodeInfo"}}, "text": "And so , we have to price p ermanently for those items.  ", "start_char_idx": 1965, "end_char_idx": 2022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ec0e57d-0fd1-4870-b9ba-7edc704089cb": {"__data__": {"id_": "4ec0e57d-0fd1-4870-b9ba-7edc704089cb", "embedding": null, "metadata": {"window": "They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized. ", "original_text": "We priced temporarily for \nthe international freight. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d1d74e2-e230-4d32-b6f3-0b2a9555114b", "node_type": "1", "metadata": {"window": "All those other costs have plateaued.  They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices. ", "original_text": "And so , we have to price p ermanently for those items.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fb6f9dea14fae3e147f04b7d0a91340ff948b14deddbf982af4713361c06b51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bffcaf4e-bcae-4aca-acbe-db69b8d335a7", "node_type": "1", "metadata": {"window": "We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices. ", "original_text": "And as those costs on the international freight roll off, we need to maintain \nhigher prices. "}, "hash": "0a957ae95e55449705898d7ec84e30ca86ae20f44a82d05b01128ae1c9646a75", "class_name": "RelatedNodeInfo"}}, "text": "We priced temporarily for \nthe international freight. ", "start_char_idx": 2022, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bffcaf4e-bcae-4aca-acbe-db69b8d335a7": {"__data__": {"id_": "bffcaf4e-bcae-4aca-acbe-db69b8d335a7", "embedding": null, "metadata": {"window": "We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices. ", "original_text": "And as those costs on the international freight roll off, we need to maintain \nhigher prices. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ec0e57d-0fd1-4870-b9ba-7edc704089cb", "node_type": "1", "metadata": {"window": "They are not coming down.  We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized. ", "original_text": "We priced temporarily for \nthe international freight. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "398a20167d8c1fe91f9ba698010c6d0013d0e980ba0a01f74af302da9f12425b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fead66a-1146-41a3-a9d0-9a46daaedfc5", "node_type": "1", "metadata": {"window": "And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs. ", "original_text": "And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices. "}, "hash": "83c68c03236919d8503d2c403b90761efa60ea21bc6a858ad5a89ae2c804fcd4", "class_name": "RelatedNodeInfo"}}, "text": "And as those costs on the international freight roll off, we need to maintain \nhigher prices. ", "start_char_idx": 2076, "end_char_idx": 2170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fead66a-1146-41a3-a9d0-9a46daaedfc5": {"__data__": {"id_": "3fead66a-1146-41a3-a9d0-9a46daaedfc5", "embedding": null, "metadata": {"window": "And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs. ", "original_text": "And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bffcaf4e-bcae-4aca-acbe-db69b8d335a7", "node_type": "1", "metadata": {"window": "We don't see any signs of \nthem coming down.  And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices. ", "original_text": "And as those costs on the international freight roll off, we need to maintain \nhigher prices. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e3b828f73a2268b564846889bab44c0448706f7bc6656870d7002919e2293e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5f6fea7-dfa1-44b9-83b4-c788411e8aaa", "node_type": "1", "metadata": {"window": "We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.  ", "original_text": "And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized. "}, "hash": "71aa0fe8586a2f6e242e50fbe32ce458eb26f63f66b2e2eeff5e14934c2a9be3", "class_name": "RelatedNodeInfo"}}, "text": "And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices. ", "start_char_idx": 2170, "end_char_idx": 2291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5f6fea7-dfa1-44b9-83b4-c788411e8aaa": {"__data__": {"id_": "e5f6fea7-dfa1-44b9-83b4-c788411e8aaa", "embedding": null, "metadata": {"window": "We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.  ", "original_text": "And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fead66a-1146-41a3-a9d0-9a46daaedfc5", "node_type": "1", "metadata": {"window": "And so , we have to price p ermanently for those items.   We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs. ", "original_text": "And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b69811fd665bf94dd7c7514e3a0a87d20bb3a6f5e4236cf526dff77a519dc47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32563cca-159f-43ff-99cd-e62edfaa8f57", "node_type": "1", "metadata": {"window": "And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down. ", "original_text": "Let me be  very clear, we're not rolling back \nprices. "}, "hash": "e825c98d5ab3904bf95c48526917ce0117dc2a59edf00bf51143dc8949630b33", "class_name": "RelatedNodeInfo"}}, "text": "And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized. ", "start_char_idx": 2291, "end_char_idx": 2416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32563cca-159f-43ff-99cd-e62edfaa8f57": {"__data__": {"id_": "32563cca-159f-43ff-99cd-e62edfaa8f57", "embedding": null, "metadata": {"window": "And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down. ", "original_text": "Let me be  very clear, we're not rolling back \nprices. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5f6fea7-dfa1-44b9-83b4-c788411e8aaa", "node_type": "1", "metadata": {"window": "We priced temporarily for \nthe international freight.  And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.  ", "original_text": "And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76bbb808eda5d442a1e7c8800f88e078125743f134987244d066958751dca7fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba6541bb-28d4-4937-91a0-c530ba2bca12", "node_type": "1", "metadata": {"window": "And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year. ", "original_text": "We've not increased prices beyond the point of our costs. "}, "hash": "5c7a889016d94233276796b35eeb43dcdde3e88a0ac44926320d8668cba84d61", "class_name": "RelatedNodeInfo"}}, "text": "Let me be  very clear, we're not rolling back \nprices. ", "start_char_idx": 2416, "end_char_idx": 2471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba6541bb-28d4-4937-91a0-c530ba2bca12": {"__data__": {"id_": "ba6541bb-28d4-4937-91a0-c530ba2bca12", "embedding": null, "metadata": {"window": "And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year. ", "original_text": "We've not increased prices beyond the point of our costs. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32563cca-159f-43ff-99cd-e62edfaa8f57", "node_type": "1", "metadata": {"window": "And as those costs on the international freight roll off, we need to maintain \nhigher prices.  And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down. ", "original_text": "Let me be  very clear, we're not rolling back \nprices. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5ad5a5dae946dc0c2a6e415638e15a266e075b806ab159ece518a359314822f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e847521-c289-425f-9c6e-ab9ce8a1597c", "node_type": "1", "metadata": {"window": "And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n", "original_text": "At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.  "}, "hash": "86078209bb3fb1be6a899e50e88ce056f0a75ad7b3628618ff6b79a7b0bb3472", "class_name": "RelatedNodeInfo"}}, "text": "We've not increased prices beyond the point of our costs. ", "start_char_idx": 2471, "end_char_idx": 2529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e847521-c289-425f-9c6e-ab9ce8a1597c": {"__data__": {"id_": "1e847521-c289-425f-9c6e-ab9ce8a1597c", "embedding": null, "metadata": {"window": "And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n", "original_text": "At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba6541bb-28d4-4937-91a0-c530ba2bca12", "node_type": "1", "metadata": {"window": "And so we are continuing to price , and some of those temporary prices are now bein g \nrolled into the permanent prices.  And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year. ", "original_text": "We've not increased prices beyond the point of our costs. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19946a124871b717b2a5d8901ada1be2b6026ffb215c7198e7d9a4c08abc3a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78c71df4-c66b-482a-bedf-5efd780d63da", "node_type": "1", "metadata": {"window": "Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure. ", "original_text": "But over the course of \nthis year, we do expect the international freight to come down. "}, "hash": "f76dda81f752e30da5ae908878b5343e583229e40d0d1f06e6957a1c79397b34", "class_name": "RelatedNodeInfo"}}, "text": "At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.  ", "start_char_idx": 2529, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78c71df4-c66b-482a-bedf-5efd780d63da": {"__data__": {"id_": "78c71df4-c66b-482a-bedf-5efd780d63da", "embedding": null, "metadata": {"window": "Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure. ", "original_text": "But over the course of \nthis year, we do expect the international freight to come down. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e847521-c289-425f-9c6e-ab9ce8a1597c", "node_type": "1", "metadata": {"window": "And so , we would expect that as those contracts renew that we'll \ncontinue to see more and more of that pricing recognized.  Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n", "original_text": "At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c15f71ca0bb4490d0221ddb3c850c404835f55f99752d468fa4deca0ae3f483e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a58aa69f-7282-4dbc-9dc7-20409b67462a", "node_type": "1", "metadata": {"window": "We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this. ", "original_text": "And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year. "}, "hash": "d8f1c29a0ab6d09f4a031e7f3392a43df16e5fc1b2e6df812cc75a127537e7c9", "class_name": "RelatedNodeInfo"}}, "text": "But over the course of \nthis year, we do expect the international freight to come down. ", "start_char_idx": 2644, "end_char_idx": 2732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a58aa69f-7282-4dbc-9dc7-20409b67462a": {"__data__": {"id_": "a58aa69f-7282-4dbc-9dc7-20409b67462a", "embedding": null, "metadata": {"window": "We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this. ", "original_text": "And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78c71df4-c66b-482a-bedf-5efd780d63da", "node_type": "1", "metadata": {"window": "Let me be  very clear, we're not rolling back \nprices.  We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure. ", "original_text": "But over the course of \nthis year, we do expect the international freight to come down. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1209e06cd1af5f666d6d64c45260fb5c6dcd9aec6f7f59d589e8e1f67496e987", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ca9ebe4-6cfb-4620-b696-10bf2428486f", "node_type": "1", "metadata": {"window": "At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year . ", "original_text": "Aaron, on the first question?  \n \n"}, "hash": "f2ac4d406c4313b7a60d4a841ca48ed4f9b264833ffdc7630f702fb4989da849", "class_name": "RelatedNodeInfo"}}, "text": "And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year. ", "start_char_idx": 2732, "end_char_idx": 3015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ca9ebe4-6cfb-4620-b696-10bf2428486f": {"__data__": {"id_": "6ca9ebe4-6cfb-4620-b696-10bf2428486f", "embedding": null, "metadata": {"window": "At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year . ", "original_text": "Aaron, on the first question?  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a58aa69f-7282-4dbc-9dc7-20409b67462a", "node_type": "1", "metadata": {"window": "We've not increased prices beyond the point of our costs.  At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this. ", "original_text": "And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5acda7b368fd30dd6d4b9cc03eb40ac6249b18bc71fabdf5181bb8ee01b6b904", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e450eada-fe5f-4614-b7e5-d0591519c833", "node_type": "1", "metadata": {"window": "But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.  ", "original_text": "Aaron Alt:  Sure. "}, "hash": "294d07d0edd669a4de8ab7abadb5bc436a85d9f701a3e21f2bd0e57a3af693b0", "class_name": "RelatedNodeInfo"}}, "text": "Aaron, on the first question?  \n \n", "start_char_idx": 3015, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e450eada-fe5f-4614-b7e5-d0591519c833": {"__data__": {"id_": "e450eada-fe5f-4614-b7e5-d0591519c833", "embedding": null, "metadata": {"window": "But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.  ", "original_text": "Aaron Alt:  Sure. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ca9ebe4-6cfb-4620-b696-10bf2428486f", "node_type": "1", "metadata": {"window": "At the 50% level, we're still only \nbeing compensated for half of that overall growth impact that we've incurred.   But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year . ", "original_text": "Aaron, on the first question?  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fb4dfda3362bade348de347dda95b995343e0134cf077fb91de8043d1c28c03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3080387e-7fc3-4664-a904-024eed425029", "node_type": "1", "metadata": {"window": "And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year. ", "original_text": "I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this. "}, "hash": "a11ef52e96b59b7e98734496ca1f7ac19b00446ef5910293276fdba0cf12d13b", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Sure. ", "start_char_idx": 3049, "end_char_idx": 3067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3080387e-7fc3-4664-a904-024eed425029": {"__data__": {"id_": "3080387e-7fc3-4664-a904-024eed425029", "embedding": null, "metadata": {"window": "And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year. ", "original_text": "I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e450eada-fe5f-4614-b7e5-d0591519c833", "node_type": "1", "metadata": {"window": "But over the course of \nthis year, we do expect the international freight to come down.  And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.  ", "original_text": "Aaron Alt:  Sure. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81c15befa380fd3a0fae4e76a7ebad6093ea02d7866c392b97e34fcb25388148", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a274a09d-0024-428d-afe1-6f76d51f72fa", "node_type": "1", "metadata": {"window": "Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts. ", "original_text": "So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year . "}, "hash": "8814c527b7227d3c212d17b192ef0f1d9731a3bc16419d9619a9305cafbc39f0", "class_name": "RelatedNodeInfo"}}, "text": "I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this. ", "start_char_idx": 3067, "end_char_idx": 3204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a274a09d-0024-428d-afe1-6f76d51f72fa": {"__data__": {"id_": "a274a09d-0024-428d-afe1-6f76d51f72fa", "embedding": null, "metadata": {"window": "Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts. ", "original_text": "So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year . ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3080387e-7fc3-4664-a904-024eed425029", "node_type": "1", "metadata": {"window": "And by the time we exit fiscal \u201824, the \nprices will continue to increase as we go through the course of the year , as we get more of those \ncontracts renewed permanently, and then that will cross over with the lower cost  and then we'll exit in \nthat manner at the end of the year.  Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year. ", "original_text": "I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e6ae0f99608c4571a8c4f39a17416f114c55ea30129621f8d041de7f9abf7d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8f49e65-4c70-489d-a3c1-d87a0d01a470", "node_type": "1", "metadata": {"window": "Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day. ", "original_text": "Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.  "}, "hash": "2dfa3e24e46a963cd36fa64d88711385322728785a1bdc6dbcd5a59cedbdde1d", "class_name": "RelatedNodeInfo"}}, "text": "So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year . ", "start_char_idx": 3204, "end_char_idx": 3458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8f49e65-4c70-489d-a3c1-d87a0d01a470": {"__data__": {"id_": "b8f49e65-4c70-489d-a3c1-d87a0d01a470", "embedding": null, "metadata": {"window": "Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day. ", "original_text": "Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a274a09d-0024-428d-afe1-6f76d51f72fa", "node_type": "1", "metadata": {"window": "Aaron, on the first question?  \n \n Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts. ", "original_text": "So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year . ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d28ff52712268184a39896803bc044c25d3d4f4c553d5ec78e9cce0a23598102", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb205e6-c14d-4f2a-a8a1-3deba0eaf108", "node_type": "1", "metadata": {"window": "I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half. ", "original_text": "As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year. "}, "hash": "d0d3d4b5d3ef1d96ca75930b7cc5564ba10f76824c0ecb2c4f82a833f958d712", "class_name": "RelatedNodeInfo"}}, "text": "Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.  ", "start_char_idx": 3458, "end_char_idx": 3636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb205e6-c14d-4f2a-a8a1-3deba0eaf108": {"__data__": {"id_": "1bb205e6-c14d-4f2a-a8a1-3deba0eaf108", "embedding": null, "metadata": {"window": "I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half. ", "original_text": "As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8f49e65-4c70-489d-a3c1-d87a0d01a470", "node_type": "1", "metadata": {"window": "Aaron Alt:  Sure.  I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day. ", "original_text": "Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.  ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5c90f72dcc6247187e2b55013ef6b40372ed7e78e20406f11619cdbb56aa8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6d49d58-c6d9-4674-8d58-073d950fac54", "node_type": "1", "metadata": {"window": "So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n", "original_text": "I want to \nemphasize the  simplification efforts. "}, "hash": "dbde8c9a4b2f1e03ee14324fba318242ead1f5bda57bbfb9d285ff47d2396b23", "class_name": "RelatedNodeInfo"}}, "text": "As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year. ", "start_char_idx": 3636, "end_char_idx": 3772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6d49d58-c6d9-4674-8d58-073d950fac54": {"__data__": {"id_": "f6d49d58-c6d9-4674-8d58-073d950fac54", "embedding": null, "metadata": {"window": "So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n", "original_text": "I want to \nemphasize the  simplification efforts. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb205e6-c14d-4f2a-a8a1-3deba0eaf108", "node_type": "1", "metadata": {"window": "I think I heard a couple of different things, and so I'm going to answer the question I \nthink I heard, and it goes something like this.  So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half. ", "original_text": "As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08ff8c9acd305554f51d2c959256e622e99f0ddc12be1df2f70de6232a8e222b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27768d51-29a7-49b9-a4ab-278aacdadbf1", "node_type": "1", "metadata": {"window": "Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well. ", "original_text": "Steve and the team are working really hard at that every day. "}, "hash": "c4ea3f7956bf493249800b3547c618319f9e1698e62208f926517ad0382fd24a", "class_name": "RelatedNodeInfo"}}, "text": "I want to \nemphasize the  simplification efforts. ", "start_char_idx": 3772, "end_char_idx": 3822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27768d51-29a7-49b9-a4ab-278aacdadbf1": {"__data__": {"id_": "27768d51-29a7-49b9-a4ab-278aacdadbf1", "embedding": null, "metadata": {"window": "Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well. ", "original_text": "Steve and the team are working really hard at that every day. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6d49d58-c6d9-4674-8d58-073d950fac54", "node_type": "1", "metadata": {"window": "So, we did , I did comment earlier that in addition to the \nannualization of the core performa nce and indeed the inflation mitigation that Jason just touched on , \nthat there was $60 million dollars of other benefit coming over the course of the year .  Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n", "original_text": "I want to \nemphasize the  simplification efforts. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9d06117872a2b2bd92feef7a81efbf690147aa65355765f5bea3368cf58d943", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dbf1b48-1a12-433e-b8b2-cf9e32f1878e", "node_type": "1", "metadata": {"window": "As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "We \njust see the benefit coming more in the back -half. "}, "hash": "bcc9c59e826bfb730276aae55d1ea0243fd62d6094715f9b348cfeae2499eeff", "class_name": "RelatedNodeInfo"}}, "text": "Steve and the team are working really hard at that every day. ", "start_char_idx": 3822, "end_char_idx": 3884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dbf1b48-1a12-433e-b8b2-cf9e32f1878e": {"__data__": {"id_": "5dbf1b48-1a12-433e-b8b2-cf9e32f1878e", "embedding": null, "metadata": {"window": "As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "We \njust see the benefit coming more in the back -half. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27768d51-29a7-49b9-a4ab-278aacdadbf1", "node_type": "1", "metadata": {"window": "Really driven by \nthe three other pillars within the Med Improvement Plan : the contribution of the growth businesses, \nthe simplification,  and the Cardinal Health Brand work.   As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well. ", "original_text": "Steve and the team are working really hard at that every day. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e630929c50ca0e2e192b571f3b58aa97d457536425de48d61287fef5e16ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25624afe-2a7f-4c77-987f-d62cf2095186", "node_type": "1", "metadata": {"window": "I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "The growth businesses are making good progress. \n"}, "hash": "484c1eb888e63ef8811b95a16f90928f0174f14599947cd921c1899d3c005031", "class_name": "RelatedNodeInfo"}}, "text": "We \njust see the benefit coming more in the back -half. ", "start_char_idx": 3884, "end_char_idx": 3940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25624afe-2a7f-4c77-987f-d62cf2095186": {"__data__": {"id_": "25624afe-2a7f-4c77-987f-d62cf2095186", "embedding": null, "metadata": {"window": "I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "The growth businesses are making good progress. \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dbf1b48-1a12-433e-b8b2-cf9e32f1878e", "node_type": "1", "metadata": {"window": "As I was touching on, that work progresses \nover the course of the year, and we've seen more benefit towards the back half of the year.  I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "We \njust see the benefit coming more in the back -half. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e11fb6a3ee838b91bc04ae86108d14046673d0bf4dc25a57fc48e96dfe5ed573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca19f180-ffe7-42ab-8f8f-767218b3dc3e", "node_type": "1", "metadata": {"window": "Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "They have some seasonality as well. "}, "hash": "2b74e3fa75668db24649e5e8e39c9addae55ca973a2a0a141bee8e8beaf3a006", "class_name": "RelatedNodeInfo"}}, "text": "The growth businesses are making good progress. \n", "start_char_idx": 3940, "end_char_idx": 3989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca19f180-ffe7-42ab-8f8f-767218b3dc3e": {"__data__": {"id_": "ca19f180-ffe7-42ab-8f8f-767218b3dc3e", "embedding": null, "metadata": {"window": "Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "They have some seasonality as well. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25624afe-2a7f-4c77-987f-d62cf2095186", "node_type": "1", "metadata": {"window": "I want to \nemphasize the  simplification efforts.  Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "The growth businesses are making good progress. \n", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "478d8d14e0c1c97af637ea9300114fbe36a80891851b7e75f20955c86f4d3884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5ddfaf2-0182-4258-8ff2-ca6611321236", "node_type": "1", "metadata": {"window": "We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "They are certainly a strong con tributor to the additional $60 "}, "hash": "990a04695fc7b30217f3f17592530728e002ce2980053b448718ca52932bfd01", "class_name": "RelatedNodeInfo"}}, "text": "They have some seasonality as well. ", "start_char_idx": 3989, "end_char_idx": 4025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5ddfaf2-0182-4258-8ff2-ca6611321236": {"__data__": {"id_": "f5ddfaf2-0182-4258-8ff2-ca6611321236", "embedding": null, "metadata": {"window": "We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "They are certainly a strong con tributor to the additional $60 ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52915087b7d0087278f4d2bf40789637f831848eec5a3f0b7416dff8751e54f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca19f180-ffe7-42ab-8f8f-767218b3dc3e", "node_type": "1", "metadata": {"window": "Steve and the team are working really hard at that every day.  We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "They have some seasonality as well. ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "481117c972d5edd13afc57dfbfe8f027ec3f351245c749f74245417b75a3521f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9cb5e3d-5b41-46e2-889a-e25d4969e315", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n", "original_text": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year. "}, "hash": "72e90c38db2fd9ee91ba31d0e9b9a36750f59f9291361b65309f2a252d68aaa9", "class_name": "RelatedNodeInfo"}}, "text": "They are certainly a strong con tributor to the additional $60 ", "start_char_idx": 4025, "end_char_idx": 4088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9cb5e3d-5b41-46e2-889a-e25d4969e315": {"__data__": {"id_": "c9cb5e3d-5b41-46e2-889a-e25d4969e315", "embedding": null, "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n", "original_text": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5ddfaf2-0182-4258-8ff2-ca6611321236", "node_type": "1", "metadata": {"window": "We \njust see the benefit coming more in the back -half.  The growth businesses are making good progress. \n They have some seasonality as well.  They are certainly a strong con tributor to the additional $60 ", "original_text": "They are certainly a strong con tributor to the additional $60 ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5a1b114cc32102db741c0ca7f1a61ea920f331ca1c0143f62a2e3b22717295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d52e0153-40d8-4998-8cc4-61d27f004df8", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi. ", "original_text": "And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n"}, "hash": "5f087212729b01433561b5f9c50ca3651c3044b650424309ea0b046a7d3db7ae", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year. ", "start_char_idx": 0, "end_char_idx": 66, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d52e0153-40d8-4998-8cc4-61d27f004df8": {"__data__": {"id_": "d52e0153-40d8-4998-8cc4-61d27f004df8", "embedding": null, "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi. ", "original_text": "And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9cb5e3d-5b41-46e2-889a-e25d4969e315", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n", "original_text": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0db2569a9480b3d59f2b74398c6f9ba004805b75d931ca86e2a02ddbc0cafda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc172c05-024d-4e34-baba-3007cb7c84ef", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question. ", "original_text": "Kevin Moran:  Next question  please , Operator.  \n \n"}, "hash": "a69e8072514b7691f30852e6791d1d9c9775f1e4f6921066596d76c6a0e0e1e0", "class_name": "RelatedNodeInfo"}}, "text": "And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n", "start_char_idx": 66, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc172c05-024d-4e34-baba-3007cb7c84ef": {"__data__": {"id_": "cc172c05-024d-4e34-baba-3007cb7c84ef", "embedding": null, "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question. ", "original_text": "Kevin Moran:  Next question  please , Operator.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d52e0153-40d8-4998-8cc4-61d27f004df8", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi. ", "original_text": "And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ba26ebb8062ea5bcb9e825a129fb101ae64d5144a5905991a7bba3564f6ef0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5b0685e-91e2-4cb0-8c22-947d9a25fff6", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question. ", "original_text": "Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n"}, "hash": "fa82f90e546c2e9013fdae025df286c691a0c720bee3ec90de8a8d06624e6104", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question  please , Operator.  \n \n", "start_char_idx": 153, "end_char_idx": 205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5b0685e-91e2-4cb0-8c22-947d9a25fff6": {"__data__": {"id_": "f5b0685e-91e2-4cb0-8c22-947d9a25fff6", "embedding": null, "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question. ", "original_text": "Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc172c05-024d-4e34-baba-3007cb7c84ef", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question. ", "original_text": "Kevin Moran:  Next question  please , Operator.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0dbc0e6c0b53e72f5d4e0431ffd934a183120d733b886203870a98da62b5212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af0e459e-9443-44a2-9b37-6cb054c54344", "node_type": "1", "metadata": {"window": "And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation. ", "original_text": "Daniel Grosslight:  Hi. "}, "hash": "30e08f8ae060535e65bf1fa101f539e83a0a20780e06ab3858916f023e3235c7", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n", "start_char_idx": 205, "end_char_idx": 277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af0e459e-9443-44a2-9b37-6cb054c54344": {"__data__": {"id_": "af0e459e-9443-44a2-9b37-6cb054c54344", "embedding": null, "metadata": {"window": "And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation. ", "original_text": "Daniel Grosslight:  Hi. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5b0685e-91e2-4cb0-8c22-947d9a25fff6", "node_type": "1", "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question. ", "original_text": "Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34b800c06d80cbc7db4ee2ff0076ace9272a992f85d4909c89d07607b483864a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ebe87b4-79e1-42a5-9d88-0081c16fada9", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating. ", "original_text": "Thanks for taking the question. "}, "hash": "fb164570e1e1d4e07849b4b0695f094e1cbfc752e0ff67d8dab76b5734048a3a", "class_name": "RelatedNodeInfo"}}, "text": "Daniel Grosslight:  Hi. ", "start_char_idx": 277, "end_char_idx": 301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ebe87b4-79e1-42a5-9d88-0081c16fada9": {"__data__": {"id_": "2ebe87b4-79e1-42a5-9d88-0081c16fada9", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating. ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af0e459e-9443-44a2-9b37-6cb054c54344", "node_type": "1", "metadata": {"window": "And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation. ", "original_text": "Daniel Grosslight:  Hi. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef5ce0f6aa9e09a16dd280acecfc22600b2d2c3aa7ae131dc8385981e1d01343", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76e96cb7-6a52-4ae9-8283-550fe7653edf", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things? ", "original_text": "I just have one quick housekeeping question, \nand then I'll ask my real question. "}, "hash": "c956ae0949d36543fc1b8299483a164e3d2996bc675862cb9936c513a37aca06", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 301, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76e96cb7-6a52-4ae9-8283-550fe7653edf": {"__data__": {"id_": "76e96cb7-6a52-4ae9-8283-550fe7653edf", "embedding": null, "metadata": {"window": "Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things? ", "original_text": "I just have one quick housekeeping question, \nand then I'll ask my real question. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ebe87b4-79e1-42a5-9d88-0081c16fada9", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating. ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c99cbf498e8d569e8a82c15ea37e75bc4a03bbc225ef69f8ccd4bb0cdbaa2483", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8921a777-40b0-4e19-a6e0-2e5d2c657691", "node_type": "1", "metadata": {"window": "Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n", "original_text": "There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation. "}, "hash": "68e04084cf717b50d8df21d529af3390223cbe7b1e3c1db76f38dca1c9574fef", "class_name": "RelatedNodeInfo"}}, "text": "I just have one quick housekeeping question, \nand then I'll ask my real question. ", "start_char_idx": 333, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8921a777-40b0-4e19-a6e0-2e5d2c657691": {"__data__": {"id_": "8921a777-40b0-4e19-a6e0-2e5d2c657691", "embedding": null, "metadata": {"window": "Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n", "original_text": "There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76e96cb7-6a52-4ae9-8283-550fe7653edf", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things? ", "original_text": "I just have one quick housekeeping question, \nand then I'll ask my real question. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c606f0dd5c5ec5551580bf1adba891ec67a6a6174aff03e2d0b329600ba4f9b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "650ab26a-bd77-4a24-bf90-2d79a01edea6", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business. ", "original_text": "You went from fully \nmitigating by the end of  \u201924 to just mitigating. "}, "hash": "8ae796863198efe044e6f5915efdd8ae7449fbb8763ddd2c81588448836eceb5", "class_name": "RelatedNodeInfo"}}, "text": "There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation. ", "start_char_idx": 415, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "650ab26a-bd77-4a24-bf90-2d79a01edea6": {"__data__": {"id_": "650ab26a-bd77-4a24-bf90-2d79a01edea6", "embedding": null, "metadata": {"window": "Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business. ", "original_text": "You went from fully \nmitigating by the end of  \u201924 to just mitigating. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8921a777-40b0-4e19-a6e0-2e5d2c657691", "node_type": "1", "metadata": {"window": "Daniel Grosslight:  Hi.  Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n", "original_text": "There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f093885de1597234423c3d20b5f8edd417915a271114b1a0760e2808df645d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65cf0647-5a9e-41b9-a8b1-e768872a9f10", "node_type": "1", "metadata": {"window": "I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment. ", "original_text": "Curious if there's been some change in how you're \nthinking about things? "}, "hash": "f8a9ede595780f131276b48a94456cf23293959941488cc9d27cd6b3f69e9613", "class_name": "RelatedNodeInfo"}}, "text": "You went from fully \nmitigating by the end of  \u201924 to just mitigating. ", "start_char_idx": 559, "end_char_idx": 630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65cf0647-5a9e-41b9-a8b1-e768872a9f10": {"__data__": {"id_": "65cf0647-5a9e-41b9-a8b1-e768872a9f10", "embedding": null, "metadata": {"window": "I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment. ", "original_text": "Curious if there's been some change in how you're \nthinking about things? ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "650ab26a-bd77-4a24-bf90-2d79a01edea6", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business. ", "original_text": "You went from fully \nmitigating by the end of  \u201924 to just mitigating. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db8ef127772fa06b6e87e3ec93c5bdf7426e23af81739886fc45e0bf0419484b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa13de8b-2560-4e6a-9af0-661e53f81223", "node_type": "1", "metadata": {"window": "There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year. ", "original_text": "Or if it was kind of a simplification of the language?  \n \n"}, "hash": "32611325eeeebbee74bf196ec1e0e40bc29398bb5d29bb87a262d4f2eab2ccd4", "class_name": "RelatedNodeInfo"}}, "text": "Curious if there's been some change in how you're \nthinking about things? ", "start_char_idx": 630, "end_char_idx": 704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa13de8b-2560-4e6a-9af0-661e53f81223": {"__data__": {"id_": "aa13de8b-2560-4e6a-9af0-661e53f81223", "embedding": null, "metadata": {"window": "There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year. ", "original_text": "Or if it was kind of a simplification of the language?  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65cf0647-5a9e-41b9-a8b1-e768872a9f10", "node_type": "1", "metadata": {"window": "I just have one quick housekeeping question, \nand then I'll ask my real question.  There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment. ", "original_text": "Curious if there's been some change in how you're \nthinking about things? ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "606c7e3e025793f72aef803b465855cf7cc7ce68a2bf9744759389b8903a8fe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51606aea-80ba-4a6a-8a94-522002f3e16f", "node_type": "1", "metadata": {"window": "You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823. ", "original_text": "And then my real question is around the generics business. "}, "hash": "0b0ea8b68453ac74f1109da331c5ef33fd8cd32c5186e06d5b7d96b5db9b9887", "class_name": "RelatedNodeInfo"}}, "text": "Or if it was kind of a simplification of the language?  \n \n", "start_char_idx": 704, "end_char_idx": 763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51606aea-80ba-4a6a-8a94-522002f3e16f": {"__data__": {"id_": "51606aea-80ba-4a6a-8a94-522002f3e16f", "embedding": null, "metadata": {"window": "You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823. ", "original_text": "And then my real question is around the generics business. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa13de8b-2560-4e6a-9af0-661e53f81223", "node_type": "1", "metadata": {"window": "There was a slight change in the language around your inflation \nmitigation efforts from your I -Day presentation to your current presentation.  You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year. ", "original_text": "Or if it was kind of a simplification of the language?  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1638d9f544239fe56f50461e31043e821d6bdadbac2bef5c3fcea3956e536498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f59da9ff-188b-44ee-afa7-0c4152c3c6b2", "node_type": "1", "metadata": {"window": "Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n", "original_text": "It seems like you and your competitors \nhave all benefited from a more favorable environment. "}, "hash": "993d51b1dd14d1245354afd0bfb02282a9d193112b90eba2c75d24e7cc821f52", "class_name": "RelatedNodeInfo"}}, "text": "And then my real question is around the generics business. ", "start_char_idx": 763, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f59da9ff-188b-44ee-afa7-0c4152c3c6b2": {"__data__": {"id_": "f59da9ff-188b-44ee-afa7-0c4152c3c6b2", "embedding": null, "metadata": {"window": "Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n", "original_text": "It seems like you and your competitors \nhave all benefited from a more favorable environment. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51606aea-80ba-4a6a-8a94-522002f3e16f", "node_type": "1", "metadata": {"window": "You went from fully \nmitigating by the end of  \u201924 to just mitigating.  Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823. ", "original_text": "And then my real question is around the generics business. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "559cfaf6201acdb8fa4ca648c651a1c0daaa3faf88266f3c11086f0777fa834e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecf0bfde-9b7a-4cd4-8c05-76967b2a8e88", "node_type": "1", "metadata": {"window": "Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure. ", "original_text": "And it seems like it might have accelerated \ntowards the end of your fiscal year. "}, "hash": "00ce444bf3841e3bb923604ea020d565a9e469116c2161ee49c0ed09108fc8ec", "class_name": "RelatedNodeInfo"}}, "text": "It seems like you and your competitors \nhave all benefited from a more favorable environment. ", "start_char_idx": 822, "end_char_idx": 916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecf0bfde-9b7a-4cd4-8c05-76967b2a8e88": {"__data__": {"id_": "ecf0bfde-9b7a-4cd4-8c05-76967b2a8e88", "embedding": null, "metadata": {"window": "Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure. ", "original_text": "And it seems like it might have accelerated \ntowards the end of your fiscal year. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f59da9ff-188b-44ee-afa7-0c4152c3c6b2", "node_type": "1", "metadata": {"window": "Curious if there's been some change in how you're \nthinking about things?  Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n", "original_text": "It seems like you and your competitors \nhave all benefited from a more favorable environment. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541fdda89c37b8f13a05996764cc73c880a85fe8bb80bfe1f9179e0b4f24986b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f60ac68c-3a79-4cc1-bbbc-803accfe8fb4", "node_type": "1", "metadata": {"window": "And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest. ", "original_text": "So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823. "}, "hash": "909f001aa3a7667121fabb70d5c04071fd210b10a65a649c873e905ce4a26814", "class_name": "RelatedNodeInfo"}}, "text": "And it seems like it might have accelerated \ntowards the end of your fiscal year. ", "start_char_idx": 916, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f60ac68c-3a79-4cc1-bbbc-803accfe8fb4": {"__data__": {"id_": "f60ac68c-3a79-4cc1-bbbc-803accfe8fb4", "embedding": null, "metadata": {"window": "And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest. ", "original_text": "So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecf0bfde-9b7a-4cd4-8c05-76967b2a8e88", "node_type": "1", "metadata": {"window": "Or if it was kind of a simplification of the language?  \n \n And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure. ", "original_text": "And it seems like it might have accelerated \ntowards the end of your fiscal year. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11e4791bcb26fb0f28bacef8c07f3908d98dd071648a8206fc640848a1a6a063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cf046a4-8510-475d-85e8-18a8bad5534f", "node_type": "1", "metadata": {"window": "It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.  ", "original_text": "Thanks.  \n \n"}, "hash": "455f1d2296465925851aaaef8257630296dc1ed30c66b41376b185f4bcb86d1b", "class_name": "RelatedNodeInfo"}}, "text": "So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823. ", "start_char_idx": 998, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cf046a4-8510-475d-85e8-18a8bad5534f": {"__data__": {"id_": "0cf046a4-8510-475d-85e8-18a8bad5534f", "embedding": null, "metadata": {"window": "It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.  ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f60ac68c-3a79-4cc1-bbbc-803accfe8fb4", "node_type": "1", "metadata": {"window": "And then my real question is around the generics business.  It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest. ", "original_text": "So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "654082a23c5c7cc82c66cba95aea9773c491baa67cae08074cd4ec9def52297e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47ce1e1c-6a42-42ca-a11e-736e2bfc60e7", "node_type": "1", "metadata": {"window": "And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure. ", "original_text": "Jason Hollar:  Sure. "}, "hash": "ebe4a928ebfc758832f1aac3710bb1420e12d1af3d7ddc6707ad4c7f9e8e4558", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1229, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47ce1e1c-6a42-42ca-a11e-736e2bfc60e7": {"__data__": {"id_": "47ce1e1c-6a42-42ca-a11e-736e2bfc60e7", "embedding": null, "metadata": {"window": "And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure. ", "original_text": "Jason Hollar:  Sure. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cf046a4-8510-475d-85e8-18a8bad5534f", "node_type": "1", "metadata": {"window": "It seems like you and your competitors \nhave all benefited from a more favorable environment.  And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.  ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1279ee48650f65bd1bad856c53b82eb72711be0f70b5c457d13043850649b14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56d4442e-6374-4010-8e4f-d51b91bbecfb", "node_type": "1", "metadata": {"window": "So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation. ", "original_text": "So , in terms of the language change  for inflation mitigation, I think you said it \nbest. "}, "hash": "ad92a90344f4d7c716ada1de341b6f11a52eb8fec57828299aa0df70e6cc856b", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure. ", "start_char_idx": 1241, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56d4442e-6374-4010-8e4f-d51b91bbecfb": {"__data__": {"id_": "56d4442e-6374-4010-8e4f-d51b91bbecfb", "embedding": null, "metadata": {"window": "So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation. ", "original_text": "So , in terms of the language change  for inflation mitigation, I think you said it \nbest. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47ce1e1c-6a42-42ca-a11e-736e2bfc60e7", "node_type": "1", "metadata": {"window": "And it seems like it might have accelerated \ntowards the end of your fiscal year.  So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure. ", "original_text": "Jason Hollar:  Sure. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf09a48d7216e9795b6633ba74720a2f5822b4f8f2256d3f87466988ff069db8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ff61b11-9d32-4dfb-960a-4e21a4cb08fa", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well. ", "original_text": "It's a simplification language.  "}, "hash": "abe93de99739e0b7a9a4fbcd9b26e1642f33354a7278e34da20610a0612b12f2", "class_name": "RelatedNodeInfo"}}, "text": "So , in terms of the language change  for inflation mitigation, I think you said it \nbest. ", "start_char_idx": 1262, "end_char_idx": 1353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ff61b11-9d32-4dfb-960a-4e21a4cb08fa": {"__data__": {"id_": "0ff61b11-9d32-4dfb-960a-4e21a4cb08fa", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well. ", "original_text": "It's a simplification language.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56d4442e-6374-4010-8e4f-d51b91bbecfb", "node_type": "1", "metadata": {"window": "So , I'm just curious to get your th oughts on the generics market , \npotential shortages and how you're thinking about the benefit or tailwind of generics in your fiscal \u201824 \nguidance vis-\u00e0-vis the strength you saw in fiscal \u201823.  Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation. ", "original_text": "So , in terms of the language change  for inflation mitigation, I think you said it \nbest. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d52f4e10ac14ebe0d3019d1d0b63e2c7d91caf9a5ee793d5b30e27e3df727ecb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "642e9c6b-dc4a-439f-b5ac-96a26cf4d1e7", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.  ", "original_text": "The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure. "}, "hash": "90e36a09e0ef0d1fccd2b6cabb98a638fa45f26e96158ee72b1b5f8835b534d3", "class_name": "RelatedNodeInfo"}}, "text": "It's a simplification language.  ", "start_char_idx": 1353, "end_char_idx": 1386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "642e9c6b-dc4a-439f-b5ac-96a26cf4d1e7": {"__data__": {"id_": "642e9c6b-dc4a-439f-b5ac-96a26cf4d1e7", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.  ", "original_text": "The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ff61b11-9d32-4dfb-960a-4e21a4cb08fa", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well. ", "original_text": "It's a simplification language.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f3159fcaf98c85eea120f159b1fa3a7e21f909cbc21806a7c38cb5b4dcc89ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c277a448-1626-47e0-9ae2-e0465f2ec065", "node_type": "1", "metadata": {"window": "So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight. ", "original_text": "So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation. "}, "hash": "187240ac0cab66e96045d7038cac60a433cf8ede6aaa0fc97cdd29f5435d1742", "class_name": "RelatedNodeInfo"}}, "text": "The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure. ", "start_char_idx": 1386, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c277a448-1626-47e0-9ae2-e0465f2ec065": {"__data__": {"id_": "c277a448-1626-47e0-9ae2-e0465f2ec065", "embedding": null, "metadata": {"window": "So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight. ", "original_text": "So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "642e9c6b-dc4a-439f-b5ac-96a26cf4d1e7", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure.  So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.  ", "original_text": "The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83b7fce7b787130dabb4eb20e8c879b3ad41ba37de96067503ba1975e2c9f0ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0888b4d3-e2b9-4448-819d-6eee995d9d76", "node_type": "1", "metadata": {"window": "It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging. ", "original_text": "Well, there's normal inflation as well. "}, "hash": "f35638ea7aa20af9d5145e62a734209557c8b010bd71173e10af2586cac78919", "class_name": "RelatedNodeInfo"}}, "text": "So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation. ", "start_char_idx": 1521, "end_char_idx": 1678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0888b4d3-e2b9-4448-819d-6eee995d9d76": {"__data__": {"id_": "0888b4d3-e2b9-4448-819d-6eee995d9d76", "embedding": null, "metadata": {"window": "It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging. ", "original_text": "Well, there's normal inflation as well. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c277a448-1626-47e0-9ae2-e0465f2ec065", "node_type": "1", "metadata": {"window": "So , in terms of the language change  for inflation mitigation, I think you said it \nbest.  It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight. ", "original_text": "So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0981258134ef80e49fcca0df28a4c3aa24e5c5d5c6d22195a39fef8a5a491997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee899906-2028-4c0a-9fa0-bf774a2e0429", "node_type": "1", "metadata": {"window": "The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement. ", "original_text": "So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.  "}, "hash": "e4c95d18b005383cb9b66b0b4b3593911ecf40cbbb88c10332ca53dc67167ee8", "class_name": "RelatedNodeInfo"}}, "text": "Well, there's normal inflation as well. ", "start_char_idx": 1678, "end_char_idx": 1718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee899906-2028-4c0a-9fa0-bf774a2e0429": {"__data__": {"id_": "ee899906-2028-4c0a-9fa0-bf774a2e0429", "embedding": null, "metadata": {"window": "The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement. ", "original_text": "So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0888b4d3-e2b9-4448-819d-6eee995d9d76", "node_type": "1", "metadata": {"window": "It's a simplification language.   The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging. ", "original_text": "Well, there's normal inflation as well. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "529bda186b394a203d23e6b85a190e11fa2957f02a3c7f0c19f52c5f671331d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07fd94e8-a250-4069-a08e-9e0da023f9c9", "node_type": "1", "metadata": {"window": "So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit. ", "original_text": "We have a good \nunderstanding of the most significant impacts , like the international freight. "}, "hash": "d516dbcf86c0f86e2d8c050c3a324722472e579c6c7dd560bf1e00d68351e9be", "class_name": "RelatedNodeInfo"}}, "text": "So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.  ", "start_char_idx": 1718, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07fd94e8-a250-4069-a08e-9e0da023f9c9": {"__data__": {"id_": "07fd94e8-a250-4069-a08e-9e0da023f9c9", "embedding": null, "metadata": {"window": "So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit. ", "original_text": "We have a good \nunderstanding of the most significant impacts , like the international freight. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee899906-2028-4c0a-9fa0-bf774a2e0429", "node_type": "1", "metadata": {"window": "The one thing I would highlight is similar to our disclosures with \nCOVID, over time those became more difficult to precisely measure.  So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement. ", "original_text": "So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d0a54ee8927311c4e69f10124ed7dd64f96f4e3e3009ebefd933b3aa9d6c184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa2b9260-6ea0-4a02-a56a-f9aa07654006", "node_type": "1", "metadata": {"window": "Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ? ", "original_text": "But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging. "}, "hash": "b1f5010a2f0760dc77e497a6b35dadcc3c912bb3afe1514d59b1e8253e8603ec", "class_name": "RelatedNodeInfo"}}, "text": "We have a good \nunderstanding of the most significant impacts , like the international freight. ", "start_char_idx": 1851, "end_char_idx": 1947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa2b9260-6ea0-4a02-a56a-f9aa07654006": {"__data__": {"id_": "aa2b9260-6ea0-4a02-a56a-f9aa07654006", "embedding": null, "metadata": {"window": "Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ? ", "original_text": "But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07fd94e8-a250-4069-a08e-9e0da023f9c9", "node_type": "1", "metadata": {"window": "So now we are , and this inflation \nmitigation was always focused on the incremental inflation because we had spikes, unusual dramatic \nspikes in inflation.  Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit. ", "original_text": "We have a good \nunderstanding of the most significant impacts , like the international freight. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1ed177b636a5ffda9ed84c8549dd7956a3a6fa7f1d846e404c4797746b7c436", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cdcc515-e281-4ac9-9500-7ef0cdc32593", "node_type": "1", "metadata": {"window": "So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense. ", "original_text": "And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement. "}, "hash": "c67174bbe9b10d61026d2f8ab9c862834119d232fa7caad8b9f4f53595a881d7", "class_name": "RelatedNodeInfo"}}, "text": "But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging. ", "start_char_idx": 1947, "end_char_idx": 2041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cdcc515-e281-4ac9-9500-7ef0cdc32593": {"__data__": {"id_": "6cdcc515-e281-4ac9-9500-7ef0cdc32593", "embedding": null, "metadata": {"window": "So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense. ", "original_text": "And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa2b9260-6ea0-4a02-a56a-f9aa07654006", "node_type": "1", "metadata": {"window": "Well, there's normal inflation as well.  So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ? ", "original_text": "But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b111845142bd298db9b1ac25a75d82e8ed8f867bc4097342c7debaac6dae4d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19ecef9c-79ec-40d4-a2ad-223c6e7f05b8", "node_type": "1", "metadata": {"window": "We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model. ", "original_text": "We're still doing as deep of analytics as possible to get a reasonable understanding of \nit. "}, "hash": "2ff626e9a9bd8e2eb3c1998fbfdcb8520789760d2607c42723ea994a151d23db", "class_name": "RelatedNodeInfo"}}, "text": "And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement. ", "start_char_idx": 2041, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19ecef9c-79ec-40d4-a2ad-223c6e7f05b8": {"__data__": {"id_": "19ecef9c-79ec-40d4-a2ad-223c6e7f05b8", "embedding": null, "metadata": {"window": "We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model. ", "original_text": "We're still doing as deep of analytics as possible to get a reasonable understanding of \nit. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cdcc515-e281-4ac9-9500-7ef0cdc32593", "node_type": "1", "metadata": {"window": "So , this is just a little bit broader language to \nrecognize that over time it's becoming harder to differentiate between the two.   We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense. ", "original_text": "And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69b03e5b558f9863f28f7a359063d51ca59ab31251bd40046b2caaae42b2f989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afe8617c-2107-480e-89da-860dc9d132b6", "node_type": "1", "metadata": {"window": "But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged. ", "original_text": "As it relates to well, I think the key takeaway with that is we a re on track, right ? "}, "hash": "e412997d49e0d4fa2296eef4fcee2a3d5888c1d064eeaf7f61f90a304f4ddad8", "class_name": "RelatedNodeInfo"}}, "text": "We're still doing as deep of analytics as possible to get a reasonable understanding of \nit. ", "start_char_idx": 2180, "end_char_idx": 2273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afe8617c-2107-480e-89da-860dc9d132b6": {"__data__": {"id_": "afe8617c-2107-480e-89da-860dc9d132b6", "embedding": null, "metadata": {"window": "But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged. ", "original_text": "As it relates to well, I think the key takeaway with that is we a re on track, right ? ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19ecef9c-79ec-40d4-a2ad-223c6e7f05b8", "node_type": "1", "metadata": {"window": "We have a good \nunderstanding of the most significant impacts , like the international freight.  But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model. ", "original_text": "We're still doing as deep of analytics as possible to get a reasonable understanding of \nit. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1ef4147c71506cd2f89ec31fcd28392c9bbc751a5d1c72d79d0327586adf839", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e9862c3-347f-46d0-ac82-994bd8d8c0b4", "node_type": "1", "metadata": {"window": "And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n", "original_text": "Ultimately, the \nstrategy makes sense. "}, "hash": "39d5158755c23a567221a41c73b5cd34f4eb28eb0276240674ee69228b2ada1e", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to well, I think the key takeaway with that is we a re on track, right ? ", "start_char_idx": 2273, "end_char_idx": 2360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e9862c3-347f-46d0-ac82-994bd8d8c0b4": {"__data__": {"id_": "0e9862c3-347f-46d0-ac82-994bd8d8c0b4", "embedding": null, "metadata": {"window": "And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n", "original_text": "Ultimately, the \nstrategy makes sense. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afe8617c-2107-480e-89da-860dc9d132b6", "node_type": "1", "metadata": {"window": "But when you get into \nlabor, what's normal, what's incremental, it becomes more challenging.  And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged. ", "original_text": "As it relates to well, I think the key takeaway with that is we a re on track, right ? ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13dda60bf23a1b279b67e8ae00f03d71a45a9498236515da40548f41c4221516", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ff8b1e3-c6fd-4859-bdb8-734fded56001", "node_type": "1", "metadata": {"window": "We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business. ", "original_text": "It should be pushed down to the final customer, the final user of the products \nand services, given the business model. "}, "hash": "ca8c030ef27c5242818ffe99b56f78dd883d017946ad01cada16819b23b0f0c4", "class_name": "RelatedNodeInfo"}}, "text": "Ultimately, the \nstrategy makes sense. ", "start_char_idx": 2360, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ff8b1e3-c6fd-4859-bdb8-734fded56001": {"__data__": {"id_": "3ff8b1e3-c6fd-4859-bdb8-734fded56001", "embedding": null, "metadata": {"window": "We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business. ", "original_text": "It should be pushed down to the final customer, the final user of the products \nand services, given the business model. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e9862c3-347f-46d0-ac82-994bd8d8c0b4", "node_type": "1", "metadata": {"window": "And we just have a little bit \nbroader language to recognize that it is going to be less precise than it was early on in our \nmeasurement.  We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n", "original_text": "Ultimately, the \nstrategy makes sense. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eef5baadc22b3f6869c299ebc9d2366bce52ea9fd5b494659e4deb030b9fc219", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22f968fe-2508-4407-8a6e-4d7b8ddd1e0f", "node_type": "1", "metadata": {"window": "As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred. ", "original_text": "And so, we believe that the basic tenets are absolutely \nunchanged. "}, "hash": "2b5c25936f696b0f7d0dd08d35e16c4edaa8e7bc96a481da2f76356961fc816b", "class_name": "RelatedNodeInfo"}}, "text": "It should be pushed down to the final customer, the final user of the products \nand services, given the business model. ", "start_char_idx": 2399, "end_char_idx": 2519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22f968fe-2508-4407-8a6e-4d7b8ddd1e0f": {"__data__": {"id_": "22f968fe-2508-4407-8a6e-4d7b8ddd1e0f", "embedding": null, "metadata": {"window": "As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred. ", "original_text": "And so, we believe that the basic tenets are absolutely \nunchanged. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ff8b1e3-c6fd-4859-bdb8-734fded56001", "node_type": "1", "metadata": {"window": "We're still doing as deep of analytics as possible to get a reasonable understanding of \nit.  As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business. ", "original_text": "It should be pushed down to the final customer, the final user of the products \nand services, given the business model. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98326f779fbf887486a1bb0f9f3b94d0acfe4cdcaa5957060f3793d250f35bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4be8c52-735e-4d35-88fb-65eb6ef1f3c7", "node_type": "1", "metadata": {"window": "Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that. ", "original_text": "It's just ref lecting the level of precision.  \n \n"}, "hash": "7b257e88695c6fc4e6710004d5fc63dd252370c18bb266c4cf7c1c8295c38299", "class_name": "RelatedNodeInfo"}}, "text": "And so, we believe that the basic tenets are absolutely \nunchanged. ", "start_char_idx": 2519, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4be8c52-735e-4d35-88fb-65eb6ef1f3c7": {"__data__": {"id_": "d4be8c52-735e-4d35-88fb-65eb6ef1f3c7", "embedding": null, "metadata": {"window": "Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that. ", "original_text": "It's just ref lecting the level of precision.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22f968fe-2508-4407-8a6e-4d7b8ddd1e0f", "node_type": "1", "metadata": {"window": "As it relates to well, I think the key takeaway with that is we a re on track, right ?  Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred. ", "original_text": "And so, we believe that the basic tenets are absolutely \nunchanged. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24866b9d59a610395c8da5795779639eb32ea84ad6ecb1482c915ab4a9e5c98c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d810fdb1-a52f-4e18-a3d5-2a9716b8c271", "node_type": "1", "metadata": {"window": "It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.  ", "original_text": "On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business. "}, "hash": "87a90ca9fc323e633a130616412d1719e95b932c39a5f258c2537896ed9e2533", "class_name": "RelatedNodeInfo"}}, "text": "It's just ref lecting the level of precision.  \n \n", "start_char_idx": 2587, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d810fdb1-a52f-4e18-a3d5-2a9716b8c271": {"__data__": {"id_": "d810fdb1-a52f-4e18-a3d5-2a9716b8c271", "embedding": null, "metadata": {"window": "It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.  ", "original_text": "On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4be8c52-735e-4d35-88fb-65eb6ef1f3c7", "node_type": "1", "metadata": {"window": "Ultimately, the \nstrategy makes sense.  It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that. ", "original_text": "It's just ref lecting the level of precision.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b634efa693a845406e73cacde1184ab0fc451b093fb9e8fe2b7caf43a3d2835e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dedd141e-5f57-45dc-815c-1a7bf23470d4", "node_type": "1", "metadata": {"window": "And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize. ", "original_text": "There's a couple of things that have occurred. "}, "hash": "55f987745709043f4df1683748df130a8c9898130ad1c7841db077c5f8154d82", "class_name": "RelatedNodeInfo"}}, "text": "On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business. ", "start_char_idx": 2637, "end_char_idx": 2872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dedd141e-5f57-45dc-815c-1a7bf23470d4": {"__data__": {"id_": "dedd141e-5f57-45dc-815c-1a7bf23470d4", "embedding": null, "metadata": {"window": "And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize. ", "original_text": "There's a couple of things that have occurred. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d810fdb1-a52f-4e18-a3d5-2a9716b8c271", "node_type": "1", "metadata": {"window": "It should be pushed down to the final customer, the final user of the products \nand services, given the business model.  And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.  ", "original_text": "On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a911eef9416e1b6358641980443990b2ab1e2927e98ccb9a9b291a5f88fe8b62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ddde1d1-7a81-4548-95ab-a14e160b55f9", "node_type": "1", "metadata": {"window": "It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth. ", "original_text": "There is the overall \nmarket utilization has been very strong, and our performance has been very good within that. "}, "hash": "db62d412dfbb9b6613e5c6dc577faf8ecc25dfaef70de94f1d6cb0873b48a2f2", "class_name": "RelatedNodeInfo"}}, "text": "There's a couple of things that have occurred. ", "start_char_idx": 2872, "end_char_idx": 2919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ddde1d1-7a81-4548-95ab-a14e160b55f9": {"__data__": {"id_": "7ddde1d1-7a81-4548-95ab-a14e160b55f9", "embedding": null, "metadata": {"window": "It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth. ", "original_text": "There is the overall \nmarket utilization has been very strong, and our performance has been very good within that. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dedd141e-5f57-45dc-815c-1a7bf23470d4", "node_type": "1", "metadata": {"window": "And so, we believe that the basic tenets are absolutely \nunchanged.  It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize. ", "original_text": "There's a couple of things that have occurred. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cb31bc8b82a4b126ee70ef4f095cb3345220d573840b73cc39f6211f3725e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5fc80fa-934a-471b-abe1-2803f4a4d0ac", "node_type": "1", "metadata": {"window": "On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that. ", "original_text": "And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.  "}, "hash": "47703400bff8657ff1db1b4a6c04e9eaf1a03d4e7dd5f931693585e0c1606bcf", "class_name": "RelatedNodeInfo"}}, "text": "There is the overall \nmarket utilization has been very strong, and our performance has been very good within that. ", "start_char_idx": 2919, "end_char_idx": 3034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5fc80fa-934a-471b-abe1-2803f4a4d0ac": {"__data__": {"id_": "d5fc80fa-934a-471b-abe1-2803f4a4d0ac", "embedding": null, "metadata": {"window": "On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that. ", "original_text": "And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ddde1d1-7a81-4548-95ab-a14e160b55f9", "node_type": "1", "metadata": {"window": "It's just ref lecting the level of precision.  \n \n On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth. ", "original_text": "There is the overall \nmarket utilization has been very strong, and our performance has been very good within that. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a9353593d0a6a693d96c251ae6c7f43b00c46cf9c962957769991a7bdef19b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "713b3194-3286-468f-80fa-53c883b90c15", "node_type": "1", "metadata": {"window": "There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages. ", "original_text": "And as I think forward to \nfiscal \u201824, we expect that to normalize. "}, "hash": "b619406926544c8bb7007d034c64fe4f38bd0468d58bf5ed22303401811f8c4e", "class_name": "RelatedNodeInfo"}}, "text": "And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.  ", "start_char_idx": 3034, "end_char_idx": 3228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "713b3194-3286-468f-80fa-53c883b90c15": {"__data__": {"id_": "713b3194-3286-468f-80fa-53c883b90c15", "embedding": null, "metadata": {"window": "There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages. ", "original_text": "And as I think forward to \nfiscal \u201824, we expect that to normalize. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5fc80fa-934a-471b-abe1-2803f4a4d0ac", "node_type": "1", "metadata": {"window": "On your second question as it relates to generics, as I step back and think about performance for the \nPharma segment this year, inclusive of generics, I think you can think about the overall segment as \nwell as the generics business.  There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that. ", "original_text": "And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e747dd9affb753006ee7075bbc98969d7d9c0833b9da8627bbb0aa6d729a3f20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15292f2d-e99c-4794-9130-6d51b8c76442", "node_type": "1", "metadata": {"window": "There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "We expect it to still be favorable growth. "}, "hash": "d1fad2822a89a941e96c0690ee3a620754a7adb2b296a200fd7cdb3e855f980c", "class_name": "RelatedNodeInfo"}}, "text": "And as I think forward to \nfiscal \u201824, we expect that to normalize. ", "start_char_idx": 3228, "end_char_idx": 3296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15292f2d-e99c-4794-9130-6d51b8c76442": {"__data__": {"id_": "15292f2d-e99c-4794-9130-6d51b8c76442", "embedding": null, "metadata": {"window": "There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "We expect it to still be favorable growth. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "713b3194-3286-468f-80fa-53c883b90c15", "node_type": "1", "metadata": {"window": "There's a couple of things that have occurred.  There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages. ", "original_text": "And as I think forward to \nfiscal \u201824, we expect that to normalize. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fa0b82c738a033d724755c615a8beb5f86d0f5083017c338175f7c6959f9a82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845c93d2-e075-4677-849c-7fb336f74e9f", "node_type": "1", "metadata": {"window": "And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that. "}, "hash": "68c1c50320d72fb4b544dd9ea2f4d561b738327102d6b91903e93e44cf344d2b", "class_name": "RelatedNodeInfo"}}, "text": "We expect it to still be favorable growth. ", "start_char_idx": 3296, "end_char_idx": 3339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845c93d2-e075-4677-849c-7fb336f74e9f": {"__data__": {"id_": "845c93d2-e075-4677-849c-7fb336f74e9f", "embedding": null, "metadata": {"window": "And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15292f2d-e99c-4794-9130-6d51b8c76442", "node_type": "1", "metadata": {"window": "There is the overall \nmarket utilization has been very strong, and our performance has been very good within that.  And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "We expect it to still be favorable growth. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d76c34cf2cb5e61226f7d89aabc5075b234432a28cacd017c59c547522c1873", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8660c78-7aad-433d-a530-8ad235930a71", "node_type": "1", "metadata": {"window": "And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages. "}, "hash": "7eb2f295f36b0ca8c93e0e564969ad2378aa23991fb86a76d13c76384a61d7d4", "class_name": "RelatedNodeInfo"}}, "text": "We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that. ", "start_char_idx": 3339, "end_char_idx": 3479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8660c78-7aad-433d-a530-8ad235930a71": {"__data__": {"id_": "e8660c78-7aad-433d-a530-8ad235930a71", "embedding": null, "metadata": {"window": "And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845c93d2-e075-4677-849c-7fb336f74e9f", "node_type": "1", "metadata": {"window": "And it's \nat levels  that, for all the reasons Aaron highlighted , is that a growth rate  is a bit higher than what \nnormal is and certainly higher than what our long -term growth targets are.   And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9b991e98c33478c7be2f5a447e23899a5d17eff7ece09992721f093609257e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c3da0c5-23c0-4278-9067-6de24b67129b", "node_type": "1", "metadata": {"window": "We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  "}, "hash": "7e5bcef67c45b076bd3a0aa7f61aff28ee23c8d95bc087a752b3580fe072f7d5", "class_name": "RelatedNodeInfo"}}, "text": "And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages. ", "start_char_idx": 3479, "end_char_idx": 3655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c3da0c5-23c0-4278-9067-6de24b67129b": {"__data__": {"id_": "4c3da0c5-23c0-4278-9067-6de24b67129b", "embedding": null, "metadata": {"window": "We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68ac55c9-2fc8-4728-9b52-07caa1509930", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4791802cf8f477226f061f7906b62c843a0a57445f15c7f4e0f2f6f3e0d2405", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8660c78-7aad-433d-a530-8ad235930a71", "node_type": "1", "metadata": {"window": "And as I think forward to \nfiscal \u201824, we expect that to normalize.  We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "506d967da302beb55a7bac04c8abe83c3670bd5531ba709f66f26f1fec4ee28d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ce9fb5e-ad83-4675-8979-5a1e0b9822bf", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  ", "original_text": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon . "}, "hash": "b5d0eb4ae457146d350020094385925fe2d3fb5806b10416a3fa593409192a9c", "class_name": "RelatedNodeInfo"}}, "text": "They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "start_char_idx": 3655, "end_char_idx": 3757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ce9fb5e-ad83-4675-8979-5a1e0b9822bf": {"__data__": {"id_": "1ce9fb5e-ad83-4675-8979-5a1e0b9822bf", "embedding": null, "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  ", "original_text": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon . ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c3da0c5-23c0-4278-9067-6de24b67129b", "node_type": "1", "metadata": {"window": "We expect it to still be favorable growth.  We indicated during \nInvestor Day in the 2 to  3% type of range from a unit volume growth, and we would expect to \nparticipate within that.  And we expect our performance to continue with areas like Red Oak Sourcing , \nto continue to drive both the cost as well as to your other related point, the product shortages.  They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "original_text": "They \nhave a dual mandate to drive performance for both cost as well as service levels to customers.  ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f5e5f45c8f7b3a4d3951d0add266ba0dba570ed311da150a7ca6c4777fc8228", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a214b2f-2ce1-468a-8d2c-5ff4bf917591", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well. ", "original_text": "There's various demand driven spikes and supply driven spikes. \n"}, "hash": "16fa353e2fab806d8436873a3a79218ec3bc2e08a49ad67da9d4f2612304a447", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon . ", "start_char_idx": 0, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a214b2f-2ce1-468a-8d2c-5ff4bf917591": {"__data__": {"id_": "9a214b2f-2ce1-468a-8d2c-5ff4bf917591", "embedding": null, "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well. ", "original_text": "There's various demand driven spikes and supply driven spikes. \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ce9fb5e-ad83-4675-8979-5a1e0b9822bf", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  ", "original_text": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon . ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3a5a8a1b9a035f8eb7f477dbaf00393fcd28cd1bf1abcff2fe2e4cbd6517f1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2700cdb-7089-4c14-93c2-29f026bfb75d", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n", "original_text": "Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service. "}, "hash": "8e565dd8a3378d84a4ab12b120daccdc6503b3f7aa5463d27800fb315532c368", "class_name": "RelatedNodeInfo"}}, "text": "There's various demand driven spikes and supply driven spikes. \n", "start_char_idx": 158, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2700cdb-7089-4c14-93c2-29f026bfb75d": {"__data__": {"id_": "f2700cdb-7089-4c14-93c2-29f026bfb75d", "embedding": null, "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n", "original_text": "Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a214b2f-2ce1-468a-8d2c-5ff4bf917591", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well. ", "original_text": "There's various demand driven spikes and supply driven spikes. \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5147bc542b22551513b6feaea7097986694f64d034de95797bfb1e89f4a87785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d7e9d00-5ade-42c0-89b7-bea6407d76ba", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics. ", "original_text": "And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  "}, "hash": "cf5a8479452103860a2749006551d74ea15d05f1b38b8156507ad48c43b00fd3", "class_name": "RelatedNodeInfo"}}, "text": "Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service. ", "start_char_idx": 222, "end_char_idx": 338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d7e9d00-5ade-42c0-89b7-bea6407d76ba": {"__data__": {"id_": "9d7e9d00-5ade-42c0-89b7-bea6407d76ba", "embedding": null, "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics. ", "original_text": "And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2700cdb-7089-4c14-93c2-29f026bfb75d", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n", "original_text": "Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1fc92d638ccd16f8406be144d5219f93516604e6fd5f147fe1b5111e5c4e458", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb82c369-31cc-445e-90e7-51ac171a0297", "node_type": "1", "metadata": {"window": "There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n", "original_text": "So overall, that was a slight \npositive for us this year as well. "}, "hash": "37ed43e9a1df4c47b0a68eeb110eeacfe5064a0383dd0f715dd6961a9126ac97", "class_name": "RelatedNodeInfo"}}, "text": "And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  ", "start_char_idx": 338, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb82c369-31cc-445e-90e7-51ac171a0297": {"__data__": {"id_": "eb82c369-31cc-445e-90e7-51ac171a0297", "embedding": null, "metadata": {"window": "There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n", "original_text": "So overall, that was a slight \npositive for us this year as well. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d7e9d00-5ade-42c0-89b7-bea6407d76ba", "node_type": "1", "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics. ", "original_text": "And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ee420e4260bf0bbe4e41e233d7d94437f292465c6b6bbaefe4cd8476a286a95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "337a8b6f-a142-41af-94bb-3ff96ab8f61b", "node_type": "1", "metadata": {"window": "Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n"}, "hash": "5c8474eff0106d16cb65025f0c5d31b6e4e6971d139935a83ce51c05ae74da37", "class_name": "RelatedNodeInfo"}}, "text": "So overall, that was a slight \npositive for us this year as well. ", "start_char_idx": 600, "end_char_idx": 666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "337a8b6f-a142-41af-94bb-3ff96ab8f61b": {"__data__": {"id_": "337a8b6f-a142-41af-94bb-3ff96ab8f61b", "embedding": null, "metadata": {"window": "Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb82c369-31cc-445e-90e7-51ac171a0297", "node_type": "1", "metadata": {"window": "There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n", "original_text": "So overall, that was a slight \npositive for us this year as well. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbf48037b2ccd78d27e02884455532faf5961e4360bcfe3c3e589baa38954d69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbca08ca-e877-40cf-b1dd-f50cacb36ba3", "node_type": "1", "metadata": {"window": "And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J. ", "original_text": "Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics. "}, "hash": "98e939b30b98a23428c9463246c1a4db3ba2a5a12ffb678ac43956620f76b3a2", "class_name": "RelatedNodeInfo"}}, "text": "And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n", "start_char_idx": 666, "end_char_idx": 800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbca08ca-e877-40cf-b1dd-f50cacb36ba3": {"__data__": {"id_": "fbca08ca-e877-40cf-b1dd-f50cacb36ba3", "embedding": null, "metadata": {"window": "And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J. ", "original_text": "Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "337a8b6f-a142-41af-94bb-3ff96ab8f61b", "node_type": "1", "metadata": {"window": "Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n", "original_text": "And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9f9df47928b9ff863e18a4f81c3e06a84a35c68fb63ac8a62836019eaa8cd0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0cd526a-2f87-4b46-a8ab-89bbcac4032d", "node_type": "1", "metadata": {"window": "So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n", "original_text": "And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n"}, "hash": "1b8f50ed90705ad62b125cdf00c7a76a5f6ca49b891aa5954275c42f675ac040", "class_name": "RelatedNodeInfo"}}, "text": "Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics. ", "start_char_idx": 800, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0cd526a-2f87-4b46-a8ab-89bbcac4032d": {"__data__": {"id_": "c0cd526a-2f87-4b46-a8ab-89bbcac4032d", "embedding": null, "metadata": {"window": "So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n", "original_text": "And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbca08ca-e877-40cf-b1dd-f50cacb36ba3", "node_type": "1", "metadata": {"window": "And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.   So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J. ", "original_text": "Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80f32f222f64ad02a96f6a48b04a1917febddb7ec593e1c4c1ac27764aa65189", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e2fa2e3-05b1-45b3-82ee-8ff8de90889b", "node_type": "1", "metadata": {"window": "And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J. ", "original_text": "Kevin Moran:  Next question, please.  \n \n"}, "hash": "25ffc692faa67138577e08e018a458f27aa4f764e855ee4e6155fcd02c5900e6", "class_name": "RelatedNodeInfo"}}, "text": "And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n", "start_char_idx": 945, "end_char_idx": 1102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e2fa2e3-05b1-45b3-82ee-8ff8de90889b": {"__data__": {"id_": "1e2fa2e3-05b1-45b3-82ee-8ff8de90889b", "embedding": null, "metadata": {"window": "And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0cd526a-2f87-4b46-a8ab-89bbcac4032d", "node_type": "1", "metadata": {"window": "So overall, that was a slight \npositive for us this year as well.  And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n", "original_text": "And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e7eff897e081d1c42021c3c78f15eb2def7bbc7128eea565cba52c63d335061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e24844a9-33fb-4145-b239-e0a7bed4aca9", "node_type": "1", "metadata": {"window": "Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks. ", "original_text": "Operator:  Next question today comes from A.J. "}, "hash": "e4418f40c9a38d1bb166552b48afb1231eea520756ca56f254dafdeef8e3503d", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question, please.  \n \n", "start_char_idx": 1102, "end_char_idx": 1143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e24844a9-33fb-4145-b239-e0a7bed4aca9": {"__data__": {"id_": "e24844a9-33fb-4145-b239-e0a7bed4aca9", "embedding": null, "metadata": {"window": "Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks. ", "original_text": "Operator:  Next question today comes from A.J. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e2fa2e3-05b1-45b3-82ee-8ff8de90889b", "node_type": "1", "metadata": {"window": "And we expect those types of things to be more normalized in fiscal \n\u201824 and feel well -positioned to participate in that growth.  \n \n Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J. ", "original_text": "Kevin Moran:  Next question, please.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dd97634c14402c9c2770fa284a511dd9f1e3eb1b79c2ed63cc110e76b538372", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b373789e-0b09-48c5-a022-33a35f8f9d53", "node_type": "1", "metadata": {"window": "And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody. ", "original_text": "Rice of Credit Suisse.  \n \n"}, "hash": "dbdeb065e85803b24bb4c5acd31fe402de725513a03921af3e78fa33c9a24a97", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Next question today comes from A.J. ", "start_char_idx": 1143, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b373789e-0b09-48c5-a022-33a35f8f9d53": {"__data__": {"id_": "b373789e-0b09-48c5-a022-33a35f8f9d53", "embedding": null, "metadata": {"window": "And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody. ", "original_text": "Rice of Credit Suisse.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e24844a9-33fb-4145-b239-e0a7bed4aca9", "node_type": "1", "metadata": {"window": "Aaron  Alt:  I would just add one thought, which is in Q4 , we saw strong volume, as Jason highlighted, \nbut overall consistent market dynamics.  And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks. ", "original_text": "Operator:  Next question today comes from A.J. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e9309f4b4f83744031a9a34451b3397f32d746054aa34989d82d78037ef0dc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01d4a0ba-d8cc-4f8b-9537-8eeeeccde48c", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported. ", "original_text": "A.J. "}, "hash": "8fc777a16e1851dad57f123b2787db00e4b1a2759e509bcbc87bda85de86ce7c", "class_name": "RelatedNodeInfo"}}, "text": "Rice of Credit Suisse.  \n \n", "start_char_idx": 1190, "end_char_idx": 1217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01d4a0ba-d8cc-4f8b-9537-8eeeeccde48c": {"__data__": {"id_": "01d4a0ba-d8cc-4f8b-9537-8eeeeccde48c", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported. ", "original_text": "A.J. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b373789e-0b09-48c5-a022-33a35f8f9d53", "node_type": "1", "metadata": {"window": "And indeed, as we look forward, Jason called out the unit \ngrowth, but we are also guiding to consistent market dynamics  for the upcoming year as well.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody. ", "original_text": "Rice of Credit Suisse.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13037bfc6171dd34a001c9c39286ec52b4aef12d49174cdd92376fb7b3a842b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b78153c-b4ed-4973-bc60-4b42ccdef210", "node_type": "1", "metadata": {"window": "Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers. ", "original_text": "Rice:  Thanks. "}, "hash": "fa762ab6079c60cc11f1b3a10239e484b0cd94fc5a3e40802ed7841d0bbe4f57", "class_name": "RelatedNodeInfo"}}, "text": "A.J. ", "start_char_idx": 1185, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b78153c-b4ed-4973-bc60-4b42ccdef210": {"__data__": {"id_": "2b78153c-b4ed-4973-bc60-4b42ccdef210", "embedding": null, "metadata": {"window": "Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers. ", "original_text": "Rice:  Thanks. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01d4a0ba-d8cc-4f8b-9537-8eeeeccde48c", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question, please.  \n \n Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported. ", "original_text": "A.J. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3775c932e4b375ca8b6320580cf869658317a55aa305e75f5c780b8f8a488593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5b70081-8159-4066-b62b-daae956a2ad2", "node_type": "1", "metadata": {"window": "Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n", "original_text": "Hi, everybody. "}, "hash": "0b4f635532443fa3fc17d95d4b872f220c43ddb8144dded48c0791cf382cc4c1", "class_name": "RelatedNodeInfo"}}, "text": "Rice:  Thanks. ", "start_char_idx": 1222, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5b70081-8159-4066-b62b-daae956a2ad2": {"__data__": {"id_": "d5b70081-8159-4066-b62b-daae956a2ad2", "embedding": null, "metadata": {"window": "Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n", "original_text": "Hi, everybody. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b78153c-b4ed-4973-bc60-4b42ccdef210", "node_type": "1", "metadata": {"window": "Operator:  Next question today comes from A.J.  Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers. ", "original_text": "Rice:  Thanks. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "203686ab0c6f932e66f75377ad332cf2ebb1f4e13e13eca3161e6a7ead017569", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de639602-87e8-4513-88a5-90645507ca0c", "node_type": "1", "metadata": {"window": "A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here. ", "original_text": "I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported. "}, "hash": "63d888fb226dc07ec2ee0c257d14f9ab2aa08acf19392d9ae583becc4bbe90e9", "class_name": "RelatedNodeInfo"}}, "text": "Hi, everybody. ", "start_char_idx": 1237, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de639602-87e8-4513-88a5-90645507ca0c": {"__data__": {"id_": "de639602-87e8-4513-88a5-90645507ca0c", "embedding": null, "metadata": {"window": "A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here. ", "original_text": "I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5b70081-8159-4066-b62b-daae956a2ad2", "node_type": "1", "metadata": {"window": "Rice of Credit Suisse.  \n \n A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n", "original_text": "Hi, everybody. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f92bf0407b8eb6bced2d6954eec2d68c5f3a59a792961df2a76fa31cc8753acc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f364187-b280-473e-9d33-ae7b871174d5", "node_type": "1", "metadata": {"window": "Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady? ", "original_text": "But we've heard this \ndiscussion about an uptick in utilization from some of the providers. "}, "hash": "4239c9bd02f6fd175a97a9da87e1e5c703fcfbd973b60e562f9a2592e2cf0c8c", "class_name": "RelatedNodeInfo"}}, "text": "I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported. ", "start_char_idx": 1252, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f364187-b280-473e-9d33-ae7b871174d5": {"__data__": {"id_": "4f364187-b280-473e-9d33-ae7b871174d5", "embedding": null, "metadata": {"window": "Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady? ", "original_text": "But we've heard this \ndiscussion about an uptick in utilization from some of the providers. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de639602-87e8-4513-88a5-90645507ca0c", "node_type": "1", "metadata": {"window": "A.J.  Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here. ", "original_text": "I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "823fe3b011ca806852131eeb6ef0fc7833aeade1c5e38c895f08edccba387a02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72161d4a-5d9a-433f-a021-caf931e8954e", "node_type": "1", "metadata": {"window": "Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n", "original_text": "And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n"}, "hash": "146d51df4a3413bb0b9e4bf658718d0e279d7ac2a1c0725c09c2e68c78f6f3d4", "class_name": "RelatedNodeInfo"}}, "text": "But we've heard this \ndiscussion about an uptick in utilization from some of the providers. ", "start_char_idx": 1399, "end_char_idx": 1491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72161d4a-5d9a-433f-a021-caf931e8954e": {"__data__": {"id_": "72161d4a-5d9a-433f-a021-caf931e8954e", "embedding": null, "metadata": {"window": "Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n", "original_text": "And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f364187-b280-473e-9d33-ae7b871174d5", "node_type": "1", "metadata": {"window": "Rice:  Thanks.  Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady? ", "original_text": "But we've heard this \ndiscussion about an uptick in utilization from some of the providers. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0248f7752768f1a7885714f30bf39cf001ae4a46e667f56a94b7ee7036b91cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29ffc177-c0e5-4874-9247-a2fc13df4e0f", "node_type": "1", "metadata": {"window": "I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah. ", "original_text": "And then just on the PPE comment, you're calling it normalization of profits from here. "}, "hash": "ffb09890e8f7bb9e7c60f0a88508a3ec33d3576c911d4ad10ebc31addd4a6361", "class_name": "RelatedNodeInfo"}}, "text": "And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n", "start_char_idx": 1491, "end_char_idx": 1684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29ffc177-c0e5-4874-9247-a2fc13df4e0f": {"__data__": {"id_": "29ffc177-c0e5-4874-9247-a2fc13df4e0f", "embedding": null, "metadata": {"window": "I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah. ", "original_text": "And then just on the PPE comment, you're calling it normalization of profits from here. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72161d4a-5d9a-433f-a021-caf931e8954e", "node_type": "1", "metadata": {"window": "Hi, everybody.  I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n", "original_text": "And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7712665740fdad22b87d9fab3f583b9420ecc7e10efdbec5469759df8c412fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c270c25-ed14-49a9-9d8e-085f0c0d815d", "node_type": "1", "metadata": {"window": "But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent. ", "original_text": "Do you think \nsequentially from here, we're pretty steady? "}, "hash": "9ef149d1000c29fd776b4e7e9a39957616a3c464e1f134d678754b95784cb880", "class_name": "RelatedNodeInfo"}}, "text": "And then just on the PPE comment, you're calling it normalization of profits from here. ", "start_char_idx": 1684, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c270c25-ed14-49a9-9d8e-085f0c0d815d": {"__data__": {"id_": "1c270c25-ed14-49a9-9d8e-085f0c0d815d", "embedding": null, "metadata": {"window": "But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent. ", "original_text": "Do you think \nsequentially from here, we're pretty steady? ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29ffc177-c0e5-4874-9247-a2fc13df4e0f", "node_type": "1", "metadata": {"window": "I know on your Medical side, there's a lot going on, and you're a \nlittle more skewed toward inpatient than some of the others that have reported.  But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah. ", "original_text": "And then just on the PPE comment, you're calling it normalization of profits from here. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83843b4b202b0c542c1861c541f032f9ff9121482a6a857e8737f1dc2d5be9e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9b25b21-4f32-4bf5-801e-5791fa93a579", "node_type": "1", "metadata": {"window": "And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything. ", "original_text": "And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n"}, "hash": "9bf0b6347f1de6dae12e32951e4086fd55c6db96a5f12fa84c0a63a04e4575f8", "class_name": "RelatedNodeInfo"}}, "text": "Do you think \nsequentially from here, we're pretty steady? ", "start_char_idx": 1772, "end_char_idx": 1831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9b25b21-4f32-4bf5-801e-5791fa93a579": {"__data__": {"id_": "d9b25b21-4f32-4bf5-801e-5791fa93a579", "embedding": null, "metadata": {"window": "And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything. ", "original_text": "And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c270c25-ed14-49a9-9d8e-085f0c0d815d", "node_type": "1", "metadata": {"window": "But we've heard this \ndiscussion about an uptick in utilization from some of the providers.  And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent. ", "original_text": "Do you think \nsequentially from here, we're pretty steady? ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1a89718f4e3a04e852fe7c18a027fe7464c6f8a6f7ce94172f9f993f4ed1e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46570ff3-2458-4ebe-a95e-c6395b736344", "node_type": "1", "metadata": {"window": "And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n", "original_text": "Jason Hollar:  Yeah. "}, "hash": "1f766ca572e1672a68593b2b5591990f14aaf0136006c14ececc4c05d3e1a106", "class_name": "RelatedNodeInfo"}}, "text": "And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n", "start_char_idx": 1831, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46570ff3-2458-4ebe-a95e-c6395b736344": {"__data__": {"id_": "46570ff3-2458-4ebe-a95e-c6395b736344", "embedding": null, "metadata": {"window": "And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n", "original_text": "Jason Hollar:  Yeah. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9b25b21-4f32-4bf5-801e-5791fa93a579", "node_type": "1", "metadata": {"window": "And I wondered if I peel back \neverything that's going on in Medical, did you see any change in behavior on the part of your \ncustomers to suggest that there was an uptick in utilization?   \n \n And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything. ", "original_text": "And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4315986d8c74fcf2b56ac5a4adfc4def828cb2fe9909eb2cc364fe02e98da6b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60651cc5-2897-47b2-a15d-bd334a3a93f5", "node_type": "1", "metadata": {"window": "Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n", "original_text": "The utilization, we think, has been fairly consistent. "}, "hash": "754442dc663eef7f7d63811d254cc4d6ce2a5eb3f018febcf8009272de89eed6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah. ", "start_char_idx": 1991, "end_char_idx": 2012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60651cc5-2897-47b2-a15d-bd334a3a93f5": {"__data__": {"id_": "60651cc5-2897-47b2-a15d-bd334a3a93f5", "embedding": null, "metadata": {"window": "Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n", "original_text": "The utilization, we think, has been fairly consistent. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46570ff3-2458-4ebe-a95e-c6395b736344", "node_type": "1", "metadata": {"window": "And then just on the PPE comment, you're calling it normalization of profits from here.  Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n", "original_text": "Jason Hollar:  Yeah. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f520cb0766b06a3682245be6213ea46cd6a08c5a56360827766174fe658f0d93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b82f569-c940-44d5-9dc3-50c0f8b221b1", "node_type": "1", "metadata": {"window": "And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points. ", "original_text": "I wouldn't call it an \nacceleration or anything. "}, "hash": "4a4631cb1811712b97758bfa0fe608403269848e7f5e3fdcb292a5ecf78848d1", "class_name": "RelatedNodeInfo"}}, "text": "The utilization, we think, has been fairly consistent. ", "start_char_idx": 2012, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b82f569-c940-44d5-9dc3-50c0f8b221b1": {"__data__": {"id_": "0b82f569-c940-44d5-9dc3-50c0f8b221b1", "embedding": null, "metadata": {"window": "And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points. ", "original_text": "I wouldn't call it an \nacceleration or anything. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60651cc5-2897-47b2-a15d-bd334a3a93f5", "node_type": "1", "metadata": {"window": "Do you think \nsequentially from here, we're pretty steady?  And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n", "original_text": "The utilization, we think, has been fairly consistent. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28affefd2ebc42bdd89cc7891dd1022a0b7f05fdc6addd517ccdf0f9fececc8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9ebe9ba-2ede-463a-9c6c-88a835e6de7f", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us. ", "original_text": "We're seeing pretty consistent underlying same -store sales type of growth. \n"}, "hash": "adb69c04e06fd69a1fa5d21aa927e229f65ff34bd5ff79729cf8f72cdf36842c", "class_name": "RelatedNodeInfo"}}, "text": "I wouldn't call it an \nacceleration or anything. ", "start_char_idx": 2067, "end_char_idx": 2116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9ebe9ba-2ede-463a-9c6c-88a835e6de7f": {"__data__": {"id_": "b9ebe9ba-2ede-463a-9c6c-88a835e6de7f", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us. ", "original_text": "We're seeing pretty consistent underlying same -store sales type of growth. \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b82f569-c940-44d5-9dc3-50c0f8b221b1", "node_type": "1", "metadata": {"window": "And as we retu rn to a normal environment, is there any \nseasonality around that category to call out to remember when we get back to a normal environment?  \n \n Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points. ", "original_text": "I wouldn't call it an \nacceleration or anything. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c489c0a1553e04b321e85e453f6e3f69874b4528c6a2e8a2db93cdd3ee158ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63eb1648-1bed-4bb3-a074-788c012ad253", "node_type": "1", "metadata": {"window": "The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value. ", "original_text": "So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n"}, "hash": "3148ad67a7b03d2081372d690540ece3c74cc6c6c6b0e7c093d20c9967c4614b", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing pretty consistent underlying same -store sales type of growth. \n", "start_char_idx": 2116, "end_char_idx": 2193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63eb1648-1bed-4bb3-a074-788c012ad253": {"__data__": {"id_": "63eb1648-1bed-4bb3-a074-788c012ad253", "embedding": null, "metadata": {"window": "The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value. ", "original_text": "So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9ebe9ba-2ede-463a-9c6c-88a835e6de7f", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us. ", "original_text": "We're seeing pretty consistent underlying same -store sales type of growth. \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acf8c5b1f60c1545265f90294f95de418d72e05a2a00032fe71a2cc047c191a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ff50de3-bbb5-457a-8565-b13f3e04f779", "node_type": "1", "metadata": {"window": "I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers. ", "original_text": "As it relates to PPE normalization, a couple of points. "}, "hash": "2e1b835d9bfc5339820b2461b88b51abbc4d5873ab7d621796f93dfd082725bc", "class_name": "RelatedNodeInfo"}}, "text": "So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n", "start_char_idx": 2193, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ff50de3-bbb5-457a-8565-b13f3e04f779": {"__data__": {"id_": "9ff50de3-bbb5-457a-8565-b13f3e04f779", "embedding": null, "metadata": {"window": "I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers. ", "original_text": "As it relates to PPE normalization, a couple of points. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63eb1648-1bed-4bb3-a074-788c012ad253", "node_type": "1", "metadata": {"window": "The utilization, we think, has been fairly consistent.  I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value. ", "original_text": "So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cd9e0fe9766ac2268adb9262a6bea8d1a7ff2ea7b170d7fe88bf7f16d413605", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee450f8a-b9bc-4ef3-82ce-068efcad4261", "node_type": "1", "metadata": {"window": "We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.  ", "original_text": "So , normalized is good for us. "}, "hash": "22a9686aa1e379ab4ff7eb68c6c0ef02395d1717c6df05fdb918be0daa587dc6", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to PPE normalization, a couple of points. ", "start_char_idx": 2335, "end_char_idx": 2391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee450f8a-b9bc-4ef3-82ce-068efcad4261": {"__data__": {"id_": "ee450f8a-b9bc-4ef3-82ce-068efcad4261", "embedding": null, "metadata": {"window": "We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.  ", "original_text": "So , normalized is good for us. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ff50de3-bbb5-457a-8565-b13f3e04f779", "node_type": "1", "metadata": {"window": "I wouldn't call it an \nacceleration or anything.  We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers. ", "original_text": "As it relates to PPE normalization, a couple of points. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab0a482a4abbc8155b75ac82875c559e60358161358030d0a10e51cb7c482810", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dee9b74-cfe8-41a6-9444-244c727158a6", "node_type": "1", "metadata": {"window": "So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that. ", "original_text": "This is not a \ncategory that we've ever made a tremendous amount of money and value. "}, "hash": "f16f16436e9940a52877bda2229426adbd1c79db80d534e15116c81806161403", "class_name": "RelatedNodeInfo"}}, "text": "So , normalized is good for us. ", "start_char_idx": 2391, "end_char_idx": 2423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dee9b74-cfe8-41a6-9444-244c727158a6": {"__data__": {"id_": "5dee9b74-cfe8-41a6-9444-244c727158a6", "embedding": null, "metadata": {"window": "So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that. ", "original_text": "This is not a \ncategory that we've ever made a tremendous amount of money and value. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee450f8a-b9bc-4ef3-82ce-068efcad4261", "node_type": "1", "metadata": {"window": "We're seeing pretty consistent underlying same -store sales type of growth. \n So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.  ", "original_text": "So , normalized is good for us. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d28274225aee4565ad683935b0d7fb52c21f236fd0128dd74f7c53dbbb925fdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fee44863-969c-45c3-a6c2-3d3ee6203ba2", "node_type": "1", "metadata": {"window": "As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other. ", "original_text": "It's an important category \nfor our customers. "}, "hash": "999f602e0329d62359290b14010eed0c94c3ec615c2995aa6d388159819ae9af", "class_name": "RelatedNodeInfo"}}, "text": "This is not a \ncategory that we've ever made a tremendous amount of money and value. ", "start_char_idx": 2423, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fee44863-969c-45c3-a6c2-3d3ee6203ba2": {"__data__": {"id_": "fee44863-969c-45c3-a6c2-3d3ee6203ba2", "embedding": null, "metadata": {"window": "As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other. ", "original_text": "It's an important category \nfor our customers. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dee9b74-cfe8-41a6-9444-244c727158a6", "node_type": "1", "metadata": {"window": "So, it's sufficient within our business model and where we laid it out from Investor Day, but I wouldn't \ncall out anything unique there.  \n \n As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that. ", "original_text": "This is not a \ncategory that we've ever made a tremendous amount of money and value. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "174a08f4cc3bb82b1f0a3c0439f33167320786dd87bf1eafdff578687c2cb5cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "752f48a0-c808-4b71-87a8-a44350b32d78", "node_type": "1", "metadata": {"window": "So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.  ", "original_text": "And so, we do everything we can to satisfy their needs.  "}, "hash": "4e2cf47f6e2e0cd40d55b24d5c8a4a2a90cc7e7920b0626070c5d817478411a5", "class_name": "RelatedNodeInfo"}}, "text": "It's an important category \nfor our customers. ", "start_char_idx": 2508, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "752f48a0-c808-4b71-87a8-a44350b32d78": {"__data__": {"id_": "752f48a0-c808-4b71-87a8-a44350b32d78", "embedding": null, "metadata": {"window": "So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.  ", "original_text": "And so, we do everything we can to satisfy their needs.  ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fee44863-969c-45c3-a6c2-3d3ee6203ba2", "node_type": "1", "metadata": {"window": "As it relates to PPE normalization, a couple of points.  So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other. ", "original_text": "It's an important category \nfor our customers. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be86a3b2ea6519b02c45a15cccdabeb2e7ca6cc140fc8576ec4fe8a25286f421", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f257d1f-3f09-4c14-865c-286a74faa562", "node_type": "1", "metadata": {"window": "This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily. ", "original_text": "So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that. "}, "hash": "fe68248d96b71257478ac232a5566b83f75e810f1dd4c3d8dbe190ad1d5b81d1", "class_name": "RelatedNodeInfo"}}, "text": "And so, we do everything we can to satisfy their needs.  ", "start_char_idx": 2555, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f257d1f-3f09-4c14-865c-286a74faa562": {"__data__": {"id_": "1f257d1f-3f09-4c14-865c-286a74faa562", "embedding": null, "metadata": {"window": "This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily. ", "original_text": "So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "752f48a0-c808-4b71-87a8-a44350b32d78", "node_type": "1", "metadata": {"window": "So , normalized is good for us.  This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.  ", "original_text": "And so, we do everything we can to satisfy their needs.  ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "189336657353da9c781579fb1690ec674d3a1387b1e4d13b0af9a2df50a819c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe789158-afef-4320-947d-d74c8e571bf3", "node_type": "1", "metadata": {"window": "It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable. ", "original_text": "But I just don't see it being a material driver one way or the other. "}, "hash": "10984b7d40fa0f7d14bd6e405d021198488d822249e379ee95d63c8fa1d1a525", "class_name": "RelatedNodeInfo"}}, "text": "So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that. ", "start_char_idx": 2612, "end_char_idx": 2759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe789158-afef-4320-947d-d74c8e571bf3": {"__data__": {"id_": "fe789158-afef-4320-947d-d74c8e571bf3", "embedding": null, "metadata": {"window": "It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable. ", "original_text": "But I just don't see it being a material driver one way or the other. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f257d1f-3f09-4c14-865c-286a74faa562", "node_type": "1", "metadata": {"window": "This is not a \ncategory that we've ever made a tremendous amount of money and value.  It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily. ", "original_text": "So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "684217192f8f34654fbba843af639399b0489d4dc8cb89ff98c2f36dc2539d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67579d92-16af-4023-a771-69d88bcf20ef", "node_type": "1", "metadata": {"window": "And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging. ", "original_text": "Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.  "}, "hash": "efff74ed01151bf52aa5165aeaae7883cc0fef9aa86116f0466d0eb0648311e2", "class_name": "RelatedNodeInfo"}}, "text": "But I just don't see it being a material driver one way or the other. ", "start_char_idx": 2759, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67579d92-16af-4023-a771-69d88bcf20ef": {"__data__": {"id_": "67579d92-16af-4023-a771-69d88bcf20ef", "embedding": null, "metadata": {"window": "And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging. ", "original_text": "Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.  ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe789158-afef-4320-947d-d74c8e571bf3", "node_type": "1", "metadata": {"window": "It's an important category \nfor our customers.  And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable. ", "original_text": "But I just don't see it being a material driver one way or the other. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34604069b74e9d3069927229aba1afc323812e7dc8b8778c250ddddb32c44a70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49a5d31e-a4ce-4380-9654-213db8dfe54c", "node_type": "1", "metadata": {"window": "So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily. "}, "hash": "7b1922d9b59e86289b3621e30e5524617f725bd33641d64dc9b7912dd6e5a166", "class_name": "RelatedNodeInfo"}}, "text": "Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.  ", "start_char_idx": 2829, "end_char_idx": 2928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49a5d31e-a4ce-4380-9654-213db8dfe54c": {"__data__": {"id_": "49a5d31e-a4ce-4380-9654-213db8dfe54c", "embedding": null, "metadata": {"window": "So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67579d92-16af-4023-a771-69d88bcf20ef", "node_type": "1", "metadata": {"window": "And so, we do everything we can to satisfy their needs.   So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging. ", "original_text": "Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.  ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a67cad2334f0698f1f501e659679ae224bbe61184af087abf6050b5f942223ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95cb3547-9a93-4ccb-926d-4af553ed638f", "node_type": "1", "metadata": {"window": "But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable. "}, "hash": "fc574e7b13a07ad8c895e6bf749f2462606026fa4766fdb168003d076966f858", "class_name": "RelatedNodeInfo"}}, "text": "What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily. ", "start_char_idx": 2928, "end_char_idx": 3088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95cb3547-9a93-4ccb-926d-4af553ed638f": {"__data__": {"id_": "95cb3547-9a93-4ccb-926d-4af553ed638f", "embedding": null, "metadata": {"window": "But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49a5d31e-a4ce-4380-9654-213db8dfe54c", "node_type": "1", "metadata": {"window": "So going forward, our \nobjective is to ensure that we get customers the product they need and  minimize the volatility that \ngoes along with that.  But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2dab98dd1a6b3f360d132ab098acf206771a5190ab0e0c0917297860b2734e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0741c12b-a3c1-403e-a2d4-3601714c20aa", "node_type": "1", "metadata": {"window": "Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "And it's that volume that's been a little bit more \nchallenging. "}, "hash": "d8e049890daa7f9a45a7562eeef09aaacc7b2af117fc48fe12f78be037340c15", "class_name": "RelatedNodeInfo"}}, "text": "And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable. ", "start_char_idx": 3088, "end_char_idx": 3201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0741c12b-a3c1-403e-a2d4-3601714c20aa": {"__data__": {"id_": "0741c12b-a3c1-403e-a2d4-3601714c20aa", "embedding": null, "metadata": {"window": "Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "And it's that volume that's been a little bit more \nchallenging. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95cb3547-9a93-4ccb-926d-4af553ed638f", "node_type": "1", "metadata": {"window": "But I just don't see it being a material driver one way or the other.  Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5535229b7d09a52784c7d15f514b403ad1c5d1b1921eca234b9aa2ada6bb8823", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68586bd5-c4c2-4bcd-aef5-d3c09b867124", "node_type": "1", "metadata": {"window": "What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of "}, "hash": "be710eaeb8eb6f9113b99038f6a2cfe50bf48e32fc4973d4b8ea688101fecd9e", "class_name": "RelatedNodeInfo"}}, "text": "And it's that volume that's been a little bit more \nchallenging. ", "start_char_idx": 3201, "end_char_idx": 3266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68586bd5-c4c2-4bcd-aef5-d3c09b867124": {"__data__": {"id_": "68586bd5-c4c2-4bcd-aef5-d3c09b867124", "embedding": null, "metadata": {"window": "What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f090a3a6d11bd7d6c3dce92a1313e82db78de251a7ca6deb83fdcca5051d1292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0741c12b-a3c1-403e-a2d4-3601714c20aa", "node_type": "1", "metadata": {"window": "Recall that the \nchallenges with PPE was th at we had volatile price cost and volume all at once.   What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "And it's that volume that's been a little bit more \nchallenging. ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8aab294b3107f5c77544c4a09f98aa3046b39920edcb67d1006cabb16d2f48f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5e1dbf9-47e6-4cc1-a386-ffba65915e78", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n", "original_text": " \nPage 16 of 17 \n \nincremental volume or incremental margins. "}, "hash": "aef7989631c8c1c8385f22c10c4420266fb3f7a76e88bc0a5b68b02b64acff05", "class_name": "RelatedNodeInfo"}}, "text": "We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "start_char_idx": 3266, "end_char_idx": 3662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5e1dbf9-47e6-4cc1-a386-ffba65915e78": {"__data__": {"id_": "b5e1dbf9-47e6-4cc1-a386-ffba65915e78", "embedding": null, "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n", "original_text": " \nPage 16 of 17 \n \nincremental volume or incremental margins. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68586bd5-c4c2-4bcd-aef5-d3c09b867124", "node_type": "1", "metadata": {"window": "What you have right \nnow is a normalization that's been occurring over the last couple of years of both price and cost has \nbeen coming down somewhat steadily.  And they've been staying in a relative type of spread close \nenough to one another that, that's been manageable.  And it's that volume that's been a little bit more \nchallenging.  We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "original_text": "We've highlighted that it was destocking beginning about \u2013 well, over a year ago now in \nterms of the underlying volume ther e. But given the margins are relatively tight for this type of \nproduct, getting those margins right and relatively low margins , means that the volume volatility or the \nlack of volume growth is not much of an issue for us  because it's just not a large contr ibutor of ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99de73732e35c5742bf544b06347367c3326a81807209c55985c6e22dab51c36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59906c78-c0a4-4e30-8571-b7533f62c903", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning. ", "original_text": "So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n"}, "hash": "a3a8b4d87125c903536dd7359dcb0108eb560ac9c143a8308d48b606ddf7a845", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 17 \n \nincremental volume or incremental margins. ", "start_char_idx": 0, "end_char_idx": 62, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59906c78-c0a4-4e30-8571-b7533f62c903": {"__data__": {"id_": "59906c78-c0a4-4e30-8571-b7533f62c903", "embedding": null, "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning. ", "original_text": "So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5e1dbf9-47e6-4cc1-a386-ffba65915e78", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n", "original_text": " \nPage 16 of 17 \n \nincremental volume or incremental margins. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe50a14d4829dad313a73d567fe298e575c4f5fb5e775d61f21a1d36c7055597", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93ae3505-622e-40b7-87bb-b00704e5904d", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian. ", "original_text": "Kevin Moran:  Next question please , Operator.  \n \n"}, "hash": "a5105d3baadfb938d3e490fcd5aa343cf8bc443889ab577474c31ef11858cf68", "class_name": "RelatedNodeInfo"}}, "text": "So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n", "start_char_idx": 62, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93ae3505-622e-40b7-87bb-b00704e5904d": {"__data__": {"id_": "93ae3505-622e-40b7-87bb-b00704e5904d", "embedding": null, "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian. ", "original_text": "Kevin Moran:  Next question please , Operator.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59906c78-c0a4-4e30-8571-b7533f62c903", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning. ", "original_text": "So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a5f2d597e4a07413d1b1a5b1a67eaa6f71000695305fb2f2cb49a52c53fa592", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "474a4964-867a-4a28-866a-90dd715b251b", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024. ", "original_text": "Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n"}, "hash": "14471aef324842aeeb9cbc075cee927218aaca58f462649a58d989469bb070cb", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:  Next question please , Operator.  \n \n", "start_char_idx": 166, "end_char_idx": 217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "474a4964-867a-4a28-866a-90dd715b251b": {"__data__": {"id_": "474a4964-867a-4a28-866a-90dd715b251b", "embedding": null, "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024. ", "original_text": "Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93ae3505-622e-40b7-87bb-b00704e5904d", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian. ", "original_text": "Kevin Moran:  Next question please , Operator.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3ab98dc13ba37e68c43073ca541b3143796dc75774b223031ade12408b1a770", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60550029-29e6-4d38-8aab-325cfcb5d159", "node_type": "1", "metadata": {"window": "So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n", "original_text": "Brian Tanquilut:   Good morning. "}, "hash": "61d0c777e38099d770bd6fce5ccdad08992c6f77e045690be1befcbcba08e211", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n", "start_char_idx": 217, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60550029-29e6-4d38-8aab-325cfcb5d159": {"__data__": {"id_": "60550029-29e6-4d38-8aab-325cfcb5d159", "embedding": null, "metadata": {"window": "So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n", "original_text": "Brian Tanquilut:   Good morning. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "474a4964-867a-4a28-866a-90dd715b251b", "node_type": "1", "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024. ", "original_text": "Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f410d9d12cfbcee869ad37dac18dca3efb60f022fd020020b49a40c84849c6b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2c6a420-20ba-43a5-b82b-7c9fb196916c", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year? ", "original_text": "This is [indiscernible] in for Brian. "}, "hash": "a70906f2e5d5f5c8665224bac5c9528abbe95d4f09dff1bca56ad47ef72b0cab", "class_name": "RelatedNodeInfo"}}, "text": "Brian Tanquilut:   Good morning. ", "start_char_idx": 299, "end_char_idx": 332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2c6a420-20ba-43a5-b82b-7c9fb196916c": {"__data__": {"id_": "c2c6a420-20ba-43a5-b82b-7c9fb196916c", "embedding": null, "metadata": {"window": "Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year? ", "original_text": "This is [indiscernible] in for Brian. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60550029-29e6-4d38-8aab-325cfcb5d159", "node_type": "1", "metadata": {"window": "So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n", "original_text": "Brian Tanquilut:   Good morning. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "670b978511b2b8fb8437993e20352fd2111524d15d3e536345803045f0fe5d62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71858f65-8be9-461c-bca3-ea21d19a06a3", "node_type": "1", "metadata": {"window": "Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n", "original_text": "I had a question about your capital \nallocation priorities for the fiscal year 2024. "}, "hash": "bb0ec5f7e73d6990296b0f78f3e366c1152530e55f5ee2a9f153abc5b168be12", "class_name": "RelatedNodeInfo"}}, "text": "This is [indiscernible] in for Brian. ", "start_char_idx": 332, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71858f65-8be9-461c-bca3-ea21d19a06a3": {"__data__": {"id_": "71858f65-8be9-461c-bca3-ea21d19a06a3", "embedding": null, "metadata": {"window": "Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n", "original_text": "I had a question about your capital \nallocation priorities for the fiscal year 2024. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2c6a420-20ba-43a5-b82b-7c9fb196916c", "node_type": "1", "metadata": {"window": "Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year? ", "original_text": "This is [indiscernible] in for Brian. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8e2022edeaa41180cbdb09b037698d4dc161d178de2f923ed5fd764b5551b04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f42e3a4-9c4d-4622-92ac-b6a50c233f32", "node_type": "1", "metadata": {"window": "Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question. ", "original_text": "Generated quite a bit of free cash flow this fiscal year. \n"}, "hash": "61b9d188cf89b1f5d64e9f1633006d23c32e73e5c442ffc85069ab22038c27fe", "class_name": "RelatedNodeInfo"}}, "text": "I had a question about your capital \nallocation priorities for the fiscal year 2024. ", "start_char_idx": 370, "end_char_idx": 455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f42e3a4-9c4d-4622-92ac-b6a50c233f32": {"__data__": {"id_": "4f42e3a4-9c4d-4622-92ac-b6a50c233f32", "embedding": null, "metadata": {"window": "Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question. ", "original_text": "Generated quite a bit of free cash flow this fiscal year. \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71858f65-8be9-461c-bca3-ea21d19a06a3", "node_type": "1", "metadata": {"window": "Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n", "original_text": "I had a question about your capital \nallocation priorities for the fiscal year 2024. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d73d28056846b51d8b3e8baff2a15153d8ff6d3de11bbbd8024109ee4128ddef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8df56155-d291-4582-ba56-ff4f22b4ea35", "node_type": "1", "metadata": {"window": "This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us. ", "original_text": "And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year? "}, "hash": "ec393a266477a30b436982eabf3f605b4d799080ea9bdaceaa8c55b1043c408c", "class_name": "RelatedNodeInfo"}}, "text": "Generated quite a bit of free cash flow this fiscal year. \n", "start_char_idx": 455, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8df56155-d291-4582-ba56-ff4f22b4ea35": {"__data__": {"id_": "8df56155-d291-4582-ba56-ff4f22b4ea35", "embedding": null, "metadata": {"window": "This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us. ", "original_text": "And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year? ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f42e3a4-9c4d-4622-92ac-b6a50c233f32", "node_type": "1", "metadata": {"window": "Brian Tanquilut:   Good morning.  This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question. ", "original_text": "Generated quite a bit of free cash flow this fiscal year. \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8070d00f72d536a119c0c29d0a69bfd5ede682f235f6661b5201865b5fec2747", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5462ba1-093d-47be-af1c-dba1925559ed", "node_type": "1", "metadata": {"window": "I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply. ", "original_text": "Thank you.  \n \n"}, "hash": "95ae5e6f5c842c923f728aac6442f5423b7073bcc815781b9a590c48397c3c51", "class_name": "RelatedNodeInfo"}}, "text": "And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year? ", "start_char_idx": 514, "end_char_idx": 652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5462ba1-093d-47be-af1c-dba1925559ed": {"__data__": {"id_": "a5462ba1-093d-47be-af1c-dba1925559ed", "embedding": null, "metadata": {"window": "I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply. ", "original_text": "Thank you.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8df56155-d291-4582-ba56-ff4f22b4ea35", "node_type": "1", "metadata": {"window": "This is [indiscernible] in for Brian.  I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us. ", "original_text": "And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year? ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4476cdfbcaf6271c4ddb3db62df3a9329f2169bda638c6a358c360b57cb559b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5857dfa-b119-4fb9-9a19-969582c92323", "node_type": "1", "metadata": {"window": "Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n", "original_text": "Aaron Alt:  Hey, great question. "}, "hash": "22d9441f6756e5f79f0fe0d7c2c58ee729374302f7993137f109a16f0a8f964b", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 652, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5857dfa-b119-4fb9-9a19-969582c92323": {"__data__": {"id_": "c5857dfa-b119-4fb9-9a19-969582c92323", "embedding": null, "metadata": {"window": "Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n", "original_text": "Aaron Alt:  Hey, great question. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5462ba1-093d-47be-af1c-dba1925559ed", "node_type": "1", "metadata": {"window": "I had a question about your capital \nallocation priorities for the fiscal year 2024.  Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply. ", "original_text": "Thank you.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e19f131deff30eba649f150fbc802dccbb8e494aae866c8610f7cb5533d7a1f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a33151f-1be4-452d-a1ab-073517e122c7", "node_type": "1", "metadata": {"window": "And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer. ", "original_text": "Thank you for putting it on the table for us. "}, "hash": "b8545e4ce74f13aabbf5bf2186a804d9fa47d0feb7786252d528e97a670e686a", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Hey, great question. ", "start_char_idx": 667, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a33151f-1be4-452d-a1ab-073517e122c7": {"__data__": {"id_": "1a33151f-1be4-452d-a1ab-073517e122c7", "embedding": null, "metadata": {"window": "And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer. ", "original_text": "Thank you for putting it on the table for us. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5857dfa-b119-4fb9-9a19-969582c92323", "node_type": "1", "metadata": {"window": "Generated quite a bit of free cash flow this fiscal year. \n And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n", "original_text": "Aaron Alt:  Hey, great question. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e989785f5516926582e9d403ce54d7dc71dc6c039c86c9b2900f36b5bf09b241", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec3cd200-f3b8-4e39-934d-d153e9ac61c8", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect. ", "original_text": "Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply. "}, "hash": "2446be739ca752dcb4bff90d37a06e61face4f4414e98d73eb1b2811cfff6caf", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for putting it on the table for us. ", "start_char_idx": 700, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec3cd200-f3b8-4e39-934d-d153e9ac61c8": {"__data__": {"id_": "ec3cd200-f3b8-4e39-934d-d153e9ac61c8", "embedding": null, "metadata": {"window": "Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect. ", "original_text": "Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a33151f-1be4-452d-a1ab-073517e122c7", "node_type": "1", "metadata": {"window": "And I'm just curious if there's any specifics you can get into with regards to where you see capital \nallocation in the next fiscal year?  Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer. ", "original_text": "Thank you for putting it on the table for us. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1794c7560146fd117748d70a84974add8bc081bbfddcfec95cea464d116b83b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3418fea6-2e1f-4d87-9db2-e0d969ef8bd8", "node_type": "1", "metadata": {"window": "Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth. ", "original_text": "And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n"}, "hash": "5e4b371518d032a3dde05f07895971891c9cf9b96a649fef965f54081ec4bd99", "class_name": "RelatedNodeInfo"}}, "text": "Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply. ", "start_char_idx": 746, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3418fea6-2e1f-4d87-9db2-e0d969ef8bd8": {"__data__": {"id_": "3418fea6-2e1f-4d87-9db2-e0d969ef8bd8", "embedding": null, "metadata": {"window": "Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth. ", "original_text": "And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec3cd200-f3b8-4e39-934d-d153e9ac61c8", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect. ", "original_text": "Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1df5568361cb6e3833dc8246bbd82048ec0530a77273a5a2c6856a29325bb2f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1285c5b3-9468-4ac2-9a1f-b9f9f35348d5", "node_type": "1", "metadata": {"window": "Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823. ", "original_text": "Here's the simple answer. "}, "hash": "d0644a99a5a94a0f9f080513971655ab051af18b82c8326cd7d31b657e0e428e", "class_name": "RelatedNodeInfo"}}, "text": "And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n", "start_char_idx": 876, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1285c5b3-9468-4ac2-9a1f-b9f9f35348d5": {"__data__": {"id_": "1285c5b3-9468-4ac2-9a1f-b9f9f35348d5", "embedding": null, "metadata": {"window": "Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823. ", "original_text": "Here's the simple answer. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3418fea6-2e1f-4d87-9db2-e0d969ef8bd8", "node_type": "1", "metadata": {"window": "Aaron Alt:  Hey, great question.  Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth. ", "original_text": "And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d5b8ca52089320766ecce268992383201a3a8c939ffa3afbd92e28199960e46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ed4c852-48e1-4922-a502-504e29fb5471", "node_type": "1", "metadata": {"window": "Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n", "original_text": "We're going to do what we said we were go ing to do at Investor Day in that \nrespect. "}, "hash": "563883a93618ec5e1b27909d73abb7cc2c0edb202f49b7aae7745fda7fb039e0", "class_name": "RelatedNodeInfo"}}, "text": "Here's the simple answer. ", "start_char_idx": 983, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ed4c852-48e1-4922-a502-504e29fb5471": {"__data__": {"id_": "9ed4c852-48e1-4922-a502-504e29fb5471", "embedding": null, "metadata": {"window": "Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n", "original_text": "We're going to do what we said we were go ing to do at Investor Day in that \nrespect. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1285c5b3-9468-4ac2-9a1f-b9f9f35348d5", "node_type": "1", "metadata": {"window": "Thank you for putting it on the table for us.  Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823. ", "original_text": "Here's the simple answer. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7928fbbdd321f1aa17d53e30c0280c8090fb1b8aa1b904cf6abd4a5b4887914b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de7c7020-f419-4094-ad76-11b73a8b82a4", "node_type": "1", "metadata": {"window": "And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet. ", "original_text": "And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth. "}, "hash": "2b95ecb71e1551d4f804eb1c9f9665a3bfa3159578292fa47437eede93f9d083", "class_name": "RelatedNodeInfo"}}, "text": "We're going to do what we said we were go ing to do at Investor Day in that \nrespect. ", "start_char_idx": 1009, "end_char_idx": 1095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de7c7020-f419-4094-ad76-11b73a8b82a4": {"__data__": {"id_": "de7c7020-f419-4094-ad76-11b73a8b82a4", "embedding": null, "metadata": {"window": "And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet. ", "original_text": "And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ed4c852-48e1-4922-a502-504e29fb5471", "node_type": "1", "metadata": {"window": "Look, we were very \nfocused on our Investo r Day in laying out the disciplined capital allocation decision matrix that we \napply.  And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n", "original_text": "We're going to do what we said we were go ing to do at Investor Day in that \nrespect. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f15562ac8574cd0cb7e607fb4cbb0deb05e29afcff450c6b86820aeeeea4490c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2a33782-525c-46c6-ab38-41698baabe1c", "node_type": "1", "metadata": {"window": "Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities. ", "original_text": "We spent $480 \nmillion  in fiscal \u201823. "}, "hash": "3079669e7e393fc58c21e84ec51e20c064fa187325836ab0da1e53eee80ed61f", "class_name": "RelatedNodeInfo"}}, "text": "And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth. ", "start_char_idx": 1095, "end_char_idx": 1276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2a33782-525c-46c6-ab38-41698baabe1c": {"__data__": {"id_": "b2a33782-525c-46c6-ab38-41698baabe1c", "embedding": null, "metadata": {"window": "Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities. ", "original_text": "We spent $480 \nmillion  in fiscal \u201823. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de7c7020-f419-4094-ad76-11b73a8b82a4", "node_type": "1", "metadata": {"window": "And we were also very pleased to see the overall cash generation for fiscal \u201823 and Q4 in \nparticular.  \n \n Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet. ", "original_text": "And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e84c9c2b2e69ccbb8a2c1073541d7d8db5310f6206db39e186023f5b11c132d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "826a76a8-bfab-4ded-905c-235d0f02d22b", "node_type": "1", "metadata": {"window": "We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance. ", "original_text": "We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n"}, "hash": "69fdeee7407f426ae301970e4c2c8aaa9bacd2963aefa98548b98cc15a984956", "class_name": "RelatedNodeInfo"}}, "text": "We spent $480 \nmillion  in fiscal \u201823. ", "start_char_idx": 1276, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "826a76a8-bfab-4ded-905c-235d0f02d22b": {"__data__": {"id_": "826a76a8-bfab-4ded-905c-235d0f02d22b", "embedding": null, "metadata": {"window": "We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance. ", "original_text": "We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2a33782-525c-46c6-ab38-41698baabe1c", "node_type": "1", "metadata": {"window": "Here's the simple answer.  We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities. ", "original_text": "We spent $480 \nmillion  in fiscal \u201823. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "520645d13dddca9dbecb067344cea31f6a3c2b08026cc32f5d40b63a76be4195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "578f2298-a7f8-4cc1-a8f5-3f1752d40f52", "node_type": "1", "metadata": {"window": "And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n", "original_text": "Our second priority, of course, is maintaining our investment -grade balance sheet. "}, "hash": "68e22004222554a658bd3c1899fef0d72f5ae0d751d4fa1ed6a53f167e52cf2b", "class_name": "RelatedNodeInfo"}}, "text": "We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n", "start_char_idx": 1315, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "578f2298-a7f8-4cc1-a8f5-3f1752d40f52": {"__data__": {"id_": "578f2298-a7f8-4cc1-a8f5-3f1752d40f52", "embedding": null, "metadata": {"window": "And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n", "original_text": "Our second priority, of course, is maintaining our investment -grade balance sheet. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "826a76a8-bfab-4ded-905c-235d0f02d22b", "node_type": "1", "metadata": {"window": "We're going to do what we said we were go ing to do at Investor Day in that \nrespect.  And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance. ", "original_text": "We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1717898c2c566a76449990ece3969d00867c8a98e91b9016483e970de82d464e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89dafadf-4e2a-4d14-93e3-ee8f562d21f1", "node_type": "1", "metadata": {"window": "We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend. ", "original_text": "And you'll recall \nfrom our Investor Day that we d on't have short -term maturities. "}, "hash": "bb421fc2256fb444337a4d9b5f902011af15186fe91e539e39f82f830345319b", "class_name": "RelatedNodeInfo"}}, "text": "Our second priority, of course, is maintaining our investment -grade balance sheet. ", "start_char_idx": 1440, "end_char_idx": 1524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89dafadf-4e2a-4d14-93e3-ee8f562d21f1": {"__data__": {"id_": "89dafadf-4e2a-4d14-93e3-ee8f562d21f1", "embedding": null, "metadata": {"window": "We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend. ", "original_text": "And you'll recall \nfrom our Investor Day that we d on't have short -term maturities. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "578f2298-a7f8-4cc1-a8f5-3f1752d40f52", "node_type": "1", "metadata": {"window": "And just as a quick reminder, there are a couple of things which are table stakes for us, \nwhich is first, we're going to invest back into the business to drive the organic growth.  We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n", "original_text": "Our second priority, of course, is maintaining our investment -grade balance sheet. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f060a823388cfec9f80d88b1ea69705ec60caa36ee09b6f81bc773d0fc0d06f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87a53179-15a6-497e-a20e-6b107f3ea49e", "node_type": "1", "metadata": {"window": "We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row. ", "original_text": "We have some bonds coming due at \nthe end of the year that we will likely just refinance. "}, "hash": "a209e8a5336c478d13c21ed30b42ba544d7619ae6f1b212ab4deeb80c4615c50", "class_name": "RelatedNodeInfo"}}, "text": "And you'll recall \nfrom our Investor Day that we d on't have short -term maturities. ", "start_char_idx": 1524, "end_char_idx": 1609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87a53179-15a6-497e-a20e-6b107f3ea49e": {"__data__": {"id_": "87a53179-15a6-497e-a20e-6b107f3ea49e", "embedding": null, "metadata": {"window": "We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row. ", "original_text": "We have some bonds coming due at \nthe end of the year that we will likely just refinance. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89dafadf-4e2a-4d14-93e3-ee8f562d21f1", "node_type": "1", "metadata": {"window": "We spent $480 \nmillion  in fiscal \u201823.  We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend. ", "original_text": "And you'll recall \nfrom our Investor Day that we d on't have short -term maturities. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1ea3d816444dc2476f0b9e3a395d816354142765d09e75a2329c8cb1ef3874c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95f679b5-baf6-469b-9a5c-a7f955bbd156", "node_type": "1", "metadata": {"window": "Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823. ", "original_text": "But we're feeling good about our investment -\ngrade balance sheet . \n \n"}, "hash": "dcc768bb79ad3fef948bb5b8edf65977b388e71f2061a85bf549dea00b92892a", "class_name": "RelatedNodeInfo"}}, "text": "We have some bonds coming due at \nthe end of the year that we will likely just refinance. ", "start_char_idx": 1609, "end_char_idx": 1699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95f679b5-baf6-469b-9a5c-a7f955bbd156": {"__data__": {"id_": "95f679b5-baf6-469b-9a5c-a7f955bbd156", "embedding": null, "metadata": {"window": "Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823. ", "original_text": "But we're feeling good about our investment -\ngrade balance sheet . \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87a53179-15a6-497e-a20e-6b107f3ea49e", "node_type": "1", "metadata": {"window": "We've guided , we're going to spend about $500 million dollars in CapEx against \nour business plans across the business.  \n \n Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row. ", "original_text": "We have some bonds coming due at \nthe end of the year that we will likely just refinance. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6175163f42b5ffcb30f8f482f14ba370e1cb115af50aee836528508a4280d83a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e190dd9-3db8-442b-8e61-ddbecf28800e", "node_type": "1", "metadata": {"window": "And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n", "original_text": "And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend. "}, "hash": "b4b0d2b3cf9cb60232b04fbb030863d95125d52fb9d63899c189dbb5432acc85", "class_name": "RelatedNodeInfo"}}, "text": "But we're feeling good about our investment -\ngrade balance sheet . \n \n", "start_char_idx": 1699, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e190dd9-3db8-442b-8e61-ddbecf28800e": {"__data__": {"id_": "0e190dd9-3db8-442b-8e61-ddbecf28800e", "embedding": null, "metadata": {"window": "And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n", "original_text": "And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95f679b5-baf6-469b-9a5c-a7f955bbd156", "node_type": "1", "metadata": {"window": "Our second priority, of course, is maintaining our investment -grade balance sheet.  And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823. ", "original_text": "But we're feeling good about our investment -\ngrade balance sheet . \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b23fdc3684cde5dcb391b8d459d358caea9b806bf76de11831a007da35e016c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cabc583c-f714-46d2-b381-3147a05d4779", "node_type": "1", "metadata": {"window": "We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at. ", "original_text": "We've raised it 34 years in a row. "}, "hash": "aa2546f613faffb98edb612edabcc67a8e562c636439442ad6263ab6bba40491", "class_name": "RelatedNodeInfo"}}, "text": "And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend. ", "start_char_idx": 1770, "end_char_idx": 1881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cabc583c-f714-46d2-b381-3147a05d4779": {"__data__": {"id_": "cabc583c-f714-46d2-b381-3147a05d4779", "embedding": null, "metadata": {"window": "We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at. ", "original_text": "We've raised it 34 years in a row. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e190dd9-3db8-442b-8e61-ddbecf28800e", "node_type": "1", "metadata": {"window": "And you'll recall \nfrom our Investor Day that we d on't have short -term maturities.  We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n", "original_text": "And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "486c68c4c630f78de41a5f73b7696cc4f7e7b97ae861568f1df409bc8eef3409", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d64a898-89ca-42fd-95ee-014cc909c568", "node_type": "1", "metadata": {"window": "But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.  ", "original_text": "Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823. "}, "hash": "39f5cc5c4a347b2a1faabd887c72a4d6660fae93ac9a661f732c543843924ef3", "class_name": "RelatedNodeInfo"}}, "text": "We've raised it 34 years in a row. ", "start_char_idx": 1881, "end_char_idx": 1916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d64a898-89ca-42fd-95ee-014cc909c568": {"__data__": {"id_": "2d64a898-89ca-42fd-95ee-014cc909c568", "embedding": null, "metadata": {"window": "But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.  ", "original_text": "Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cabc583c-f714-46d2-b381-3147a05d4779", "node_type": "1", "metadata": {"window": "We have some bonds coming due at \nthe end of the year that we will likely just refinance.  But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at. ", "original_text": "We've raised it 34 years in a row. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75592f0d2936ffee6ef8e2bde3d70fce537f675959508303803c996883806d1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3742af53-c409-4d60-81af-af13e916285a", "node_type": "1", "metadata": {"window": "And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders. ", "original_text": "Those are the table  stakes parts of how we're going to use our cash.   \n \n"}, "hash": "137568edf19b4bd065d302e1d3bce63eef21a7eff7b481a042812a8fbda1a1ea", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823. ", "start_char_idx": 1916, "end_char_idx": 2009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3742af53-c409-4d60-81af-af13e916285a": {"__data__": {"id_": "3742af53-c409-4d60-81af-af13e916285a", "embedding": null, "metadata": {"window": "And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders. ", "original_text": "Those are the table  stakes parts of how we're going to use our cash.   \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d64a898-89ca-42fd-95ee-014cc909c568", "node_type": "1", "metadata": {"window": "But we're feeling good about our investment -\ngrade balance sheet . \n \n And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.  ", "original_text": "Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5da08dbb2c1c2a1667dbb6399082b77491b0b40d4c633c6aedef1870a6141b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd823a16-7933-43fa-893a-bd72c2680563", "node_type": "1", "metadata": {"window": "We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n", "original_text": "As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at. "}, "hash": "672abde93f424062aad9c31d956867edf606eed28e09c1606301a4cee30b32aa", "class_name": "RelatedNodeInfo"}}, "text": "Those are the table  stakes parts of how we're going to use our cash.   \n \n", "start_char_idx": 2009, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd823a16-7933-43fa-893a-bd72c2680563": {"__data__": {"id_": "fd823a16-7933-43fa-893a-bd72c2680563", "embedding": null, "metadata": {"window": "We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n", "original_text": "As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3742af53-c409-4d60-81af-af13e916285a", "node_type": "1", "metadata": {"window": "And then we've committed to a baseline of return of capital to shareholders, continuing to grow the \ndividend.  We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders. ", "original_text": "Those are the table  stakes parts of how we're going to use our cash.   \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "773e1983c82a670156d79a63bfaaf0e987e76fc94985333cccae6457cb2af007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a61e18b7-6165-4631-a952-228de34cdf9c", "node_type": "1", "metadata": {"window": "Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call. ", "original_text": "The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.  "}, "hash": "960f5cadb6f5ccdd7c7d4d13c046786fb72690ba664d94fc3403bf9cf79484c4", "class_name": "RelatedNodeInfo"}}, "text": "As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at. ", "start_char_idx": 2084, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a61e18b7-6165-4631-a952-228de34cdf9c": {"__data__": {"id_": "a61e18b7-6165-4631-a952-228de34cdf9c", "embedding": null, "metadata": {"window": "Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call. ", "original_text": "The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.  ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd823a16-7933-43fa-893a-bd72c2680563", "node_type": "1", "metadata": {"window": "We've raised it 34 years in a row.  Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n", "original_text": "As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41e7fd349161586f7ab248487428bb2f3780da1156a86a8cec6a7e1565c713d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d4900c6-17b4-488e-b62e-c095914db791", "node_type": "1", "metadata": {"window": "Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders. "}, "hash": "0a05498b8dab37ddde96e38bbcf410d79433e865a0ffb3d2f1b1668200f4da86", "class_name": "RelatedNodeInfo"}}, "text": "The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.  ", "start_char_idx": 2277, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d4900c6-17b4-488e-b62e-c095914db791": {"__data__": {"id_": "5d4900c6-17b4-488e-b62e-c095914db791", "embedding": null, "metadata": {"window": "Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a61e18b7-6165-4631-a952-228de34cdf9c", "node_type": "1", "metadata": {"window": "Similarly, we committed to buy back at least $500 million \nof shares during fiscal year \u201823.  Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call. ", "original_text": "The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.  ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8357c7d995f39abf0e652e49a425821d750808f209ea9cbf19a08cc969758fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d5790d5-85c7-419d-b586-74f191f2e996", "node_type": "1", "metadata": {"window": "As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n"}, "hash": "6790e7d915dabc65acb19689f2d6768c980af4b48ff2dfd11f95c55e6d2d4331", "class_name": "RelatedNodeInfo"}}, "text": "And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders. ", "start_char_idx": 2419, "end_char_idx": 2525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d5790d5-85c7-419d-b586-74f191f2e996": {"__data__": {"id_": "6d5790d5-85c7-419d-b586-74f191f2e996", "embedding": null, "metadata": {"window": "As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d4900c6-17b4-488e-b62e-c095914db791", "node_type": "1", "metadata": {"window": "Those are the table  stakes parts of how we're going to use our cash.   \n \n As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e5d139528d3311acb02285340445cca4fc3606df297e7f7505c729a8735637d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3816f934-c8d9-4406-9f24-cdc98dbc8d8a", "node_type": "1", "metadata": {"window": "The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "Operator:   And that does conclude the question -and-answer  session of today's call. "}, "hash": "b1026be140cf1ae8e4d43fbb8628b0b4e6d4af134f9bece11911a25a6d2e3651", "class_name": "RelatedNodeInfo"}}, "text": "Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n", "start_char_idx": 2525, "end_char_idx": 2743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3816f934-c8d9-4406-9f24-cdc98dbc8d8a": {"__data__": {"id_": "3816f934-c8d9-4406-9f24-cdc98dbc8d8a", "embedding": null, "metadata": {"window": "The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "Operator:   And that does conclude the question -and-answer  session of today's call. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d5790d5-85c7-419d-b586-74f191f2e996", "node_type": "1", "metadata": {"window": "As we then move through the year, as we assess the opportunities in front of us, as we assess how \nthe business is performing, we have two opportunistic levers that we will also be looking at.  The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86c58f539c13e0e1fa82dcb4988f16e446ced7581e6730a9e78f5a60745475d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61b9beec-2279-46d2-99f5-2516f25bb3d9", "node_type": "1", "metadata": {"window": "And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n "}, "hash": "cd1872dcbbc46296da52384a637ed3fa5bceef33a86a55636d65d5873e327dac", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And that does conclude the question -and-answer  session of today's call. ", "start_char_idx": 2743, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61b9beec-2279-46d2-99f5-2516f25bb3d9": {"__data__": {"id_": "61b9beec-2279-46d2-99f5-2516f25bb3d9", "embedding": null, "metadata": {"window": "And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40b1e34ac956061ea2431ee095a424e7c25667b272c3697ba1fe2fc2ec821b1c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3816f934-c8d9-4406-9f24-cdc98dbc8d8a", "node_type": "1", "metadata": {"window": "The first \nis active, disciplined,  and targeted M&A largely in specialty, and we have opportunities there , that \nwe're looking at as well.   And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "Operator:   And that does conclude the question -and-answer  session of today's call. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e96fa86c05123f7d6996fc6a7ece0435a8831c3462dd9193990e78fc7a093c6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3ce8038-872d-40d5-b8be-334ef7788af2", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. ", "original_text": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great. "}, "hash": "078fd8fa8eb13052cf58769683606f01799b0128be1b0bcffc46e51b01f93e6a", "class_name": "RelatedNodeInfo"}}, "text": "I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "start_char_idx": 2829, "end_char_idx": 2933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3ce8038-872d-40d5-b8be-334ef7788af2": {"__data__": {"id_": "e3ce8038-872d-40d5-b8be-334ef7788af2", "embedding": null, "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. ", "original_text": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61b9beec-2279-46d2-99f5-2516f25bb3d9", "node_type": "1", "metadata": {"window": "And then on top of that, we will also continue to look at incremental return of \ncapital to shareholders.  Nothing additional to annou nce today on either of those two levers , but we \nwant to be clear that we are going to do what we said we were going to do with respect to our \ndisciplined capital allocation strategy.  \n \n Operator:   And that does conclude the question -and-answer  session of today's call.  I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "original_text": "I would now like \nto turn the call over to CEO, Jason Hollar, for any additional or closing remarks.  \n ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ed66d7c6b55465fa0a7f848a053730d92619c585a9717b602b26aafd0582bf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e581add7-e40e-4a9e-875c-8331d9d37aa3", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n", "original_text": "Thanks again for joining us this morning. "}, "hash": "26f1945165cc4f6958abf873ae27134badd03a2ecb8a38f2c892a25d5547ec20", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great. ", "start_char_idx": 0, "end_char_idx": 47, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e581add7-e40e-4a9e-875c-8331d9d37aa3": {"__data__": {"id_": "e581add7-e40e-4a9e-875c-8331d9d37aa3", "embedding": null, "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n", "original_text": "Thanks again for joining us this morning. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3ce8038-872d-40d5-b8be-334ef7788af2", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. ", "original_text": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1f9f9bbcd4114852d4251fd1b9eb397e985c6b80f0824cdc12297ed0b36a8eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5531c0ea-cccc-464e-8e9a-1d9b4373ef19", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc. ", "original_text": "To summarize, fiscal \u201823 was a \ngreat year. "}, "hash": "9ff936f9b08e5556f8b8ee293b0b8dd74efc080fe352ed1c812d9795e832feb0", "class_name": "RelatedNodeInfo"}}, "text": "Thanks again for joining us this morning. ", "start_char_idx": 47, "end_char_idx": 89, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5531c0ea-cccc-464e-8e9a-1d9b4373ef19": {"__data__": {"id_": "5531c0ea-cccc-464e-8e9a-1d9b4373ef19", "embedding": null, "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc. ", "original_text": "To summarize, fiscal \u201823 was a \ngreat year. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e581add7-e40e-4a9e-875c-8331d9d37aa3", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n", "original_text": "Thanks again for joining us this morning. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3b4fe687c4df8277afb3f89d57d019c726f3d462342522876bf891269403cd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c37918b1-dea5-4c85-bdc1-94ca0cb2c9aa", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call. ", "original_text": "It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. "}, "hash": "f30827ebb923c506c4ab563e20d42f5272acb869d6611528a65a5d236c9a7753", "class_name": "RelatedNodeInfo"}}, "text": "To summarize, fiscal \u201823 was a \ngreat year. ", "start_char_idx": 89, "end_char_idx": 133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c37918b1-dea5-4c85-bdc1-94ca0cb2c9aa": {"__data__": {"id_": "c37918b1-dea5-4c85-bdc1-94ca0cb2c9aa", "embedding": null, "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call. ", "original_text": "It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5531c0ea-cccc-464e-8e9a-1d9b4373ef19", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc. ", "original_text": "To summarize, fiscal \u201823 was a \ngreat year. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3237676b2fae90d5af3c7e5a4441514d1ec76faeb8fd705f8c78b6e2420fa6cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ea36d1a-ac47-4964-9cea-219e415aaa52", "node_type": "1", "metadata": {"window": "Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "With that, thank you and have a great day.  \n \n"}, "hash": "a484473674605c6b16fc1dc85564a54a76d12be073472bf636d67d78e2860e72", "class_name": "RelatedNodeInfo"}}, "text": "It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. ", "start_char_idx": 133, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ea36d1a-ac47-4964-9cea-219e415aaa52": {"__data__": {"id_": "1ea36d1a-ac47-4964-9cea-219e415aaa52", "embedding": null, "metadata": {"window": "Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "With that, thank you and have a great day.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c37918b1-dea5-4c85-bdc1-94ca0cb2c9aa", "node_type": "1", "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call. ", "original_text": "It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b63b6f771b856b31d4a8406e759286640a020b76c9b6ae53060eb02b7cb1069", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a77bdcb-2aa6-4e60-9015-4c7fa63c81bc", "node_type": "1", "metadata": {"window": "To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc. "}, "hash": "9cb76ffba9d711df5d3cd4d3370c8e58a928efc5f2f5ee470f6e30791236336b", "class_name": "RelatedNodeInfo"}}, "text": "With that, thank you and have a great day.  \n \n", "start_char_idx": 236, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a77bdcb-2aa6-4e60-9015-4c7fa63c81bc": {"__data__": {"id_": "6a77bdcb-2aa6-4e60-9015-4c7fa63c81bc", "embedding": null, "metadata": {"window": "To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ea36d1a-ac47-4964-9cea-219e415aaa52", "node_type": "1", "metadata": {"window": "Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "With that, thank you and have a great day.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0186ca2e76c36174b55fb2b77734541dac4cefb0e73da14504d1a43b5e3710a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f422d96-b81d-4668-a4fa-d59a3b2be891", "node_type": "1", "metadata": {"window": "It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "Earnings \nConference Call. "}, "hash": "0416e54462f53f6ae8671ac3aeea9866e4562dc39e298dac8a6d75b78c918e13", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc. ", "start_char_idx": 283, "end_char_idx": 376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f422d96-b81d-4668-a4fa-d59a3b2be891": {"__data__": {"id_": "0f422d96-b81d-4668-a4fa-d59a3b2be891", "embedding": null, "metadata": {"window": "It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "Earnings \nConference Call. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a77bdcb-2aa6-4e60-9015-4c7fa63c81bc", "node_type": "1", "metadata": {"window": "To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32added01d5c37a0f838830ed86eb4a4b61afb6b95dac2c5975bfb810ce6737b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37aff1ef-0106-4eb9-9d61-31b1aa1f5183", "node_type": "1", "metadata": {"window": "With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "We thank yo u all for your participation and you may now disconnect.  "}, "hash": "01243ea8389ac70e176b4373208771b016fe81e76b27139b0a59f1812377a7d6", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call. ", "start_char_idx": 376, "end_char_idx": 403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37aff1ef-0106-4eb9-9d61-31b1aa1f5183": {"__data__": {"id_": "37aff1ef-0106-4eb9-9d61-31b1aa1f5183", "embedding": null, "metadata": {"window": "With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "We thank yo u all for your participation and you may now disconnect.  ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2762fe12dfb9c1bb6cd2ad60d14e862c3a74941c8826aee01b1bababad723df7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f422d96-b81d-4668-a4fa-d59a3b2be891", "node_type": "1", "metadata": {"window": "It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond.  With that, thank you and have a great day.  \n \n Operator :  And that does conclude the Fourth -Quarter F ull-Year 2023 Cardinal Health, Inc.  Earnings \nConference Call.  We thank yo u all for your participation and you may now disconnect.  ", "original_text": "Earnings \nConference Call. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f5dfc9034d9e95d516f2e37fa164a53f03f48e5a96776bbce1a7c4212e7a632", "class_name": "RelatedNodeInfo"}}, "text": "We thank yo u all for your participation and you may now disconnect.  ", "start_char_idx": 403, "end_char_idx": 473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"88da5561-31d4-44fc-a4bb-31f9024da8d5": {"doc_hash": "a66bc9baa0084bf0089a3a24d84189c2c441955027cfb8bcf4b3c6da4247e0e1", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "6e2cd6a9-e422-4503-aff5-44df60ce4646": {"doc_hash": "5001a3e35c92adab185f88902ac326e007807db2920a3059f9a52a7edb69b44a", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "8e87ae1d-c5fb-4160-8249-7a6f6144c300": {"doc_hash": "1b137ae33b12be975b4020dfe9e291c4632879177e8d062a64bc8c807eaa8df9", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "be8c35f9-ea58-466f-b3a8-935fa1801e23": {"doc_hash": "7eeac1f1baf000430092c9d004cb9574c0e3b1d7553100159cd864b9f450965d", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "cba687d2-bee8-440b-8f50-710c2733fb82": {"doc_hash": "74651b7f657d8c8bcba33f83b9704c606af7cc411569811b2c578be571dc3c08", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "23093277-e8ce-4309-a269-e89f1b1ccc94": {"doc_hash": "a29ab8ae39fbedc83ff99192b60529d5474bdcf729854c3ce3841e674f1512c3", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "c9915611-4e09-4b1e-8c84-240039a0ff75": {"doc_hash": "6076b42be7d365cf325befb310c7ea1792087862e9ee3ddabfc8380be5c73eae", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "427fe606-c3bf-462e-b51b-8ae9b85dc6ab": {"doc_hash": "77276e63327ad3ebb96eb68dbaf68c33b950bbb28309a31d9e57ced589478269", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "0d32dce3-0da3-4924-b074-363556d3fb18": {"doc_hash": "5daa8665cbbd503a42d51d4b298db2dfd7cfe74a1894c4bf0bff7039c167bebf", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "917d91d7-38d8-4b37-903e-9f23c37b8477": {"doc_hash": "0d110e6339c20e8b6cc0dc9c577ed8d7930619332ab990890f5aa943a5f1cb3e", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "42d28cfd-2db0-4575-9a0c-53b4d55ba7e8": {"doc_hash": "d5b1d2d1620afc4e6cad5d92302f3bb0c68ed6ef513e9ef8626213e98e3e11ad", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "5ad7282b-5036-435e-bcc2-dd057320ec54": {"doc_hash": "4f8fefd06f48b70230c5887f10f4d02d2895200d1227ff6d79f2a009f4b96b19", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "eb472fe4-9dbf-4aa4-90db-11c11807e981": {"doc_hash": "3c07603d9d6e03574347eb03e30c1bb721c0002e09873860b1da48ed54016e01", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "a5af57c8-dc3d-434c-9396-25267f5332db": {"doc_hash": "a51d706d11948ac7a39ed1fd6f47f92e6f70bf61c6a2de16c1f508e345b66826", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "1ae372d5-f841-4cf7-8af1-ac031b9185f8": {"doc_hash": "c15b4065c8daae2fd2e59b4d6d545fc26729c5af7150a2669ef40b273c9075e3", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "205f8030-c27d-40a4-9eb2-c71787bfac5c": {"doc_hash": "33a3e0874f00d3b4f99233daece290754ae10a3b4afabcef240e528fb608243c", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "05be60c7-fe8f-4a26-a8d1-adb94e239f79": {"doc_hash": "42e85720b4e8a29f73a0b1ad2f0513ecb5d8db1c84dd326eadbc650c0bd047b1", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "4ef99ac2-1280-4b5c-b53b-8388160b0f8a": {"doc_hash": "efe63e525a80d424467fceb4f8d91dc3d7ceee7ae5259462e7dbed53651d844d", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "de8ca352-0e50-418d-8c0b-a0d0b285fbad": {"doc_hash": "f544a20a233c3dd8d157d4721e4d7701cc6ec22e09bbd2e45812a19defd09430", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "1b59db2c-3a98-455f-85a1-a8b77910ceb7": {"doc_hash": "29d40833622a564fac155ec4710e24f1b95077aa2ee9b32cecb6fd05643842bf", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "bc511975-e2d4-4ad5-87ba-da3cab827d2f": {"doc_hash": "23fda5ebba5264c7e7a173be65db4116a04b34cf9534ccc0728c80a326359a7f", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "f0bae8ca-c0c3-48b6-bc0c-5ce0758c09b8": {"doc_hash": "57393072731061ccb44bf8511e5591dddd0267c3d53caca8ca9cf3913d758e39", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "c905ed45-62ca-4d5c-8944-8a57d2b23de8": {"doc_hash": "15ffba4e84faa0d31b2501dd1029788c0edab7d1af78791a9512ace1dce28f1b", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "3d03b2e7-ddbf-4074-a4bf-d5d04ed5d076": {"doc_hash": "9821ceac9ea17ca9b080c63aa8ccfc2c429f6a99e85af04b08b1728d14e55ecf", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "72684f76-71ba-44e6-a292-7dfe6e8cf14e": {"doc_hash": "a36c91f8a2a10e63dcbda81e8402dbd0e51f241793184ad8969c6ababf43caac", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "e59afd44-9671-4d27-b439-d3c036cae57f": {"doc_hash": "fa0799c0a9ea27a2883cb8836c63d4fe1e04c7a2bf03a8624f5736f1c7185697", "ref_doc_id": "64802266-2d8d-491d-951b-cc5ea8f030fe"}, "166b63ef-9a7e-4d46-9fcc-841fa6e01a22": {"doc_hash": "d6339f0046b1d0766944184e6aa1f14808a1780ffa3250f8295b9ff14ca9614a", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "f5078a19-a2d1-479f-b1f5-2a34316db517": {"doc_hash": "8ec1f10a1592526525bc50bea9a6bdeae7f6f736644c8d23a1022e6d03fab93e", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "d2e066dd-8c5d-4636-a3e2-9317ded7bcb2": {"doc_hash": "f333b927b7b4802f92d7ec5cfcab0a2ab0b652540a2be8ffb4b1e8816715b6eb", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "6e97f9bd-edeb-4475-91d1-cdcfc0ce468b": {"doc_hash": "9fd2087bf171043942c98d3f012f14a0ed66ff644dd07ae7810d1960df5f6a1c", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "3c82c188-f51f-42e8-8bcf-a988969c87a2": {"doc_hash": "6945874bd90485ec32f451e289f72ea6acd9188c07080c99a51a41ad80c77339", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "0eea32ff-c933-4843-962b-566559975def": {"doc_hash": "fcb56c3c870a348348d52d5488cfad3fb422f0f7900eae97b70573837376f82c", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "515272ec-c36e-4369-a481-9cdd761a6ff8": {"doc_hash": "cf766ae40b5ed9894e95446a416761eddc3c57d246d1aa187151ce42b7149d41", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "4249c533-9f6f-494a-b8ce-fdba82067239": {"doc_hash": "76a1761ecf8fd04f6bef3ec8ff3c5fc81e8cf0aa6a98603171e708f584a12a69", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "d51f7a70-e11d-48d7-9d2c-19dbcd1e8305": {"doc_hash": "18122477ccb4d293cb9f6749a2196b7c80a1e66ecca2e7ab45dd28b274206593", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "bdacd99c-60a8-44b8-8217-6700cfe81252": {"doc_hash": "f97afe3f84367c438f70d90393d9c25ae629b83f803743b1d1b38285b0c33be1", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "701401a6-55d0-42db-ab9e-41513da4518d": {"doc_hash": "b136347dbfec70e6cc886d479bc0f84c4b4c86a9029f1219592bde3b055e5fe7", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "496f493c-121b-4c84-8aff-79c9bee41817": {"doc_hash": "0d905a88c5360e6cba0418bd2fce5f7755f5e18f447a1705beb39ed05f1030b1", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "a7a3949c-9be4-4c8e-b58f-05d39903225b": {"doc_hash": "effaae59ad4b5ef5de152c493e33a0fadf78f79612ef124b36ed72c2f482aaca", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "eed708d2-a584-4820-aefd-06aa75e1c2fb": {"doc_hash": "b478d30554bd361e53e8e16c148112f0f21d43fc8e355c230aa37fb407fb4c40", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "298b7bbb-3ed7-48f9-81b6-d31044f77a64": {"doc_hash": "db1493be7d23d17253dabd4a11897637bb13b4c3631ca9b7ed9afcc5e263a8b0", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "c734d1d7-1b52-4a22-a6fe-b351433e0402": {"doc_hash": "9d9c32670c28cc4f6f0d7045ad9da5484a155ad1728d574886c9a31e46707754", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "e4204b0f-e2ef-473b-8668-2bb2741e0c24": {"doc_hash": "f9ddac6f44144ec956a2ee1770106853fa91143a1573ee2c15e35358aff66721", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "4e528811-492f-4dba-a03f-52d382c00d86": {"doc_hash": "1aca043424918555f566913278ec83613d4bdbd8d2bdc7e4ccf5d20cddcd40bc", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "a922a572-68fa-4077-beb2-874a4e91445e": {"doc_hash": "c694020b28cdfd1bda142ca3cd2d485d71ecbb6acf243cb906e913f01e174254", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "e8681dad-339e-45e7-8fdb-76ada0fcf283": {"doc_hash": "05e9b2889e8e99a039479a89de5daff39d97f15b14c14601d96112f8309bb924", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "bbf2d342-f9bb-4aca-8bf4-15092edb6b10": {"doc_hash": "f9e8bea2319293f2deab359f11c43fc1b05a1590afc55a8c6f906513f9a9bae5", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "6ba345bb-0379-4987-8446-e5f2e76deab6": {"doc_hash": "cbd6bc12c4902423e5a635241a02ee50cd68cc2fae5ccf53b4929ac8adab3176", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "a5931aad-e8a4-4743-96f2-b6e86d205b12": {"doc_hash": "a7d9951d83ba3c77c636e59a3b81c3f27ef1d7a69e3ca609c02a7f6d20682d7a", "ref_doc_id": "89727101-48ae-4724-ac27-149dad43c9b4"}, "9477ede3-70e0-4693-916d-494c7167e393": {"doc_hash": "101e631929de9d95654a2e939d254495394f6516b5592c86ca2b9a56f00f34b3", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "aba2fd48-f8ea-48ea-94b6-d1be324965c8": {"doc_hash": "44464f378c399936d6f3a04d0869399ba16537b741f096adc92acbdbc61180c1", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "68b44d40-1ae3-4850-8023-a81b572f2256": {"doc_hash": "40357faef8b86c2525f0a766db5b4ac4342538d6d2cf18481eb682b0c5c60df0", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "f3b8fd27-e554-47c2-9f9c-88ddd76c956e": {"doc_hash": "0e3c61bc4b41516397250d28991280bf8e67bfc140c6f1b181de089bc483b5d4", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "f310a3c2-5594-40a6-aa35-d5cbd5e7fe27": {"doc_hash": "a3265526c4da80d02017446d2cb62c318ff6fa4df623396330ec831f92242896", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "94249de4-a430-49ba-83d3-97a53a48befd": {"doc_hash": "0c4cb4831c8b2cfa6c099e1448873280c650e867ca592ef9e5fae5ef77494146", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "c2da952b-6bca-46e4-bacb-ce2400aa64cc": {"doc_hash": "2d5df1d8d8e927a4582271f0ff22490430980593fed1151b9bc57ca1f0bf903a", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "8c8ec3f2-b4cc-4abd-8f3c-915af0a6bc07": {"doc_hash": "7bb54578b1afd6a2eab24e5cd85dce91d265ba6d29e4addb6bbcf43d64a380a9", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "2eacadc9-0433-4d48-b61e-7836fb5b5fce": {"doc_hash": "44b036e583a6a1515520360e40c3c8241af45209bf7314f34cba201b9f17bc7f", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "9bcb4f92-dc41-4672-b450-0a8d0b6e186b": {"doc_hash": "71c2e0ad4dcafc3fcde9111a1cae969610ec80cd961e7e3a58e80de47dcd36b3", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "5feb727c-ffec-45e6-97ea-7d8e14abb7f3": {"doc_hash": "1feda5cf11cb78d80afb778d34105a27ca86eeb0278c8445a764332268100f32", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "4b8e135f-72de-4f75-ac5d-dbe9897d730a": {"doc_hash": "70a700932e941982678b8c1f841d175e8401967af3c1411082cfcf90a00beca4", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "2e2da64f-e0a9-4289-b8b6-81dfc385c65c": {"doc_hash": "4a7b7bf79c7bba8968c4b6e362493c76704ca2e6753643d2815836b2e95f948b", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "810eeaa7-ce44-4909-8f69-08f2ece43762": {"doc_hash": "f6c0e743b833f1b135f8376485604acebd6114320132f9fff2d025026bba2d9f", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "7230ccba-4d85-4302-b5be-a39460476a13": {"doc_hash": "9726b00c4aa994a4a1379e84b3b917a147a1195c9a9568ebc49005fb343a5c73", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "0cf34444-fd12-4416-85a1-9fde60b51212": {"doc_hash": "d53bed82f2f471191f6cce17852bf49e2bdb51edbdd3a3603aaca8b536660cec", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "3f7ff235-6133-4602-a875-7ee53164ce90": {"doc_hash": "7a760b38cf9bc91bfdf7f3f43e9596d8fe9a503ffc5970105e33c4eb8b39d98c", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "1b57cd05-297e-443e-b587-6f190f09810a": {"doc_hash": "ef612a4c147ab004403a8e09d6ac5d6fc2254e80408f8dc402b0faac0a75d17b", "ref_doc_id": "b5c9377e-27a6-46c4-aade-5fbe085d1d5c"}, "d5ccb620-9390-44ba-b5be-c33e37aa1e25": {"doc_hash": "c898ca8e7aa4153746e5c5f9d289a361186418efffce0248095f4c5ded07e927", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "d0d4a4e8-7835-41cb-9585-c30ed44b6cb9": {"doc_hash": "ee500ee9e3ccff66248813e27b095f3b445851bd8407a28368f3960d4cdd0224", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "17a68372-53cf-4801-b78f-e652f16a4c5b": {"doc_hash": "e07d1d2b8ce41f9ba1adcc8ea6beaee8060e1ee5aae58526b6716c8f90afc104", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "c6eaeb18-9326-4db6-8f46-1743ba2e94ae": {"doc_hash": "7c97a28fe2d8dcdcff6016eb1b435b53e871fc11a85aa3f2d3f4509426e4c7e4", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "a71b7f4d-6ec7-4f26-9199-81688b358d2b": {"doc_hash": "f85315036f0b17a9ba7d2dfd4b86042efab0c14b69104313679d370a411ab6eb", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "93ec2ed2-7a20-47df-97a8-e5bc9ed2b813": {"doc_hash": "d021abf317888a3076657bbeb8de4aa685af07284a1e56dfbac15af4641d9f82", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "4957ebc6-7375-47aa-92e7-568d224a0105": {"doc_hash": "d1791816d537f78fe97abd7f1964ccf36f04e8565cdde73c2ebd24638fb98e54", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "66296142-3ea9-4693-b2b8-3de48fc7ead8": {"doc_hash": "8eb581bcc24e43d7348522e8ca8f5c319d6e483141327ae58afa83cc39a78c0e", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "d21ed4f5-d7c7-43ca-938b-a88fe9e83a2e": {"doc_hash": "994db891ea756882c723f83561aaa80d987babed7765db98f7dc8ab24e7b53b2", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "54b4afec-538a-47e0-aeb7-b10387dec56c": {"doc_hash": "ea942e1c3f8ec74d0db45e3750845ef206279515aab117c2c1403cbdf93316d8", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "303a45e0-c2d4-45a6-81e7-1e62bf0c02d1": {"doc_hash": "3e4e958fe56c4b64036e8dd74c35bb7a36318673ecdca4fd91eafb0d58e0e9fe", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "cbec174d-a558-424f-9dac-183ed63da9db": {"doc_hash": "cbfa741408f6f8254cd6c1b062886cd9a141f9dd625708a8b4357d23405c9781", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "1bb917c0-0111-4b7d-b5f6-f81ce3ff94bb": {"doc_hash": "d1ba4c337eb452fc8e375dd34b4cc7e883e0fc842cd54495cd123f86c1e2c701", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "dac417ef-2c88-48f8-bf8b-e74c9e17450b": {"doc_hash": "a8168051e69d86e9a7d120af52db53622e28198f8915ca12096f07b7ad22d0e5", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "e9668c0a-50c8-4e12-935b-e3da688d0571": {"doc_hash": "317c9e0a49c3b6ba09f7fbeaa714d845875b136c2c8026ab96d0b1235149a412", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "2a968db3-c1a8-473c-8552-aeb2cc0be92c": {"doc_hash": "d767165e0c9a8da9e5517a3e429c0d987f53119a53d28deb05b403234d2941a6", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "039a43d0-3a80-4dfd-b5a6-865c5805d052": {"doc_hash": "f0292961fa646ecc480a1a6645b21d2a14fbdfd7c9242b15c845b44f8e28b560", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "9a608b3b-7906-4156-acfc-34febd97ab85": {"doc_hash": "e6741f57d2ad094732db3629b199bd63cefda4106ee1917a69abd6f98d0611e2", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "e95e9fff-78be-4b45-b2c5-74b2fc03c77d": {"doc_hash": "249d2c521304126ce1f7c37b10a768a4050a49153b9ea2872b384fad31c0dfca", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "2ae75bd2-2843-4625-8bca-608f5cba6a80": {"doc_hash": "077f3311ee7d2dc787784bb60bfaabe96f4336aa4fa4d59d3c083a38ae5544a8", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "413e2623-6363-44dc-a16f-f5e09d1d5c6a": {"doc_hash": "b37d2aec9ccb7a5f6a00b6a6339c038be031006194453a0f681799b2cdf05e56", "ref_doc_id": "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809"}, "dfa107dc-1a42-4e88-a3cd-033b20cd0adc": {"doc_hash": "da54deeaf20f709a0586b571f7350872c92fb73708f7054a0e8b2ed77053dab5", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "2bc4e15b-64bb-43df-9f07-e421bb90e1a2": {"doc_hash": "64fea267a456aca318ec16f2e1cfb34a30bb050ca4fa79187874c562795737e2", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "43757f29-9c46-4c9e-8d1e-99cef10bf522": {"doc_hash": "c960ead9b8213c27c7941574c9216b86ca74ef0128bb86095c98b40b00fc6941", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "6ac71937-96e4-4830-9780-741dc0e61a27": {"doc_hash": "1430bb2a4fccd1049a77d5c4059931c5d073f9f38654b10396e1e05bacf17546", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "ea31b501-eba6-412c-941a-0ae6a7db57c9": {"doc_hash": "059b304f63ea5abf96577799d49692703e5789980276a59317efae27e05edd17", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "d5503f90-2bd1-499d-8d0c-0cb490ad3993": {"doc_hash": "5067331db05172bac6726fbcf11ba5403a0d9ce1290fa5e9ab11447d061273ad", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "36cabcb7-e0a7-4711-baba-3be6fceaffee": {"doc_hash": "0c87259d79c4ad964eea9e012d4bd8e221769545a63dd72c14d13a50d783233f", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "30fab555-74f4-42f5-bd78-28d5595fd877": {"doc_hash": "d0b86254374a34b1b758042903e754c2ee7fb031f2c7cfc3e177293bb538f757", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "fa648c58-6d82-48a2-8129-61b57d4bcdd7": {"doc_hash": "827982604af185599368d49eba3400435919d63728f02a9d1d6bfa1bc939e336", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "24bdd1c5-fa2d-477f-acb3-7865b9fe1403": {"doc_hash": "90fec14292c64b6179d2668bc2d10a5b3025db0e180b9ff0f36fe304f1810f75", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "85e23d64-bfa4-46fe-823d-80d3dbe4985b": {"doc_hash": "64de0c40141e6dc44fd7cd7abb744526b94838632ab0f965c2c1ef88e9a7d785", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "5084410c-c200-4d36-833f-3012139888c7": {"doc_hash": "de858490e47bed357e678ed8ef04fcafde054507433673b97209d3bf7679054d", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "63e5ded4-9739-4ff4-8f07-d897a17dc707": {"doc_hash": "4e542a4cdebc14aac6fb983229e18799a1289464e461d648ce8025c47c65a992", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "76920d0f-a3e4-48b5-9c5b-b9e44c6792ad": {"doc_hash": "45b9f35dcfbc61d6c5758002147bd5579b2ec65cedc8d413d5879f95945fe034", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "582b388b-9156-4ef5-bc1c-854d0192abfa": {"doc_hash": "b033aa409b48605cd67734d10da5168e694f008ac7cbad89189a0de45f840d65", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "009dd424-b337-44fd-a353-cf0460f16909": {"doc_hash": "e66037db2097a11429bbb11ac47ebe823b0d1dadb2c1367071eaf519564e1411", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "8ecdcae3-1d99-47eb-89d1-925cf0ba6ced": {"doc_hash": "c44dd08af5aae0667fdd340cffd32a14a37b4f41ed8eee63f75c659a621c73b2", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "ab5a66fe-efa7-46d2-8972-869105e580d2": {"doc_hash": "3906f264de2c08e11381a808ea38df907b5b3b863807d2ba6961d2e12dae4f52", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "ae901550-525d-434b-bb1c-eeae49d28bfc": {"doc_hash": "89f14eb760d6416e6763282aafa34383b4b36d76ac385fec39117f79ce7a854a", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "7d8ed1b2-e5cc-43af-8085-e5b97dd00590": {"doc_hash": "5099f61cd489755ab4813a70dd1391f7be6a921e99d496e6b578dfcb86e0d15b", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "903b2121-9f48-45ed-91d0-44cdb113b1f3": {"doc_hash": "9406a3bb67ffc31a0bef070d939a74818bc64f758bd0f8c262e1253beb47d28a", "ref_doc_id": "3101b821-a68d-4b32-9de5-866a93fd0c59"}, "d169ac13-3016-43b5-bb8c-30e27fd50300": {"doc_hash": "fc51e5a40914e24c6c81ea026879bd8936f667bceb1ce70e806eb156d90b8f24", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "0eae0238-20e6-4b39-b7f5-acb4be36b288": {"doc_hash": "ac1f8254fe5ab239acb7a96a332919fdb04bd3b9a2c05f15916bf23ef46d5403", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "8e3788b9-cc70-4e3a-b06b-edccf696b23a": {"doc_hash": "a6f7b52798737899e9a004e34d6759c5033c8b4bb7348015d0866c6ced624a76", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "ca1d4ad1-b8c0-4904-88c3-4d3c3164a536": {"doc_hash": "7aeaa92f05019ee04571b7474076e5755eec4731a8fc979e1c23d4b4f82c90e3", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "3c61208e-040c-4cb7-968c-7c895e50debd": {"doc_hash": "62db4e9f429af71fdf4c6e95cc674f52de0a87e233566ab99e7fff3a0ff8617a", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "e9507469-333e-4c6e-b45b-edf3ab438e36": {"doc_hash": "aac951d6f0cade7410a1d4133ffaf4f97a51974a77239da56800f46e5affc2fc", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "43f2e71c-8d4d-45a8-8d50-656c7389a198": {"doc_hash": "a1261be5f39e98128cec29018469edd5d7991030e4896eec7e9a3c8c839883e6", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "24e47404-edb1-45d2-912a-f71c80b29416": {"doc_hash": "64a36bbfce4030d7904dc3eab9b5e6432b9fffcac8c03fef34ef52667d4b4c0a", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "c68c68b5-e242-4a46-b245-701abd2daa21": {"doc_hash": "460a47411658f0c1b48800a8911f0b65284ea21ccf9345848ae95d99c2457cf6", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "20f8ceb3-671b-489a-807e-195fe926871f": {"doc_hash": "2d25cc8603e0389323f5c5508efbe8942d60878b27f494321f88e2befac8a805", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "6161f968-d565-40b4-b694-64989d6e554f": {"doc_hash": "238591906f741b0ceec4ab6b187faf46c25d11d3d9c19e31399d0bd977c5036c", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "aa802423-d3f7-4bcb-8046-cccbe5958639": {"doc_hash": "c92639d501cb2e1e750af17a9105bece475566e5182ce6915af6b76bb2303a60", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "9ef56dbf-8817-48f2-84c9-dda7278bf258": {"doc_hash": "964d15c49950cf5f00450156a54c9be3dc81d061d36ddbfcc4c59c4f8e33b6ab", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "6f983785-1bba-493d-8759-15e9aa145c31": {"doc_hash": "1810cc5dbefed720187509abe80b6b521400a2166cbee2ef02394a8b646f210c", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "e98f7dce-8c50-4095-8341-04585798811d": {"doc_hash": "432e76103aed5bb0c996152240d4f5ebf41d43f34f00a040a4edc912700a29b5", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "644ba488-4644-4c1d-b7d2-d27586cab05c": {"doc_hash": "438bb4e49ffc6652efcca05fede7a4861808aa337c3646a21bbd0113666f569e", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "b3942536-000f-4d64-9dd2-80ccd74a300f": {"doc_hash": "fe40cf9a607e19d59f77028bde2b0c6fb5144ced98a6d9a9785d846168a7c73a", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "0c38f6a0-4fa6-418c-a1e7-4feb8012cf1c": {"doc_hash": "c51033e7b29f760f92bac0a079b95b49c5608d41d9ca4fde4e188cf5833b5014", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "d9d15344-245a-4899-b32b-87f7abf9bdf6": {"doc_hash": "06b4a667160bfb4157694062dbf0f78db0fd8385190b9fcd8bfb65dc75a789e9", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "e2f1c861-06a0-4079-8b26-8a922199654b": {"doc_hash": "3a5d1f56452a8d8c3dcf747e8223906bb6003c624e10d21272265e16037ea8a3", "ref_doc_id": "d755be45-a796-4158-87c6-ee9e872de8b5"}, "9bd256b5-b63f-4732-a9ae-c101380448b5": {"doc_hash": "2a00e98ba0aa500475b62511e6a237f091a5e152befee7be0ed1423866c3eb1c", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "a12ffec3-05a8-4189-b17b-765f85a8a9e9": {"doc_hash": "c5672e2ce18b8a7bad51cfddfc730715477334f514cbc3f8d3bb179df5e8c6ea", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "60441b74-8d09-4a3d-956f-5817d4d90bad": {"doc_hash": "4e49e1ac146d9f59853bdb330913d8f7951805f181ae682d367ad55ffd783038", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "4b29fc33-4272-4eb2-bd15-7a6715d9ee50": {"doc_hash": "b75de621a7a8e531691bc4495a700e3999376a6834d8025a93154f482574175e", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "56827d84-4870-4a32-b6af-92a760db2f83": {"doc_hash": "bcdd414c86c9914305cd5169af2acf926654233f0ce4fc822f878eace6ef63a4", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "e5d61093-2145-40a3-8d60-3ce4fd3ca80c": {"doc_hash": "d759276a2088f8cbe2ce051cce2266a395fb2e5c63168db8a79780462831891f", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "9ed78569-4e0f-4f54-ba35-6e79b80921de": {"doc_hash": "3d9bfe6c337845a337684684cfc39604d47aa7ddac70e25694c61e3979508301", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "ed3e882d-f1f1-41bb-92c2-28a169fcc427": {"doc_hash": "0dd7d0bc19955df40ee284558cfff14c7bf1ed84d434533cee8940e94dade5e8", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "95885a67-5975-47cd-98a0-ccb5e430324d": {"doc_hash": "f2f2ea3b3a341b06fdb182ef96ac89762226bcd8099af4280fe7703650ee1985", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "ccdfbcee-4cd0-439b-8845-51730a89fa1a": {"doc_hash": "03f4ffce1dfd8a8dafaec6cb18f278c7ae3e812c5b7cb2a730180e9d393c426f", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "74d331ba-baca-4416-a4cb-abf62ed789c6": {"doc_hash": "231450db6dec8e4ce1421c0d7aefe899685f25c47b4956cbb8a5f6652334d4de", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "9fb47b4f-07d9-4b6c-bc98-213a83e379a6": {"doc_hash": "89ac2d9cb353ced4c4c57c70e333d28795097ece28e67ae5d3e126fd023824c9", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "b265f6cd-963b-47b4-a2dc-2c22251086f9": {"doc_hash": "2c08dd030d2891661c90e4979a7b7a99fb59ca12ec3e3e650d7aeca30460ca54", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "9db3d0a9-1819-4468-9b36-28f603133d86": {"doc_hash": "87d14cbc3fa59f33da61cc5154afec054569e43cb54d987a005d865d0da5e54f", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "6a9b5ca7-5999-47b1-bbd7-aa86b5c9f846": {"doc_hash": "e2af6b718bf40d8e2895c029f9a8f1b0deff078512b8538a51129ccf5f5bccd8", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "ed1cf52f-9cb6-4115-b33c-48c01dff6fc0": {"doc_hash": "ec205b2e69e6fd98ccd60a1e4b62358392b733b7989046b5f1dca2d2e0e3c3a7", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "73f6d7f3-b9cb-46fd-9b4e-72785e761d93": {"doc_hash": "dabc408d53f30a576c38e2faa9c3791c987ad6f36df2a9f8e6709f80fb63964a", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "bce6ae60-570b-4207-a697-42a23520b943": {"doc_hash": "67d6d40596626bc7f3643f22a6e359da9e753a19977ee23a30864cc54daae7bf", "ref_doc_id": "7148d394-2e3e-419b-b7f5-454eafcf9fef"}, "63268705-9624-4a76-8639-38d2793ebe1c": {"doc_hash": "85ea23ad95b24f116a3b6200f69db99617d4d2ec6dceb3d01188cd0878aab3e8", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "49476bc3-4d31-4b27-a9df-587a9cf6bb68": {"doc_hash": "6190b104bd1f7646c0b7e3b9475c5f2cf953fed41d0910b5abe3eb8d444501cf", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "6c71a0fe-7e6f-4a3e-9b2f-3964fe6fac1e": {"doc_hash": "48156f5d5e3c642bc11bdc32507a8806d1d16a3b989e9e02d800e9518eec3360", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "5030e6c0-fbf2-4509-8fc9-8b9aff5cced6": {"doc_hash": "e89d027a6222436dbe171e2c79d1ea674b793564951cb9386cd7fd4ab300b87a", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "b19c0ca7-41cc-4f2e-a1ce-bdd2ee12c994": {"doc_hash": "89d5560fed8f13404c0ef4c579658319b8ad3b4ed58b1fc3cf0b73ac09e7c3bc", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "9ca61a85-1032-4ede-8117-bf76dfdf53d3": {"doc_hash": "e63bbb43feed83fafa460b4c66d967b9c042243c40019def1eed329378251bc6", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "a8680e73-fd21-4b4d-b37e-4bbca6f28825": {"doc_hash": "8e79c4db41978b03674c6c052d3d69654894738b7ccc8aa96277c93f8ac33d79", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "25954ea2-7485-4b5b-94a7-ce3ad65d10ea": {"doc_hash": "ea4e9e1166c19222be862896e779b28ac9526b3ad93da48be70cd6e0269fd5a4", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "f9943039-9864-413b-bd41-01de4a434964": {"doc_hash": "5d7415e7c3c5c148c89dca4aafecbf9473b1fdfae442432f5d81d3e0898c0654", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "4e48fd71-bc99-4345-8557-6935e60ee1ac": {"doc_hash": "546fe4d966257a628cea7e828eaf4b9c8e531b55cf2ee5e621954a6e8b18ccbf", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "03618b23-cad9-448c-8b19-092fd7a44e30": {"doc_hash": "39ad3b46243839ef86aaac7c875049743956fa8c9f7cfc3db55fe87f858d7f8e", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "b16a1e49-c49e-4f63-ba8a-db1af107a74b": {"doc_hash": "02d1856277b6bc20dacc486b9518e1b516f7d80a022b330768ef6c20032c14f3", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "8ebfb7a0-4340-458b-85ef-ac782b54f3c5": {"doc_hash": "31d8eddcca6df432038850ef6e32b100a71b5f219e1ad2f7b1d9384d42d6bd93", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "d0aef6e2-59f7-4db5-8f92-4caa835adb49": {"doc_hash": "090216642add9f7cc99b429d9f4a96b614759f9ff1e1270bf07a82b18555f700", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "bcde74a7-b781-4a5d-bda5-7acbf38d5c3b": {"doc_hash": "d5fc171b5766f6f692f2aaf0ee955e2e1701128cc44a84ed4a9f0c6c3f38dbdd", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "2dd9527f-609c-4e61-b008-8fdcb09428ec": {"doc_hash": "d2cafe7ef6678b4dc48ff94d938d026ef0cd401118812b27139d44f33771d8dc", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "f420e328-08a1-45ea-a922-2092dc4336fe": {"doc_hash": "4eb45a3aef5fe59ff78bf23b7a23261017d130047552298ef6d2858dcb7e268c", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "16f966a3-667c-4557-9833-b4fe43c251d3": {"doc_hash": "5736168e9273dad76f963bf241b780db49bca40b02bfae4307ae24e01861c3ab", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "0c88371d-e90a-49e0-8128-8ce91603198a": {"doc_hash": "e10a843df2077c5ee48b63f39baa8d6b668f892bef3fe9632dce49ff6504a1d8", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "6f64570f-3207-4ffd-9956-6b7127e380bb": {"doc_hash": "c1a868288e4950366b3a57ad1d08b2f8f004cc8ad8d6ca04d57942fa8034d9ff", "ref_doc_id": "4011977a-fb56-4b0a-9225-35b630559899"}, "7f79a725-8ddb-4748-83ab-cf44b417fcc3": {"doc_hash": "b6c88a0f91e4286f1e237c0cbb56bcbd41f0513571c07c6b0a8aa32836c04a36", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "a0bd912c-f0c2-409a-9ef6-6987eb4fafbf": {"doc_hash": "2d809a699f22c6cf66388df4ce557ddf5cbf7f990c785c5d3f1369a6eb035fe0", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "da4e7b2c-e0f6-4356-b1eb-b033bee04b3f": {"doc_hash": "3aff1ac44448d8d55c2e1daa9dd12b0564980184b5dd0fda63a71d3e91bf22dd", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "cb132b82-a764-4d82-b913-680cce267497": {"doc_hash": "899be76aa8bf4ea81355b6bec093a33daad4db64f5d583c9b0a5bbf21ada82ec", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "ea292c90-a592-48e0-9774-25123687cb42": {"doc_hash": "0b69fc8edb4f9e6c4988ee2ada7651db2102f43c61f7cd6ae7f06e5c692d1391", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "bdc82a0a-a47f-43e6-a5ee-914fac439699": {"doc_hash": "4e0142440dfe10949d976543913822eaab590a7b8b1e240065f6a3dac64b3824", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "0ad1eb2a-7f5c-4b61-8921-f6fb62033a11": {"doc_hash": "68287c10485b2bde45478adf75d428bc6417a095c021dd6f0e11f8a06b1e63c9", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "800a78dc-7051-44bf-9802-571f8e1cc924": {"doc_hash": "54ea0afb8a0f044dd253d1b66f89620f9c4d60127d009c42fe8293d3432ffacf", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "4f3ea902-562e-42af-bb22-86d1b7773529": {"doc_hash": "0ed9bc698a5aa7a378e9002da22f22574749420fef53d8b84d228d4703c64270", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "d3366999-d480-4ffa-9f62-33d8c97b4ca9": {"doc_hash": "9a6930d56ef3751149b1b56bc48859b5dbae91063492ae179236669ae3a4bfa1", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "5e8306f4-4e14-4a2d-86ee-136a14589b61": {"doc_hash": "a3f8f79aac9238f93fec1dc1f580c0556b4c95987e4e162854bead9b0e121ea9", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "f67619bf-d96e-472b-8fd3-95382688d1eb": {"doc_hash": "2776a2feec1301b784a81efeac977506f7191ea1d4191d3e4c35e3278d75148a", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "55f8472b-6686-495c-a08d-188e05384f3e": {"doc_hash": "e1e2b1a022c9c481a1f6128a4f20e3afbc255ecd528e47a6b4a2bed5ffb8e3ec", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "2b88111c-17fe-408d-9c97-3f1c9720ee60": {"doc_hash": "683605afe7dd8ac02f3ec40a5d375e13ec84092d72a0b067e7e3a03cdc17357f", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "f4f63e2b-5df2-4908-8b25-2f41ca8a34af": {"doc_hash": "2eb46e88b65d0ca178eba52e488b00df5795411b6846a461ef6abcc210772b43", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "c9048aac-e95c-4976-b8ea-555e8a71a832": {"doc_hash": "216a204150d31d76b5163d7630e36c829b4fa1239f7e8dd4a31d43cde3d031a6", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "e4e5a609-4d37-450c-b488-b4906c4c9264": {"doc_hash": "fe80413c23a4b8bb18967db56f8f4d133dc2ac660c735f3500477fa84db8d646", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "2443380e-8a22-4cb2-8558-49d5c37d92b5": {"doc_hash": "11c5c48bf60ec97d0fb085326dcd29cc1717ee04618e098f3db7e529204b42fe", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "03686922-a56d-4235-8a0f-0749474c7300": {"doc_hash": "1001e1a03429873123489913e2be4c67f722c03d37ce5e8e4fa97d7dd7312205", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "b77b4473-6615-4004-87e9-74f8b78a68da": {"doc_hash": "c7b8fc752db035c3daacd78d3efd7247bdd335525d91890df6b9b09a47d750c4", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "ae2a8932-de6a-48fd-961c-5157ec1c23e8": {"doc_hash": "6f46d8712da056f80b6700ed371c5664527eb4298271bcb0ba92c1a4cea149d7", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "ae0fee92-7240-41db-b108-b0feb6cb2082": {"doc_hash": "e66afcc34d6df8a6d0a338c069f572ec3ac6e1e9ae43724a5454b7fd2a6efa5e", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "191e01eb-05f9-4ee9-a66b-69ba49d8ba0a": {"doc_hash": "64ed265c80ef6f6ece143f1d929d117eff1660ebae6a1d0496cdb3dbd75bfa7d", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "26d356bd-8427-4027-a4a7-3ae524604852": {"doc_hash": "4cb5584230841b32daf8c3daeeab1ba119b264b9bf68623e6ddb4104628e4d31", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "b3d0c591-1f9b-4bb5-b11a-7f118013f2cd": {"doc_hash": "d490fe0d3ac211a28dce4040f074e895d6484e9a16ddc518ff2cc4e478a86618", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "f63a07ed-a853-4268-b87c-fd7e2162e3e9": {"doc_hash": "54bcd9fa4f7cdeadd7e39ade2a0399557371a1678cb5a61446b1b586908e23a9", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "6317ab7a-0b39-427b-93ba-5d08b7cf8bd7": {"doc_hash": "4bfa506829ba0f04f29ef48efcdd2242ba9da2d7a7b779eef10db51491173b70", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "acb59e7b-56ba-4cf5-a983-4e3e864d6a48": {"doc_hash": "975b5fefa3977991c319df8135875ac3ec1f2432fb78a4bcb2ace6194c1c7bcf", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "bc7f1541-c476-4604-beb1-19798eff413b": {"doc_hash": "bc7e486ece0b4ca845ed4da3de1cf854bb365d159173a6b96abf97ae3732aaca", "ref_doc_id": "ff03f30f-7f67-4dae-8496-bf0dbfc13507"}, "8a390a3a-cf35-4939-a7ee-aa78f3ec08b5": {"doc_hash": "fd8f26f8f3ac312210a425728653b4b2bd88fdfc1fca91547a1258e76a64c360", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "baf9fa0d-35a0-459a-bb12-384a702a05df": {"doc_hash": "b120492ad60ec3f4f2ab5ed1b9f70ab84ea0203423cf51478a37301f0bc4f1ce", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "64f389c1-dc97-4993-9f65-a7a1ae70da62": {"doc_hash": "d55c5f333cf37b1923e7874b2da31cf6d3b1c322fa6da986cd14de527fb86a36", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "4f920913-5773-4b2e-b747-b7f8cb653cad": {"doc_hash": "06bc54ae02320cd94baeec3be94e1f6e58a441b855ef490637b08ba5fec6383f", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "605be9d0-65f7-47ba-bc46-9a1f9d7f30da": {"doc_hash": "72a456fbcee55d7c36157ec17fe23f02d875b26b1a7916e32fa0b7f9f7a6a7c4", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "d639fc70-5340-4de3-9ec8-cccdabca7f2c": {"doc_hash": "357a6a46e302a6adcb67c3426b5e3bbb4376bb073721db416bd824eb8dc52845", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "6fd36ed9-bf10-426d-a8d9-cf6587ffe8ba": {"doc_hash": "ba1bbc7c010ead271b85b76bee8891e1f08e7bd413de8ece509fdd16a2db64da", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "befbbe65-c5c6-4cd4-abfa-547deb152c09": {"doc_hash": "bc0d3e4e7773066c1997a3f72b9c8b43b64e49afbcb1e3eae726f9063b02bcaf", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "d4bfad88-458c-4406-8fd5-2cda264161dc": {"doc_hash": "42ce9815a4f12ce885276a979e87b6e2b41c9854b3aac6584a035b11c9955d72", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "dc407028-0830-46f2-92c7-35ba1feb53ca": {"doc_hash": "b842286dfb285b13a68aac2185fb0dabb210b754cad6c97218719b9c0267c6d3", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "002c969e-2743-4f35-a0b5-8623944eea17": {"doc_hash": "7d3eed6cc8ea8026b8f64b84fb8f0e71b5f3ede61aaef088013f1720f3726eb0", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "92ad6e4d-0d29-4630-8652-1cec521e4630": {"doc_hash": "663cf8134ddad5fa1b0daae37294dafdadcc4abaceeb33407df3b14d53194786", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "68dc9ab7-a5ac-4c75-bd4b-85c17d4eb99d": {"doc_hash": "9c36c6ecc27ef5bc3606e7cc2debef75a4183a2ebe784f43dfe6cae31e7a93bf", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "50730c4f-18ae-4282-a42d-48db5afa7ed8": {"doc_hash": "101f8aac56354246b64783b83920e8ccb567980f254ea5d6385a37c19f8b9dbb", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "70636836-aac2-4955-8aca-5aaf9d58aaba": {"doc_hash": "522530e78de0bd6cb648d029e1b530b4c77c4492359714fcec86b9e2b615d68c", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "e6ca834b-3f89-43c1-bcf4-50dff9aff771": {"doc_hash": "1c242192dbd280aaa7e546940aed45ac44116c009b6fc15717356bc5fa2b337a", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "5d2bb25c-2cd2-48bb-9b13-58f4ba30f85e": {"doc_hash": "8cb8d1dfd6f2c891b555ccdd5c7f7703541bcf9fc17e43b3f85e711b91619eff", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "7173154b-5743-4e9d-8f35-11e9a9cb720c": {"doc_hash": "7f0c9aba4021cd74163da9277b38af1ff044075008a51f7a984be36e019f8556", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "d2a85ba8-fa02-422a-bf8b-4fa2b0682cfe": {"doc_hash": "397bc79fe8392736c5fc0974feb5c9d282021e885bd1f90aa73a2cf2e506e926", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "2cddc03d-83e0-47d4-b30e-6b09528272b5": {"doc_hash": "ab6c5e66c896da414b4466eaa6572bb9cc332e86f2f07cf23b4bc1b7434285b5", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "e61369bd-8c50-4609-a430-63917b232bb1": {"doc_hash": "fb9ba7ac0fe87ecd6421fe153f984745c105cce1cde6d026000f832090d52113", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "f7ddf1bd-edc4-435c-aedc-ab0910d482c2": {"doc_hash": "758c40f17f6da819837afce4c3629ae1443b21748577ef720d997d4bf6800d54", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "5a03e2ac-c3a6-4881-8955-f383ecde5cff": {"doc_hash": "c34c33c936f3cc6fac6d90f1c3a4eb646ebf3db1bbe3e37225a46377c7fdb791", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "0f55b4d3-5b7f-4cbb-a5b8-828c23fff459": {"doc_hash": "4f0ee7e28d6b823681e7aee560a8ebde69817422d83851f4c5fe356b68942f8c", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "877438de-935c-4c62-a1eb-5b1f60d6a7da": {"doc_hash": "5ff9c84fb67779b68d24d86f1f3cadcf3fe5ca831d0127f0afd72ea8a74f73b9", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "fe8ce034-8adf-4f73-a340-089f9764eb67": {"doc_hash": "c4f0b18fe3dc6c95fe9b4904349b2198c63f46c3dc94ae8fe2a85974c9683e99", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "a6d7e618-5423-4c20-8435-63511e745d0b": {"doc_hash": "543f5516dc116f85fbe8f6832737f4178d1670832d69d01715ed0866af98a7f5", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "6a51c71e-c819-4e16-8fb8-2b93809f9f95": {"doc_hash": "1d4b68dd5d0d8d341cac0f31216328be8c14086f612da92bfb8227adb1156f32", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "6ccf31a6-3812-4e44-adae-f7882741a3ec": {"doc_hash": "959f9bb40773fab792f94f5a90023e11e4c8cdf64183813f01fc3aa7d87cc6d7", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "0fb8a479-db7d-426f-844d-9e38327b5129": {"doc_hash": "d7581cfd5b236c7860e3a9ad08795d215e63cef4bd535964e4059412d62c0565", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "c21a018f-e7e0-492a-8412-d0cbfad66933": {"doc_hash": "7b28598579edc5994e9bc1916e163280c322eba731b9e01121bd16f5c5b58a16", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "17401196-61f6-4928-9d46-a057791dae04": {"doc_hash": "2f59668c76c56f129b3a8523acadf72afa686f4c44abbac2d9693368bb24fd47", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "efd66b2f-a89d-4c23-8dbd-890b38674cf9": {"doc_hash": "9aecbb609f406fe85d7f5c5719d37d0e4e8944e0421d26013a22db3511019ce1", "ref_doc_id": "10757ed1-0a02-4eae-8d16-e6f43d486b69"}, "13e9b329-f899-4eef-b7e3-70be7695dd47": {"doc_hash": "c200ee788795aea611cd7aa3a9b1e235161d51ff72a9f754992402b0adf02cb8", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "d2a88f7c-7ad2-4635-847a-7b061eb457d2": {"doc_hash": "c6087b7620fe9a621f21ca6cb6f4ac472975e27c4cfe8e2c713e31c3570d4705", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "02d25b04-8d8b-4c50-ba9a-ac7ea264906d": {"doc_hash": "302585917cb5f807dd0a87e7b3d26a61925671c00717f417dde469380d7910a4", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "64195392-e73e-40d7-8520-36a75f5f608d": {"doc_hash": "afbf2e610e08436c2bd2a755dec4ca5d0bf7fde396d20da612ff30374b382c0c", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "8b198f3a-87d5-4cb2-acc1-132fb5868a77": {"doc_hash": "a9cb43a0d6c6805f15cb803a9372da1928f285112a04bd017199c3fdcc3abdaa", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "2a72f48f-3ee6-4964-84ac-78d47c3aa632": {"doc_hash": "5c2b3474a6d93f4a2c3cb5a143a2b875e2ca3e8eaae0b359870622b4ea5b2f95", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "4b4f069f-1d1e-4747-b109-50438ac43f52": {"doc_hash": "361b679acebf092c10db972aa29241f6156a7bed1f47b97e80ee460d0166f365", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "870dccb7-9ac5-4270-8bd3-911a37178daf": {"doc_hash": "934545cc84cd618d906e6bc7053530ec408322c442e67b84df6eb5dd96a783f1", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "6ecb31e9-ef17-4d5e-8322-072f3bdb3d58": {"doc_hash": "d817c72ca6a6f1cebcf36167d65e481c8ba01e42c3797f16e57b6f0b0625c744", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "4384bbcf-99ac-4a4e-8c3d-72976522aea0": {"doc_hash": "35976599e65c9d3b940a7c2ffed0028cc6b545594ca28d414d8491f111149d7c", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "a8c6f492-b753-4292-bef3-67156e8e8cc6": {"doc_hash": "8acd2d237e6336dae7058f34ce2a40bd768c79777fecdc26620c2e63c196a2c5", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "c3de03b4-25d3-4e1a-aea7-e890410cbd57": {"doc_hash": "170f9d598dcc8377d9f58dd73e5dcb8bc9895315548ba29f882030ec86b14bf3", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "4e8f62b7-546f-4812-86de-42f050f48705": {"doc_hash": "3f426c5a1c5bc0f88691fc9d9736446600ac5e9c5c9aaf6f75ded548e5966f93", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "74b4f385-e3f6-4f61-8e0b-66d135aeff63": {"doc_hash": "7d081f1e9101cce4393d6d3fc7bd7bc703ba3f714bb4d36ec3268fd8b7e47e5e", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "60426720-1e22-4b84-a88c-3be230105588": {"doc_hash": "337418c8419018a88c7e06c20c4f2dc047daa7f18a4b5d13e87b3aa7cc1d1fa7", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "2507812e-8faf-491e-be5a-24145b1f670e": {"doc_hash": "d7ae1e78542d44bed9d94fca87826e65db02202d874a9b0c98377267462d2b29", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "b7848d64-0b0d-4e24-8e27-f27f903f0848": {"doc_hash": "623444f60c1c9e6ee4a1cea2a86074e41164f04b704cf6fdd9d05ace61df70ff", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "3364032f-cd81-4ce3-97ac-03d1e3d3e183": {"doc_hash": "3ceaa4c12edcdbe0e91561e014bb0243c8df922250ef1a90c107ee87172f134d", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "e3d77d07-5751-4c85-a6cd-a1b4e0dfdf59": {"doc_hash": "72325185895af63df3560d76bc2688de9eaa623f1342e9cb67cb30a6354f64f6", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "40e68b07-92ee-4470-a0b8-0c19a624f7d9": {"doc_hash": "e6d21310587e4f31ca2521b6dd2f31d13e975a49ea2b9fb7bbba37ec0644cc7a", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "e145d2cb-0394-4d8b-9abf-2222f4db3f4c": {"doc_hash": "0ad1c0cc67d7477a9cfb122af0f044bff669888af836a54e19c07397db254aa3", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "980eaa4e-eccc-437c-adab-dc5d1f3522d5": {"doc_hash": "14890cefbac83a9f12ef8d7e3717ceacfbe6e58f18d8910f6e3cf9973da314d3", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "3c67930b-6e0e-4501-9439-6afdc9219642": {"doc_hash": "7b3f193e77d5f0efa3cdd0f6db8b4fcedbbcfdcf4011cb8edfdb7dde4d37684c", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "f2261992-db97-41db-9c81-7670742ae1ee": {"doc_hash": "e7d9c9d077db8ec3423079cad28647139d467e703943437e4d6c5cec119dc5e0", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "956e5be3-57e1-467c-b40e-72ed31a6ad9f": {"doc_hash": "ff84c069caae125fa1fe1ba4639f20a462a4226778245a750cefc13a3deec763", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "41eb43c8-34cb-4b70-8f5b-a13aeb69f2e5": {"doc_hash": "d4755fe560f5c740ef09e53f3c290937650eec37eaaeff3827b168c6d910a44d", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "57723e69-045e-4572-a45a-ba8a5e34cae7": {"doc_hash": "95f466f8159ba064642f4d34727c3e2708637c2e256f459d8ce1bba7ec047a57", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "7302a17e-301d-4532-9c64-f743b776ebaa": {"doc_hash": "ea75196400e0b3a6fe07c6e0c11fc80028aadcc63d7186d82cd635bfbb3d81ff", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "063572b8-3cf1-4ac0-bb0b-3d37c632a121": {"doc_hash": "0fea2c6fc09bd8bea181f97e1ea78af70a9a40bf020a8fd43752143b6da2acaf", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "85de2d77-6d1b-4793-be03-37167c508054": {"doc_hash": "253a7689d29b20180e14a4f71680e00415b7c01b2cf434e9ad672e2a98dc76f7", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "bc1f09cd-eb42-461b-88e9-22ae7aa24427": {"doc_hash": "94154bf1282e07e5c7508d6c5b040446de9208cf4399855b3ab5aefbfe9ef278", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "0c910911-4b9b-4dbc-8c65-542065802d5d": {"doc_hash": "c1b30a9ddb320115ee80f65aa7ee7f66bb66158d93146bcb323d89b0f2bdc2ad", "ref_doc_id": "24d28397-258c-43d0-b16c-9fb41cefe513"}, "19c8a1d7-0982-4149-80fb-fa06ca5d1cf2": {"doc_hash": "97adba7d917877cc1c4895b86caaea77e0a1e8b8c564a5d0180bb3e990072efb", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "d61f5004-2a3c-4109-a040-cd6014e0e351": {"doc_hash": "65196ad532f6b5b128d1044cade30ce3eb405973c2e6e708fe819028f3455881", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "19e1dd03-da54-4761-9b3f-04c4e505132e": {"doc_hash": "5919305b640d08d1a304c56c46eff0086b723387e6a0e1fc77b4e975643c98c9", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "9e98a8c6-a7ed-43ed-8236-54d9225e39ea": {"doc_hash": "7bad437e7d7b453fefd6aef841f31814b84cf3887c3124b91d93f85e50f1b56b", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "3f60e3ea-15cd-465e-9cac-26ccc2ef0acf": {"doc_hash": "9f76f33dec67b0fb1172e4f215e4956c2f66e7952dad12cb9af02e86d034b805", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "8c535ef5-8533-4d2f-aaaf-aa5e044e6085": {"doc_hash": "bd923beffdbf4542024c3c95bd46a5702c573dd5cac59b096df08c3d107fa283", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "8b8e502c-5284-458d-86a7-8bad55ff2609": {"doc_hash": "cfd18533ab5b57736a3e99a1ec0725f0fa1bcfb231e6bd6d09dc556602fb26f3", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "279c9a10-60dd-496d-8a5a-a2221e01df39": {"doc_hash": "d546d35762298326448bee0b7482632eb6cd45b4a16b7e948dab779f1379857e", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "c379a6fc-2b83-42f9-9e5c-50fcd09f5713": {"doc_hash": "135c0248e3dbf8e403000eca1133b2279353ffa49cb4e59a56ec6708249ca5ee", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "78500d99-3926-45bb-bf18-540a3db139ba": {"doc_hash": "109d61169ba951c0c31f1a4e28f965a999514f06ee8ba4cdcc81713e31aa1c61", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "708e8218-7914-4388-be12-cd345da97183": {"doc_hash": "3eda524c9ce6da906d477b7a2028149e49d4291aecc82b7ebdb009757354dfd9", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "0806f6a1-6143-4fbd-bb02-3db53301301d": {"doc_hash": "19048756aadaf5cc3234480ad31789651ec3dab5f0693ccb33a8cc92f7115f3e", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "794ba273-bcb7-4a18-9c92-f3d30f46bb71": {"doc_hash": "e5bbd4210e46f9f7fcde53f7d602b054769c021cba94b286330904d3a2d3ef1b", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "f99c5ca1-2698-43d7-8d00-8924bc7a0f06": {"doc_hash": "1517112bedd7b4116d0789ba9f63a11a7910c648852ee99052deb887929d12e6", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "b6cba428-eb4e-4d6b-b17a-b2edd419ac7f": {"doc_hash": "f114904c38b97dceafb1ccc63836d7ee3d9ef6351d50603d5e1d5001635e24eb", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "f352954c-d5e4-4640-8955-9fddfa65a81f": {"doc_hash": "34fc6c78b6fbc6f98a8b2f176c05013577c710713f5d0c7a15f6ab6f2a9a6bc6", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "17ef221b-0ccb-4a96-8bce-e5c363ff20ba": {"doc_hash": "df3e2b2608c3be68ee0f1b05407e86f10a8f31f6a2568652b067f46198f80e06", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "6a4dd7f9-75f8-481e-9771-007c4c527eb1": {"doc_hash": "cb44d414f05d8aae6f4a003a726cc889c4922dda493efa8e8e2035d4840e12d1", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "dabc60ea-5ad6-4d35-807c-4d0f6686ed25": {"doc_hash": "eabe39dcc44917c0ad59032e8a122157f4862b863697dadc6e349b964424a807", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "eee40301-ff20-4f59-9024-67fa71f1b440": {"doc_hash": "73962d49053a9800d5dc11e25c8fbc9b71d4866ec9d3591a219248c58696ed1e", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "7bb175f5-480b-4bad-b5f9-320d75a6e120": {"doc_hash": "de0478620e2a92ea952d370f48c775352226e73347693e97a7ad5a3930916e0e", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "980f54ab-372c-4c9d-9379-7e844abc3216": {"doc_hash": "80b0fdcc6bd5a36c0532af2308182f620b122994caa70dacf41e367bf23eea71", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "1f8b2dde-bb88-426c-99e3-6e951cfa0523": {"doc_hash": "a8bc5403328923799b6acb9cecfc6a6f006c92cf45eafe66853a0b951abc01d3", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "59c9327f-2d90-4619-b4ec-079ccb8bf479": {"doc_hash": "4e2289626cc094d75f5414b54a4e634da59422572a3f7005fae74f22329bdbb9", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "e581b466-6efb-4b1b-a0f8-64c983f7f705": {"doc_hash": "398ff05e4c4c9a21f4866bd974e9fe96ca9ea365360711de123165ed3df5d645", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "81209834-c320-4adb-8c68-f5739cca4651": {"doc_hash": "d2613646553d459efe5a84c790d24af6d48c6e99ca138c92e0b1ceff5dc02157", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "c03621df-75af-48f8-8955-e0f539d6a5d8": {"doc_hash": "5cb3876013a4b60b1dd93708921c4d941f4b9728c161794ded2a3ca7bf72e6cc", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "e4c113b7-8bb6-4bb9-8902-b4fbc5e89419": {"doc_hash": "41142bcc2845e30b26b831121db4593e57a4b5e32e8c98eb9933aa6a3bcdee6a", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "8b296e85-5ecc-4954-9187-8c1ec6100996": {"doc_hash": "f2daf1a9392a0cdecfb2270a5367df4fc003a07b9cec17c11cb37c8690333429", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "17c1dcd8-804a-482c-8726-dbddad326536": {"doc_hash": "b7bf9434d290a020f046b8177d608e48b74b99d1f113489ad281c0dd37a64864", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "b5bab8ac-680a-4513-b489-afc8fd99bdb0": {"doc_hash": "2ec46b42b343164365d3e4670fe1dbc7d9b509b222b6d7964554faaf8f12cb87", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "5c4e400d-9e93-4aca-9714-2d699d52322b": {"doc_hash": "da4063986145c3f35d98c9d3b00c13db2fb480f2bc4b9bc6d5da35ac33264bd0", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "0d65a6f4-d9fd-4cc1-bfba-63edb820966c": {"doc_hash": "b1c9a5ef14e33dca4f7dad4f9674fb804bd096bd1bf3bf064fdba16d4eecedb9", "ref_doc_id": "a39adb85-e94b-4022-a926-62e962c0fefc"}, "28a93f70-ec3d-4174-aee8-45bd1021c682": {"doc_hash": "36807df2eb18877d54556975256731a2e2bcc86bd9932328dbc3727fb016c039", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "dbe8a030-9b9e-400a-b960-1f093f4c0879": {"doc_hash": "01677af0789cccc676bca11880d8e14c18a28a6b682a5dbe3430d18cf620f59c", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "f9672a73-6dee-495a-9a60-c458db0d5f36": {"doc_hash": "7eea694891ca7f9a228f4030df173fd44aad52ff87baee0965a5f3fb2595182d", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "ee3e92ec-643f-4ef8-8456-7d595fdde3b1": {"doc_hash": "cc3768ae4ad37ccbcaa3b8d3d450a89e975011d950d93afbdb098c5e2b456da2", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "3c143f4a-683d-4c9c-934a-e8cc37751e66": {"doc_hash": "dd696cff5697068becc733275b4d3d2312226508f723e5841e9b4ee40c9b275b", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "6070d7fb-823d-4b6b-bab1-241665eeb980": {"doc_hash": "96dc2960d55010e6cd400fc090faaf6f7bd4a243c6eb8ef288393e56877794f3", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "72c7ed76-2f3f-41db-a3b8-a663e74cc34c": {"doc_hash": "62cdb1e407a29007b70db64cd8aabac294ec2f8985cc5ea466026d3332d649ca", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "7ea2f5cc-1fb2-41df-b2a5-566fc0ee54df": {"doc_hash": "4f00345491196344e94b4e7c36a788ece7d149366dc01781c1707a9e6f29646a", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "c681f77c-4a5a-4724-9dea-a87bd1bfef6e": {"doc_hash": "40c4b99a4c5ca0c643e9586b6c1b6cbb31cdcc19202cffaeff219a66cb6de651", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "efc97c6a-4dde-4fde-8a93-8996aeb9f450": {"doc_hash": "89475264e12da2e3e720adab279c9a4b4f2237788085562c0f5628f6b831f9be", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "d36a4926-bfaf-479a-bc9c-9193c426e079": {"doc_hash": "0137adea31fa8b09e4633d3e348fc0b55e6964d9949fb2088821ffc2f6dd3402", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "725c4fb5-9752-4c52-9f02-b5938d873a70": {"doc_hash": "da48b41068c0a5466e89f0742b677ba44740ab382fbda1acbeac856ecfed4344", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "ca507966-194c-481a-bb73-afc6a154b0e8": {"doc_hash": "6689ff3126f8e3dfc9350634b316cdf5ad07f2bf64faf5637f5cbce6d111fb49", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "47d710a6-8088-4ba8-a576-d7ce181ce336": {"doc_hash": "6452951192e58b6e2a53ad626a528ffa4adbbcaaa0fdc0755735a6599254336c", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "d0d1ddfa-3abf-4f65-af41-887446e5f344": {"doc_hash": "5d332ab2a275c0c803ba8157d0c4f7133e9c8c1089104f616a748fcb13fd06c8", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "e35f47ed-cdb3-48ba-bda6-8ad46e3ac2ed": {"doc_hash": "303f22a4666f8d6f62128f84a7e02d710390eabe16a57b338f0ac8e3515a6783", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "1a5374b4-3d14-49e2-98a4-c0098afd6521": {"doc_hash": "58f8caa32d259c92b761d1658647904b62db1e04f96927ea2c4af82977dc63db", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "49cae840-e330-430e-9761-a064fb688ab3": {"doc_hash": "d1f9fe0aa85468672ef6e99d4ac5c482766f5b941124b18e3acc2e4728475006", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "0b41b0a2-8bb7-42ab-8606-26c6b4ab5a35": {"doc_hash": "cf2a1f2266a90f7a468c22c6fea99c7af3aacc6e46541cfed1c164d3423a24aa", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "fa6ce2c4-668c-4b42-acb9-ef9022b40c5d": {"doc_hash": "6de49b346339c79aa58a3744bb6bb25cefaa5762c832a5c8206dba8d4cb576f6", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "a9d6ca22-4517-4070-905c-6228d5449031": {"doc_hash": "0e1cc3142a7cdeba59aebf0661bce49358215d2d892652108bae428d2cec3ebf", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "2d1d74e2-e230-4d32-b6f3-0b2a9555114b": {"doc_hash": "6fb6f9dea14fae3e147f04b7d0a91340ff948b14deddbf982af4713361c06b51", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "4ec0e57d-0fd1-4870-b9ba-7edc704089cb": {"doc_hash": "398a20167d8c1fe91f9ba698010c6d0013d0e980ba0a01f74af302da9f12425b", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "bffcaf4e-bcae-4aca-acbe-db69b8d335a7": {"doc_hash": "6e3b828f73a2268b564846889bab44c0448706f7bc6656870d7002919e2293e9", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "3fead66a-1146-41a3-a9d0-9a46daaedfc5": {"doc_hash": "6b69811fd665bf94dd7c7514e3a0a87d20bb3a6f5e4236cf526dff77a519dc47", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "e5f6fea7-dfa1-44b9-83b4-c788411e8aaa": {"doc_hash": "76bbb808eda5d442a1e7c8800f88e078125743f134987244d066958751dca7fd", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "32563cca-159f-43ff-99cd-e62edfaa8f57": {"doc_hash": "f5ad5a5dae946dc0c2a6e415638e15a266e075b806ab159ece518a359314822f", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "ba6541bb-28d4-4937-91a0-c530ba2bca12": {"doc_hash": "19946a124871b717b2a5d8901ada1be2b6026ffb215c7198e7d9a4c08abc3a62", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "1e847521-c289-425f-9c6e-ab9ce8a1597c": {"doc_hash": "c15f71ca0bb4490d0221ddb3c850c404835f55f99752d468fa4deca0ae3f483e", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "78c71df4-c66b-482a-bedf-5efd780d63da": {"doc_hash": "1209e06cd1af5f666d6d64c45260fb5c6dcd9aec6f7f59d589e8e1f67496e987", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "a58aa69f-7282-4dbc-9dc7-20409b67462a": {"doc_hash": "5acda7b368fd30dd6d4b9cc03eb40ac6249b18bc71fabdf5181bb8ee01b6b904", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "6ca9ebe4-6cfb-4620-b696-10bf2428486f": {"doc_hash": "7fb4dfda3362bade348de347dda95b995343e0134cf077fb91de8043d1c28c03", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "e450eada-fe5f-4614-b7e5-d0591519c833": {"doc_hash": "81c15befa380fd3a0fae4e76a7ebad6093ea02d7866c392b97e34fcb25388148", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "3080387e-7fc3-4664-a904-024eed425029": {"doc_hash": "6e6ae0f99608c4571a8c4f39a17416f114c55ea30129621f8d041de7f9abf7d8", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "a274a09d-0024-428d-afe1-6f76d51f72fa": {"doc_hash": "d28ff52712268184a39896803bc044c25d3d4f4c553d5ec78e9cce0a23598102", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "b8f49e65-4c70-489d-a3c1-d87a0d01a470": {"doc_hash": "2c5c90f72dcc6247187e2b55013ef6b40372ed7e78e20406f11619cdbb56aa8b", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "1bb205e6-c14d-4f2a-a8a1-3deba0eaf108": {"doc_hash": "08ff8c9acd305554f51d2c959256e622e99f0ddc12be1df2f70de6232a8e222b", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "f6d49d58-c6d9-4674-8d58-073d950fac54": {"doc_hash": "f9d06117872a2b2bd92feef7a81efbf690147aa65355765f5bea3368cf58d943", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "27768d51-29a7-49b9-a4ab-278aacdadbf1": {"doc_hash": "a5e630929c50ca0e2e192b571f3b58aa97d457536425de48d61287fef5e16ab6", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "5dbf1b48-1a12-433e-b8b2-cf9e32f1878e": {"doc_hash": "e11fb6a3ee838b91bc04ae86108d14046673d0bf4dc25a57fc48e96dfe5ed573", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "25624afe-2a7f-4c77-987f-d62cf2095186": {"doc_hash": "478d8d14e0c1c97af637ea9300114fbe36a80891851b7e75f20955c86f4d3884", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "ca19f180-ffe7-42ab-8f8f-767218b3dc3e": {"doc_hash": "481117c972d5edd13afc57dfbfe8f027ec3f351245c749f74245417b75a3521f", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "f5ddfaf2-0182-4258-8ff2-ca6611321236": {"doc_hash": "5d5a1b114cc32102db741c0ca7f1a61ea920f331ca1c0143f62a2e3b22717295", "ref_doc_id": "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa"}, "c9cb5e3d-5b41-46e2-889a-e25d4969e315": {"doc_hash": "d0db2569a9480b3d59f2b74398c6f9ba004805b75d931ca86e2a02ddbc0cafda", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "d52e0153-40d8-4998-8cc4-61d27f004df8": {"doc_hash": "4ba26ebb8062ea5bcb9e825a129fb101ae64d5144a5905991a7bba3564f6ef0f", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "cc172c05-024d-4e34-baba-3007cb7c84ef": {"doc_hash": "c0dbc0e6c0b53e72f5d4e0431ffd934a183120d733b886203870a98da62b5212", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "f5b0685e-91e2-4cb0-8c22-947d9a25fff6": {"doc_hash": "34b800c06d80cbc7db4ee2ff0076ace9272a992f85d4909c89d07607b483864a", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "af0e459e-9443-44a2-9b37-6cb054c54344": {"doc_hash": "ef5ce0f6aa9e09a16dd280acecfc22600b2d2c3aa7ae131dc8385981e1d01343", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "2ebe87b4-79e1-42a5-9d88-0081c16fada9": {"doc_hash": "c99cbf498e8d569e8a82c15ea37e75bc4a03bbc225ef69f8ccd4bb0cdbaa2483", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "76e96cb7-6a52-4ae9-8283-550fe7653edf": {"doc_hash": "c606f0dd5c5ec5551580bf1adba891ec67a6a6174aff03e2d0b329600ba4f9b3", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "8921a777-40b0-4e19-a6e0-2e5d2c657691": {"doc_hash": "5f093885de1597234423c3d20b5f8edd417915a271114b1a0760e2808df645d1", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "650ab26a-bd77-4a24-bf90-2d79a01edea6": {"doc_hash": "db8ef127772fa06b6e87e3ec93c5bdf7426e23af81739886fc45e0bf0419484b", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "65cf0647-5a9e-41b9-a8b1-e768872a9f10": {"doc_hash": "606c7e3e025793f72aef803b465855cf7cc7ce68a2bf9744759389b8903a8fe1", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "aa13de8b-2560-4e6a-9af0-661e53f81223": {"doc_hash": "1638d9f544239fe56f50461e31043e821d6bdadbac2bef5c3fcea3956e536498", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "51606aea-80ba-4a6a-8a94-522002f3e16f": {"doc_hash": "559cfaf6201acdb8fa4ca648c651a1c0daaa3faf88266f3c11086f0777fa834e", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "f59da9ff-188b-44ee-afa7-0c4152c3c6b2": {"doc_hash": "541fdda89c37b8f13a05996764cc73c880a85fe8bb80bfe1f9179e0b4f24986b", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "ecf0bfde-9b7a-4cd4-8c05-76967b2a8e88": {"doc_hash": "11e4791bcb26fb0f28bacef8c07f3908d98dd071648a8206fc640848a1a6a063", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "f60ac68c-3a79-4cc1-bbbc-803accfe8fb4": {"doc_hash": "654082a23c5c7cc82c66cba95aea9773c491baa67cae08074cd4ec9def52297e", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "0cf046a4-8510-475d-85e8-18a8bad5534f": {"doc_hash": "d1279ee48650f65bd1bad856c53b82eb72711be0f70b5c457d13043850649b14", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "47ce1e1c-6a42-42ca-a11e-736e2bfc60e7": {"doc_hash": "bf09a48d7216e9795b6633ba74720a2f5822b4f8f2256d3f87466988ff069db8", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "56d4442e-6374-4010-8e4f-d51b91bbecfb": {"doc_hash": "d52f4e10ac14ebe0d3019d1d0b63e2c7d91caf9a5ee793d5b30e27e3df727ecb", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "0ff61b11-9d32-4dfb-960a-4e21a4cb08fa": {"doc_hash": "3f3159fcaf98c85eea120f159b1fa3a7e21f909cbc21806a7c38cb5b4dcc89ea", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "642e9c6b-dc4a-439f-b5ac-96a26cf4d1e7": {"doc_hash": "83b7fce7b787130dabb4eb20e8c879b3ad41ba37de96067503ba1975e2c9f0ec", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "c277a448-1626-47e0-9ae2-e0465f2ec065": {"doc_hash": "0981258134ef80e49fcca0df28a4c3aa24e5c5d5c6d22195a39fef8a5a491997", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "0888b4d3-e2b9-4448-819d-6eee995d9d76": {"doc_hash": "529bda186b394a203d23e6b85a190e11fa2957f02a3c7f0c19f52c5f671331d9", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "ee899906-2028-4c0a-9fa0-bf774a2e0429": {"doc_hash": "8d0a54ee8927311c4e69f10124ed7dd64f96f4e3e3009ebefd933b3aa9d6c184", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "07fd94e8-a250-4069-a08e-9e0da023f9c9": {"doc_hash": "b1ed177b636a5ffda9ed84c8549dd7956a3a6fa7f1d846e404c4797746b7c436", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "aa2b9260-6ea0-4a02-a56a-f9aa07654006": {"doc_hash": "3b111845142bd298db9b1ac25a75d82e8ed8f867bc4097342c7debaac6dae4d1", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "6cdcc515-e281-4ac9-9500-7ef0cdc32593": {"doc_hash": "69b03e5b558f9863f28f7a359063d51ca59ab31251bd40046b2caaae42b2f989", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "19ecef9c-79ec-40d4-a2ad-223c6e7f05b8": {"doc_hash": "c1ef4147c71506cd2f89ec31fcd28392c9bbc751a5d1c72d79d0327586adf839", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "afe8617c-2107-480e-89da-860dc9d132b6": {"doc_hash": "13dda60bf23a1b279b67e8ae00f03d71a45a9498236515da40548f41c4221516", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "0e9862c3-347f-46d0-ac82-994bd8d8c0b4": {"doc_hash": "eef5baadc22b3f6869c299ebc9d2366bce52ea9fd5b494659e4deb030b9fc219", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "3ff8b1e3-c6fd-4859-bdb8-734fded56001": {"doc_hash": "98326f779fbf887486a1bb0f9f3b94d0acfe4cdcaa5957060f3793d250f35bbc", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "22f968fe-2508-4407-8a6e-4d7b8ddd1e0f": {"doc_hash": "24866b9d59a610395c8da5795779639eb32ea84ad6ecb1482c915ab4a9e5c98c", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "d4be8c52-735e-4d35-88fb-65eb6ef1f3c7": {"doc_hash": "b634efa693a845406e73cacde1184ab0fc451b093fb9e8fe2b7caf43a3d2835e", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "d810fdb1-a52f-4e18-a3d5-2a9716b8c271": {"doc_hash": "a911eef9416e1b6358641980443990b2ab1e2927e98ccb9a9b291a5f88fe8b62", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "dedd141e-5f57-45dc-815c-1a7bf23470d4": {"doc_hash": "1cb31bc8b82a4b126ee70ef4f095cb3345220d573840b73cc39f6211f3725e9c", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "7ddde1d1-7a81-4548-95ab-a14e160b55f9": {"doc_hash": "7a9353593d0a6a693d96c251ae6c7f43b00c46cf9c962957769991a7bdef19b5", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "d5fc80fa-934a-471b-abe1-2803f4a4d0ac": {"doc_hash": "e747dd9affb753006ee7075bbc98969d7d9c0833b9da8627bbb0aa6d729a3f20", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "713b3194-3286-468f-80fa-53c883b90c15": {"doc_hash": "9fa0b82c738a033d724755c615a8beb5f86d0f5083017c338175f7c6959f9a82", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "15292f2d-e99c-4794-9130-6d51b8c76442": {"doc_hash": "0d76c34cf2cb5e61226f7d89aabc5075b234432a28cacd017c59c547522c1873", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "845c93d2-e075-4677-849c-7fb336f74e9f": {"doc_hash": "c9b991e98c33478c7be2f5a447e23899a5d17eff7ece09992721f093609257e1", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "e8660c78-7aad-433d-a530-8ad235930a71": {"doc_hash": "506d967da302beb55a7bac04c8abe83c3670bd5531ba709f66f26f1fec4ee28d", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "4c3da0c5-23c0-4278-9067-6de24b67129b": {"doc_hash": "9f5e5f45c8f7b3a4d3951d0add266ba0dba570ed311da150a7ca6c4777fc8228", "ref_doc_id": "68ac55c9-2fc8-4728-9b52-07caa1509930"}, "1ce9fb5e-ad83-4675-8979-5a1e0b9822bf": {"doc_hash": "b3a5a8a1b9a035f8eb7f477dbaf00393fcd28cd1bf1abcff2fe2e4cbd6517f1a", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "9a214b2f-2ce1-468a-8d2c-5ff4bf917591": {"doc_hash": "5147bc542b22551513b6feaea7097986694f64d034de95797bfb1e89f4a87785", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "f2700cdb-7089-4c14-93c2-29f026bfb75d": {"doc_hash": "d1fc92d638ccd16f8406be144d5219f93516604e6fd5f147fe1b5111e5c4e458", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "9d7e9d00-5ade-42c0-89b7-bea6407d76ba": {"doc_hash": "4ee420e4260bf0bbe4e41e233d7d94437f292465c6b6bbaefe4cd8476a286a95", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "eb82c369-31cc-445e-90e7-51ac171a0297": {"doc_hash": "dbf48037b2ccd78d27e02884455532faf5961e4360bcfe3c3e589baa38954d69", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "337a8b6f-a142-41af-94bb-3ff96ab8f61b": {"doc_hash": "c9f9df47928b9ff863e18a4f81c3e06a84a35c68fb63ac8a62836019eaa8cd0c", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "fbca08ca-e877-40cf-b1dd-f50cacb36ba3": {"doc_hash": "80f32f222f64ad02a96f6a48b04a1917febddb7ec593e1c4c1ac27764aa65189", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "c0cd526a-2f87-4b46-a8ab-89bbcac4032d": {"doc_hash": "1e7eff897e081d1c42021c3c78f15eb2def7bbc7128eea565cba52c63d335061", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "1e2fa2e3-05b1-45b3-82ee-8ff8de90889b": {"doc_hash": "9dd97634c14402c9c2770fa284a511dd9f1e3eb1b79c2ed63cc110e76b538372", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "e24844a9-33fb-4145-b239-e0a7bed4aca9": {"doc_hash": "1e9309f4b4f83744031a9a34451b3397f32d746054aa34989d82d78037ef0dc7", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "b373789e-0b09-48c5-a022-33a35f8f9d53": {"doc_hash": "13037bfc6171dd34a001c9c39286ec52b4aef12d49174cdd92376fb7b3a842b6", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "01d4a0ba-d8cc-4f8b-9537-8eeeeccde48c": {"doc_hash": "3775c932e4b375ca8b6320580cf869658317a55aa305e75f5c780b8f8a488593", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "2b78153c-b4ed-4973-bc60-4b42ccdef210": {"doc_hash": "203686ab0c6f932e66f75377ad332cf2ebb1f4e13e13eca3161e6a7ead017569", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "d5b70081-8159-4066-b62b-daae956a2ad2": {"doc_hash": "f92bf0407b8eb6bced2d6954eec2d68c5f3a59a792961df2a76fa31cc8753acc", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "de639602-87e8-4513-88a5-90645507ca0c": {"doc_hash": "823fe3b011ca806852131eeb6ef0fc7833aeade1c5e38c895f08edccba387a02", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "4f364187-b280-473e-9d33-ae7b871174d5": {"doc_hash": "b0248f7752768f1a7885714f30bf39cf001ae4a46e667f56a94b7ee7036b91cc", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "72161d4a-5d9a-433f-a021-caf931e8954e": {"doc_hash": "c7712665740fdad22b87d9fab3f583b9420ecc7e10efdbec5469759df8c412fb", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "29ffc177-c0e5-4874-9247-a2fc13df4e0f": {"doc_hash": "83843b4b202b0c542c1861c541f032f9ff9121482a6a857e8737f1dc2d5be9e9", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "1c270c25-ed14-49a9-9d8e-085f0c0d815d": {"doc_hash": "7d1a89718f4e3a04e852fe7c18a027fe7464c6f8a6f7ce94172f9f993f4ed1e2", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "d9b25b21-4f32-4bf5-801e-5791fa93a579": {"doc_hash": "4315986d8c74fcf2b56ac5a4adfc4def828cb2fe9909eb2cc364fe02e98da6b9", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "46570ff3-2458-4ebe-a95e-c6395b736344": {"doc_hash": "f520cb0766b06a3682245be6213ea46cd6a08c5a56360827766174fe658f0d93", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "60651cc5-2897-47b2-a15d-bd334a3a93f5": {"doc_hash": "28affefd2ebc42bdd89cc7891dd1022a0b7f05fdc6addd517ccdf0f9fececc8b", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "0b82f569-c940-44d5-9dc3-50c0f8b221b1": {"doc_hash": "7c489c0a1553e04b321e85e453f6e3f69874b4528c6a2e8a2db93cdd3ee158ba", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "b9ebe9ba-2ede-463a-9c6c-88a835e6de7f": {"doc_hash": "acf8c5b1f60c1545265f90294f95de418d72e05a2a00032fe71a2cc047c191a2", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "63eb1648-1bed-4bb3-a074-788c012ad253": {"doc_hash": "7cd9e0fe9766ac2268adb9262a6bea8d1a7ff2ea7b170d7fe88bf7f16d413605", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "9ff50de3-bbb5-457a-8565-b13f3e04f779": {"doc_hash": "ab0a482a4abbc8155b75ac82875c559e60358161358030d0a10e51cb7c482810", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "ee450f8a-b9bc-4ef3-82ce-068efcad4261": {"doc_hash": "d28274225aee4565ad683935b0d7fb52c21f236fd0128dd74f7c53dbbb925fdc", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "5dee9b74-cfe8-41a6-9444-244c727158a6": {"doc_hash": "174a08f4cc3bb82b1f0a3c0439f33167320786dd87bf1eafdff578687c2cb5cf", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "fee44863-969c-45c3-a6c2-3d3ee6203ba2": {"doc_hash": "be86a3b2ea6519b02c45a15cccdabeb2e7ca6cc140fc8576ec4fe8a25286f421", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "752f48a0-c808-4b71-87a8-a44350b32d78": {"doc_hash": "189336657353da9c781579fb1690ec674d3a1387b1e4d13b0af9a2df50a819c8", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "1f257d1f-3f09-4c14-865c-286a74faa562": {"doc_hash": "684217192f8f34654fbba843af639399b0489d4dc8cb89ff98c2f36dc2539d5a", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "fe789158-afef-4320-947d-d74c8e571bf3": {"doc_hash": "34604069b74e9d3069927229aba1afc323812e7dc8b8778c250ddddb32c44a70", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "67579d92-16af-4023-a771-69d88bcf20ef": {"doc_hash": "a67cad2334f0698f1f501e659679ae224bbe61184af087abf6050b5f942223ad", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "49a5d31e-a4ce-4380-9654-213db8dfe54c": {"doc_hash": "2dab98dd1a6b3f360d132ab098acf206771a5190ab0e0c0917297860b2734e58", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "95cb3547-9a93-4ccb-926d-4af553ed638f": {"doc_hash": "5535229b7d09a52784c7d15f514b403ad1c5d1b1921eca234b9aa2ada6bb8823", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "0741c12b-a3c1-403e-a2d4-3601714c20aa": {"doc_hash": "a8aab294b3107f5c77544c4a09f98aa3046b39920edcb67d1006cabb16d2f48f", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "68586bd5-c4c2-4bcd-aef5-d3c09b867124": {"doc_hash": "99de73732e35c5742bf544b06347367c3326a81807209c55985c6e22dab51c36", "ref_doc_id": "5528090c-2c7a-4caf-b9b1-b6d00bafb415"}, "b5e1dbf9-47e6-4cc1-a386-ffba65915e78": {"doc_hash": "fe50a14d4829dad313a73d567fe298e575c4f5fb5e775d61f21a1d36c7055597", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "59906c78-c0a4-4e30-8571-b7533f62c903": {"doc_hash": "3a5f2d597e4a07413d1b1a5b1a67eaa6f71000695305fb2f2cb49a52c53fa592", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "93ae3505-622e-40b7-87bb-b00704e5904d": {"doc_hash": "c3ab98dc13ba37e68c43073ca541b3143796dc75774b223031ade12408b1a770", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "474a4964-867a-4a28-866a-90dd715b251b": {"doc_hash": "f410d9d12cfbcee869ad37dac18dca3efb60f022fd020020b49a40c84849c6b9", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "60550029-29e6-4d38-8aab-325cfcb5d159": {"doc_hash": "670b978511b2b8fb8437993e20352fd2111524d15d3e536345803045f0fe5d62", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "c2c6a420-20ba-43a5-b82b-7c9fb196916c": {"doc_hash": "b8e2022edeaa41180cbdb09b037698d4dc161d178de2f923ed5fd764b5551b04", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "71858f65-8be9-461c-bca3-ea21d19a06a3": {"doc_hash": "d73d28056846b51d8b3e8baff2a15153d8ff6d3de11bbbd8024109ee4128ddef", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "4f42e3a4-9c4d-4622-92ac-b6a50c233f32": {"doc_hash": "8070d00f72d536a119c0c29d0a69bfd5ede682f235f6661b5201865b5fec2747", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "8df56155-d291-4582-ba56-ff4f22b4ea35": {"doc_hash": "4476cdfbcaf6271c4ddb3db62df3a9329f2169bda638c6a358c360b57cb559b9", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "a5462ba1-093d-47be-af1c-dba1925559ed": {"doc_hash": "e19f131deff30eba649f150fbc802dccbb8e494aae866c8610f7cb5533d7a1f3", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "c5857dfa-b119-4fb9-9a19-969582c92323": {"doc_hash": "e989785f5516926582e9d403ce54d7dc71dc6c039c86c9b2900f36b5bf09b241", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "1a33151f-1be4-452d-a1ab-073517e122c7": {"doc_hash": "1794c7560146fd117748d70a84974add8bc081bbfddcfec95cea464d116b83b2", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "ec3cd200-f3b8-4e39-934d-d153e9ac61c8": {"doc_hash": "1df5568361cb6e3833dc8246bbd82048ec0530a77273a5a2c6856a29325bb2f9", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "3418fea6-2e1f-4d87-9db2-e0d969ef8bd8": {"doc_hash": "0d5b8ca52089320766ecce268992383201a3a8c939ffa3afbd92e28199960e46", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "1285c5b3-9468-4ac2-9a1f-b9f9f35348d5": {"doc_hash": "7928fbbdd321f1aa17d53e30c0280c8090fb1b8aa1b904cf6abd4a5b4887914b", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "9ed4c852-48e1-4922-a502-504e29fb5471": {"doc_hash": "f15562ac8574cd0cb7e607fb4cbb0deb05e29afcff450c6b86820aeeeea4490c", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "de7c7020-f419-4094-ad76-11b73a8b82a4": {"doc_hash": "e84c9c2b2e69ccbb8a2c1073541d7d8db5310f6206db39e186023f5b11c132d5", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "b2a33782-525c-46c6-ab38-41698baabe1c": {"doc_hash": "520645d13dddca9dbecb067344cea31f6a3c2b08026cc32f5d40b63a76be4195", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "826a76a8-bfab-4ded-905c-235d0f02d22b": {"doc_hash": "1717898c2c566a76449990ece3969d00867c8a98e91b9016483e970de82d464e", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "578f2298-a7f8-4cc1-a8f5-3f1752d40f52": {"doc_hash": "6f060a823388cfec9f80d88b1ea69705ec60caa36ee09b6f81bc773d0fc0d06f", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "89dafadf-4e2a-4d14-93e3-ee8f562d21f1": {"doc_hash": "a1ea3d816444dc2476f0b9e3a395d816354142765d09e75a2329c8cb1ef3874c", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "87a53179-15a6-497e-a20e-6b107f3ea49e": {"doc_hash": "6175163f42b5ffcb30f8f482f14ba370e1cb115af50aee836528508a4280d83a", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "95f679b5-baf6-469b-9a5c-a7f955bbd156": {"doc_hash": "b23fdc3684cde5dcb391b8d459d358caea9b806bf76de11831a007da35e016c5", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "0e190dd9-3db8-442b-8e61-ddbecf28800e": {"doc_hash": "486c68c4c630f78de41a5f73b7696cc4f7e7b97ae861568f1df409bc8eef3409", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "cabc583c-f714-46d2-b381-3147a05d4779": {"doc_hash": "75592f0d2936ffee6ef8e2bde3d70fce537f675959508303803c996883806d1d", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "2d64a898-89ca-42fd-95ee-014cc909c568": {"doc_hash": "5da08dbb2c1c2a1667dbb6399082b77491b0b40d4c633c6aedef1870a6141b30", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "3742af53-c409-4d60-81af-af13e916285a": {"doc_hash": "773e1983c82a670156d79a63bfaaf0e987e76fc94985333cccae6457cb2af007", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "fd823a16-7933-43fa-893a-bd72c2680563": {"doc_hash": "41e7fd349161586f7ab248487428bb2f3780da1156a86a8cec6a7e1565c713d5", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "a61e18b7-6165-4631-a952-228de34cdf9c": {"doc_hash": "8357c7d995f39abf0e652e49a425821d750808f209ea9cbf19a08cc969758fce", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "5d4900c6-17b4-488e-b62e-c095914db791": {"doc_hash": "3e5d139528d3311acb02285340445cca4fc3606df297e7f7505c729a8735637d", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "6d5790d5-85c7-419d-b586-74f191f2e996": {"doc_hash": "86c58f539c13e0e1fa82dcb4988f16e446ced7581e6730a9e78f5a60745475d4", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "3816f934-c8d9-4406-9f24-cdc98dbc8d8a": {"doc_hash": "e96fa86c05123f7d6996fc6a7ece0435a8831c3462dd9193990e78fc7a093c6e", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "61b9beec-2279-46d2-99f5-2516f25bb3d9": {"doc_hash": "3ed66d7c6b55465fa0a7f848a053730d92619c585a9717b602b26aafd0582bf6", "ref_doc_id": "1dc77c60-3a83-4494-bbc4-84cbd7994d85"}, "e3ce8038-872d-40d5-b8be-334ef7788af2": {"doc_hash": "e1f9f9bbcd4114852d4251fd1b9eb397e985c6b80f0824cdc12297ed0b36a8eb", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}, "e581add7-e40e-4a9e-875c-8331d9d37aa3": {"doc_hash": "f3b4fe687c4df8277afb3f89d57d019c726f3d462342522876bf891269403cd3", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}, "5531c0ea-cccc-464e-8e9a-1d9b4373ef19": {"doc_hash": "3237676b2fae90d5af3c7e5a4441514d1ec76faeb8fd705f8c78b6e2420fa6cf", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}, "c37918b1-dea5-4c85-bdc1-94ca0cb2c9aa": {"doc_hash": "4b63b6f771b856b31d4a8406e759286640a020b76c9b6ae53060eb02b7cb1069", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}, "1ea36d1a-ac47-4964-9cea-219e415aaa52": {"doc_hash": "0186ca2e76c36174b55fb2b77734541dac4cefb0e73da14504d1a43b5e3710a4", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}, "6a77bdcb-2aa6-4e60-9015-4c7fa63c81bc": {"doc_hash": "32added01d5c37a0f838830ed86eb4a4b61afb6b95dac2c5975bfb810ce6737b", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}, "0f422d96-b81d-4668-a4fa-d59a3b2be891": {"doc_hash": "9f5dfc9034d9e95d516f2e37fa164a53f03f48e5a96776bbce1a7c4212e7a632", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}, "37aff1ef-0106-4eb9-9d61-31b1aa1f5183": {"doc_hash": "c6ed5902decdba1b6a25393fa725d58df76f76d76569a8e6d260d2b26af49ef6", "ref_doc_id": "3e1c769f-39d2-4d2e-b6d7-46674e144a84"}}, "docstore/ref_doc_info": {"64802266-2d8d-491d-951b-cc5ea8f030fe": {"node_ids": ["88da5561-31d4-44fc-a4bb-31f9024da8d5", "6e2cd6a9-e422-4503-aff5-44df60ce4646", "8e87ae1d-c5fb-4160-8249-7a6f6144c300", "be8c35f9-ea58-466f-b3a8-935fa1801e23", "cba687d2-bee8-440b-8f50-710c2733fb82", "23093277-e8ce-4309-a269-e89f1b1ccc94", "c9915611-4e09-4b1e-8c84-240039a0ff75", "427fe606-c3bf-462e-b51b-8ae9b85dc6ab", "0d32dce3-0da3-4924-b074-363556d3fb18", "917d91d7-38d8-4b37-903e-9f23c37b8477", "42d28cfd-2db0-4575-9a0c-53b4d55ba7e8", "5ad7282b-5036-435e-bcc2-dd057320ec54", "eb472fe4-9dbf-4aa4-90db-11c11807e981", "a5af57c8-dc3d-434c-9396-25267f5332db", "1ae372d5-f841-4cf7-8af1-ac031b9185f8", "205f8030-c27d-40a4-9eb2-c71787bfac5c", "05be60c7-fe8f-4a26-a8d1-adb94e239f79", "4ef99ac2-1280-4b5c-b53b-8388160b0f8a", "de8ca352-0e50-418d-8c0b-a0d0b285fbad", "1b59db2c-3a98-455f-85a1-a8b77910ceb7", "bc511975-e2d4-4ad5-87ba-da3cab827d2f", "f0bae8ca-c0c3-48b6-bc0c-5ce0758c09b8", "c905ed45-62ca-4d5c-8944-8a57d2b23de8", "3d03b2e7-ddbf-4074-a4bf-d5d04ed5d076", "72684f76-71ba-44e6-a292-7dfe6e8cf14e", "e59afd44-9671-4d27-b439-d3c036cae57f"], "metadata": {"window": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 15 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to the Fourth -Quarter FY 2023 Cardinal Health , Inc.  Earnings \nConference Call.  Please note, this conference is being recorded and for the duration of the call, your \nlines will be on listen -only. ", "original_text": " \nPage 1 of 17 \n \nQ4 FY23 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "89727101-48ae-4724-ac27-149dad43c9b4": {"node_ids": ["166b63ef-9a7e-4d46-9fcc-841fa6e01a22", "f5078a19-a2d1-479f-b1f5-2a34316db517", "d2e066dd-8c5d-4636-a3e2-9317ded7bcb2", "6e97f9bd-edeb-4475-91d1-cdcfc0ce468b", "3c82c188-f51f-42e8-8bcf-a988969c87a2", "0eea32ff-c933-4843-962b-566559975def", "515272ec-c36e-4369-a481-9cdd761a6ff8", "4249c533-9f6f-494a-b8ce-fdba82067239", "d51f7a70-e11d-48d7-9d2c-19dbcd1e8305", "bdacd99c-60a8-44b8-8217-6700cfe81252", "701401a6-55d0-42db-ab9e-41513da4518d", "496f493c-121b-4c84-8aff-79c9bee41817", "a7a3949c-9be4-4c8e-b58f-05d39903225b", "eed708d2-a584-4820-aefd-06aa75e1c2fb", "298b7bbb-3ed7-48f9-81b6-d31044f77a64", "c734d1d7-1b52-4a22-a6fe-b351433e0402", "e4204b0f-e2ef-473b-8668-2bb2741e0c24", "4e528811-492f-4dba-a03f-52d382c00d86", "a922a572-68fa-4077-beb2-874a4e91445e", "e8681dad-339e-45e7-8fdb-76ada0fcf283", "bbf2d342-f9bb-4aca-8bf4-15092edb6b10", "6ba345bb-0379-4987-8446-e5f2e76deab6", "a5931aad-e8a4-4743-96f2-b6e86d205b12"], "metadata": {"window": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.   We made key leadership \nchanges and governance enhancements , adding talent in key positions across the enterprise and to \nour Board.  We formed and extended the Business Review Committee ta sked with evaluating our \nstrategy, portfolio, operations and capital deployment.  \n \n On that note, we completed our review of the Pharma segment, including announcements at Investor \nDay to further invest in our Nuclear & Precision Health Solutions business an d launch our new \nNavista \u2122 Network supporting community oncologists , which I will discuss more later in my remarks. \n", "original_text": " \nPage 2 of 17 \n \nWe simplified how we operate by streamlining our organizational structure, exiting non -core product  \nlines,  and rationalizing our geographic and manufacturing footprints.  ", "page_label": "2", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b5c9377e-27a6-46c4-aade-5fbe085d1d5c": {"node_ids": ["9477ede3-70e0-4693-916d-494c7167e393", "aba2fd48-f8ea-48ea-94b6-d1be324965c8", "68b44d40-1ae3-4850-8023-a81b572f2256", "f3b8fd27-e554-47c2-9f9c-88ddd76c956e", "f310a3c2-5594-40a6-aa35-d5cbd5e7fe27", "94249de4-a430-49ba-83d3-97a53a48befd", "c2da952b-6bca-46e4-bacb-ce2400aa64cc", "8c8ec3f2-b4cc-4abd-8f3c-915af0a6bc07", "2eacadc9-0433-4d48-b61e-7836fb5b5fce", "9bcb4f92-dc41-4672-b450-0a8d0b6e186b", "5feb727c-ffec-45e6-97ea-7d8e14abb7f3", "4b8e135f-72de-4f75-ac5d-dbe9897d730a", "2e2da64f-e0a9-4289-b8b6-81dfc385c65c", "810eeaa7-ce44-4909-8f69-08f2ece43762", "7230ccba-4d85-4302-b5be-a39460476a13", "0cf34444-fd12-4416-85a1-9fde60b51212", "3f7ff235-6133-4602-a875-7ee53164ce90", "1b57cd05-297e-443e-b587-6f190f09810a"], "metadata": {"window": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend.  We saw a decrease \nin Products and Distribution sales related to lower PPE volumes and pricing, partially offset by \ninflationary impacts, inclu ding our mitigation initiatives.  This decrease within Products and Distribution \nwas offset by growth in at -Home Solutions.  \n \n In the fourth  quarter  we delivered Medical segment profit of $82 million  dollars , a nearly $100 million  \ndollar  increase from the pri or year loss. ", "original_text": " \nPage 3 of 17 \n \nFourth -quarter revenue was flat at $3.8 billion  dollars , an improvement in trend. ", "page_label": "3", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6ac36e1f-5f7b-4e4d-b228-71ba5f3cf809": {"node_ids": ["d5ccb620-9390-44ba-b5be-c33e37aa1e25", "d0d4a4e8-7835-41cb-9585-c30ed44b6cb9", "17a68372-53cf-4801-b78f-e652f16a4c5b", "c6eaeb18-9326-4db6-8f46-1743ba2e94ae", "a71b7f4d-6ec7-4f26-9199-81688b358d2b", "93ec2ed2-7a20-47df-97a8-e5bc9ed2b813", "4957ebc6-7375-47aa-92e7-568d224a0105", "66296142-3ea9-4693-b2b8-3de48fc7ead8", "d21ed4f5-d7c7-43ca-938b-a88fe9e83a2e", "54b4afec-538a-47e0-aeb7-b10387dec56c", "303a45e0-c2d4-45a6-81e7-1e62bf0c02d1", "cbec174d-a558-424f-9dac-183ed63da9db", "1bb917c0-0111-4b7d-b5f6-f81ce3ff94bb", "dac417ef-2c88-48f8-bf8b-e74c9e17450b", "e9668c0a-50c8-4e12-935b-e3da688d0571", "2a968db3-c1a8-473c-8552-aeb2cc0be92c", "039a43d0-3a80-4dfd-b5a6-865c5805d052", "9a608b3b-7906-4156-acfc-34febd97ab85", "e95e9fff-78be-4b45-b2c5-74b2fc03c77d", "2ae75bd2-2843-4625-8bca-608f5cba6a80", "413e2623-6363-44dc-a16f-f5e09d1d5c6a"], "metadata": {"window": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n Interest and Other decreased 46% to  $89 million  dollars , primarily driven by increased interest \nincome from cash and equivalents.  As a reminder, our debt is largely fixed rate, resulting in a net \nbenefit from rising interest rates in the near term.  \n \n Our annual effective tax rate finished at  23%.  \n \n", "original_text": " \nPage 4 of 17 \n \nOperating earnings increased 3% to $2.1 billion  dollars . \n \n", "page_label": "4", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3101b821-a68d-4b32-9de5-866a93fd0c59": {"node_ids": ["dfa107dc-1a42-4e88-a3cd-033b20cd0adc", "2bc4e15b-64bb-43df-9f07-e421bb90e1a2", "43757f29-9c46-4c9e-8d1e-99cef10bf522", "6ac71937-96e4-4830-9780-741dc0e61a27", "ea31b501-eba6-412c-941a-0ae6a7db57c9", "d5503f90-2bd1-499d-8d0c-0cb490ad3993", "36cabcb7-e0a7-4711-baba-3be6fceaffee", "30fab555-74f4-42f5-bd78-28d5595fd877", "fa648c58-6d82-48a2-8129-61b57d4bcdd7", "24bdd1c5-fa2d-477f-acb3-7865b9fe1403", "85e23d64-bfa4-46fe-823d-80d3dbe4985b", "5084410c-c200-4d36-833f-3012139888c7", "63e5ded4-9739-4ff4-8f07-d897a17dc707", "76920d0f-a3e4-48b5-9c5b-b9e44c6792ad", "582b388b-9156-4ef5-bc1c-854d0192abfa", "009dd424-b337-44fd-a353-cf0460f16909", "8ecdcae3-1d99-47eb-89d1-925cf0ba6ced", "ab5a66fe-efa7-46d2-8972-869105e580d2", "ae901550-525d-434b-bb1c-eeae49d28bfc", "7d8ed1b2-e5cc-43af-8085-e5b97dd00590", "903b2121-9f48-45ed-91d0-44cdb113b1f3"], "metadata": {"window": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75.  This increase reflects \nthe strong finish to fiscal \u201823, particularly within Pharma, where w e are now entering the year at a \nhigher jump -off point.  We also are tightening our shares range to $250 million to $253 million, which \nreflects the recent share repurchases, as well as our continued expectation of $500 million  dollars  in \nbase share repurch ases over the course of fiscal \u201824.  \n \n As you will calculate, the mid -point of our newly raised fiscal \u2018 24 EPS guidance is 15% above our \nfiscal \u201823 EPS results. ", "original_text": " \nPage 5 of 17 \n \nToday, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.50 to $6.75. ", "page_label": "5", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d755be45-a796-4158-87c6-ee9e872de8b5": {"node_ids": ["d169ac13-3016-43b5-bb8c-30e27fd50300", "0eae0238-20e6-4b39-b7f5-acb4be36b288", "8e3788b9-cc70-4e3a-b06b-edccf696b23a", "ca1d4ad1-b8c0-4904-88c3-4d3c3164a536", "3c61208e-040c-4cb7-968c-7c895e50debd", "e9507469-333e-4c6e-b45b-edf3ab438e36", "43f2e71c-8d4d-45a8-8d50-656c7389a198", "24e47404-edb1-45d2-912a-f71c80b29416", "c68c68b5-e242-4a46-b245-701abd2daa21", "20f8ceb3-671b-489a-807e-195fe926871f", "6161f968-d565-40b4-b694-64989d6e554f", "aa802423-d3f7-4bcb-8046-cccbe5958639", "9ef56dbf-8817-48f2-84c9-dda7278bf258", "6f983785-1bba-493d-8759-15e9aa145c31", "e98f7dce-8c50-4095-8341-04585798811d", "644ba488-4644-4c1d-b7d2-d27586cab05c", "b3942536-000f-4d64-9dd2-80ccd74a300f", "0c38f6a0-4fa6-418c-a1e7-4feb8012cf1c", "d9d15344-245a-4899-b32b-87f7abf9bdf6", "e2f1c861-06a0-4079-8b26-8a922199654b"], "metadata": {"window": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n Stepping back, we are pleased to see growth across our businesses continuing in fiscal \u201824.  \n Consistent with our messaging from Investor Day, we are targeting a 12  to 14% EPS growth CAGR \nfor fiscal \u201824 to \u201826, now from the higher fiscal \u201823 base line of $5.79.  \n \n Now, regarding our intended deployment of cash, which is consistent with our disciplined capital \nallocation framework, as seen on slide 18. ", "original_text": " \nPage 6 of 17 \n \nSo, in summary, for Medical for fiscal year \u201924, continued work in front of us with each quarter \nimproving from our Q1 launching point to get us to the approximately $400  million dollar  guidance for  \nthe year.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7148d394-2e3e-419b-b7f5-454eafcf9fef": {"node_ids": ["9bd256b5-b63f-4732-a9ae-c101380448b5", "a12ffec3-05a8-4189-b17b-765f85a8a9e9", "60441b74-8d09-4a3d-956f-5817d4d90bad", "4b29fc33-4272-4eb2-bd15-7a6715d9ee50", "56827d84-4870-4a32-b6af-92a760db2f83", "e5d61093-2145-40a3-8d60-3ce4fd3ca80c", "9ed78569-4e0f-4f54-ba35-6e79b80921de", "ed3e882d-f1f1-41bb-92c2-28a169fcc427", "95885a67-5975-47cd-98a0-ccb5e430324d", "ccdfbcee-4cd0-439b-8845-51730a89fa1a", "74d331ba-baca-4416-a4cb-abf62ed789c6", "9fb47b4f-07d9-4b6c-bc98-213a83e379a6", "b265f6cd-963b-47b4-a2dc-2c22251086f9", "9db3d0a9-1819-4468-9b36-28f603133d86", "6a9b5ca7-5999-47b1-bbd7-aa86b5c9f846", "ed1cf52f-9cb6-4115-b33c-48c01dff6fc0", "73f6d7f3-b9cb-46fd-9b4e-72785e761d93", "bce6ae60-570b-4207-a697-42a23520b943"], "metadata": {"window": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations.  For example, we are offering modern payment solutions \nthrough our collaboration with Square to help independent pharmacies seamlessly manage business \noperat ions, integrate flexible payment options,  and reduce payment processing costs.  \n \n We\u2019ve conveyed that Specialty is our priority area of focus , and a key enabler to our long -term \ngrowth.  We\u2019re continuing to invest to expand downstream across key therapeutic areas, such as \nOncology, Rheumatology, and other emerging areas.  \n \n", "original_text": " \nPage 7 of 17 \n \nwe brought together nearly 4,500 attendees from across the country to celebrate the critical role \nindependent pharmacies play in caring  for their communities and showcase our commitment to our \ncustomers through our newest innovations. ", "page_label": "7", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4011977a-fb56-4b0a-9225-35b630559899": {"node_ids": ["63268705-9624-4a76-8639-38d2793ebe1c", "49476bc3-4d31-4b27-a9df-587a9cf6bb68", "6c71a0fe-7e6f-4a3e-9b2f-3964fe6fac1e", "5030e6c0-fbf2-4509-8fc9-8b9aff5cced6", "b19c0ca7-41cc-4f2e-a1ce-bdd2ee12c994", "9ca61a85-1032-4ede-8117-bf76dfdf53d3", "a8680e73-fd21-4b4d-b37e-4bbca6f28825", "25954ea2-7485-4b5b-94a7-ce3ad65d10ea", "f9943039-9864-413b-bd41-01de4a434964", "4e48fd71-bc99-4345-8557-6935e60ee1ac", "03618b23-cad9-448c-8b19-092fd7a44e30", "b16a1e49-c49e-4f63-ba8a-db1af107a74b", "8ebfb7a0-4340-458b-85ef-ac782b54f3c5", "d0aef6e2-59f7-4db5-8f92-4caa835adb49", "bcde74a7-b781-4a5d-bda5-7acbf38d5c3b", "2dd9527f-609c-4e61-b008-8fdcb09428ec", "f420e328-08a1-45ea-a922-2092dc4336fe", "16f966a3-667c-4557-9833-b4fe43c251d3", "0c88371d-e90a-49e0-8128-8ce91603198a", "6f64570f-3207-4ffd-9956-6b7127e380bb"], "metadata": {"window": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n When we introduced the  Medical Improvement Plan last August, our immediate focus was turning \naround the performance in the core , Products and Distribution , where we\u2019ve achieved tremendous \nprogress over the past 12 months.  \n \n We are on track to address the impact of inflation and global supply chain constraints by the time we \nexit fiscal \u201824.  This is the number one  key to returning to a more normalized level of profitability, and \nwe are now over halfway to our target.  \n \n", "original_text": " \nPage 8 of 17 \n \nNow turning to Medical and priority number two.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ff03f30f-7f67-4dae-8496-bf0dbfc13507": {"node_ids": ["7f79a725-8ddb-4748-83ab-cf44b417fcc3", "a0bd912c-f0c2-409a-9ef6-6987eb4fafbf", "da4e7b2c-e0f6-4356-b1eb-b033bee04b3f", "cb132b82-a764-4d82-b913-680cce267497", "ea292c90-a592-48e0-9774-25123687cb42", "bdc82a0a-a47f-43e6-a5ee-914fac439699", "0ad1eb2a-7f5c-4b61-8921-f6fb62033a11", "800a78dc-7051-44bf-9802-571f8e1cc924", "4f3ea902-562e-42af-bb22-86d1b7773529", "d3366999-d480-4ffa-9f62-33d8c97b4ca9", "5e8306f4-4e14-4a2d-86ee-136a14589b61", "f67619bf-d96e-472b-8fd3-95382688d1eb", "55f8472b-6686-495c-a08d-188e05384f3e", "2b88111c-17fe-408d-9c97-3f1c9720ee60", "f4f63e2b-5df2-4908-8b25-2f41ca8a34af", "c9048aac-e95c-4976-b8ea-555e8a71a832", "e4e5a609-4d37-450c-b488-b4906c4c9264", "2443380e-8a22-4cb2-8558-49d5c37d92b5", "03686922-a56d-4235-8a0f-0749474c7300", "b77b4473-6615-4004-87e9-74f8b78a68da", "ae2a8932-de6a-48fd-961c-5157ec1c23e8", "ae0fee92-7240-41db-b108-b0feb6cb2082", "191e01eb-05f9-4ee9-a66b-69ba49d8ba0a", "26d356bd-8427-4027-a4a7-3ae524604852", "b3d0c591-1f9b-4bb5-b11a-7f118013f2cd", "f63a07ed-a853-4268-b87c-fd7e2162e3e9", "6317ab7a-0b39-427b-93ba-5d08b7cf8bd7", "acb59e7b-56ba-4cf5-a983-4e3e864d6a48", "bc7f1541-c476-4604-beb1-19798eff413b"], "metadata": {"window": " \nPage 9 of 17 \n \nGreenville, South Carolina DC.  This facility, the 11th in our national network, will be fully operational \nin 18 -24 months  and equipped with advanced automation technology and robotics to drive \noperational efficiencies.  In OptiFreight, we provide premier logistics management powered by our \ntechnology capabilities and expertise.  We\u2019re continuing to invest in digital tools to s upport core \nvolume growth and sustain our strong performance.  \n \n", "original_text": " \nPage 9 of 17 \n \nGreenville, South Carolina DC. ", "page_label": "9", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "10757ed1-0a02-4eae-8d16-e6f43d486b69": {"node_ids": ["8a390a3a-cf35-4939-a7ee-aa78f3ec08b5", "baf9fa0d-35a0-459a-bb12-384a702a05df", "64f389c1-dc97-4993-9f65-a7a1ae70da62", "4f920913-5773-4b2e-b747-b7f8cb653cad", "605be9d0-65f7-47ba-bc46-9a1f9d7f30da", "d639fc70-5340-4de3-9ec8-cccdabca7f2c", "6fd36ed9-bf10-426d-a8d9-cf6587ffe8ba", "befbbe65-c5c6-4cd4-abfa-547deb152c09", "d4bfad88-458c-4406-8fd5-2cda264161dc", "dc407028-0830-46f2-92c7-35ba1feb53ca", "002c969e-2743-4f35-a0b5-8623944eea17", "92ad6e4d-0d29-4630-8652-1cec521e4630", "68dc9ab7-a5ac-4c75-bd4b-85c17d4eb99d", "50730c4f-18ae-4282-a42d-48db5afa7ed8", "70636836-aac2-4955-8aca-5aaf9d58aaba", "e6ca834b-3f89-43c1-bcf4-50dff9aff771", "5d2bb25c-2cd2-48bb-9b13-58f4ba30f85e", "7173154b-5743-4e9d-8f35-11e9a9cb720c", "d2a85ba8-fa02-422a-bf8b-4fa2b0682cfe", "2cddc03d-83e0-47d4-b30e-6b09528272b5", "e61369bd-8c50-4609-a430-63917b232bb1", "f7ddf1bd-edc4-435c-aedc-ab0910d482c2", "5a03e2ac-c3a6-4881-8955-f383ecde5cff", "0f55b4d3-5b7f-4cbb-a5b8-828c23fff459", "877438de-935c-4c62-a1eb-5b1f60d6a7da", "fe8ce034-8adf-4f73-a340-089f9764eb67", "a6d7e618-5423-4c20-8435-63511e745d0b", "6a51c71e-c819-4e16-8fb8-2b93809f9f95", "6ccf31a6-3812-4e44-adae-f7882741a3ec", "0fb8a479-db7d-426f-844d-9e38327b5129", "c21a018f-e7e0-492a-8412-d0cbfad66933", "17401196-61f6-4928-9d46-a057791dae04", "efd66b2f-a89d-4c23-8dbd-890b38674cf9"], "metadata": {"window": " \nPage 10 of 17 \n \nJason Hollar:  Yeah.  Good morning, Lisa.  Thanks for the question.  Yes, the primary reason for the \nraise in the guidance on the revenue is related to the GLP -1. ", "original_text": " \nPage 10 of 17 \n \nJason Hollar:  Yeah. ", "page_label": "10", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "24d28397-258c-43d0-b16c-9fb41cefe513": {"node_ids": ["13e9b329-f899-4eef-b7e3-70be7695dd47", "d2a88f7c-7ad2-4635-847a-7b061eb457d2", "02d25b04-8d8b-4c50-ba9a-ac7ea264906d", "64195392-e73e-40d7-8520-36a75f5f608d", "8b198f3a-87d5-4cb2-acc1-132fb5868a77", "2a72f48f-3ee6-4964-84ac-78d47c3aa632", "4b4f069f-1d1e-4747-b109-50438ac43f52", "870dccb7-9ac5-4270-8bd3-911a37178daf", "6ecb31e9-ef17-4d5e-8322-072f3bdb3d58", "4384bbcf-99ac-4a4e-8c3d-72976522aea0", "a8c6f492-b753-4292-bef3-67156e8e8cc6", "c3de03b4-25d3-4e1a-aea7-e890410cbd57", "4e8f62b7-546f-4812-86de-42f050f48705", "74b4f385-e3f6-4f61-8e0b-66d135aeff63", "60426720-1e22-4b84-a88c-3be230105588", "2507812e-8faf-491e-be5a-24145b1f670e", "b7848d64-0b0d-4e24-8e27-f27f903f0848", "3364032f-cd81-4ce3-97ac-03d1e3d3e183", "e3d77d07-5751-4c85-a6cd-a1b4e0dfdf59", "40e68b07-92ee-4470-a0b8-0c19a624f7d9", "e145d2cb-0394-4d8b-9abf-2222f4db3f4c", "980eaa4e-eccc-437c-adab-dc5d1f3522d5", "3c67930b-6e0e-4501-9439-6afdc9219642", "f2261992-db97-41db-9c81-7670742ae1ee", "956e5be3-57e1-467c-b40e-72ed31a6ad9f", "41eb43c8-34cb-4b70-8f5b-a13aeb69f2e5", "57723e69-045e-4572-a45a-ba8a5e34cae7", "7302a17e-301d-4532-9c64-f743b776ebaa", "063572b8-3cf1-4ac0-bb0b-3d37c632a121", "85de2d77-6d1b-4793-be03-37167c508054", "bc1f09cd-eb42-461b-88e9-22ae7aa24427", "0c910911-4b9b-4dbc-8c65-542065802d5d"], "metadata": {"window": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823.  Our view is that Q1 will h ave similar core \nperformance with Q4 , with sequential performance thereafter.  Q1 is the seasonal low point for the \nMed Products and Distribution business due to both the timing of volume , as well as our cost \nrecognition.  That's an important point.  ", "original_text": " \nPage 11 of 17 \n \nNow as we think about the cadence, though, we are being clear that the profit will be back -half \nweighted during the year just like it was in fiscal year \u201823. ", "page_label": "11", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a39adb85-e94b-4022-a926-62e962c0fefc": {"node_ids": ["19c8a1d7-0982-4149-80fb-fa06ca5d1cf2", "d61f5004-2a3c-4109-a040-cd6014e0e351", "19e1dd03-da54-4761-9b3f-04c4e505132e", "9e98a8c6-a7ed-43ed-8236-54d9225e39ea", "3f60e3ea-15cd-465e-9cac-26ccc2ef0acf", "8c535ef5-8533-4d2f-aaaf-aa5e044e6085", "8b8e502c-5284-458d-86a7-8bad55ff2609", "279c9a10-60dd-496d-8a5a-a2221e01df39", "c379a6fc-2b83-42f9-9e5c-50fcd09f5713", "78500d99-3926-45bb-bf18-540a3db139ba", "708e8218-7914-4388-be12-cd345da97183", "0806f6a1-6143-4fbd-bb02-3db53301301d", "794ba273-bcb7-4a18-9c92-f3d30f46bb71", "f99c5ca1-2698-43d7-8d00-8924bc7a0f06", "b6cba428-eb4e-4d6b-b17a-b2edd419ac7f", "f352954c-d5e4-4640-8955-9fddfa65a81f", "17ef221b-0ccb-4a96-8bce-e5c363ff20ba", "6a4dd7f9-75f8-481e-9771-007c4c527eb1", "dabc60ea-5ad6-4d35-807c-4d0f6686ed25", "eee40301-ff20-4f59-9024-67fa71f1b440", "7bb175f5-480b-4bad-b5f9-320d75a6e120", "980f54ab-372c-4c9d-9379-7e844abc3216", "1f8b2dde-bb88-426c-99e3-6e951cfa0523", "59c9327f-2d90-4619-b4ec-079ccb8bf479", "e581b466-6efb-4b1b-a0f8-64c983f7f705", "81209834-c320-4adb-8c68-f5739cca4651", "c03621df-75af-48f8-8955-e0f539d6a5d8", "e4c113b7-8bb6-4bb9-8902-b4fbc5e89419", "8b296e85-5ecc-4954-9187-8c1ec6100996", "17c1dcd8-804a-482c-8726-dbddad326536", "b5bab8ac-680a-4513-b489-afc8fd99bdb0", "5c4e400d-9e93-4aca-9714-2d699d52322b", "0d65a6f4-d9fd-4cc1-bfba-63edb820966c"], "metadata": {"window": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n Kevin Moran:  Next question, please.  \n \n Operator:  The next question comes from George Hill of Deutsche Bank.  \n \n George Hill:  Yeah. ", "original_text": " \nPage 12 of 17 \n \nSo, all the leading indicators are going as anticipated and consistent with how we laid it out at the \nInvestor Day and  gives us the visibility and the confidence that we'll be able to participate in that \nmarket growth that we anticipate that will be there over the course of this next year.  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0e9c5ca7-8e1a-4b8d-9d7c-78866bb823fa": {"node_ids": ["28a93f70-ec3d-4174-aee8-45bd1021c682", "dbe8a030-9b9e-400a-b960-1f093f4c0879", "f9672a73-6dee-495a-9a60-c458db0d5f36", "ee3e92ec-643f-4ef8-8456-7d595fdde3b1", "3c143f4a-683d-4c9c-934a-e8cc37751e66", "6070d7fb-823d-4b6b-bab1-241665eeb980", "72c7ed76-2f3f-41db-a3b8-a663e74cc34c", "7ea2f5cc-1fb2-41df-b2a5-566fc0ee54df", "c681f77c-4a5a-4724-9dea-a87bd1bfef6e", "efc97c6a-4dde-4fde-8a93-8996aeb9f450", "d36a4926-bfaf-479a-bc9c-9193c426e079", "725c4fb5-9752-4c52-9f02-b5938d873a70", "ca507966-194c-481a-bb73-afc6a154b0e8", "47d710a6-8088-4ba8-a576-d7ce181ce336", "d0d1ddfa-3abf-4f65-af41-887446e5f344", "e35f47ed-cdb3-48ba-bda6-8ad46e3ac2ed", "1a5374b4-3d14-49e2-98a4-c0098afd6521", "49cae840-e330-430e-9761-a064fb688ab3", "0b41b0a2-8bb7-42ab-8606-26c6b4ab5a35", "fa6ce2c4-668c-4b42-acb9-ef9022b40c5d", "a9d6ca22-4517-4070-905c-6228d5449031", "2d1d74e2-e230-4d32-b6f3-0b2a9555114b", "4ec0e57d-0fd1-4870-b9ba-7edc704089cb", "bffcaf4e-bcae-4aca-acbe-db69b8d335a7", "3fead66a-1146-41a3-a9d0-9a46daaedfc5", "e5f6fea7-dfa1-44b9-83b4-c788411e8aaa", "32563cca-159f-43ff-99cd-e62edfaa8f57", "ba6541bb-28d4-4937-91a0-c530ba2bca12", "1e847521-c289-425f-9c6e-ab9ce8a1597c", "78c71df4-c66b-482a-bedf-5efd780d63da", "a58aa69f-7282-4dbc-9dc7-20409b67462a", "6ca9ebe4-6cfb-4620-b696-10bf2428486f", "e450eada-fe5f-4614-b7e5-d0591519c833", "3080387e-7fc3-4664-a904-024eed425029", "a274a09d-0024-428d-afe1-6f76d51f72fa", "b8f49e65-4c70-489d-a3c1-d87a0d01a470", "1bb205e6-c14d-4f2a-a8a1-3deba0eaf108", "f6d49d58-c6d9-4674-8d58-073d950fac54", "27768d51-29a7-49b9-a4ab-278aacdadbf1", "5dbf1b48-1a12-433e-b8b2-cf9e32f1878e", "25624afe-2a7f-4c77-987f-d62cf2095186", "ca19f180-ffe7-42ab-8f8f-767218b3dc3e", "f5ddfaf2-0182-4258-8ff2-ca6611321236"], "metadata": {"window": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing?  A little \nbit more help there would be very helpful.  \n And then secondarily, can you talk about what is different about getting this next 50% of the inflation \noffset this year that was not the same last year?  We obviously know that you've been getting more \n[indiscern ible] in your contracts, et cetera, but I'm just looking for any more additional commentary \nyou can provide on what might be different about this remaining 50%. ", "original_text": " \nPage 13 of 17 \n \nthrough, those cuts are going through , have gone through already , and are just annualizing? ", "page_label": "13", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "68ac55c9-2fc8-4728-9b52-07caa1509930": {"node_ids": ["c9cb5e3d-5b41-46e2-889a-e25d4969e315", "d52e0153-40d8-4998-8cc4-61d27f004df8", "cc172c05-024d-4e34-baba-3007cb7c84ef", "f5b0685e-91e2-4cb0-8c22-947d9a25fff6", "af0e459e-9443-44a2-9b37-6cb054c54344", "2ebe87b4-79e1-42a5-9d88-0081c16fada9", "76e96cb7-6a52-4ae9-8283-550fe7653edf", "8921a777-40b0-4e19-a6e0-2e5d2c657691", "650ab26a-bd77-4a24-bf90-2d79a01edea6", "65cf0647-5a9e-41b9-a8b1-e768872a9f10", "aa13de8b-2560-4e6a-9af0-661e53f81223", "51606aea-80ba-4a6a-8a94-522002f3e16f", "f59da9ff-188b-44ee-afa7-0c4152c3c6b2", "ecf0bfde-9b7a-4cd4-8c05-76967b2a8e88", "f60ac68c-3a79-4cc1-bbbc-803accfe8fb4", "0cf046a4-8510-475d-85e8-18a8bad5534f", "47ce1e1c-6a42-42ca-a11e-736e2bfc60e7", "56d4442e-6374-4010-8e4f-d51b91bbecfb", "0ff61b11-9d32-4dfb-960a-4e21a4cb08fa", "642e9c6b-dc4a-439f-b5ac-96a26cf4d1e7", "c277a448-1626-47e0-9ae2-e0465f2ec065", "0888b4d3-e2b9-4448-819d-6eee995d9d76", "ee899906-2028-4c0a-9fa0-bf774a2e0429", "07fd94e8-a250-4069-a08e-9e0da023f9c9", "aa2b9260-6ea0-4a02-a56a-f9aa07654006", "6cdcc515-e281-4ac9-9500-7ef0cdc32593", "19ecef9c-79ec-40d4-a2ad-223c6e7f05b8", "afe8617c-2107-480e-89da-860dc9d132b6", "0e9862c3-347f-46d0-ac82-994bd8d8c0b4", "3ff8b1e3-c6fd-4859-bdb8-734fded56001", "22f968fe-2508-4407-8a6e-4d7b8ddd1e0f", "d4be8c52-735e-4d35-88fb-65eb6ef1f3c7", "d810fdb1-a52f-4e18-a3d5-2a9716b8c271", "dedd141e-5f57-45dc-815c-1a7bf23470d4", "7ddde1d1-7a81-4548-95ab-a14e160b55f9", "d5fc80fa-934a-471b-abe1-2803f4a4d0ac", "713b3194-3286-468f-80fa-53c883b90c15", "15292f2d-e99c-4794-9130-6d51b8c76442", "845c93d2-e075-4677-849c-7fb336f74e9f", "e8660c78-7aad-433d-a530-8ad235930a71", "4c3da0c5-23c0-4278-9067-6de24b67129b"], "metadata": {"window": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year.  And then Jason has already touched on Cardinal Health \nBrand, so I won't go there.  \n \n Kevin Moran:  Next question  please , Operator.  \n \n Operator:  The next question comes from Daniel Gro sslight of Citi.  \n \n", "original_text": " \nPage 14 of 17 \n \nmillion  dollars  over the course of the year. ", "page_label": "14", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5528090c-2c7a-4caf-b9b1-b6d00bafb415": {"node_ids": ["1ce9fb5e-ad83-4675-8979-5a1e0b9822bf", "9a214b2f-2ce1-468a-8d2c-5ff4bf917591", "f2700cdb-7089-4c14-93c2-29f026bfb75d", "9d7e9d00-5ade-42c0-89b7-bea6407d76ba", "eb82c369-31cc-445e-90e7-51ac171a0297", "337a8b6f-a142-41af-94bb-3ff96ab8f61b", "fbca08ca-e877-40cf-b1dd-f50cacb36ba3", "c0cd526a-2f87-4b46-a8ab-89bbcac4032d", "1e2fa2e3-05b1-45b3-82ee-8ff8de90889b", "e24844a9-33fb-4145-b239-e0a7bed4aca9", "b373789e-0b09-48c5-a022-33a35f8f9d53", "01d4a0ba-d8cc-4f8b-9537-8eeeeccde48c", "2b78153c-b4ed-4973-bc60-4b42ccdef210", "d5b70081-8159-4066-b62b-daae956a2ad2", "de639602-87e8-4513-88a5-90645507ca0c", "4f364187-b280-473e-9d33-ae7b871174d5", "72161d4a-5d9a-433f-a021-caf931e8954e", "29ffc177-c0e5-4874-9247-a2fc13df4e0f", "1c270c25-ed14-49a9-9d8e-085f0c0d815d", "d9b25b21-4f32-4bf5-801e-5791fa93a579", "46570ff3-2458-4ebe-a95e-c6395b736344", "60651cc5-2897-47b2-a15d-bd334a3a93f5", "0b82f569-c940-44d5-9dc3-50c0f8b221b1", "b9ebe9ba-2ede-463a-9c6c-88a835e6de7f", "63eb1648-1bed-4bb3-a074-788c012ad253", "9ff50de3-bbb5-457a-8565-b13f3e04f779", "ee450f8a-b9bc-4ef3-82ce-068efcad4261", "5dee9b74-cfe8-41a6-9444-244c727158a6", "fee44863-969c-45c3-a6c2-3d3ee6203ba2", "752f48a0-c808-4b71-87a8-a44350b32d78", "1f257d1f-3f09-4c14-865c-286a74faa562", "fe789158-afef-4320-947d-d74c8e571bf3", "67579d92-16af-4023-a771-69d88bcf20ef", "49a5d31e-a4ce-4380-9654-213db8dfe54c", "95cb3547-9a93-4ccb-926d-4af553ed638f", "0741c12b-a3c1-403e-a2d4-3601714c20aa", "68586bd5-c4c2-4bcd-aef5-d3c09b867124"], "metadata": {"window": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon .  There's various demand driven spikes and supply driven spikes. \n Our goal, of course, is to minimize those challenges within  that to give our customers the best \npossible service.  And what we saw, in fact, in fiscal \u201823, it was a little bit of a benefit by being able to \nsupply products as a second distributor as not the primary distributor, but we had some opportunities \nwhere we  were able to provide when others were short on product.  ", "original_text": " \nPage 15 of 17 \n \nSo, while there are product shortages sporadic within the overall Pharmaceutical distribution supply \nchain, that's not a new phenomenon . ", "page_label": "15", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1dc77c60-3a83-4494-bbc4-84cbd7994d85": {"node_ids": ["b5e1dbf9-47e6-4cc1-a386-ffba65915e78", "59906c78-c0a4-4e30-8571-b7533f62c903", "93ae3505-622e-40b7-87bb-b00704e5904d", "474a4964-867a-4a28-866a-90dd715b251b", "60550029-29e6-4d38-8aab-325cfcb5d159", "c2c6a420-20ba-43a5-b82b-7c9fb196916c", "71858f65-8be9-461c-bca3-ea21d19a06a3", "4f42e3a4-9c4d-4622-92ac-b6a50c233f32", "8df56155-d291-4582-ba56-ff4f22b4ea35", "a5462ba1-093d-47be-af1c-dba1925559ed", "c5857dfa-b119-4fb9-9a19-969582c92323", "1a33151f-1be4-452d-a1ab-073517e122c7", "ec3cd200-f3b8-4e39-934d-d153e9ac61c8", "3418fea6-2e1f-4d87-9db2-e0d969ef8bd8", "1285c5b3-9468-4ac2-9a1f-b9f9f35348d5", "9ed4c852-48e1-4922-a502-504e29fb5471", "de7c7020-f419-4094-ad76-11b73a8b82a4", "b2a33782-525c-46c6-ab38-41698baabe1c", "826a76a8-bfab-4ded-905c-235d0f02d22b", "578f2298-a7f8-4cc1-a8f5-3f1752d40f52", "89dafadf-4e2a-4d14-93e3-ee8f562d21f1", "87a53179-15a6-497e-a20e-6b107f3ea49e", "95f679b5-baf6-469b-9a5c-a7f955bbd156", "0e190dd9-3db8-442b-8e61-ddbecf28800e", "cabc583c-f714-46d2-b381-3147a05d4779", "2d64a898-89ca-42fd-95ee-014cc909c568", "3742af53-c409-4d60-81af-af13e916285a", "fd823a16-7933-43fa-893a-bd72c2680563", "a61e18b7-6165-4631-a952-228de34cdf9c", "5d4900c6-17b4-488e-b62e-c095914db791", "6d5790d5-85c7-419d-b586-74f191f2e996", "3816f934-c8d9-4406-9f24-cdc98dbc8d8a", "61b9beec-2279-46d2-99f5-2516f25bb3d9"], "metadata": {"window": " \nPage 16 of 17 \n \nincremental volume or incremental margins.  So , we're at a level that I think it's fairly stable, and it's \nour objective to keep it that way.  \n \n Kevin Moran:  Next question please , Operator.  \n \n Operator:  Our final question today comes from Brian Tanq uilut of Jefferies.  \n \n", "original_text": " \nPage 16 of 17 \n \nincremental volume or incremental margins. ", "page_label": "16", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3e1c769f-39d2-4d2e-b6d7-46674e144a84": {"node_ids": ["e3ce8038-872d-40d5-b8be-334ef7788af2", "e581add7-e40e-4a9e-875c-8331d9d37aa3", "5531c0ea-cccc-464e-8e9a-1d9b4373ef19", "c37918b1-dea5-4c85-bdc1-94ca0cb2c9aa", "1ea36d1a-ac47-4964-9cea-219e415aaa52", "6a77bdcb-2aa6-4e60-9015-4c7fa63c81bc", "0f422d96-b81d-4668-a4fa-d59a3b2be891", "37aff1ef-0106-4eb9-9d61-31b1aa1f5183"], "metadata": {"window": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great.  Thanks again for joining us this morning.  To summarize, fiscal \u201823 was a \ngreat year.  It was a year of inflection, and we are excited to continue this momentum into fiscal \u201824 \nand beyond. ", "original_text": " \nPage 17 of 17 \n \nJason Hollar:  Okay, great. ", "page_label": "17", "file_name": "CAH-Q4-FY23-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 201712, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}